Facial B-Claim
hirsutism I-Claim
is I-Claim
one I-Claim
of I-Claim
the I-Claim
characteristic I-Claim
features I-Claim
of I-Claim
polycystic I-Claim
ovary I-Claim
syndrome I-Claim
( I-Claim
PCOS I-Claim
) I-Claim
, I-Claim
and I-Claim
this I-Claim
can I-Claim
lead I-Claim
to I-Claim
high I-Claim
levels I-Claim
of I-Claim
depression I-Claim
and I-Claim
anxiety I-Claim
. I-Claim

To O
evaluate O
the O
impact O
of O
laser O
treatment O
on O
the O
severity O
of O
facial O
hirsutism O
and O
on O
psychological O
morbidity O
in O
women O
with O
PCOS O
. O

A O
randomized O
controlled O
trial O
of O
five O
high O
- O
fluence O
treatments O
( O
intervention O
) O
vs O
. O
five O
low O
- O
fluence O
treatments O
( O
control O
) O
was O
performed O
over O
6 O
months O
in O
a O
National O
Health O
Service O
teaching O
hospital O
. O

Subjects O
were O
88 O
women O
with O
facial O
hirsutism O
due O
to O
PCOS O
recruited O
from O
hospital O
outpatient O
clinics O
and O
a O
patient O
support O
group O
in O
2001 O
- O
2002 O
. O

The O
main O
outcomes O
were O
self O
- O
reported O
severity O
of O
facial O
hair O
( O
measured O
on O
a O
scale O
of O
1 O
- O
10 O
) O
, O
depression O
, O
anxiety O
( O
measured O
on O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
) O
and O
quality O
of O
life O
( O
measured O
on O
the O
WHOQOL O
- O
BREF O
) O
. O

Self B-Premise
- B-Premise
reported B-Premise
severity I-Premise
of I-Premise
facial I-Premise
hair I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
51 I-Premise
) I-Premise
fell I-Premise
from I-Premise
7 I-Premise
. I-Premise
3 I-Premise
to I-Premise
3 I-Premise
. I-Premise
6 I-Premise
over I-Premise
the I-Premise
6 I-Premise
- I-Premise
month I-Premise
study I-Premise
period I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
37 I-Premise
) I-Premise
the I-Premise
corresponding I-Premise
scores I-Premise
were I-Premise
7 I-Premise
. I-Premise
1 I-Premise
and I-Premise
6 I-Premise
. I-Premise
1 I-Premise
. I-Premise

The B-Premise
change I-Premise
was I-Premise
significantly I-Premise
greater I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
[ I-Premise
ancova I-Premise
F I-Premise
( I-Premise
( I-Premise
1 I-Premise
, I-Premise
83 I-Premise
) I-Premise
) I-Premise
= I-Premise
24 I-Premise
. I-Premise
5 I-Premise
, I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
] I-Premise
. I-Premise

Self B-Premise
- B-Premise
reported B-Premise
time I-Premise
spent I-Premise
on I-Premise
hair I-Premise
removal I-Premise
declined I-Premise
from I-Premise
112 I-Premise
to I-Premise
21 I-Premise
min I-Premise
per I-Premise
week I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
and I-Premise
from I-Premise
92 I-Premise
to I-Premise
56 I-Premise
min I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1 I-Premise
, I-Premise
80 I-Premise
) I-Premise
) I-Premise
= I-Premise
10 I-Premise
. I-Premise
2 I-Premise
, I-Premise
P I-Premise
< I-Premise
/ I-Premise
= I-Premise
0 I-Premise
. I-Premise
05 I-Premise
] I-Premise
. I-Premise

Mean B-Premise
depression I-Premise
scores I-Premise
fell I-Premise
from I-Premise
6 I-Premise
. I-Premise
7 I-Premise
to I-Premise
3 I-Premise
. I-Premise
6 I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
compared I-Premise
with I-Premise
6 I-Premise
. I-Premise
1 I-Premise
to I-Premise
5 I-Premise
. I-Premise
4 I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1 I-Premise
, I-Premise
83 I-Premise
) I-Premise
) I-Premise
= I-Premise
14 I-Premise
. I-Premise
7 I-Premise
, I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
] I-Premise
. I-Premise

A B-Premise
similar I-Premise
change I-Premise
was I-Premise
seen I-Premise
for I-Premise
mean I-Premise
anxiety I-Premise
scores I-Premise
: I-Premise
intervention I-Premise
11 I-Premise
. I-Premise
1 I-Premise
to I-Premise
8 I-Premise
. I-Premise
2 I-Premise
, I-Premise
control I-Premise
9 I-Premise
. I-Premise
6 I-Premise
to I-Premise
9 I-Premise
. I-Premise
3 I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1 I-Premise
, I-Premise
84 I-Premise
) I-Premise
) I-Premise
= I-Premise
17 I-Premise
. I-Premise
8 I-Premise
, I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
] I-Premise
. I-Premise

Psychological B-Premise
quality I-Premise
of I-Premise
life I-Premise
also I-Premise
improved I-Premise
more I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
from I-Premise
49 I-Premise
. I-Premise
6 I-Premise
to I-Premise
61 I-Premise
. I-Premise
2 I-Premise
vs I-Premise
. I-Premise
50 I-Premise
. I-Premise
1 I-Premise
to I-Premise
51 I-Premise
. I-Premise
5 I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1 I-Premise
, I-Premise
84 I-Premise
) I-Premise
) I-Premise
= I-Premise
10 I-Premise
. I-Premise
9 I-Premise
, I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
] I-Premise
. I-Premise

Laser B-Claim
treatment I-Claim
appeared I-Claim
to I-Claim
reduce I-Claim
the I-Claim
severity I-Claim
of I-Claim
facial I-Claim
hair I-Claim
and I-Claim
time I-Claim
spent I-Claim
on I-Claim
hair I-Claim
removal I-Claim
as I-Claim
well I-Claim
as I-Claim
alleviating I-Claim
depression I-Claim
and I-Claim
anxiety I-Claim
in I-Claim
women I-Claim
with I-Claim
PCOS I-Claim
. I-Claim

These B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
ways I-Claim
of I-Claim
making I-Claim
this I-Claim
method I-Claim
of I-Claim
hair I-Claim
removal I-Claim
more I-Claim
widely I-Claim
available I-Claim
to I-Claim
women I-Claim
with I-Claim
facial I-Claim
hirsutism I-Claim
should I-Claim
be I-Claim
considered I-Claim
. I-Claim

Despite B-Claim
considerable I-Claim
improvement I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
, I-Claim
the I-Claim
optimization I-Claim
of I-Claim
efficacy I-Claim
and I-Claim
tolerability I-Claim
remains I-Claim
an I-Claim
important I-Claim
issue I-Claim
. I-Claim

Therefore O
, O
we O
performed O
a O
randomized O
, O
phase O
III O
non O
- O
inferiority O
trial O
comparing O
paclitaxel O
plus O
cisplatin O
( O
PT O
) O
with O
paclitaxel O
plus O
carboplatin O
( O
TC O
) O
in O
patients O
with O
advanced O
ovarian O
cancer O
. O

A O
total O
of O
798 O
patients O
with O
International O
Federation O
of O
Gynecology O
and O
Obstetrics O
stage O
IIB O
- O
IV O
were O
randomly O
assigned O
to O
receive O
six O
courses O
of O
either O
PT O
or O
TC O
at O
3 O
- O
week O
intervals O
. O

The O
primary O
endpoint O
was O
the O
proportion O
of O
patients O
without O
progression O
at O
2 O
years O
. O

Secondary O
endpoints O
included O
toxicity O
, O
response O
to O
treatment O
, O
quality O
of O
life O
, O
and O
overall O
and O
progression O
- O
free O
survival O
time O
. O

Quality O
of O
life O
was O
evaluated O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
quality O
- O
of O
- O
life O
questionnaire O
( O
QLQ O
) O
- O
C30 O
, O
version O
2 O
. O
0 O
. O

Survival O
curves O
were O
calculated O
using O
the O
Kaplan O
- O
Meier O
method O
, O
and O
hazard O
ratios O
were O
estimated O
using O
the O
Cox O
proportional O
hazards O
model O
. O

The B-Premise
proportion I-Premise
of I-Premise
patients I-Premise
without I-Premise
progression I-Premise
at I-Premise
2 I-Premise
years I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
40 I-Premise
. I-Premise
0 I-Premise
% I-Premise
for I-Premise
PT I-Premise
versus I-Premise
37 I-Premise
. I-Premise
5 I-Premise
% I-Premise
for I-Premise
TC I-Premise
, I-Premise
difference I-Premise
= I-Premise
2 I-Premise
. I-Premise
5 I-Premise
% I-Premise
, I-Premise
one I-Premise
- I-Premise
sided I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
- I-Premise
infinity I-Premise
to I-Premise
8 I-Premise
. I-Premise
2 I-Premise
% I-Premise
) I-Premise
. I-Premise

Median B-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
time I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
17 I-Premise
. I-Premise
2 I-Premise
months I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
15 I-Premise
. I-Premise
2 I-Premise
to I-Premise
19 I-Premise
. I-Premise
3 I-Premise
months I-Premise
) I-Premise
and I-Premise
the I-Premise
PT I-Premise
arm I-Premise
( I-Premise
19 I-Premise
. I-Premise
1 I-Premise
months I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
16 I-Premise
. I-Premise
7 I-Premise
to I-Premise
21 I-Premise
. I-Premise
5 I-Premise
months I-Premise
) I-Premise
were I-Premise
also I-Premise
not I-Premise
statistically I-Premise
significantly I-Premise
different I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
the B-Premise
same I-Premise
was I-Premise
TRUE I-Premise
of I-Premise
median I-Premise
overall I-Premise
survival I-Premise
time I-Premise
( I-Premise
43 I-Premise
. I-Premise
3 I-Premise
months I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
37 I-Premise
. I-Premise
2 I-Premise
to I-Premise
47 I-Premise
. I-Premise
8 I-Premise
months I-Premise
versus I-Premise
44 I-Premise
. I-Premise
1 I-Premise
months I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
40 I-Premise
. I-Premise
2 I-Premise
to I-Premise
49 I-Premise
. I-Premise
4 I-Premise
months I-Premise
, I-Premise
for I-Premise
the I-Premise
TC I-Premise
and I-Premise
PT I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
TC I-Premise
regimen I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
higher I-Premise
frequency I-Premise
of I-Premise
hematologic I-Premise
toxicity I-Premise
, I-Premise
but B-Premise
a I-Premise
lower I-Premise
frequency I-Premise
of I-Premise
gastrointestinal I-Premise
and I-Premise
neurologic I-Premise
toxicity I-Premise
, I-Premise
than I-Premise
the I-Premise
PT I-Premise
regimen I-Premise
. I-Premise

Mean B-Premise
global I-Premise
quality I-Premise
- I-Premise
of I-Premise
- I-Premise
life I-Premise
scores I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
treatment I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
PT I-Premise
arm I-Premise
( I-Premise
65 I-Premise
. I-Premise
25 I-Premise
versus I-Premise
51 I-Premise
. I-Premise
97 I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
difference I-Premise
= I-Premise
- I-Premise
13 I-Premise
. I-Premise
28 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
- I-Premise
18 I-Premise
. I-Premise
88 I-Premise
to I-Premise
- I-Premise
7 I-Premise
. I-Premise
68 I-Premise
) I-Premise
. I-Premise

The B-Claim
TC I-Claim
regimen I-Claim
achieved I-Claim
comparable I-Claim
efficacy I-Claim
to I-Claim
the I-Claim
PT I-Claim
regimen I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
tolerability I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
should I-Claim
, I-Claim
therefore I-Claim
, I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
important I-Claim
alternative I-Claim
for I-Claim
standard I-Claim
first I-Claim
- I-Claim
line I-Claim
chemotherapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
2 O
- O
year O
functional O
performance O
and O
quality O
of O
life O
in O
patients O
with O
operable O
squamous O
cell O
carcinoma O
of O
the O
esophagus O
, O
who O
have O
received O
either O
surgery O
or O
definitive O
chemoradiation O
( O
CRT O
) O
. O

The O
functional O
outcomes O
and O
quality O
of O
life O
in O
patients O
receiving O
esophagectomy O
or O
definitive O
CRT O
is O
uncertain O
. O

Data O
were O
extracted O
from O
the O
database O
of O
a O
prospective O
randomized O
controlled O
trial O
that O
included O
patients O
with O
resectable O
mid O
or O
lower O
thoracic O
esophageal O
cancers O
. O

The O
patients O
were O
randomized O
to O
either O
standard O
esophagectomy O
or O
definitive O
CRT O
. O

Quality O
of O
life O
assessments O
were O
performed O
using O
the O
EORTC O
QLQ O
- O
C30 O
and O
QLQ O
- O
OES24 O
modules O
. O

Other O
functional O
assessments O
included O
pulmonary O
and O
eating O
functions O
. O

From O
July O
2000 O
to O
December O
2004 O
, O
a O
total O
of O
81 O
patients O
were O
enrolled O
into O
the O
study O
. O

No B-Premise
significant I-Premise
longitudinal I-Premise
changes I-Premise
were I-Premise
detected I-Premise
in I-Premise
the I-Premise
global I-Premise
health I-Premise
status I-Premise
in I-Premise
both I-Premise
groups I-Premise
upon I-Premise
available I-Premise
follow I-Premise
- I-Premise
up I-Premise
. I-Premise

Surgery B-Premise
was I-Premise
associated I-Premise
with I-Premise
worsened I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
fatigue I-Premise
symptoms I-Premise
up I-Premise
to I-Premise
6 I-Premise
months I-Premise
after I-Premise
treatment I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
and I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
021 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
and I-Premise
these I-Premise
scales I-Premise
improved I-Premise
at I-Premise
2 I-Premise
years I-Premise
. I-Premise

In B-Premise
terms I-Premise
of I-Premise
pulmonary I-Premise
function I-Premise
, I-Premise
dyspnoic I-Premise
and I-Premise
coughing I-Premise
symptoms I-Premise
were I-Premise
significantly I-Premise
worsened I-Premise
3 I-Premise
months I-Premise
after I-Premise
surgery I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
024 I-Premise
and I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
036 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
whereas I-Premise
symptoms I-Premise
in I-Premise
the I-Premise
CRT I-Premise
group I-Premise
progressively I-Premise
deteriorated I-Premise
over I-Premise
time I-Premise
. I-Premise

Concerning B-Premise
the I-Premise
eating I-Premise
function I-Premise
, I-Premise
both I-Premise
groups I-Premise
had I-Premise
improvements I-Premise
in I-Premise
dysphagia I-Premise
but I-Premise
there I-Premise
were I-Premise
frequent I-Premise
need I-Premise
for I-Premise
endoscopic I-Premise
intervention I-Premise
. I-Premise

Neither B-Premise
surgery I-Premise
nor I-Premise
definitive I-Premise
CRT I-Premise
significantly I-Premise
impaired I-Premise
the I-Premise
global I-Premise
health I-Premise
status I-Premise
of I-Premise
patients I-Premise
. I-Premise

Surgery B-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
short I-Claim
- I-Claim
term I-Claim
negative I-Claim
impact I-Claim
in I-Claim
some I-Claim
aspects I-Claim
of I-Claim
health I-Claim
related I-Claim
quality I-Claim
of I-Claim
life I-Claim
assessments I-Claim
but B-Claim
these I-Claim
changes I-Claim
became I-Claim
insignificant I-Claim
2 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
. I-Claim

However O
, O
CRT B-Claim
was I-Claim
associated I-Claim
with I-Claim
progressive I-Claim
deteriorations I-Claim
in I-Claim
pulmonary I-Claim
function I-Claim
in I-Claim
the I-Claim
longer I-Claim
term I-Claim
. I-Claim

To O
observe O
the O
effect O
of O
TCM O
therapy O
for O
removing O
toxic O
substance O
and O
unblocking O
meridians O
on O
post O
- O
radiation O
quality O
of O
life O
( O
QOF O
) O
in O
55 O
patients O
with O
lung O
cancer O
. O

All O
patients O
were O
randomly O
assigned O
to O
two O
groups O
, O
the O
55 O
patients O
in O
the O
treated O
group O
were O
treated O
with O
radiotherapy O
combined O
with O
the O
TCM O
therapy O
, O
and O
the O
53 O
in O
the O
control O
group O
were O
given O
radiotherapy O
alone O
. O

The O
clinical O
efficacy O
was O
evaluated O
by O
indexes O
including O
KPS O
scores O
, O
QLQ O
- O
C30 O
questionnaire O
, O
LC13 O
specific O
scale O
for O
lung O
cancer O
, O
evaluation O
criteria O
for O
TCM O
efficacy O
, O
the O
6 O
- O
min O
walking O
distance O
, O
and O
body O
weight O
, O
etc O
. O

The B-Premise
KPS I-Premise
score I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
after I-Premise
treatment I-Premise
was I-Premise
improved I-Premise
in I-Premise
13 I-Premise
patients I-Premise
( I-Premise
23 I-Premise
. I-Premise
6 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
27 I-Premise
( I-Premise
49 I-Premise
. I-Premise
6 I-Premise
% I-Premise
) I-Premise
and I-Premise
declined I-Premise
in I-Premise
15 I-Premise
( I-Premise
27 I-Premise
. I-Premise
3 I-Premise
% I-Premise
) I-Premise
, I-Premise
while I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
it I-Premise
was I-Premise
improved I-Premise
in I-Premise
7 I-Premise
( I-Premise
13 I-Premise
. I-Premise
2 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
21 I-Premise
( I-Premise
39 I-Premise
. I-Premise
6 I-Premise
% I-Premise
) I-Premise
and I-Premise
declined I-Premise
in I-Premise
25 I-Premise
( I-Premise
47 I-Premise
. I-Premise
2 I-Premise
% I-Premise
) I-Premise
, I-Premise
the I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
was I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

The B-Premise
results I-Premise
from I-Premise
evaluation I-Premise
with I-Premise
QLQ I-Premise
- I-Premise
C30 I-Premise
questionnaire I-Premise
and I-Premise
LC30 I-Premise
scale I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
was I-Premise
also I-Premise
superior I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
scores I-Premise
of I-Premise
TCM I-Premise
efficacy I-Premise
( I-Premise
24 I-Premise
. I-Premise
52 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
8 I-Premise
. I-Premise
98 I-Premise
vs I-Premise
29 I-Premise
. I-Premise
76 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
7 I-Premise
. I-Premise
09 I-Premise
, I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
and I-Premise
the I-Premise
6 I-Premise
- I-Premise
min I-Premise
walking I-Premise
distance I-Premise
( I-Premise
233 I-Premise
. I-Premise
4 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
29 I-Premise
. I-Premise
2 I-Premise
m I-Premise
vs I-Premise
205 I-Premise
. I-Premise
8 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
31 I-Premise
. I-Premise
9 I-Premise
m I-Premise
, I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
were I-Premise
better I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
. I-Premise

After B-Premise
treatment I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
, I-Premise
the I-Premise
body I-Premise
weight I-Premise
was I-Premise
increased I-Premise
in I-Premise
11 I-Premise
patients I-Premise
( I-Premise
20 I-Premise
. I-Premise
0 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
28 I-Premise
( I-Premise
50 I-Premise
. I-Premise
9 I-Premise
% I-Premise
) I-Premise
and I-Premise
decreased I-Premise
in I-Premise
16 I-Premise
( I-Premise
29 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
, I-Premise
while I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
it I-Premise
was I-Premise
increased I-Premise
in I-Premise
5 I-Premise
( I-Premise
9 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
26 I-Premise
( I-Premise
49 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
and I-Premise
decreased I-Premise
in I-Premise
22 I-Premise
( I-Premise
41 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
, I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
was I-Premise
significant I-Premise
, I-Premise
too I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

TCM B-Claim
therapy I-Claim
for I-Claim
removing I-Claim
toxic I-Claim
substance I-Claim
and I-Claim
unblocking I-Claim
meridians I-Claim
can I-Claim
improve I-Claim
the I-Claim
post I-Claim
- I-Claim
radiation I-Claim
QOL I-Claim
of I-Claim
patients I-Claim
with I-Claim
lung I-Claim
cancer I-Claim
to I-Claim
some I-Claim
extent I-Claim
. I-Claim

The O
AVEREL O
trial O
[ O
A O
Study O
of O
Avastin O
( O
Bevacizumab O
) O
in O
Combination O
With O
Herceptin O
( O
Trastuzumab O
) O
/ O
Docetaxel O
in O
Patients O
With O
HER2 O
- O
Positive O
Metastatic O
Breast O
Cancer O
] O
evaluated O
first O
- O
line O
bevacizumab O
- O
containing O
therapy O
for O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER2 O
) O
- O
positive O
locally O
recurrent O
/ O
metastatic O
breast O
cancer O
( O
LR O
/ O
MBC O
) O
. O

Patients O
with O
measurable O
/ O
evaluable O
HER2 O
- O
positive O
LR O
/ O
MBC O
who O
had O
not O
received O
trastuzumab O
or O
chemotherapy O
for O
LR O
/ O
MBC O
were O
stratified O
by O
prior O
adjuvant O
trastuzumab O
, O
prior O
( O
neo O
) O
adjuvant O
taxane O
, O
hormone O
receptor O
status O
, O
and O
measurable O
disease O
and O
were O
randomly O
assigned O
to O
receive O
docetaxel O
100 O
mg O
/ O
m O
( O
2 O
) O
plus O
trastuzumab O
8 O
mg O
/ O
kg O
loading O
dose O
followed O
by O
6 O
mg O
/ O
kg O
either O
with O
bevacizumab O
15 O
mg O
/ O
kg O
or O
without O
bevacizumab O
, O
all O
administered O
every O
3 O
weeks O
. O

The O
primary O
end O
point O
was O
progression O
- O
free O
survival O
( O
PFS O
) O
. O

Additional O
end O
points O
included O
overall O
survival O
, O
response O
rate O
( O
RR O
) O
, O
safety O
, O
quality O
of O
life O
, O
and O
translational O
research O
. O

Results O
Baseline O
characteristics O
of O
the O
424 O
patients O
were O
balanced O
between O
treatment O
arms O
. O

Most O
patients O
had O
visceral O
metastases O
, O
43 O
% O
had O
a O
disease O
- O
free O
interval O
less O
than O
12 O
months O
, O
and O
85 O
% O
had O
measurable O
disease O
. O

Median O
follow O
- O
up O
was O
26 O
months O
. O

The B-Premise
hazard I-Premise
ratio I-Premise
for I-Premise
investigator I-Premise
- I-Premise
assessed I-Premise
PFS I-Premise
was I-Premise
0 I-Premise
. I-Premise
82 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
65 I-Premise
to I-Premise
1 I-Premise
. I-Premise
02 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
0775 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
median I-Premise
PFS I-Premise
, I-Premise
13 I-Premise
. I-Premise
7 I-Premise
v I-Premise
16 I-Premise
. I-Premise
5 I-Premise
months I-Premise
in I-Premise
the I-Premise
non I-Premise
- I-Premise
bevacizumab I-Premise
and I-Premise
bevacizumab I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
PFS I-Premise
events I-Premise
in I-Premise
72 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
Independent I-Premise
Review I-Premise
Committee I-Premise
- I-Premise
assessed I-Premise
PFS I-Premise
hazard I-Premise
ratio I-Premise
was I-Premise
0 I-Premise
. I-Premise
72 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
54 I-Premise
to I-Premise
0 I-Premise
. I-Premise
94 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
0162 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
median I-Premise
PFS I-Premise
, I-Premise
13 I-Premise
. I-Premise
9 I-Premise
v I-Premise
16 I-Premise
. I-Premise
8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
PFS I-Premise
events I-Premise
in I-Premise
53 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
RR I-Premise
was I-Premise
70 I-Premise
% I-Premise
versus I-Premise
74 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
3492 I-Premise
) I-Premise
. I-Premise

Grade B-Claim
â‰¥ I-Claim
3 I-Claim
febrile I-Claim
neutropenia I-Claim
and I-Claim
hypertension I-Claim
were I-Claim
more I-Claim
common I-Claim
with I-Claim
bevacizumab I-Claim
- I-Claim
containing I-Claim
therapy I-Claim
. I-Claim

High B-Premise
baseline I-Premise
plasma I-Premise
vascular I-Premise
endothelial I-Premise
growth I-Premise
factor I-Premise
A I-Premise
( I-Premise
VEGF I-Premise
- I-Premise
A I-Premise
) I-Premise
concentrations I-Premise
were I-Premise
associated I-Premise
with I-Premise
greater I-Premise
bevacizumab I-Premise
benefit I-Premise
( I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
) I-Premise
. I-Premise

Combining B-Claim
bevacizumab I-Claim
with I-Claim
docetaxel I-Claim
and I-Claim
trastuzumab I-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
investigator I-Claim
- I-Claim
assessed I-Claim
PFS I-Claim
. I-Claim

The O
potential O
predictive O
value O
of O
plasma O
VEGF O
- O
A O
is O
consistent O
with O
findings O
in O
HER2 O
- O
negative O
LR O
/ O
MBC O
, O
warranting O
prospective O
evaluation O
. O

Vinorelbine B-Claim
prolongs I-Claim
survival I-Claim
and I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non I-Claim
- I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

Some B-Claim
studies I-Claim
have I-Claim
also I-Claim
suggested I-Claim
that I-Claim
gemcitabine I-Claim
is I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
effective I-Claim
in I-Claim
such I-Claim
patients I-Claim
. I-Claim

We O
compared O
the O
effectiveness O
and O
toxicity O
of O
the O
combination O
of O
vinorelbine O
plus O
gemcitabine O
with O
those O
of O
each O
drug O
given O
alone O
in O
an O
open O
- O
label O
, O
randomized O
phase O
III O
trial O
in O
elderly O
patients O
with O
advanced O
NSCLC O
. O

Patients O
aged O
70 O
years O
and O
older O
, O
enrolled O
between O
December O
1997 O
and O
November O
2000 O
, O
were O
randomly O
assigned O
to O
receive O
intravenous O
vinorelbine O
( O
30 O
mg O
/ O
m O
( O
2 O
) O
of O
body O
surface O
area O
) O
, O
gemcitabine O
( O
1200 O
mg O
/ O
m O
( O
2 O
) O
) O
, O
or O
vinorelbine O
( O
25 O
mg O
/ O
m O
( O
2 O
) O
) O
plus O
gemcitabine O
( O
1000 O
mg O
/ O
m O
( O
2 O
) O
) O
. O

All O
treatments O
were O
delivered O
on O
days O
1 O
and O
8 O
every O
3 O
weeks O
for O
a O
maximum O
of O
six O
cycles O
. O

The O
primary O
endpoint O
was O
survival O
. O

Survival O
curves O
were O
drawn O
using O
the O
Kaplan O
- O
Meier O
method O
and O
analyzed O
by O
the O
Mantel O
- O
Haenszel O
test O
. O

Secondary O
endpoints O
were O
quality O
of O
life O
and O
toxicity O
. O

Of O
698 O
patients O
available O
for O
intention O
- O
to O
- O
treat O
analysis O
, O
233 O
were O
assigned O
to O
receive O
vinorelbine O
, O
233 O
to O
gemcitabine O
, O
and O
232 O
to O
vinorelbine O
plus O
gemcitabine O
. O

Compared B-Premise
with I-Premise
each I-Premise
single I-Premise
drug I-Premise
, I-Premise
the I-Premise
combination I-Premise
treatment I-Premise
did I-Premise
not I-Premise
improve I-Premise
survival I-Premise
. I-Premise

The B-Premise
hazard I-Premise
ratio I-Premise
of I-Premise
death I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
the I-Premise
combination I-Premise
treatment I-Premise
was I-Premise
1 I-Premise
. I-Premise
17 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0 I-Premise
. I-Premise
95 I-Premise
to I-Premise
1 I-Premise
. I-Premise
44 I-Premise
) I-Premise
that I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
vinorelbine I-Premise
and I-Premise
1 I-Premise
. I-Premise
06 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0 I-Premise
. I-Premise
86 I-Premise
to I-Premise
1 I-Premise
. I-Premise
29 I-Premise
) I-Premise
that I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
gemcitabine I-Premise
. I-Premise

Although B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
similar I-Premise
across I-Premise
the I-Premise
three I-Premise
treatment I-Premise
arms I-Premise
, I-Premise
the B-Premise
combination I-Premise
treatment I-Premise
was I-Premise
more I-Premise
toxic I-Premise
than I-Premise
the I-Premise
two I-Premise
drugs I-Premise
given I-Premise
singly I-Premise
. I-Premise

The B-Claim
combination I-Claim
of I-Claim
vinorelbine I-Claim
plus I-Claim
gemcitabine I-Claim
is I-Claim
not I-Claim
more I-Claim
effective I-Claim
than I-Claim
single I-Claim
- I-Claim
agent I-Claim
vinorelbine I-Claim
or I-Claim
gemcitabine I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

To O
evaluate O
the O
efficacy O
of O
a O
psychoeducational O
intervention O
in O
improving O
cancer O
- O
related O
fatigue O
. O

This O
randomized O
controlled O
trial O
involved O
109 O
women O
commencing O
adjuvant O
chemotherapy O
for O
stage O
I O
or O
II O
breast O
cancer O
in O
five O
chemotherapy O
treatment O
centers O
. O

Intervention O
group O
patients O
received O
an O
individualized O
fatigue O
education O
and O
support O
program O
delivered O
in O
the O
clinic O
and O
by O
phone O
over O
three O
- O
10 O
to O
20 O
- O
minute O
sessions O
1 O
week O
apart O
. O

Instruments O
included O
a O
numeric O
rating O
scale O
assessing O
confidence O
with O
managing O
fatigue O
"""" O
; O
"""" O
11 O
- O
point O
numeric O
rating O
scales O
measuring O
fatigue O
at O
worst O
, O
average O
, O
and O
best O
"""" O
; O
"""" O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
- O
Fatigue O
and O
Piper O
Fatigue O
Scales O
"""" O
; O
"""" O
the O
Cancer O
Self O
- O
Efficacy O
Scale O
"""" O
; O
"""" O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
"""" O
; O
"""" O
and O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
. O

For O
each O
outcome O
, O
separate O
analyses O
of O
covariance O
of O
change O
scores O
between O
baseline O
( O
T1 O
) O
and O
the O
three O
follow O
- O
up O
time O
points O
( O
T2 O
, O
T3 O
, O
and O
T4 O
) O
were O
conducted O
, O
controlling O
for O
the O
variable O
' O
s O
corresponding O
baseline O
value O
. O

Compared B-Premise
with I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
mean I-Premise
difference I-Premise
scores I-Premise
between I-Premise
the I-Premise
baseline I-Premise
( I-Premise
T1 I-Premise
) I-Premise
and I-Premise
immediate I-Premise
after I-Premise
the I-Premise
test I-Premise
( I-Premise
T2 I-Premise
) I-Premise
assessments I-Premise
increased I-Premise
significantly I-Premise
more I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
for I-Premise
worst I-Premise
and I-Premise
average I-Premise
fatigue I-Premise
, I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy I-Premise
- I-Premise
Fatigue I-Premise
, I-Premise
and I-Premise
Piper I-Premise
fatigue I-Premise
severity I-Premise
and I-Premise
interference I-Premise
measures I-Premise
. I-Premise

These B-Premise
differences I-Premise
were I-Premise
not I-Premise
observed I-Premise
between I-Premise
baseline I-Premise
and I-Premise
T3 I-Premise
and I-Premise
T4 I-Premise
assessments I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
identified I-Premise
for I-Premise
any I-Premise
pre I-Premise
- I-Premise
or I-Premise
post I-Premise
- I-Premise
test I-Premise
change I-Premise
scores I-Premise
for I-Premise
confidence I-Premise
with I-Premise
managing I-Premise
fatigue I-Premise
, I-Premise
cancer I-Premise
self I-Premise
- I-Premise
efficacy I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
or I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Preparatory B-Claim
education I-Claim
and I-Claim
support I-Claim
has I-Claim
the I-Claim
potential I-Claim
to I-Claim
assist I-Claim
women I-Claim
to I-Claim
cope I-Claim
with I-Claim
cancer I-Claim
- I-Claim
related I-Claim
fatigue I-Claim
in I-Claim
the I-Claim
short I-Claim
term I-Claim
. I-Claim

However B-Claim
, I-Claim
further I-Claim
research I-Claim
is I-Claim
needed I-Claim
to I-Claim
identify I-Claim
ways I-Claim
to I-Claim
improve I-Claim
the I-Claim
potency I-Claim
and I-Claim
sustainability I-Claim
of I-Claim
psychoeducational I-Claim
interventions I-Claim
for I-Claim
managing I-Claim
cancer I-Claim
- I-Claim
related I-Claim
fatigue I-Claim
. I-Claim

To O
evaluate O
the O
incidence O
and O
temporal O
resolution O
of O
dysuria O
after O
permanent O
prostate O
brachytherapy O
, O
and O
to O
identify O
predictors O
of O
brachytherapy O
- O
related O
dysuria O
. O

The O
study O
included O
130 O
patients O
with O
no O
history O
of O
transurethral O
resection O
of O
the O
prostate O
before O
treatment O
, O
who O
had O
brachytherapy O
on O
one O
of O
two O
prospective O
randomized O
trials O
, O
with O
explicitly O
planned O
and O
executed O
urethral O
- O
sparing O
techniques O
( O
100 O
- O
150 O
% O
minimum O
peripheral O
dose O
) O
using O
either O
103Pd O
or O
125I O
for O
clinical O
T1c O
- O
T2c O
prostate O
cancer O
. O

The O
median O
follow O
- O
up O
was O
22 O
. O
6 O
months O
. O

An O
alpha O
- O
blocker O
was O
initiated O
either O
prophylactically O
2 O
weeks O
before O
implantation O
and O
continued O
at O
least O
until O
the O
International O
Prostate O
Symptom O
Score O
( O
IPSS O
) O
returned O
to O
normal O
, O
or O
withheld O
until O
the O
onset O
of O
significant O
brachytherapy O
- O
related O
urinary O
morbidity O
. O

Dysuria O
was O
evaluated O
on O
a O
0 O
- O
10 O
scale O
, O
before O
brachytherapy O
and O
then O
at O
1 O
, O
3 O
, O
6 O
and O
12 O
months O
afterward O
, O
with O
a O
median O
of O
four O
dysuria O
questionnaires O
per O
patient O
. O

Clinical O
, O
treatment O
and O
dosimetric O
variables O
evaluated O
included O
alpha O
- O
blocker O
, O
age O
, O
IPSS O
before O
and O
the O
maximum O
after O
treatment O
, O
prostate O
volume O
on O
ultrasonography O
, O
hormonal O
status O
, O
supplemental O
radiotherapy O
, O
isotope O
, O
urethral O
dose O
, O
V O
( O
100 O
/ O
200 O
) O
, O
D90 O
, O
and O
time O
to O
obtaining O
a O
normal O
IPSS O
. O

The O
maximum O
incidence O
of O
dysuria O
was O
85 O
% O
at O
1 O
month O
after O
brachytherapy O
, O
with O
subsequent O
resolution O
over O
time O
. O

The B-Premise
use I-Premise
of I-Premise
prophylactic I-Premise
tamsulosin I-Premise
resulted I-Premise
in I-Premise
a I-Premise
statistically I-Premise
lower I-Premise
dysuria I-Premise
severity I-Premise
score I-Premise
( I-Premise
difference I-Premise
of I-Premise
2 I-Premise
. I-Premise
7 I-Premise
vs I-Premise
4 I-Premise
. I-Premise
2 I-Premise
, I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
005 I-Premise
) I-Premise
at I-Premise
1 I-Premise
month I-Premise
, I-Premise
with I-Premise
no I-Premise
discernible I-Premise
differences I-Premise
at I-Premise
3 I-Premise
, I-Premise
6 I-Premise
, I-Premise
12 I-Premise
and I-Premise
18 I-Premise
months I-Premise
. I-Premise

Patients B-Premise
with I-Premise
dysuria I-Premise
had I-Premise
a I-Premise
statistically I-Premise
higher I-Premise
IPSS I-Premise
. I-Premise

The B-Premise
dysuria I-Premise
resolved I-Premise
faster I-Premise
in I-Premise
patients I-Premise
implanted I-Premise
with I-Premise
103Pd I-Premise
but B-Premise
was I-Premise
unaffected I-Premise
by I-Premise
the I-Premise
use I-Premise
of I-Premise
supplemental I-Premise
radiotherapy I-Premise
and I-Premise
/ I-Premise
or I-Premise
androgen I-Premise
deprivation I-Premise
therapy I-Premise
. I-Premise

In B-Premise
multivariate I-Premise
analysis I-Premise
, I-Premise
prophylactic I-Premise
alpha I-Premise
- I-Premise
blockers I-Premise
resulted I-Premise
in I-Premise
statistically I-Premise
lower I-Premise
maximum I-Premise
dysuria I-Premise
scores I-Premise
, I-Premise
while B-Premise
the I-Premise
maximum I-Premise
IPSS I-Premise
after I-Premise
implantation I-Premise
and I-Premise
isotope I-Premise
type I-Premise
( I-Premise
but I-Premise
only I-Premise
at I-Premise
6 I-Premise
months I-Premise
) I-Premise
were I-Premise
the I-Premise
best I-Premise
predictors I-Premise
of I-Premise
the I-Premise
resolution I-Premise
of I-Premise
dysuria I-Premise
. I-Premise

Dysuria B-Claim
is I-Claim
common I-Claim
after I-Claim
brachytherapy I-Claim
but I-Claim
is I-Claim
typically I-Claim
mild I-Claim
. I-Claim

Prophylactic B-Claim
alpha I-Claim
- I-Claim
blockers I-Claim
gave I-Claim
significantly I-Claim
lower I-Claim
maximum I-Claim
dysuria I-Claim
scores I-Claim
but B-Claim
did I-Claim
not I-Claim
affect I-Claim
the I-Claim
time I-Claim
to I-Claim
the I-Claim
resolution I-Claim
of I-Claim
dysuria I-Claim
. I-Claim

The B-Claim
maximum I-Claim
IPSS I-Claim
after I-Claim
the I-Claim
implant I-Claim
was I-Claim
the I-Claim
best I-Claim
predictor I-Claim
of I-Claim
the I-Claim
resolution I-Claim
of I-Claim
dysuria I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
bevacizumab I-Claim
to I-Claim
paclitaxel I-Claim
improved I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
( I-Claim
PFS I-Claim
) I-Claim
of I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
breast I-Claim
cancer I-Claim
( I-Claim
MBC I-Claim
) I-Claim
. I-Claim

We O
examined O
the O
efficacy O
and O
safety O
of O
adding O
gemcitabine O
to O
paclitaxel O
/ O
bevacizumab O
( O
PB O
) O
. O

In O
this O
multicenter O
, O
open O
- O
label O
, O
randomized O
phase O
II O
trial O
, O
women O
with O
locally O
advanced O
or O
MBC O
were O
randomly O
assigned O
to O
receive O
paclitaxel O
90 O
mg O
/ O
m O
( O
2 O
) O
( O
days O
1 O
, O
8 O
, O
15 O
) O
and O
bevacizumab O
10 O
mg O
/ O
kg O
( O
days O
1 O
, O
15 O
) O
with O
or O
without O
gemcitabine O
1500 O
mg O
/ O
m O
( O
2 O
) O
( O
days O
1 O
, O
15 O
) O
in O
28 O
- O
day O
cycles O
. O

Patients O
with O
prior O
cytotoxic O
therapy O
for O
MBC O
were O
ineligible O
. O

The O
primary O
endpoint O
was O
investigator O
- O
assessed O
overall O
response O
rate O
( O
ORR O
) O
"""" O
; O
"""" O
secondary O
endpoints O
were O
PFS O
, O
overall O
survival O
( O
OS O
) O
, O
safety O
, O
and O
quality O
of O
life O
. O

Ninety O
- O
four O
patients O
received O
PB O
, O
and O
93 O
received O
paclitaxel O
/ O
bevacizumab O
/ O
gemcitabine O
( O
PB O
+ O
G O
) O
. O

The B-Premise
ORRs I-Premise
were I-Premise
48 I-Premise
. I-Premise
9 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
38 I-Premise
. I-Premise
5 I-Premise
% I-Premise
- I-Premise
59 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
and I-Premise
58 I-Premise
. I-Premise
7 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
47 I-Premise
. I-Premise
9 I-Premise
% I-Premise
- I-Premise
68 I-Premise
. I-Premise
9 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
117 I-Premise
) I-Premise
with I-Premise
PB I-Premise
and I-Premise
PB I-Premise
+ I-Premise
G I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
median I-Premise
PFS I-Premise
was I-Premise
8 I-Premise
. I-Premise
8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
8 I-Premise
. I-Premise
1 I-Premise
- I-Premise
10 I-Premise
. I-Premise
4 I-Premise
months I-Premise
) I-Premise
and I-Premise
11 I-Premise
. I-Premise
3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
9 I-Premise
. I-Premise
7 I-Premise
- I-Premise
12 I-Premise
. I-Premise
7 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
247 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0 I-Premise
. I-Premise
82 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
the I-Premise
median I-Premise
OS I-Premise
was I-Premise
25 I-Premise
. I-Premise
0 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
18 I-Premise
. I-Premise
8 I-Premise
- I-Premise
not I-Premise
assessable I-Premise
[ I-Premise
N I-Premise
/ I-Premise
A I-Premise
] I-Premise
months I-Premise
) I-Premise
and I-Premise
24 I-Premise
. I-Premise
3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
20 I-Premise
. I-Premise
3 I-Premise
- I-Premise
N I-Premise
/ I-Premise
A I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
475 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0 I-Premise
. I-Premise
84 I-Premise
) I-Premise
, I-Premise
with I-Premise
PB I-Premise
and I-Premise
PB I-Premise
+ I-Premise
G I-Premise
, I-Premise
respectively I-Premise
. I-Premise

There B-Premise
was I-Premise
significantly I-Premise
more I-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
neutropenia I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
dyspnea I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
014 I-Premise
) I-Premise
with I-Premise
PB I-Premise
+ I-Premise
G I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
PB I-Premise
experienced I-Premise
more I-Premise
improvement I-Premise
in I-Premise
total I-Premise
FACT I-Premise
- I-Premise
B I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy I-Premise
- I-Premise
Breast I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
021 I-Premise
) I-Premise
, I-Premise
FACT I-Premise
- I-Premise
B I-Premise
Social I-Premise
/ I-Premise
Family I-Premise
Well I-Premise
- I-Premise
being I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
041 I-Premise
) I-Premise
, I-Premise
and I-Premise
Breast I-Premise
Cancer I-Premise
- I-Premise
Additional I-Premise
Concerns I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
008 I-Premise
) I-Premise
scores I-Premise
than I-Premise
patients I-Premise
treated I-Premise
with I-Premise
PB I-Premise
+ I-Premise
G I-Premise
. I-Premise

The B-Claim
addition I-Claim
of I-Claim
gemcitabine I-Claim
to I-Claim
PB I-Claim
was I-Claim
not I-Claim
associated I-Claim
with I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
ORR I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
PB I-Claim
+ I-Claim
G I-Claim
increased I-Claim
the I-Claim
incidence I-Claim
of I-Claim
severe I-Claim
neutropenia I-Claim
and I-Claim
dyspnea I-Claim
, I-Claim
although B-Claim
the I-Claim
regimen I-Claim
generally I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

Maintenance O
therapy O
, O
commenced O
immediately O
after O
the O
completion O
of O
first O
- O
line O
chemotherapy O
, O
is O
a O
promising O
strategy O
for O
improving O
treatment O
outcomes O
in O
patients O
with O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
NSCLC O
) O
. O

The O
global O
phase O
III O
SequentiAl O
Tarceva O
in O
UnResectable O
NSCLC O
( O
SATURN O
) O
study O
evaluated O
the O
efficacy O
and O
safety O
of O
the O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
tyrosine O
- O
kinase O
inhibitor O
erlotinib O
as O
maintenance O
treatment O
in O
NSCLC O
patients O
without O
progression O
after O
first O
- O
line O
chemotherapy O
. O

We O
report O
a O
retrospective O
subanalysis O
of O
Asian O
patients O
enrolled O
in O
SATURN O
. O

Patients O
with O
advanced O
NSCLC O
with O
no O
evidence O
of O
progression O
after O
four O
cycles O
of O
chemotherapy O
were O
randomized O
to O
receive O
erlotinib O
150 O
mg O
/ O
day O
or O
placebo O
, O
until O
progressive O
disease O
or O
limiting O
toxicity O
. O

The O
co O
- O
primary O
endpoints O
of O
SATURN O
were O
progression O
- O
free O
survival O
( O
PFS O
) O
in O
all O
patients O
and O
in O
those O
with O
positive O
EGFR O
immunohistochemistry O
( O
IHC O
) O
status O
. O

Secondary O
endpoints O
included O
overall O
survival O
( O
OS O
) O
, O
disease O
control O
rate O
, O
safety O
, O
quality O
of O
life O
( O
QoL O
) O
and O
biomarker O
analyses O
. O

In O
total O
, O
126 O
patients O
from O
East O
and O
South O
- O
East O
Asian O
centers O
were O
randomized O
( O
14 O
% O
of O
the O
intent O
- O
to O
- O
treat O
population O
) O
: O
88 O
from O
Korea O
, O
28 O
from O
China O
and O
10 O
from O
Malaysia O
"""" O
; O
"""" O
one O
patient O
was O
excluded O
from O
this O
analysis O
due O
to O
Indian O
ethnicity O
. O

PFS B-Premise
was I-Premise
significantly I-Premise
prolonged I-Premise
in I-Premise
the I-Premise
erlotinib I-Premise
treatment I-Premise
arm I-Premise
, I-Premise
both I-Premise
overall I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
: I-Premise
0 I-Premise
. I-Premise
57 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0067 I-Premise
) I-Premise
and I-Premise
in I-Premise
patients I-Premise
with I-Premise
EGFR I-Premise
IHC I-Premise
- I-Premise
positive I-Premise
disease I-Premise
( I-Premise
HR I-Premise
= I-Premise
0 I-Premise
. I-Premise
50 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0057 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
trend I-Premise
towards I-Premise
an I-Premise
increase I-Premise
in I-Premise
OS I-Premise
, I-Premise
which I-Premise
reached I-Premise
statistical I-Premise
significance I-Premise
in I-Premise
the I-Premise
EGFR I-Premise
IHC I-Premise
- I-Premise
positive I-Premise
subgroup I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0233 I-Premise
) I-Premise
. I-Premise

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
with I-Premise
erlotinib I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
24 I-Premise
% I-Premise
versus I-Premise
5 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0025 I-Premise
) I-Premise
. I-Premise

Erlotinib B-Claim
was I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
had I-Claim
no I-Claim
negative I-Claim
impact I-Claim
on I-Claim
QoL I-Claim
in I-Claim
this I-Claim
subpopulation I-Claim
. I-Claim

The B-Premise
most I-Premise
common I-Premise
treatment I-Premise
- I-Premise
related I-Premise
adverse I-Premise
events I-Premise
were I-Premise
rash I-Premise
, I-Premise
diarrhea I-Premise
and I-Premise
pruritus I-Premise
. I-Premise

Erlotinib B-Claim
was I-Claim
effective I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
in I-Claim
Asian I-Claim
patients I-Claim
, I-Claim
producing I-Claim
benefits I-Claim
consistent I-Claim
with I-Claim
those I-Claim
observed I-Claim
in I-Claim
the I-Claim
overall I-Claim
SATURN I-Claim
population I-Claim
. I-Claim

Maintenance B-Claim
treatment I-Claim
with I-Claim
erlotinib I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
useful I-Claim
option I-Claim
for I-Claim
the I-Claim
management I-Claim
of I-Claim
Asian I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
without I-Claim
progression I-Claim
after I-Claim
first I-Claim
- I-Claim
line I-Claim
chemotherapy I-Claim
. I-Claim

To O
evaluate O
the O
safety O
and O
efficacy O
of O
abatacept O
during O
2 O
years O
of O
the O
ATTAIN O
( O
Abatacept O
Trial O
in O
Treatment O
of O
Anti O
- O
TNF O
INadequate O
responders O
) O
trial O
in O
patients O
with O
rheumatoid O
arthritis O
. O

Patients O
completing O
the O
6 O
- O
month O
, O
double O
- O
blind O
period O
were O
eligible O
to O
enter O
the O
long O
- O
term O
extension O
"""" O
; O
"""" O
patients O
received O
abatacept O
approximately O
10 O
mg O
/ O
kg O
, O
plus O
disease O
- O
modifying O
antirheumatic O
drugs O
. O

Safety O
and O
efficacy O
( O
American O
College O
of O
Rheumatology O
( O
ACR O
) O
criteria O
responses O
, O
DAS28 O
( O
C O
- O
reactive O
protein O
) O
, O
HAQ O
- O
DI O
, O
SF O
- O
36 O
, O
Medical O
Outcomes O
Study O
Sleep O
Problems O
Index O
, O
fatigue O
VAS O
) O
were O
assessed O
through O
2 O
years O
. O

317 O
patients O
( O
218 O
from O
the O
abatacept O
and O
99 O
from O
the O
placebo O
group O
) O
entered O
and O
222 O
( O
70 O
% O
) O
completed O
18 O
months O
of O
long O
- O
term O
extension O
treatment O
. O

The B-Premise
incidence I-Premise
and I-Premise
type I-Premise
of I-Premise
adverse I-Premise
events I-Premise
were I-Premise
consistent I-Premise
between I-Premise
the I-Premise
double I-Premise
- I-Premise
blind I-Premise
and I-Premise
cumulative I-Premise
( I-Premise
double I-Premise
- I-Premise
blind I-Premise
plus I-Premise
long I-Premise
- I-Premise
term I-Premise
extension I-Premise
) I-Premise
periods I-Premise
. I-Premise

Rates B-Premise
of I-Premise
serious I-Premise
adverse I-Premise
events I-Premise
were I-Premise
25 I-Premise
. I-Premise
6 I-Premise
and I-Premise
23 I-Premise
. I-Premise
4 I-Premise
per I-Premise
100 I-Premise
patient I-Premise
- I-Premise
years I-Premise
in I-Premise
the I-Premise
double I-Premise
- I-Premise
blind I-Premise
versus I-Premise
cumulative I-Premise
period I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
and I-Premise
2 I-Premise
years I-Premise
, I-Premise
using I-Premise
non I-Premise
- I-Premise
responder I-Premise
analyses I-Premise
, I-Premise
ACR I-Premise
responses I-Premise
in I-Premise
abatacept I-Premise
- I-Premise
treated I-Premise
patients I-Premise
were I-Premise
: I-Premise
ACR I-Premise
20 I-Premise
, I-Premise
59 I-Premise
. I-Premise
4 I-Premise
% I-Premise
and I-Premise
56 I-Premise
. I-Premise
2 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
ACR I-Premise
50 I-Premise
, I-Premise
23 I-Premise
. I-Premise
5 I-Premise
% I-Premise
and I-Premise
33 I-Premise
. I-Premise
2 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
ACR I-Premise
70 I-Premise
, I-Premise
11 I-Premise
. I-Premise
5 I-Premise
% I-Premise
and I-Premise
16 I-Premise
. I-Premise
1 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
HAQ I-Premise
- I-Premise
DI I-Premise
responses I-Premise
were I-Premise
54 I-Premise
. I-Premise
4 I-Premise
% I-Premise
and I-Premise
47 I-Premise
. I-Premise
9 I-Premise
% I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
and I-Premise
2 I-Premise
years I-Premise
, I-Premise
using I-Premise
post I-Premise
- I-Premise
hoc I-Premise
as I-Premise
- I-Premise
observed I-Premise
analyses I-Premise
, I-Premise
the I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
) I-Premise
achieving I-Premise
DAS28 I-Premise
( I-Premise
C I-Premise
- I-Premise
reactive I-Premise
protein I-Premise
) I-Premise
low I-Premise
disease I-Premise
activity I-Premise
score I-Premise
( I-Premise
< I-Premise
or I-Premise
= I-Premise
3 I-Premise
. I-Premise
2 I-Premise
) I-Premise
and I-Premise
DAS28 I-Premise
( I-Premise
C I-Premise
- I-Premise
reactive I-Premise
protein I-Premise
) I-Premise
- I-Premise
defined I-Premise
remission I-Premise
( I-Premise
< I-Premise
2 I-Premise
. I-Premise
6 I-Premise
) I-Premise
increased I-Premise
from I-Premise
18 I-Premise
. I-Premise
3 I-Premise
% I-Premise
( I-Premise
13 I-Premise
. I-Premise
0 I-Premise
, I-Premise
23 I-Premise
. I-Premise
5 I-Premise
) I-Premise
to I-Premise
32 I-Premise
. I-Premise
0 I-Premise
% I-Premise
( I-Premise
24 I-Premise
. I-Premise
6 I-Premise
, I-Premise
39 I-Premise
. I-Premise
4 I-Premise
) I-Premise
and I-Premise
11 I-Premise
. I-Premise
1 I-Premise
% I-Premise
( I-Premise
6 I-Premise
. I-Premise
8 I-Premise
, I-Premise
15 I-Premise
. I-Premise
3 I-Premise
) I-Premise
to I-Premise
20 I-Premise
. I-Premise
3 I-Premise
% I-Premise
( I-Premise
13 I-Premise
. I-Premise
9 I-Premise
, I-Premise
26 I-Premise
. I-Premise
6 I-Premise
) I-Premise
. I-Premise

Clinically B-Premise
meaningful I-Premise
improvements I-Premise
in I-Premise
SF I-Premise
- I-Premise
36 I-Premise
, I-Premise
pain I-Premise
, I-Premise
fatigue I-Premise
and I-Premise
sleep I-Premise
problems I-Premise
were I-Premise
also I-Premise
maintained I-Premise
throughout I-Premise
the I-Premise
2 I-Premise
years I-Premise
of I-Premise
abatacept I-Premise
treatment I-Premise
. I-Premise

No B-Premise
unique I-Premise
safety I-Premise
observations I-Premise
were I-Premise
reported I-Premise
during I-Premise
open I-Premise
- I-Premise
label I-Premise
exposure I-Premise
. I-Premise

Improvements B-Premise
in I-Premise
the I-Premise
signs I-Premise
and I-Premise
symptoms I-Premise
of I-Premise
rheumatoid I-Premise
arthritis I-Premise
, I-Premise
physical I-Premise
function I-Premise
and I-Premise
health I-Premise
- I-Premise
related I-Premise
quality I-Premise
of I-Premise
life I-Premise
observed I-Premise
after I-Premise
6 I-Premise
months I-Premise
, I-Premise
were I-Premise
maintained I-Premise
throughout I-Premise
the I-Premise
2 I-Premise
years I-Premise
in I-Premise
this I-Premise
population I-Premise
with I-Premise
difficult I-Premise
- I-Premise
to I-Premise
- I-Premise
treat I-Premise
disease I-Premise
. I-Premise

Gemcitabine O
for O
advanced O
pancreatic O
cancer O
( O
APC O
) O
is O
palliative O
and O
the O
prognosis O
is O
poor O
, O
making O
health O
- O
related O
quality O
of O
life O
( O
HRQOL O
) O
particularly O
important O
. O

We O
evaluated O
HRQOL O
with O
the O
EuroQol O
( O
EQ O
- O
5Dâ„¢ O
) O
in O
patients O
with O
APC O
participating O
in O
Cancer O
and O
Leukemia O
Group O
B O
80303 O
, O
a O
multicenter O
, O
double O
- O
blind O
, O
randomized O
trial O
comparing O
overall O
survival O
( O
OS O
) O
between O
two O
treatment O
arms O
: O
gemcitabine O
with O
bevacizumab O
or O
gemcitabine O
with O
placebo O
. O

A O
consecutive O
subsample O
of O
patients O
was O
invited O
to O
complete O
the O
EQ O
- O
5D O
surveys O
. O

Because O
neither O
clinical O
nor O
HRQOL O
outcomes O
differed O
based O
on O
the O
study O
arm O
, O
analyses O
were O
pooled O
. O

Changes O
in O
mean O
scores O
from O
baseline O
to O
eight O
weeks O
and O
the O
prognostic O
value O
of O
the O
EQ O
- O
5D O
were O
evaluated O
. O

Mean B-Premise
index I-Premise
scores I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0 I-Premise
. I-Premise
78 I-Premise
at I-Premise
baseline I-Premise
[ I-Premise
n I-Premise
= I-Premise
267 I-Premise
] I-Premise
, I-Premise
0 I-Premise
. I-Premise
79 I-Premise
at I-Premise
eight I-Premise
weeks I-Premise
[ I-Premise
n I-Premise
= I-Premise
186 I-Premise
] I-Premise
, I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
34 I-Premise
, I-Premise
Wilcoxon I-Premise
signed I-Premise
rank I-Premise
test I-Premise
) I-Premise
, I-Premise
attributable I-Premise
to I-Premise
a I-Premise
modest I-Premise
deterioration I-Premise
of I-Premise
physical I-Premise
function I-Premise
domain I-Premise
scores I-Premise
coincident I-Premise
with I-Premise
small I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
and I-Premise
anxiety I-Premise
/ I-Premise
depression I-Premise
scores I-Premise
. I-Premise

A B-Premise
small I-Premise
decline I-Premise
in I-Premise
visual I-Premise
analogue I-Premise
scale I-Premise
scores I-Premise
was I-Premise
observed I-Premise
( I-Premise
70 I-Premise
. I-Premise
7 I-Premise
vs I-Premise
. I-Premise
68 I-Premise
. I-Premise
2 I-Premise
, I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
026 I-Premise
) I-Premise
. I-Premise

HRQOL B-Premise
changes I-Premise
within I-Premise
chemotherapy I-Premise
response I-Premise
strata I-Premise
revealed I-Premise
stable I-Premise
index I-Premise
scores I-Premise
but B-Premise
a I-Premise
trend I-Premise
of I-Premise
worsened I-Premise
physical I-Premise
function I-Premise
among I-Premise
patients I-Premise
with I-Premise
disease I-Premise
progression I-Premise
compared I-Premise
with I-Premise
those I-Premise
with I-Premise
stable I-Premise
or I-Premise
improved I-Premise
disease I-Premise
. I-Premise

Visual B-Premise
analogue I-Premise
scale I-Premise
scores I-Premise
trended I-Premise
downward I-Premise
over I-Premise
time I-Premise
irrespective I-Premise
of I-Premise
chemotherapy I-Premise
response I-Premise
status I-Premise
, I-Premise
with I-Premise
a I-Premise
statistically I-Premise
meaningful I-Premise
deterioration I-Premise
in I-Premise
patients I-Premise
who I-Premise
progressed I-Premise
( I-Premise
68 I-Premise
. I-Premise
9 I-Premise
vs I-Premise
. I-Premise
64 I-Premise
. I-Premise
4 I-Premise
, I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
029 I-Premise
) I-Premise
. I-Premise

Baseline O
scores O
from O
both O
EQ O
- O
5D O
scales O
were O
significant O
predictors O
of O
OS O
in O
Cox O
proportional O
hazard O
models O
. O

Response B-Claim
to I-Claim
gemcitabine I-Claim
treatment I-Claim
in I-Claim
APC I-Claim
is I-Claim
not I-Claim
associated I-Claim
with I-Claim
appreciable I-Claim
improvement I-Claim
of I-Claim
global I-Claim
HRQOL I-Claim
. I-Claim

Small O
improvements O
in O
pain O
and O
mood O
are O
observed O
despite O
progressive O
functional O
decline O
. O

Those B-Claim
who I-Claim
respond I-Claim
to I-Claim
gemcitabine I-Claim
may I-Claim
experience I-Claim
a I-Claim
slight I-Claim
slowing I-Claim
of I-Claim
functional I-Claim
deterioration I-Claim
. I-Claim

Bone O
- O
cancer O
pain O
is O
a O
common O
and O
refractory O
cancer O
pain O
. O

Opioids O
, O
on O
their O
own O
, O
do O
not O
control O
this O
type O
of O
pain O
well O
enough O
, O
and O
co O
- O
analgesics O
are O
necessary O
. O

Patients O
with O
bone O
metastasis O
- O
related O
pain O
at O
Numeric O
Rating O
Scale O
â‰¥4 O
were O
enrolled O
to O
this O
randomized O
placebo O
- O
controlled O
trial O
. O

They O
had O
also O
received O
morphine O
or O
transdermal O
fentanyl O
patches O
for O
at O
least O
1 O
week O
. O

During O
the O
3 O
- O
day O
efficacy O
phase O
, O
patients O
received O
placebo O
or O
1 O
- O
3 O
tablets O
of O
oxycodone O
/ O
paracetamol O
( O
5 O
/ O
325 O
mg O
) O
, O
four O
times O
daily O
for O
3 O
days O
. O

All O
patients O
kept O
a O
daily O
pain O
diary O
. O

The O
primary O
endpoint O
was O
the O
Pain O
Intensity O
Difference O
( O
PID O
) O
. O

Secondary O
endpoints O
were O
cases O
of O
breakthrough O
pain O
and O
rescue O
morphine O
consumption O
. O

Additional O
analyses O
included O
the O
Short O
Form O
- O
6 O
Dimensions O
( O
SF O
- O
6D O
) O
quality O
- O
of O
- O
life O
scale O
and O
a O
general O
impression O
( O
GI O
) O
of O
patient O
satisfaction O
with O
treatment O
at O
the O
end O
of O
the O
phase O
. O

Of O
the O
246 O
patients O
in O
the O
intent O
- O
to O
- O
treat O
set O
, O
89 O
Â· O
4 O
% O
completed O
the O
3 O
- O
day O
efficacy O
phase O
. O

PIDs B-Premise
were I-Premise
0 I-Premise
Â· I-Premise
9 I-Premise
and I-Premise
0 I-Premise
Â· I-Premise
3 I-Premise
in I-Premise
the I-Premise
oxycodone I-Premise
/ I-Premise
paracetamol I-Premise
and I-Premise
placebo I-Premise
groups I-Premise
respectively I-Premise
, I-Premise
on I-Premise
day I-Premise
1 I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
Â· I-Premise
001 I-Premise
) I-Premise
, I-Premise
and I-Premise
1 I-Premise
Â· I-Premise
5 I-Premise
and I-Premise
0 I-Premise
Â· I-Premise
3 I-Premise
respectively I-Premise
on I-Premise
day I-Premise
3 I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
Â· I-Premise
001 I-Premise
) I-Premise
. I-Premise

Thirty B-Premise
- B-Premise
eight B-Premise
patients I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
and I-Premise
58 I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
, I-Premise
suffered I-Premise
breakthrough I-Premise
pain I-Premise
on I-Premise
day I-Premise
3 I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
Â· I-Premise
001 I-Premise
) I-Premise
. I-Premise

The B-Premise
SF I-Premise
- I-Premise
6D I-Premise
score I-Premise
decreased I-Premise
to I-Premise
21 I-Premise
Â· I-Premise
2 I-Premise
Â± I-Premise
2 I-Premise
Â· I-Premise
5 I-Premise
in I-Premise
the I-Premise
oxycodone I-Premise
/ I-Premise
paracetamol I-Premise
group I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
phase I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
Â· I-Premise
001 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
oxycodone I-Premise
/ I-Premise
paracetamol I-Premise
group I-Premise
, I-Premise
67 I-Premise
% I-Premise
rated I-Premise
GI I-Premise
as I-Premise
good I-Premise
, I-Premise
very I-Premise
good I-Premise
, I-Premise
or I-Premise
excellent I-Premise
. I-Premise

Patients B-Claim
with I-Claim
bone I-Claim
- I-Claim
cancer I-Claim
pain I-Claim
, I-Claim
already I-Claim
on I-Claim
opioids I-Claim
, I-Claim
obtain I-Claim
clinically I-Claim
important I-Claim
, I-Claim
additional I-Claim
pain I-Claim
- I-Claim
control I-Claim
, I-Claim
with I-Claim
regular I-Claim
oxycodone I-Claim
/ I-Claim
paracetamol I-Claim
dosing I-Claim
. I-Claim

To O
examine O
the O
effects O
of O
a O
seated O
exercise O
program O
on O
fatigue O
and O
quality O
of O
life O
( O
QOL O
) O
in O
women O
with O
metastatic O
breast O
cancer O
. O

Randomized O
, O
controlled O
, O
longitudinal O
trial O
. O

Outpatient O
clinic O
of O
a O
comprehensive O
cancer O
center O
. O

Convenience O
sample O
of O
38 O
women O
who O
were O
beginning O
outpatient O
chemotherapy O
. O

Subjects O
were O
randomized O
to O
a O
control O
or O
intervention O
group O
"""" O
; O
"""" O
the O
intervention O
was O
performance O
of O
a O
seated O
exercise O
program O
using O
home O
videotape O
three O
times O
per O
week O
for O
four O
cycles O
of O
chemotherapy O
. O

All O
subjects O
completed O
the O
Functional O
Assessment O
of O
Chronic O
Illness O
Therapy O
Fatigue O
Version O
IV O
( O
FACIT O
F O
) O
at O
baseline O
and O
at O
the O
time O
of O
the O
next O
three O
cycles O
. O

Subjects O
were O
asked O
to O
document O
the O
frequency O
, O
duration O
, O
and O
intensity O
of O
all O
exercise O
participation O
on O
monthly O
calendars O
. O

Exercise O
, O
fatigue O
, O
and O
QOL O
. O

32 O
subjects O
, O
16 O
per O
group O
, O
completed O
the O
study O
follow O
- O
up O
. O

With B-Premise
a I-Premise
mixed I-Premise
modeling I-Premise
approach I-Premise
, I-Premise
total I-Premise
FACIT I-Premise
F I-Premise
scores I-Premise
for I-Premise
the I-Premise
entire I-Premise
sample I-Premise
declined I-Premise
at I-Premise
a I-Premise
significant I-Premise
rate I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
003 I-Premise
) I-Premise
beginning I-Premise
with I-Premise
cycle I-Premise
3 I-Premise
but B-Premise
at I-Premise
a I-Premise
slower I-Premise
rate I-Premise
for I-Premise
the I-Premise
experimental I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise

Fatigue B-Premise
scores I-Premise
indicated I-Premise
less I-Premise
increase I-Premise
and I-Premise
physical I-Premise
well I-Premise
- I-Premise
being I-Premise
subscale I-Premise
scores I-Premise
showed I-Premise
less I-Premise
decline I-Premise
for I-Premise
the I-Premise
experimental I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
008 I-Premise
and I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Women B-Premise
with I-Premise
advanced I-Premise
breast I-Premise
cancer I-Premise
randomized I-Premise
to I-Premise
the I-Premise
seated I-Premise
exercise I-Premise
intervention I-Premise
had I-Premise
a I-Premise
slower I-Premise
decline I-Premise
in I-Premise
total I-Premise
and I-Premise
physical I-Premise
well I-Premise
- I-Premise
being I-Premise
and I-Premise
less I-Premise
increase I-Premise
in I-Premise
fatigue I-Premise
scores I-Premise
starting I-Premise
with I-Premise
the I-Premise
third I-Premise
cycle I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

Seated B-Claim
exercise I-Claim
may I-Claim
be I-Claim
a I-Claim
feasible I-Claim
exercise I-Claim
program I-Claim
for I-Claim
women I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
for I-Claim
controlling I-Claim
fatigue I-Claim
and I-Claim
improving I-Claim
physical I-Claim
well I-Claim
- I-Claim
being I-Claim
. I-Claim

Few O
intervention O
programs O
assist O
patients O
and O
their O
family O
caregivers O
to O
manage O
advanced O
cancer O
and O
maintain O
their O
quality O
of O
life O
( O
QOL O
) O
. O

This O
study O
examined O
( O
i O
) O
whether O
patient O
- O
caregiver O
dyads O
( O
i O
. O
e O
. O
, O
pairs O
) O
randomly O
assigned O
to O
a O
brief O
or O
extensive O
dyadic O
intervention O
( O
the O
FOCUS O
Program O
) O
had O
better O
outcomes O
than O
dyads O
randomly O
assigned O
to O
usual O
care O
and O
( O
ii O
) O
whether O
patients O
' O
risk O
for O
distress O
and O
other O
factors O
moderated O
the O
effect O
of O
the O
brief O
or O
extensive O
program O
on O
outcomes O
. O

Advanced O
cancer O
patients O
and O
their O
caregivers O
( O
N O
= O
484 O
dyads O
) O
were O
stratified O
by O
patients O
' O
baseline O
risk O
for O
distress O
( O
high O
versus O
low O
) O
, O
cancer O
type O
( O
lung O
, O
colorectal O
, O
breast O
, O
or O
prostate O
) O
, O
and O
research O
site O
and O
then O
randomly O
assigned O
to O
a O
brief O
( O
three O
- O
session O
) O
or O
extensive O
( O
six O
- O
session O
) O
intervention O
or O
control O
. O

The O
interventions O
offered O
dyads O
information O
and O
support O
. O

Intermediary O
outcomes O
were O
appraisals O
( O
i O
. O
e O
. O
, O
appraisal O
of O
illness O
/ O
caregiving O
, O
uncertainty O
, O
and O
hopelessness O
) O
and O
resources O
( O
i O
. O
e O
. O
, O
coping O
, O
interpersonal O
relationships O
, O
and O
self O
- O
efficacy O
) O
. O

The O
primary O
outcome O
was O
QOL O
. O

Data O
were O
collected O
prior O
to O
intervention O
and O
post O
- O
intervention O
( O
3 O
and O
6 O
months O
from O
baseline O
) O
. O

The O
final O
sample O
was O
302 O
dyads O
. O

Repeated O
measures O
MANCOVA O
was O
used O
to O
evaluate O
outcomes O
. O

Significant B-Premise
group I-Premise
by I-Premise
time I-Premise
interactions I-Premise
showed I-Premise
that I-Premise
there I-Premise
was I-Premise
an I-Premise
improvement I-Premise
in I-Premise
dyads I-Premise
' I-Premise
coping I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
self I-Premise
- I-Premise
efficacy I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
and I-Premise
social I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
and I-Premise
in I-Premise
caregivers I-Premise
' I-Premise
emotional I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

Effects O
varied O
by O
intervention O
dose O
. O

Most O
effects O
were O
found O
at O
3 O
months O
only O
. O

Risk B-Premise
for I-Premise
distress I-Premise
accounted I-Premise
for I-Premise
very I-Premise
few I-Premise
moderation I-Premise
effects I-Premise
. I-Premise

Both B-Premise
brief I-Premise
and I-Premise
extensive I-Premise
programs I-Premise
had I-Premise
positive I-Premise
outcomes I-Premise
for I-Premise
patient I-Premise
- I-Premise
caregiver I-Premise
dyads I-Premise
, I-Premise
but B-Premise
few I-Premise
sustained I-Premise
effects I-Premise
. I-Premise

Patient B-Claim
- B-Claim
caregiver B-Claim
dyads I-Claim
benefit I-Claim
when I-Claim
viewed I-Claim
as I-Claim
the I-Claim
' I-Claim
unit I-Claim
of I-Claim
care I-Claim
' I-Claim
. I-Claim

To O
observe O
the O
clinical O
efficacy O
of O
Shenqi O
Fuzheng O
Injection O
( O
SFI O
) O
combined O
with O
chemotherapy O
in O
treating O
patients O
with O
advanced O
breast O
cancer O
. O

Sixty O
patients O
were O
randomly O
assigned O
to O
two O
groups O
by O
digital O
table O
, O
the O
control O
group O
and O
the O
treatment O
group O
, O
30 O
in O
each O
group O
. O

All O
patients O
were O
treated O
with O
the O
same O
CTF O
regimen O
of O
chemotherapy O
for O
21 O
days O
as O
one O
therapeutic O
cycle O
, O
while O
those O
in O
the O
treatment O
group O
were O
given O
SFI O
additionally O
in O
the O
meanwhite O
. O

The O
therapeutic O
efficacy O
was O
evaluated O
after O
2 O
cycles O
of O
treatment O
by O
observing O
the O
changes O
of O
short O
- O
term O
efficacy O
, O
TCM O
syndrome O
, O
quality O
of O
life O
and O
immune O
function O
, O
as O
well O
as O
the O
adverse O
reaction O
. O

The B-Premise
total I-Premise
short I-Premise
- I-Premise
term I-Premise
remission I-Premise
rate I-Premise
, I-Premise
the I-Premise
improvement I-Premise
rate I-Premise
of I-Premise
clinical I-Premise
syndrome I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
50 I-Premise
. I-Premise
0 I-Premise
% I-Premise
, I-Premise
70 I-Premise
. I-Premise
0 I-Premise
% I-Premise
and I-Premise
76 I-Premise
. I-Premise
7 I-Premise
% I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
and I-Premise
43 I-Premise
. I-Premise
3 I-Premise
% I-Premise
, I-Premise
46 I-Premise
. I-Premise
7 I-Premise
% I-Premise
and I-Premise
50 I-Premise
. I-Premise
0 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
respectively I-Premise
, I-Premise
showing I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
( I-Premise
all I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

The B-Premise
occurrence I-Premise
of I-Premise
adverse I-Premise
reaction I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
was I-Premise
lower I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

The B-Premise
level I-Premise
of I-Premise
CD3 I-Premise
+ I-Premise
CD4 I-Premise
+ I-Premise
and I-Premise
CD4 I-Premise
+ I-Premise
/ I-Premise
CD8 I-Premise
+ I-Premise
ratio I-Premise
increased I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
and I-Premise
CD8 I-Premise
+ I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
while I-Premise
they I-Premise
showed I-Premise
insignificant I-Premise
change I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

For B-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
SFI I-Claim
can I-Claim
alleviate I-Claim
the I-Claim
bone I-Claim
marrow I-Claim
inhibition I-Claim
caused I-Claim
by I-Claim
chemotherapy I-Claim
, I-Claim
improve I-Claim
clinical I-Claim
symptoms I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
prolong I-Claim
the I-Claim
survival I-Claim
period I-Claim
by I-Claim
regulating I-Claim
cellular I-Claim
immune I-Claim
function I-Claim
of I-Claim
patients I-Claim
, I-Claim
so I-Claim
as I-Claim
to I-Claim
enhance I-Claim
the I-Claim
therapeutic I-Claim
effect I-Claim
of I-Claim
chemotherapy I-Claim
. I-Claim

The O
American O
College O
of O
Surgeons O
Oncology O
Group O
phase O
III O
Surgical O
Prostatectomy O
Versus O
Interstitial O
Radiation O
Intervention O
Trial O
comparing O
radical O
prostatectomy O
( O
RP O
) O
and O
brachytherapy O
( O
BT O
) O
closed O
after O
2 O
years O
due O
to O
poor O
accrual O
. O

We O
report O
health O
- O
related O
quality O
of O
life O
( O
HRQOL O
) O
at O
a O
mean O
of O
5 O
. O
3 O
years O
for O
168 O
trial O
- O
eligible O
men O
who O
either O
chose O
or O
were O
randomly O
assigned O
to O
RP O
or O
BT O
following O
a O
multidisciplinary O
educational O
session O
. O

After O
initial O
lack O
of O
accrual O
, O
a O
multidisciplinary O
educational O
session O
was O
introduced O
for O
eligible O
patients O
. O

In O
all O
, O
263 O
men O
attended O
47 O
sessions O
. O

Of O
those O
, O
34 O
consented O
to O
random O
assignment O
, O
62 O
chose O
RP O
, O
and O
94 O
chose O
BT O
. O

Five O
years O
later O
, O
these O
190 O
men O
underwent O
HRQOL O
evaluation O
by O
using O
the O
cancer O
- O
specific O
50 O
- O
item O
Expanded O
Prostate O
Cancer O
Index O
Composite O
, O
the O
Short O
Form O
12 O
Physical O
Component O
Score O
, O
and O
Short O
Form O
12 O
Mental O
Component O
Score O
. O

Response O
rate O
was O
88 O
. O
4 O
% O
. O

The O
Wilcoxon O
rank O
sum O
test O
was O
used O
to O
compare O
summary O
scores O
between O
the O
two O
interventions O
. O

Of O
168 O
survey O
responders O
, O
60 O
. O
7 O
% O
had O
BT O
( O
9 O
. O
5 O
% O
randomly O
assigned O
) O
and O
39 O
. O
3 O
% O
had O
RP O
( O
9 O
. O
5 O
% O
randomly O
assigned O
) O
. O

Median O
age O
was O
61 O
. O
4 O
years O
for O
BT O
and O
59 O
. O
4 O
for O
RP O
( O
P O
= O
. O
05 O
) O
. O

Median O
follow O
- O
up O
was O
5 O
. O
2 O
years O
( O
range O
, O
3 O
. O
2 O
to O
6 O
. O
5 O
years O
) O
. O

For B-Premise
BT I-Premise
versus I-Premise
RP I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
bowel I-Premise
or I-Premise
hormonal I-Premise
domains I-Premise
, I-Premise
but O
men B-Premise
treated I-Premise
with I-Premise
BT I-Premise
scored I-Premise
better I-Premise
in I-Premise
urinary I-Premise
( I-Premise
91 I-Premise
. I-Premise
8 I-Premise
v I-Premise
88 I-Premise
. I-Premise
1 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
and I-Premise
sexual I-Premise
( I-Premise
52 I-Premise
. I-Premise
5 I-Premise
v I-Premise
39 I-Premise
. I-Premise
2 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
001 I-Premise
) I-Premise
domains I-Premise
, I-Premise
and I-Premise
in I-Premise
patient I-Premise
satisfaction I-Premise
( I-Premise
93 I-Premise
. I-Premise
6 I-Premise
v I-Premise
76 I-Premise
. I-Premise
9 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

Although O
treatment O
allocation O
was O
random O
in O
only O
19 O
% O
, O
all O
patients O
received O
identical O
information O
in O
a O
multidisciplinary O
setting O
before O
selecting O
RP O
, O
BT O
, O
or O
random O
assignment O
. O

HRQOL B-Claim
evaluated I-Claim
3 I-Claim
. I-Claim
2 I-Claim
to I-Claim
6 I-Claim
. I-Claim
5 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
showed I-Claim
an I-Claim
advantage I-Claim
for I-Claim
BT I-Claim
in I-Claim
urinary I-Claim
and I-Claim
sexual I-Claim
domains I-Claim
and I-Claim
in I-Claim
patient I-Claim
satisfaction I-Claim
. I-Claim

A O
multidimensional O
rehabilitation O
program O
for O
cancer O
survivors O
was O
developed O
to O
overcome O
cancer O
- O
related O
problems O
and O
to O
improve O
quality O
of O
life O
. O

The O
two O
purposes O
of O
the O
study O
were O
to O
describe O
the O
effectiveness O
of O
the O
program O
and O
to O
obtain O
information O
about O
patient O
preferences O
for O
multi O
or O
mono O
dimensional O
rehabilitation O
programs O
. O

cancer O
survivors O
with O
different O
diagnoses O
, O
and O
cancer O
- O
related O
physical O
and O
psychosocial O
problems O
. O

a O
15 O
- O
week O
rehabilitation O
program O
including O
individual O
exercise O
, O
sports O
, O
psycho O
- O
education O
, O
and O
information O
. O

Group O
- O
wise O
randomization O
was O
implemented O
by O
assigning O
one O
half O
of O
the O
patients O
to O
the O
complete O
program O
while O
the O
other O
half O
were O
allowed O
to O
choose O
which O
program O
components O
they O
considered O
relevant O
. O

Health O
- O
Related O
Quality O
of O
Life O
[ O
RAND O
- O
36 O
and O
Rotterdam O
Symptom O
Check O
List O
( O
RSCL O
) O
] O
, O
exercise O
capacity O
( O
symptom O
limited O
bicycle O
ergometry O
) O
, O
muscle O
force O
( O
hand O
- O
held O
dynamometry O
) O
, O
and O
patient O
preferences O
. O

Measurements O
were O
performed O
before O
( O
T0 O
) O
and O
after O
the O
rehabilitation O
program O
( O
T1 O
) O
, O
and O
at O
a O
3 O
- O
month O
follow O
- O
up O
( O
T2 O
) O
. O

After B-Premise
the I-Premise
rehabilitation I-Premise
program I-Premise
, I-Premise
cancer I-Premise
survivors I-Premise
( I-Premise
n I-Premise
= I-Premise
63 I-Premise
) I-Premise
displayed I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
on I-Premise
health I-Premise
- I-Premise
related I-Premise
quality I-Premise
of I-Premise
life I-Premise
with I-Premise
effect I-Premise
sizes I-Premise
( I-Premise
ES I-Premise
) I-Premise
varying I-Premise
from I-Premise
0 I-Premise
. I-Premise
38 I-Premise
to I-Premise
0 I-Premise
. I-Premise
99 I-Premise
( I-Premise
RAND I-Premise
- I-Premise
36 I-Premise
) I-Premise
and I-Premise
from I-Premise
- I-Premise
0 I-Premise
. I-Premise
34 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
57 I-Premise
( I-Premise
RSCL I-Premise
) I-Premise
, I-Premise
most I-Premise
persistent I-Premise
at I-Premise
3 I-Premise
- I-Premise
month I-Premise
follow I-Premise
- I-Premise
up I-Premise
. I-Premise

Furthermore B-Premise
, I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
exercise I-Premise
capacity I-Premise
and I-Premise
muscle I-Premise
force I-Premise
of I-Premise
upper I-Premise
and I-Premise
lower I-Premise
extremities I-Premise
were I-Premise
displayed I-Premise
after I-Premise
rehabilitation I-Premise
. I-Premise

If B-Premise
offered I-Premise
a I-Premise
choice I-Premise
, I-Premise
80 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
prior I-Premise
to I-Premise
start I-Premise
and I-Premise
58 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
after I-Premise
completion I-Premise
of I-Premise
the I-Premise
program I-Premise
indicated I-Premise
that I-Premise
they I-Premise
preferred I-Premise
the I-Premise
entire I-Premise
multidimensional I-Premise
program I-Premise
. I-Premise

A B-Claim
multidimensional I-Claim
rehabilitation I-Claim
program I-Claim
has I-Claim
statistically I-Claim
and I-Claim
clinically I-Claim
relevant I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
health I-Claim
- I-Claim
related I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
exercise I-Claim
capacity I-Claim
, I-Claim
and I-Claim
muscle I-Claim
force I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
different I-Claim
diagnoses I-Claim
. I-Claim

Furthermore O
, O
if B-Claim
offered I-Claim
the I-Claim
choice I-Claim
, I-Claim
the I-Claim
majority I-Claim
of I-Claim
cancer I-Claim
survivors I-Claim
seem I-Claim
to I-Claim
prefer I-Claim
multidimensional I-Claim
programs I-Claim
to I-Claim
programs I-Claim
with I-Claim
only I-Claim
one I-Claim
component I-Claim
. I-Claim

Surgery O
and O
radiotherapy O
commonly O
cause O
adverse O
musculoskeletal O
problems O
, O
particularly O
loss O
of O
strength O
and O
range O
of O
motion O
, O
in O
the O
upper O
quadrant O
of O
breast O
cancer O
patients O
. O

Few O
well O
- O
designed O
studies O
have O
investigated O
whether O
these O
impairments O
can O
be O
prevented O
. O

Stretching B-Claim
is I-Claim
an I-Claim
effective I-Claim
technique I-Claim
for I-Claim
increasing I-Claim
range I-Claim
of I-Claim
motion I-Claim
, I-Claim
hence O
the O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
a O
stretching O
program O
reduced O
acute O
musculoskeletal O
impairments O
in O
patients O
undergoing O
radiotherapy O
for O
breast O
cancer O
. O

Sixty O
- O
four O
women O
were O
recruited O
prior O
to O
commencement O
of O
radiotherapy O
following O
breast O
cancer O
surgery O
. O

Participants O
were O
randomised O
to O
either O
a O
control O
or O
stretch O
group O
. O

Participants O
in O
both O
groups O
were O
reviewed O
by O
the O
physical O
therapist O
on O
a O
weekly O
basis O
for O
approximately O
6 O
weeks O
, O
and O
were O
given O
general O
information O
about O
skin O
care O
and O
lymphedema O
. O

The O
control O
group O
received O
no O
advice O
about O
exercise O
. O

The O
stretch O
group O
received O
instruction O
on O
low O
- O
load O
, O
prolonged O
pectoral O
stretches O
, O
which O
were O
to O
be O
performed O
daily O
and O
were O
checked O
at O
weekly O
visits O
. O

Shoulder O
range O
of O
motion O
, O
strength O
, O
arm O
circumference O
, O
and O
quality O
of O
life O
measurements O
were O
taken O
prior O
to O
, O
and O
at O
completion O
of O
radiotherapy O
, O
and O
at O
7 O
months O
after O
radiotherapy O
. O

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
any I-Premise
outcome I-Premise
between I-Premise
groups I-Premise
. I-Premise

Breast B-Premise
symptoms I-Premise
increased I-Premise
for I-Premise
both I-Premise
groups I-Premise
during I-Premise
radiotherapy I-Premise
, I-Premise
without I-Premise
loss I-Premise
of I-Premise
strength I-Premise
or I-Premise
range I-Premise
of I-Premise
movement I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
lymphedema I-Premise
during I-Premise
the I-Premise
study I-Premise
was I-Premise
low I-Premise
for I-Premise
both I-Premise
groups I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
groups I-Premise
. I-Premise

The B-Premise
pectoral I-Premise
stretching I-Premise
program I-Premise
did I-Premise
not I-Premise
influence I-Premise
the I-Premise
outcomes I-Premise
measured I-Premise
because I-Premise
the I-Premise
symptoms I-Premise
reported I-Premise
by I-Premise
patients I-Premise
were I-Premise
not I-Premise
a I-Premise
consequence I-Premise
of I-Premise
contracture I-Premise
. I-Premise

Postoperative B-Claim
outcomes I-Claim
of I-Claim
patients I-Claim
undergoing I-Claim
laparoscopic I-Claim
- I-Claim
assisted I-Claim
colectomy I-Claim
( I-Claim
LAC I-Claim
) I-Claim
have I-Claim
shown I-Claim
modest I-Claim
improvements I-Claim
in I-Claim
recovery I-Claim
but I-Claim
only I-Claim
minimal I-Claim
differences I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
compared I-Claim
with I-Claim
open I-Claim
colectomy I-Claim
. I-Claim

We O
therefore O
sought O
to O
assess O
the O
effect O
of O
LAC O
on O
QOL O
in O
the O
short O
and O
long O
term O
, O
using O
individual O
item O
analysis O
of O
multi O
- O
item O
QOL O
assessments O
. O

QOL O
variables O
were O
analyzed O
in O
449 O
randomized O
patients O
from O
the O
COST O
trial O
93 O
- O
46 O
- O
53 O
( O
INT O
146 O
) O
. O

Both O
cross O
- O
sectional O
single O
- O
time O
and O
change O
from O
baseline O
assessments O
were O
run O
at O
day O
2 O
, O
week O
2 O
, O
month O
2 O
, O
and O
month O
18 O
postoperatively O
in O
an O
intention O
- O
to O
- O
treat O
analysis O
using O
Wilcoxon O
rank O
- O
sum O
tests O
. O

Stepwise O
regression O
models O
were O
used O
to O
determine O
predictors O
of O
QOL O
. O

Of O
449 O
colon O
cancer O
patients O
, O
230 O
underwent O
LAC O
and O
219 O
underwent O
open O
colectomy O
. O

Subdomain B-Premise
analysis I-Premise
revealed I-Premise
a I-Premise
clinically I-Premise
moderate I-Premise
improvement I-Premise
from I-Premise
baseline I-Premise
for I-Premise
LAC I-Premise
in I-Premise
total I-Premise
QOL I-Premise
index I-Premise
at I-Premise
18 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
as I-Premise
well I-Premise
as I-Premise
other I-Premise
small I-Premise
symptomatic I-Premise
improvements I-Premise
. I-Premise

Poor O
preoperative O
QOL O
as O
indicated O
by O
a O
rating O
scale O
of O
â‰¤ O
50 O
was O
an O
independent O
predictor O
of O
poor O
QOL O
at O
2 O
months O
postoperatively O
. O

QOL O
variables O
related O
to O
survival O
were O
baseline O
support O
( O
P O
= O
0 O
. O
001 O
) O
and O
baseline O
outlook O
( O
P O
= O
0 O
. O
01 O
) O
. O

Eighteen B-Premise
months I-Premise
after I-Premise
surgery I-Premise
, I-Premise
any I-Premise
differences I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
patients I-Premise
randomized I-Premise
to I-Premise
LAC I-Premise
or I-Premise
open I-Premise
colectomy I-Premise
favored I-Premise
LAC I-Premise
. I-Premise

However B-Premise
, I-Premise
the I-Premise
magnitude I-Premise
of I-Premise
the I-Premise
benefits I-Premise
was I-Premise
small I-Premise
. I-Premise

Patients B-Claim
with I-Claim
poor I-Claim
preoperative I-Claim
QOL I-Claim
appear I-Claim
to I-Claim
be I-Claim
at I-Claim
higher I-Claim
risk I-Claim
for I-Claim
difficult I-Claim
postoperative I-Claim
courses I-Claim
, I-Claim
and I-Claim
may I-Claim
be I-Claim
candidates I-Claim
for I-Claim
enhanced I-Claim
ancillary I-Claim
services I-Claim
to I-Claim
address I-Claim
their I-Claim
particular I-Claim
needs I-Claim
. I-Claim

The O
goal O
of O
this O
study O
was O
to O
assess O
the O
impact O
of O
neuronavigation O
on O
the O
cytoreductive O
treatment O
of O
solitary O
contrast O
- O
enhancing O
intracerebral O
tumors O
and O
outcomes O
of O
this O
treatment O
in O
cases O
in O
which O
neuronavigation O
was O
preoperatively O
judged O
to O
be O
redundant O
. O

The O
authors O
conducted O
a O
prospective O
randomized O
study O
in O
which O
45 O
patients O
, O
each O
harboring O
a O
solitary O
contrast O
- O
enhancing O
intracerebral O
tumor O
, O
were O
randomized O
for O
surgery O
with O
or O
without O
neuronavigation O
. O

Peri O
- O
and O
postoperative O
parameters O
under O
investigation O
included O
the O
following O
: O
duration O
of O
the O
procedure O
"""" O
; O
"""" O
surgeon O
' O
s O
estimate O
of O
the O
usefulness O
of O
neuronavigation O
"""" O
; O
"""" O
quantification O
of O
the O
extent O
of O
resection O
, O
determined O
using O
magnetic O
resonance O
imaging O
"""" O
; O
"""" O
and O
the O
postoperative O
course O
, O
as O
evaluated O
by O
neurological O
examinations O
, O
the O
patient O
' O
s O
quality O
- O
of O
- O
life O
self O
- O
assessment O
, O
application O
of O
the O
Barthel O
index O
and O
the O
Karnofsky O
Performance O
Scale O
score O
, O
and O
the O
patient O
' O
s O
time O
of O
death O
. O

The B-Premise
mean I-Premise
amount I-Premise
of I-Premise
residual I-Premise
tumor I-Premise
tissue I-Premise
was I-Premise
28 I-Premise
. I-Premise
9 I-Premise
% I-Premise
for I-Premise
standard I-Premise
surgery I-Premise
( I-Premise
SS I-Premise
) I-Premise
and I-Premise
13 I-Premise
. I-Premise
8 I-Premise
% I-Premise
for I-Premise
surgery I-Premise
involving I-Premise
neuronavigation I-Premise
( I-Premise
SN I-Premise
) I-Premise
. I-Premise

The B-Premise
corresponding I-Premise
mean I-Premise
amounts I-Premise
of I-Premise
residual I-Premise
contrast I-Premise
- I-Premise
enhancing I-Premise
tumor I-Premise
tissue I-Premise
were I-Premise
29 I-Premise
. I-Premise
2 I-Premise
and I-Premise
24 I-Premise
. I-Premise
4 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

These B-Premise
differences I-Premise
were I-Premise
not I-Premise
significant I-Premise
. I-Premise

Gross B-Premise
- B-Premise
total B-Premise
removal I-Premise
( I-Premise
GTR I-Premise
) I-Premise
was I-Premise
achieved I-Premise
in I-Premise
five I-Premise
patients I-Premise
who I-Premise
underwent I-Premise
SS I-Premise
and I-Premise
in I-Premise
three I-Premise
who I-Premise
underwent I-Premise
SN I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
significantly I-Premise
shorter I-Premise
in I-Premise
the I-Premise
SN I-Premise
group I-Premise
( I-Premise
5 I-Premise
. I-Premise
6 I-Premise
months I-Premise
compared I-Premise
with I-Premise
9 I-Premise
months I-Premise
, I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
1 I-Premise
. I-Premise
6 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
however B-Premise
, I-Premise
this I-Premise
difference I-Premise
may I-Premise
be I-Premise
attributable I-Premise
to I-Premise
the I-Premise
coincidental I-Premise
early I-Premise
death I-Premise
of I-Premise
three I-Premise
patients I-Premise
in I-Premise
the I-Premise
SN I-Premise
group I-Premise
. I-Premise

No B-Premise
discernible I-Premise
important I-Premise
effect I-Premise
on I-Premise
the I-Premise
patients I-Premise
' I-Premise
3 I-Premise
- I-Premise
month I-Premise
postoperative I-Premise
course I-Premise
was I-Premise
identified I-Premise
. I-Premise

There B-Claim
is I-Claim
no I-Claim
rationale I-Claim
for I-Claim
the I-Claim
routine I-Claim
use I-Claim
of I-Claim
neuronavigation I-Claim
to I-Claim
improve I-Claim
the I-Claim
extent I-Claim
of I-Claim
tumor I-Claim
resection I-Claim
and I-Claim
prognosis I-Claim
in I-Claim
patients I-Claim
harboring I-Claim
a I-Claim
solitary I-Claim
enhancing I-Claim
intracerebral I-Claim
lesion I-Claim
when I-Claim
neuronavigation I-Claim
is I-Claim
not I-Claim
already I-Claim
deemed I-Claim
advantageous I-Claim
because I-Claim
of I-Claim
the I-Claim
size I-Claim
or I-Claim
location I-Claim
of I-Claim
the I-Claim
lesion I-Claim
. I-Claim

To O
test O
the O
ability O
of O
the O
cytoprotectant O
, O
amifostine O
, O
to O
reduce O
chemoradiotherapy O
- O
induced O
esophagitis O
and O
evaluate O
its O
influence O
on O
quality O
of O
life O
( O
QOL O
) O
and O
swallowing O
symptoms O
. O

A O
total O
of O
243 O
patients O
with O
stage O
II O
to O
IIIA O
/ O
B O
non O
- O
small O
- O
cell O
lung O
cancer O
received O
induction O
paclitaxel O
225 O
mg O
/ O
m O
( O
2 O
) O
intravenously O
( O
IV O
) O
days O
1 O
and O
22 O
and O
carboplatin O
area O
under O
the O
curve O
( O
AUC O
) O
days O
1 O
and O
22 O
, O
followed O
by O
concurrent O
weekly O
paclitaxel O
( O
50 O
mg O
/ O
m O
( O
2 O
) O
IV O
) O
and O
carboplatin O
( O
AUC O
2 O
) O
, O
and O
hyperfractionated O
radiation O
therapy O
( O
69 O
. O
6 O
Gy O
at O
1 O
. O
2 O
Gy O
bid O
) O
. O

Patients O
were O
randomly O
assigned O
at O
registration O
to O
amifostine O
( O
AM O
) O
500 O
mg O
IV O
four O
times O
per O
week O
or O
no O
AM O
during O
chemoradiotherapy O
. O

Beyond O
standard O
toxicity O
end O
points O
, O
physician O
dysphagia O
logs O
( O
PDLs O
) O
, O
daily O
patient O
swallowing O
diaries O
, O
and O
QOL O
( O
EORTC O
QLQ O
- O
C30 O
/ O
LC O
- O
13 O
) O
were O
also O
collected O
. O

Swallowing O
AUC O
analyses O
were O
calculated O
from O
patient O
diaries O
and O
PDLs O
. O

A O
total O
of O
120 O
patients O
were O
randomly O
assigned O
to O
receive O
AM O
, O
and O
122 O
, O
to O
receive O
no O
AM O
( O
one O
patient O
was O
ineligible O
) O
"""" O
; O
"""" O
72 O
% O
received O
AM O
per O
protocol O
or O
with O
a O
minor O
deviation O
. O

AM B-Premise
was I-Premise
associated I-Premise
with I-Premise
higher I-Premise
rates I-Premise
of I-Premise
acute I-Premise
nausea I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
vomiting I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
007 I-Premise
) I-Premise
, I-Premise
cardiovascular I-Premise
toxicity I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
0001 I-Premise
) I-Premise
, I-Premise
and I-Premise
infection I-Premise
or I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
> I-Premise
/ I-Premise
= I-Premise
grade I-Premise
3 I-Premise
esophagitis I-Premise
was I-Premise
30 I-Premise
% I-Premise
with I-Premise
AM I-Premise
versus I-Premise
34 I-Premise
% I-Premise
without I-Premise
AM I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
9 I-Premise
) I-Premise
. I-Premise

Patient B-Premise
diaries I-Premise
demonstrated I-Premise
lower I-Premise
swallowing I-Premise
dysfunction I-Premise
AUC I-Premise
with I-Premise
amifostine I-Premise
( I-Premise
z I-Premise
test I-Premise
P I-Premise
= I-Premise
. I-Premise
025 I-Premise
) I-Premise
. I-Premise

QOL B-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
, I-Premise
except I-Premise
for I-Premise
pain I-Premise
, I-Premise
which I-Premise
showed I-Premise
more I-Premise
clinically I-Premise
meaningful I-Premise
improvement I-Premise
and I-Premise
less I-Premise
deterioration I-Premise
at I-Premise
6 I-Premise
weeks I-Premise
follow I-Premise
- I-Premise
up I-Premise
( I-Premise
v I-Premise
pretreatment I-Premise
) I-Premise
in I-Premise
the I-Premise
AM I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
003 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
rates I-Premise
for I-Premise
both I-Premise
arms I-Premise
were I-Premise
comparable I-Premise
( I-Premise
AM I-Premise
, I-Premise
17 I-Premise
. I-Premise
3 I-Premise
v I-Premise
no I-Premise
AM I-Premise
, I-Premise
17 I-Premise
. I-Premise
9 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
87 I-Premise
) I-Premise
. I-Premise

AM B-Claim
did I-Claim
not I-Claim
significantly I-Claim
reduce I-Claim
esophagitis I-Claim
> I-Claim
/ I-Claim
= I-Claim
grade I-Claim
3 I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
hyperfractionated I-Claim
radiation I-Claim
and I-Claim
chemotherapy I-Claim
. I-Claim

However B-Claim
, I-Claim
patient I-Claim
self I-Claim
- I-Claim
assessments I-Claim
suggested I-Claim
a I-Claim
possible I-Claim
advantage I-Claim
to I-Claim
AM I-Claim
that I-Claim
is I-Claim
being I-Claim
explored I-Claim
with I-Claim
modified I-Claim
dosing I-Claim
route I-Claim
strategies I-Claim
. I-Claim

The O
impact O
of O
the O
side O
effects O
of O
megestrol O
acetate O
on O
the O
quality O
of O
life O
of O
noncachectic O
women O
with O
advanced O
breast O
cancer O
was O
studied O
in O
a O
dose O
- O
response O
clinical O
trial O
of O
the O
Cancer O
and O
Leukemia O
Group O
B O
( O
CALGB O
8741 O
) O
. O

Side O
effects O
of O
appetite O
increase O
and O
weight O
gain O
at O
higher O
doses O
were O
predicted O
to O
have O
a O
negative O
effect O
on O
quality O
of O
life O
. O

Stage O
IV O
breast O
cancer O
patients O
were O
randomized O
to O
receive O
either O
160 O
, O
800 O
, O
or O
1 O
, O
600 O
mg O
/ O
d O
of O
megestrol O
acetate O
. O

Quality O
of O
life O
was O
assessed O
in O
131 O
patients O
at O
trial O
entry O
and O
at O
1 O
and O
3 O
months O
while O
on O
treatment O
, O
by O
telephone O
interview O
, O
using O
the O
following O
measures O
: O
the O
Functional O
Living O
Index O
- O
Cancer O
( O
FLIC O
) O
, O
Rand O
Functional O
Limitations O
Scale O
, O
Rand O
Mental O
Health O
Inventory O
( O
MHI O
) O
, O
the O
Body O
Image O
Subscale O
, O
and O
linear O
analog O
scales O
of O
drug O
side O
effects O
. O

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
women I-Premise
treated I-Premise
with I-Premise
160 I-Premise
mg I-Premise
/ I-Premise
d I-Premise
reported I-Premise
less I-Premise
severe I-Premise
side I-Premise
effects I-Premise
( I-Premise
P I-Premise
< I-Premise
. I-Premise
0005 I-Premise
) I-Premise
, I-Premise
better I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
FLS I-Premise
, I-Premise
P I-Premise
< I-Premise
. I-Premise
0005 I-Premise
) I-Premise
, I-Premise
less I-Premise
psychologic I-Premise
distress I-Premise
( I-Premise
MHI I-Premise
, I-Premise
P I-Premise
= I-Premise
. I-Premise
008 I-Premise
) I-Premise
, I-Premise
and I-Premise
an I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
FLIC I-Premise
, I-Premise
P I-Premise
= I-Premise
. I-Premise
003 I-Premise
) I-Premise
from I-Premise
the I-Premise
time I-Premise
of I-Premise
study I-Premise
entry I-Premise
as I-Premise
compared I-Premise
with I-Premise
those I-Premise
treated I-Premise
with I-Premise
1 I-Premise
, I-Premise
600 I-Premise
mg I-Premise
/ I-Premise
d I-Premise
. I-Premise

Patients B-Premise
who I-Premise
received I-Premise
the I-Premise
800 I-Premise
- I-Premise
mg I-Premise
/ I-Premise
d I-Premise
dose I-Premise
fell I-Premise
between I-Premise
the I-Premise
low I-Premise
- I-Premise
and I-Premise
high I-Premise
- I-Premise
dose I-Premise
arms I-Premise
in I-Premise
reported I-Premise
intensity I-Premise
of I-Premise
drug I-Premise
side I-Premise
effects I-Premise
, I-Premise
but B-Premise
responded I-Premise
similarly I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
160 I-Premise
- I-Premise
mg I-Premise
/ I-Premise
d I-Premise
group I-Premise
in I-Premise
terms I-Premise
of I-Premise
physical I-Premise
functioning I-Premise
, I-Premise
psychologic I-Premise
distress I-Premise
, I-Premise
and I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Unless B-Claim
additional I-Claim
follow I-Claim
- I-Claim
up I-Claim
data I-Claim
demonstrate I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
at I-Claim
higher I-Claim
doses I-Claim
, I-Claim
the I-Claim
160 I-Claim
- I-Claim
mg I-Claim
/ I-Claim
d I-Claim
dose I-Claim
is I-Claim
optimal I-Claim
, I-Claim
achieving I-Claim
maximal I-Claim
treatment I-Claim
effect I-Claim
with I-Claim
the I-Claim
fewest I-Claim
side I-Claim
effects I-Claim
and I-Claim
better I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Study O
Type O
- O
- O
Therapy O
( O
RCT O
) O
Level O
of O
Evidence O
1b O
. O

What O
' O
s O
known O
on O
the O
subject O
? O

and O
What O
does O
the O
study O
add O
? O

Androgen O
deprivation O
therapy O
( O
ADT O
) O
is O
commonly O
used O
as O
a O
primary O
treatment O
for O
patients O
with O
prostate O
cancer O
( O
PCa O
) O
who O
are O
not O
eligible O
for O
radical O
treatment O
options O
. O

ADT O
is O
also O
used O
in O
patients O
with O
PCa O
as O
neo O
- O
adjuvant O
hormone O
therapy O
to O
reduce O
prostate O
volume O
and O
down O
- O
stage O
the O
disease O
before O
radiotherapy O
with O
curative O
intent O
. O

The O
present O
study O
showed O
that O
ADT O
with O
the O
gonadotropin O
hormone O
- O
releasing O
hormone O
( O
GhRH O
) O
antagonist O
degarelix O
is O
non O
- O
inferior O
to O
combined O
treatment O
with O
the O
LHRH O
agonist O
goserelin O
and O
bicalutamide O
in O
terms O
of O
reducing O
prostate O
volume O
during O
the O
treatment O
period O
of O
3 O
months O
. O

Degarelix O
treatment O
evokes O
, O
however O
, O
significantly O
better O
relief O
of O
lower O
urinary O
tract O
symptoms O
in O
patients O
having O
moderate O
and O
severe O
voiding O
problems O
. O

To O
assess O
the O
efficacy O
of O
monthly O
degarelix O
treatment O
for O
reduction O
of O
total O
prostate O
volume O
( O
TPV O
) O
, O
relief O
of O
lower O
urinary O
tract O
symptoms O
( O
LUTS O
) O
and O
improvement O
of O
quality O
of O
life O
( O
QoL O
) O
in O
patients O
with O
prostate O
cancer O
( O
PCa O
) O
using O
monthly O
goserelin O
as O
active O
control O
. O

This O
was O
a O
randomized O
, O
parallel O
- O
arm O
, O
active O
- O
controlled O
, O
open O
- O
label O
, O
multicentre O
trial O
on O
182 O
patients O
treated O
with O
either O
monthly O
degarelix O
( O
240 O
/ O
80 O
mg O
) O
or O
goserelin O
( O
3 O
. O
6 O
mg O
) O
for O
12 O
weeks O
. O

For O
flare O
protection O
, O
goserelin O
- O
treated O
patients O
also O
received O
daily O
bicalutamide O
( O
50 O
mg O
) O
during O
the O
initial O
28 O
days O
. O

Key O
trial O
variables O
monitored O
monthly O
were O
TPV O
( O
primary O
endpoint O
) O
, O
serum O
testosterone O
, O
prostate O
- O
specific O
antigen O
( O
PSA O
) O
, O
the O
International O
Prostate O
Symptom O
Score O
( O
IPSS O
) O
and O
the O
Benign O
Prostate O
Hyperplasia O
Impact O
Index O
. O

In O
all O
, O
175 O
patients O
completed O
the O
trial O
( O
96 O
. O
1 O
% O
) O
. O

At B-Premise
week I-Premise
12 I-Premise
, I-Premise
changes I-Premise
in I-Premise
TPV I-Premise
for I-Premise
degarelix I-Premise
and I-Premise
goserelin I-Premise
were I-Premise
similar I-Premise
( I-Premise
- I-Premise
37 I-Premise
. I-Premise
2 I-Premise
% I-Premise
vs I-Premise
- I-Premise
39 I-Premise
. I-Premise
0 I-Premise
% I-Premise
) I-Premise
and I-Premise
met I-Premise
the I-Premise
predefined I-Premise
non I-Premise
- I-Premise
inferiority I-Premise
criterion I-Premise
. I-Premise

Decreases B-Premise
in I-Premise
IPSS I-Premise
were I-Premise
greater I-Premise
in I-Premise
degarelix I-Premise
than I-Premise
in I-Premise
goserelin I-Premise
- I-Premise
treated I-Premise
patients I-Premise
, I-Premise
differences I-Premise
being I-Premise
statistically I-Premise
significant I-Premise
in I-Premise
patients I-Premise
with I-Premise
baseline I-Premise
IPSS I-Premise
> I-Premise
13 I-Premise
( I-Premise
- I-Premise
6 I-Premise
. I-Premise
7 I-Premise
Â± I-Premise
1 I-Premise
. I-Premise
8 I-Premise
vs I-Premise
- I-Premise
4 I-Premise
. I-Premise
0 I-Premise
Â± I-Premise
1 I-Premise
. I-Premise
0 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise

The B-Premise
number I-Premise
of I-Premise
patients I-Premise
with I-Premise
an I-Premise
IPSS I-Premise
change I-Premise
of I-Premise
â‰¥ I-Premise
3 I-Premise
over I-Premise
baseline I-Premise
was I-Premise
also I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
patients I-Premise
treated I-Premise
with I-Premise
degarelix I-Premise
( I-Premise
61 I-Premise
. I-Premise
0 I-Premise
vs I-Premise
44 I-Premise
. I-Premise
3 I-Premise
% I-Premise
, I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise

Both B-Claim
treatments I-Claim
were I-Claim
safe I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

Medical B-Claim
castration I-Claim
reduces I-Claim
TPV I-Claim
and I-Claim
could I-Claim
also I-Claim
improve I-Claim
LUTS I-Claim
in I-Claim
patients I-Claim
with I-Claim
PCa I-Claim
. I-Claim

While O
the B-Claim
short I-Claim
- I-Claim
term I-Claim
efficacy I-Claim
of I-Claim
degarelix I-Claim
and I-Claim
goserelin I-Claim
+ I-Claim
bicalutamide I-Claim
was I-Claim
the I-Claim
same I-Claim
in I-Claim
terms I-Claim
of I-Claim
TPV I-Claim
reduction I-Claim
, I-Claim
degarelix B-Claim
showed I-Claim
superiority I-Claim
in I-Claim
LUTS I-Claim
relief I-Claim
in I-Claim
symptomatic I-Claim
patients I-Claim
, I-Claim
which I-Claim
could I-Claim
highlight I-Claim
the I-Claim
different I-Claim
actions I-Claim
of I-Claim
these I-Claim
drugs I-Claim
on I-Claim
extrapituitary I-Claim
gonadotrophin I-Claim
- I-Claim
releasing I-Claim
hormone I-Claim
( I-Claim
GnRH I-Claim
) I-Claim
receptors I-Claim
in I-Claim
the I-Claim
bladder I-Claim
and I-Claim
/ I-Claim
or I-Claim
the I-Claim
prostate I-Claim
. I-Claim

To O
assess O
whether O
omission O
of O
postoperative O
radiotherapy O
in O
women O
with O
' O
low O
- O
risk O
' O
axillary O
node O
negative O
breast O
cancer O
( O
T0 O
- O
2 O
) O
treated O
by O
breast O
- O
conserving O
surgery O
and O
endocrine O
therapy O
improves O
quality O
of O
life O
and O
is O
more O
cost O
- O
effective O
. O

A O
randomised O
controlled O
clinical O
trial O
, O
using O
a O
method O
of O
minimisation O
balanced O
by O
centre O
, O
grade O
of O
cancer O
, O
age O
, O
lymphatic O
/ O
vascular O
invasion O
and O
preoperative O
endocrine O
therapy O
, O
was O
performed O
. O

A O
non O
- O
randomised O
cohort O
was O
also O
recruited O
, O
in O
order O
to O
complete O
a O
comprehensive O
cohort O
study O
. O

The O
setting O
was O
breast O
cancer O
clinics O
in O
cancer O
centres O
in O
the O
UK O
. O

Patients O
aged O
65 O
years O
or O
more O
were O
eligible O
provided O
that O
their O
cancers O
were O
considered O
to O
be O
at O
low O
risk O
of O
local O
recurrence O
, O
were O
suitable O
for O
breast O
- O
conservation O
surgery O
, O
were O
receiving O
endocrine O
therapy O
and O
were O
able O
and O
willing O
to O
give O
informed O
consent O
. O

The O
standard O
treatment O
of O
postoperative O
breast O
irradiation O
or O
the O
omission O
of O
radiotherapy O
. O

Quality O
of O
life O
was O
the O
primary O
outcome O
measure O
, O
together O
with O
anxiety O
and O
depression O
and O
cost O
- O
effectiveness O
. O

Secondary O
outcome O
measures O
were O
recurrence O
rates O
, O
functional O
status O
, O
treatment O
- O
related O
morbidity O
and O
cosmesis O
. O

The O
principal O
method O
of O
data O
collection O
was O
by O
questionnaire O
, O
completed O
at O
home O
with O
a O
research O
nurse O
at O
four O
times O
over O
15 O
months O
. O

The B-Claim
hypothesised I-Claim
improvement I-Claim
in I-Claim
overall I-Claim
quality I-Claim
of I-Claim
life I-Claim
with I-Claim
the I-Claim
omission I-Claim
of I-Claim
radiotherapy I-Claim
was I-Claim
not I-Claim
seen I-Claim
in I-Claim
the I-Claim
EuroQol I-Claim
assessment I-Claim
or I-Claim
in I-Claim
the I-Claim
functionality I-Claim
and I-Claim
symptoms I-Claim
summary I-Claim
domains I-Claim
of I-Claim
the I-Claim
European I-Claim
Organisation I-Claim
for I-Claim
Research I-Claim
in I-Claim
the I-Claim
Treatment I-Claim
of I-Claim
Cancer I-Claim
( I-Claim
EORTC I-Claim
) I-Claim
scales I-Claim
. I-Claim

Some O
differences O
were O
apparent O
within O
subscales O
of O
the O
EORTC O
questionnaires O
, O
and O
insights O
into O
the O
impact O
of O
treatment O
were O
also O
provided O
by O
the O
qualitative O
data O
obtained O
by O
open O
- O
ended O
questions O
. O

Differences B-Premise
were I-Premise
most I-Premise
apparent I-Premise
shortly I-Premise
after I-Premise
the I-Premise
time I-Premise
of I-Premise
completion I-Premise
of I-Premise
radiotherapy I-Premise
. I-Premise

Radiotherapy B-Claim
was I-Claim
then I-Claim
associated I-Claim
with I-Claim
increased I-Claim
breast I-Claim
symptoms I-Claim
and I-Claim
with I-Claim
greater I-Claim
fatigue I-Claim
but I-Claim
with I-Claim
less I-Claim
insomnia I-Claim
and I-Claim
endocrine I-Claim
side I-Claim
- I-Claim
effects I-Claim
. I-Claim

Patients B-Premise
had I-Premise
significant I-Premise
concerns I-Premise
about I-Premise
the I-Premise
delivery I-Premise
of I-Premise
radiotherapy I-Premise
services I-Premise
, I-Premise
such I-Premise
as I-Premise
transport I-Premise
, I-Premise
accommodation I-Premise
and I-Premise
travel I-Premise
costs I-Premise
associated I-Premise
with I-Premise
receiving I-Premise
radiotherapy I-Premise
. I-Premise

By B-Premise
the I-Premise
end I-Premise
of I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
radiotherapy I-Premise
were I-Premise
expressing I-Premise
less I-Premise
anxiety I-Premise
about I-Premise
recurrence I-Premise
than I-Premise
those I-Premise
who I-Premise
had I-Premise
not I-Premise
received I-Premise
radiotherapy I-Premise
. I-Premise

Functionality B-Premise
was I-Premise
not I-Premise
greatly I-Premise
affected I-Premise
by I-Premise
treatment I-Premise
. I-Premise

Within B-Premise
the I-Premise
randomised I-Premise
controlled I-Premise
trial I-Premise
, I-Premise
the I-Premise
Barthel I-Premise
Index I-Premise
demonstrated I-Premise
a I-Premise
small I-Premise
but I-Premise
significant I-Premise
fall I-Premise
in I-Premise
functionality I-Premise
with I-Premise
radiotherapy I-Premise
compared I-Premise
with I-Premise
the I-Premise
no I-Premise
radiotherapy I-Premise
arm I-Premise
of I-Premise
the I-Premise
trial I-Premise
. I-Premise

Results B-Premise
from I-Premise
the I-Premise
non I-Premise
- I-Premise
randomised I-Premise
patients I-Premise
did I-Premise
not I-Premise
confirm I-Premise
this I-Premise
effect I-Premise
, I-Premise
however I-Premise
. I-Premise

Cosmetic B-Premise
results I-Premise
were I-Premise
better I-Premise
in I-Premise
those I-Premise
not I-Premise
receiving I-Premise
radiotherapy I-Premise
but B-Premise
this I-Premise
did I-Premise
not I-Premise
appear I-Premise
to I-Premise
be I-Premise
an I-Premise
important I-Premise
issue I-Premise
to I-Premise
the I-Premise
patients I-Premise
. I-Premise

The B-Claim
use I-Claim
of I-Claim
home I-Claim
- I-Claim
based I-Claim
assessments I-Claim
by I-Claim
a I-Claim
research I-Claim
nurse I-Claim
proved I-Claim
to I-Claim
be I-Claim
an I-Claim
effective I-Claim
way I-Claim
of I-Claim
obtaining I-Claim
high I-Claim
- I-Claim
quality I-Claim
data I-Claim
. I-Claim

Costs O
to O
the O
NHS O
associated O
with O
postoperative O
radiotherapy O
were O
calculated O
to O
be O
of O
the O
order O
of O
2000 O
pounds O
per O
patient O
. O

In B-Premise
the I-Premise
follow I-Premise
- I-Premise
up I-Premise
in I-Premise
this I-Premise
study I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
recurrences I-Premise
, I-Premise
and I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
utilities I-Premise
from I-Premise
EuroQol I-Premise
were I-Premise
almost I-Premise
identical I-Premise
. I-Premise

Although B-Premise
there I-Premise
are I-Premise
no I-Premise
differences I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
between I-Premise
the I-Premise
patients I-Premise
treated I-Premise
with I-Premise
and I-Premise
without I-Premise
radiotherapy I-Premise
, I-Premise
there I-Premise
are I-Premise
several I-Premise
dimensions I-Premise
that I-Premise
exhibit I-Premise
significant I-Premise
advantage I-Premise
to I-Premise
the I-Premise
omission I-Premise
of I-Premise
irradiation I-Premise
. I-Premise

Over B-Premise
the I-Premise
first I-Premise
15 I-Premise
months I-Premise
, I-Premise
radiotherapy I-Premise
for I-Premise
this I-Premise
population I-Premise
is I-Premise
not I-Premise
a I-Premise
cost I-Premise
- I-Premise
effective I-Premise
treatment I-Premise
. I-Premise

However O
, O
the O
early B-Claim
postoperative I-Claim
outcome I-Claim
does I-Claim
not I-Claim
give I-Claim
a I-Claim
complete I-Claim
answer I-Claim
and O
the B-Claim
eventual I-Claim
cost I-Claim
- I-Claim
effectiveness I-Claim
will I-Claim
only I-Claim
become I-Claim
clear I-Claim
after I-Claim
long I-Claim
- I-Claim
term I-Claim
follow I-Claim
- I-Claim
up I-Claim
. I-Claim

Extrapolations B-Claim
from I-Claim
these I-Claim
data I-Claim
suggest I-Claim
that I-Claim
radiotherapy I-Claim
may I-Claim
not I-Claim
be I-Claim
a I-Claim
cost I-Claim
- I-Claim
effective I-Claim
treatment I-Claim
unless I-Claim
it I-Claim
results I-Claim
in I-Claim
a I-Claim
recurrence I-Claim
rate I-Claim
that I-Claim
is I-Claim
at I-Claim
least I-Claim
5 I-Claim
% I-Claim
lower I-Claim
in I-Claim
absolute I-Claim
terms I-Claim
than I-Claim
those I-Claim
treated I-Claim
without I-Claim
radiotherapy I-Claim
. I-Claim

Further B-Claim
research I-Claim
is I-Claim
needed I-Claim
into I-Claim
a I-Claim
number I-Claim
of I-Claim
areas I-Claim
including I-Claim
the I-Claim
long I-Claim
- I-Claim
term I-Claim
aspects I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
clinical I-Claim
outcomes I-Claim
, I-Claim
costs I-Claim
and I-Claim
consequences I-Claim
of I-Claim
omitting I-Claim
radiotherapy I-Claim
. I-Claim

A O
randomized O
controlled O
trial O
was O
performed O
to O
assess O
the O
outcome O
of O
early O
oral O
postoperative O
feeding O
( O
EOF O
) O
compared O
with O
traditional O
oral O
feeding O
( O
TOF O
) O
in O
gynecologic O
oncology O
patients O
undergoing O
a O
complex O
laparotomy O
, O
including O
upper O
abdominal O
surgery O
. O

Patients O
aged O
18 O
- O
75 O
years O
, O
undergoing O
an O
elective O
laparotomy O
and O
with O
a O
preoperative O
suspicion O
of O
gynecologic O
malignancy O
, O
were O
eligible O
. O

Exclusion O
criteria O
included O
infectious O
conditions O
, O
intestinal O
obstruction O
, O
severe O
malnutrition O
, O
American O
Society O
of O
Anesthesiologists O
score O
C4 O
, O
intestinal O
resection O
, O
and O
postoperative O
stay O
in O
the O
intensive O
care O
unit O
lasting O
24 O
h O
. O
Patients O
allocated O
to O
EOF O
received O
liquid O
diet O
in O
the O
first O
postoperative O
day O
and O
then O
regular O
diet O
. O

Patients O
received O
traditional O
feeding O
scheme O
until O
resolution O
of O
postoperative O
ileus O
to O
start O
liquid O
diet O
. O

The O
primary O
end O
- O
point O
of O
the O
trial O
was O
length O
of O
hospital O
stay O
. O

Between O
January O
1 O
, O
2007 O
, O
and O
November O
17 O
, O
2007 O
, O
a O
total O
of O
143 O
patients O
were O
randomized O
to O
receive O
either O
EOF O
or O
TOF O
. O

Hospital B-Premise
stay I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
EOF I-Premise
( I-Premise
n I-Premise
= I-Premise
71 I-Premise
) I-Premise
was I-Premise
4 I-Premise
. I-Premise
7 I-Premise
vs I-Premise
. I-Premise
5 I-Premise
. I-Premise
8 I-Premise
days I-Premise
for I-Premise
the I-Premise
TOF I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
72 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
006 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
level I-Premise
of I-Premise
postoperative I-Premise
satisfaction I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
EOF I-Premise
group I-Premise
( I-Premise
82 I-Premise
. I-Premise
8 I-Premise
vs I-Premise
. I-Premise
71 I-Premise
. I-Premise
7 I-Premise
mm I-Premise
, I-Premise
P I-Premise
B I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
who I-Premise
received I-Premise
the I-Premise
TOF I-Premise
scheme I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
overall I-Premise
postoperative I-Premise
complications I-Premise
( I-Premise
39 I-Premise
vs I-Premise
. I-Premise
17 I-Premise
% I-Premise
in I-Premise
EOF I-Premise
group I-Premise
, I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
003 I-Premise
) I-Premise
and I-Premise
infective I-Premise
complications I-Premise
( I-Premise
14 I-Premise
% I-Premise
in I-Premise
TOF I-Premise
group I-Premise
vs I-Premise
. I-Premise
3 I-Premise
% I-Premise
in I-Premise
EOF I-Premise
group I-Premise
, I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
017 I-Premise
) I-Premise
. I-Premise

Variables B-Premise
such I-Premise
as I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
analgesic I-Premise
and I-Premise
antiemetic I-Premise
requirement I-Premise
as I-Premise
well I-Premise
as I-Premise
level I-Premise
of I-Premise
pain I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
were I-Premise
not I-Premise
different I-Premise
between I-Premise
groups I-Premise
. I-Premise

On B-Claim
the I-Claim
basis I-Claim
of I-Claim
these I-Claim
findings I-Claim
, I-Claim
the I-Claim
policy I-Claim
of I-Claim
EOF I-Claim
should I-Claim
be I-Claim
used I-Claim
after I-Claim
a I-Claim
complex I-Claim
gynecologic I-Claim
oncologic I-Claim
laparotomy I-Claim
. I-Claim

Insomnia B-Claim
is I-Claim
a I-Claim
common I-Claim
complaint I-Claim
among I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

Fortunately O
, O
cognitive O
- O
behavioral O
therapy O
for O
insomnia O
( O
CBT O
- O
I O
) O
has O
been O
shown O
to O
be O
an O
effective O
treatment O
in O
this O
population O
. O

However O
, O
it O
is O
rarely O
implemented O
given O
its O
limited O
availability O
. O

To O
address O
this O
barrier O
, O
we O
examined O
the O
ability O
of O
an O
easily O
accessible O
online O
CBT O
- O
I O
program O
to O
improve O
insomnia O
symptoms O
in O
cancer O
survivors O
. O

Twenty O
- O
eight O
cancer O
survivors O
with O
insomnia O
were O
randomly O
assigned O
to O
either O
an O
Internet O
insomnia O
intervention O
( O
n O
= O
14 O
) O
or O
to O
a O
waitlist O
control O
group O
( O
n O
= O
14 O
) O
. O

The O
online O
program O
, O
Sleep O
Healthy O
Using O
The O
Internet O
, O
delivers O
the O
primary O
components O
of O
CBT O
- O
I O
( O
sleep O
restriction O
, O
stimulus O
control O
, O
cognitive O
restructuring O
, O
sleep O
hygiene O
, O
and O
relapse O
prevention O
) O
. O

Pre O
- O
and O
post O
- O
assessment O
data O
were O
collected O
via O
online O
questionnaires O
and O
daily O
sleep O
diaries O
. O

Participants B-Premise
in I-Premise
the I-Premise
Internet I-Premise
group I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
at I-Premise
post I-Premise
- I-Premise
assessment I-Premise
compared I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
in I-Premise
overall I-Premise
insomnia I-Premise
severity I-Premise
( I-Premise
F I-Premise
( I-Premise
1 I-Premise
, I-Premise
26 I-Premise
) I-Premise
= I-Premise
22 I-Premise
. I-Premise
8 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
sleep I-Premise
efficiency I-Premise
( I-Premise
F I-Premise
( I-Premise
1 I-Premise
, I-Premise
24 I-Premise
) I-Premise
= I-Premise
11 I-Premise
. I-Premise
45 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
002 I-Premise
) I-Premise
, I-Premise
sleep I-Premise
onset I-Premise
latency I-Premise
( I-Premise
F I-Premise
( I-Premise
1 I-Premise
, I-Premise
24 I-Premise
) I-Premise
= I-Premise
5 I-Premise
. I-Premise
18 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
soundness I-Premise
of I-Premise
sleep I-Premise
( I-Premise
F I-Premise
( I-Premise
1 I-Premise
, I-Premise
24 I-Premise
) I-Premise
= I-Premise
9 I-Premise
. I-Premise
34 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
005 I-Premise
) I-Premise
, I-Premise
restored I-Premise
feeling I-Premise
upon I-Premise
awakening I-Premise
( I-Premise
F I-Premise
( I-Premise
1 I-Premise
, I-Premise
24 I-Premise
) I-Premise
= I-Premise
11 I-Premise
. I-Premise
95 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
002 I-Premise
) I-Premise
, I-Premise
and I-Premise
general I-Premise
fatigue I-Premise
( I-Premise
F I-Premise
( I-Premise
1 I-Premise
, I-Premise
26 I-Premise
) I-Premise
= I-Premise
13 I-Premise
. I-Premise
88 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

Although B-Premise
other I-Premise
group I-Premise
Ã— I-Premise
time I-Premise
interactions I-Premise
were I-Premise
not I-Premise
significant I-Premise
, I-Premise
overall I-Premise
adjusted I-Premise
effect I-Premise
sizes I-Premise
for I-Premise
all I-Premise
sleep I-Premise
variables I-Premise
as I-Premise
well I-Premise
as I-Premise
for I-Premise
fatigue I-Premise
, I-Premise
depression I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
ranged I-Premise
from I-Premise
small I-Premise
to I-Premise
large I-Premise
. I-Premise

CBT B-Claim
- B-Claim
I B-Claim
delivered I-Claim
through I-Claim
an I-Claim
interactive I-Claim
, I-Claim
individually I-Claim
tailored I-Claim
Internet I-Claim
intervention I-Claim
may I-Claim
be I-Claim
a I-Claim
viable I-Claim
treatment I-Claim
option I-Claim
for I-Claim
cancer I-Claim
survivors I-Claim
experiencing I-Claim
insomnia I-Claim
. I-Claim

To O
compare O
the O
effectiveness O
and O
tolerability O
of O
gemcitabine O
plus O
cisplatin O
with O
single O
- O
agent O
gemcitabine O
as O
first O
- O
line O
chemotherapy O
for O
locally O
advanced O
or O
metastatic O
pancreatic O
cancer O
. O

Patients O
with O
advanced O
adenocarcinoma O
of O
the O
pancreas O
were O
randomly O
assigned O
to O
receive O
either O
gemcitabine O
1 O
, O
000 O
mg O
/ O
m2 O
and O
cisplatin O
50 O
mg O
/ O
m2 O
given O
on O
days O
1 O
and O
15 O
of O
a O
4 O
- O
week O
cycle O
( O
GemCis O
arm O
) O
or O
gemcitabine O
alone O
at O
a O
dose O
of O
1 O
, O
000 O
mg O
/ O
m2 O
on O
days O
1 O
, O
8 O
, O
and O
15 O
of O
a O
4 O
- O
week O
regimen O
( O
Gem O
arm O
) O
. O

The O
primary O
end O
point O
was O
overall O
survival O
"""" O
; O
"""" O
secondary O
end O
points O
were O
progression O
- O
free O
survival O
, O
response O
rate O
, O
safety O
, O
and O
quality O
of O
life O
. O

One O
hundred O
ninety O
- O
five O
patients O
were O
enrolled O
and O
showed O
baseline O
characteristics O
well O
balanced O
between O
treatment O
arms O
. O

Combination B-Premise
treatment I-Premise
in I-Premise
the I-Premise
GemCis I-Premise
arm I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
prolonged I-Premise
median I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
5 I-Premise
. I-Premise
3 I-Premise
months I-Premise
v I-Premise
3 I-Premise
. I-Premise
1 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
= I-Premise
0 I-Premise
. I-Premise
75 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
053 I-Premise
) I-Premise
. I-Premise

Also B-Premise
, I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
superior I-Premise
for I-Premise
patients I-Premise
treated I-Premise
in I-Premise
the I-Premise
GemCis I-Premise
arm I-Premise
as I-Premise
compared I-Premise
with I-Premise
the I-Premise
Gem I-Premise
arm I-Premise
( I-Premise
7 I-Premise
. I-Premise
5 I-Premise
v I-Premise
6 I-Premise
. I-Premise
0 I-Premise
months I-Premise
) I-Premise
, I-Premise
an B-Premise
advantage I-Premise
which I-Premise
did I-Premise
not I-Premise
, I-Premise
however I-Premise
, I-Premise
reach I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
HR I-Premise
= I-Premise
0 I-Premise
. I-Premise
80 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
15 I-Premise
) I-Premise
. I-Premise

Tumor B-Premise
response I-Premise
rates I-Premise
were I-Premise
comparable I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
10 I-Premise
. I-Premise
2 I-Premise
% I-Premise
v I-Premise
8 I-Premise
. I-Premise
2 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
stable I-Premise
disease I-Premise
was I-Premise
, I-Premise
however I-Premise
, I-Premise
greater I-Premise
in I-Premise
the I-Premise
combination I-Premise
arm I-Premise
( I-Premise
60 I-Premise
. I-Premise
2 I-Premise
% I-Premise
v I-Premise
40 I-Premise
. I-Premise
2 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. O

Grade B-Premise
3 I-Premise
to I-Premise
4 I-Premise
hematologic I-Premise
toxicity I-Premise
did I-Premise
not I-Premise
exceed I-Premise
15 I-Premise
% I-Premise
in I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

These B-Claim
results I-Claim
support I-Claim
the I-Claim
efficacy I-Claim
and I-Claim
safety I-Claim
of I-Claim
an I-Claim
every I-Claim
- I-Claim
2 I-Claim
- I-Claim
weeks I-Claim
treatment I-Claim
with I-Claim
gemcitabine I-Claim
plus I-Claim
cisplatin I-Claim
. I-Claim

Median B-Claim
overall I-Claim
survival I-Claim
and I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
were I-Claim
more I-Claim
favorable I-Claim
in I-Claim
the I-Claim
combination I-Claim
arm I-Claim
as I-Claim
compared I-Claim
with I-Claim
gemcitabine I-Claim
alone I-Claim
, I-Claim
although B-Premise
the I-Premise
difference I-Premise
did I-Premise
not I-Premise
attain I-Premise
statistical I-Premise
significance I-Premise
. I-Premise

Extracellular O
adenosine O
5 O
' O
- O
triphosphate O
( O
ATP O
) O
is O
involved O
in O
the O
regulation O
of O
a O
variety O
of O
biologic O
processes O
, O
including O
neurotransmission O
, O
muscle O
contraction O
, O
and O
liver O
glucose O
metabolism O
, O
via O
purinergic O
receptors O
. O

In B-Claim
nonrandomized I-Claim
studies I-Claim
involving I-Claim
patients I-Claim
with I-Claim
different I-Claim
tumor I-Claim
types I-Claim
including I-Claim
non I-Claim
- I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
, I-Claim
ATP I-Claim
infusion I-Claim
appeared I-Claim
to I-Claim
inhibit I-Claim
loss I-Claim
of I-Claim
weight I-Claim
and I-Claim
deterioration I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
and I-Claim
performance I-Claim
status I-Claim
. I-Claim

We O
conducted O
a O
randomized O
clinical O
trial O
to O
evaluate O
the O
effects O
of O
ATP O
in O
patients O
with O
advanced O
NSCLC O
( O
stage O
IIIB O
or O
IV O
) O
. O

Fifty O
- O
eight O
patients O
were O
randomly O
assigned O
to O
receive O
either O
10 O
intravenous O
30 O
- O
hour O
ATP O
infusions O
, O
with O
the O
infusions O
given O
at O
- O
2 O
to O
4 O
- O
week O
intervals O
, O
or O
no O
ATP O
. O

Outcome O
parameters O
were O
assessed O
every O
4 O
weeks O
until O
28 O
weeks O
. O

Between O
- O
group O
differences O
were O
tested O
for O
statistical O
significance O
by O
use O
of O
repeated O
- O
measures O
analysis O
, O
and O
reported O
P O
values O
are O
two O
- O
sided O
. O

Twenty O
- O
eight O
patients O
were O
allocated O
to O
receive O
ATP O
treatment O
and O
30 O
received O
no O
ATP O
. O

Mean B-Premise
weight I-Premise
changes I-Premise
per I-Premise
4 I-Premise
- I-Premise
week I-Premise
period I-Premise
were I-Premise
- I-Premise
1 I-Premise
. I-Premise
0 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
- I-Premise
1 I-Premise
. I-Premise
5 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
5 I-Premise
) I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
0 I-Premise
. I-Premise
2 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
2 I-Premise
to I-Premise
+ I-Premise
0 I-Premise
. I-Premise
6 I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
. I-Premise

Serum B-Premise
albumin I-Premise
concentration I-Premise
declined I-Premise
by I-Premise
- I-Premise
1 I-Premise
. I-Premise
2 I-Premise
g I-Premise
/ I-Premise
L I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
- I-Premise
2 I-Premise
. I-Premise
0 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
4 I-Premise
) I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
but I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0 I-Premise
. I-Premise
0 I-Premise
g I-Premise
/ I-Premise
L I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
3 I-Premise
to I-Premise
+ I-Premise
0 I-Premise
. I-Premise
3 I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
006 I-Premise
) I-Premise
. I-Premise

Elbow B-Premise
flexor I-Premise
muscle I-Premise
strength I-Premise
declined I-Premise
by I-Premise
- I-Premise
5 I-Premise
. I-Premise
5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
- I-Premise
9 I-Premise
. I-Premise
6 I-Premise
% I-Premise
to I-Premise
- I-Premise
1 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
but I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0 I-Premise
. I-Premise
0 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
- I-Premise
1 I-Premise
. I-Premise
4 I-Premise
% I-Premise
to I-Premise
+ I-Premise
1 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise

A B-Premise
similar I-Premise
pattern I-Premise
was I-Premise
observed I-Premise
for I-Premise
knee I-Premise
extensor I-Premise
muscles I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise

The B-Premise
effects I-Premise
of I-Premise
ATP I-Premise
on I-Premise
body I-Premise
weight I-Premise
, I-Premise
muscle I-Premise
strength I-Premise
, I-Premise
and I-Premise
albumin I-Premise
concentration I-Premise
were I-Premise
especially I-Premise
marked I-Premise
in I-Premise
cachectic I-Premise
patients I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
0002 I-Premise
, I-Premise
P I-Premise
= I-Premise
. I-Premise
0001 I-Premise
, I-Premise
and I-Premise
P I-Premise
= I-Premise
. I-Premise
1 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
ATP I-Premise
versus I-Premise
no I-Premise
ATP I-Premise
) I-Premise
. I-Premise

QOL B-Premise
score I-Premise
changes I-Premise
per I-Premise
4 I-Premise
- I-Premise
week I-Premise
period I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
showed I-Premise
overall I-Premise
less I-Premise
deterioration I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
- I-Premise
physical I-Premise
scores I-Premise
( I-Premise
- I-Premise
0 I-Premise
. I-Premise
2 I-Premise
% I-Premise
versus I-Premise
- I-Premise
2 I-Premise
. I-Premise
4 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
2 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
functional I-Premise
scores I-Premise
( I-Premise
+ I-Premise
0 I-Premise
. I-Premise
4 I-Premise
% I-Premise
versus I-Premise
- I-Premise
5 I-Premise
. I-Premise
5 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
psychologic I-Premise
scores I-Premise
( I-Premise
- I-Premise
0 I-Premise
. I-Premise
7 I-Premise
% I-Premise
versus I-Premise
- I-Premise
2 I-Premise
. I-Premise
4 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
11 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
overall I-Premise
QOL I-Premise
score I-Premise
( I-Premise
+ I-Premise
0 I-Premise
. I-Premise
1 I-Premise
% I-Premise
versus I-Premise
- I-Premise
3 I-Premise
. I-Premise
5 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise

This O
randomized O
trial O
demonstrates O
that O
ATP B-Claim
has I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
weight I-Claim
, I-Claim
muscle I-Claim
strength I-Claim
, I-Claim
and I-Claim
QOL I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Abiraterone B-Claim
acetate I-Claim
plus I-Claim
prednisone I-Claim
significantly I-Claim
improves I-Claim
radiographic I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
in I-Claim
asymptomatic I-Claim
or I-Claim
mildly I-Claim
symptomatic I-Claim
, I-Claim
chemotherapy I-Claim
- I-Claim
naive I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
castration I-Claim
- I-Claim
resistant I-Claim
prostate I-Claim
cancer I-Claim
compared I-Claim
with I-Claim
prednisone I-Claim
alone I-Claim
. I-Claim

We O
describe O
analyses O
of O
data O
for O
patient O
- O
reported O
pain O
and O
functional O
status O
in O
a O
preplanned O
interim O
analysis O
of O
a O
phase O
3 O
trial O
. O

Between O
April O
28 O
, O
2009 O
, O
and O
June O
23 O
, O
2010 O
, O
patients O
with O
progressive O
, O
metastatic O
castration O
- O
resistant O
prostate O
cancer O
were O
enrolled O
into O
a O
multinational O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
. O

Patients O
were O
eligible O
if O
they O
were O
asymptomatic O
( O
score O
of O
0 O
or O
1 O
on O
item O
three O
of O
the O
Brief O
Pain O
Inventory O
Short O
Form O
[ O
BPI O
- O
SF O
] O
questionnaire O
) O
or O
mildly O
symptomatic O
( O
score O
of O
2 O
or O
3 O
) O
and O
had O
not O
previously O
received O
chemotherapy O
. O

Patients O
were O
randomly O
assigned O
( O
1 O
: O
1 O
) O
to O
receive O
oral O
abiraterone O
( O
1 O
g O
daily O
) O
plus O
prednisone O
( O
5 O
mg O
twice O
daily O
) O
or O
placebo O
plus O
prednisone O
in O
continuous O
4 O
- O
week O
cycles O
. O

Pain O
was O
assessed O
with O
the O
BPI O
- O
SF O
questionnaire O
, O
and O
health O
- O
related O
quality O
of O
life O
( O
HRQoL O
) O
with O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
- O
Prostate O
( O
FACT O
- O
P O
) O
questionnaire O
. O

We O
analysed O
data O
with O
prespecified O
criteria O
for O
clinically O
meaningful O
pain O
progression O
and O
deterioration O
in O
HRQoL O
. O

All O
patients O
who O
underwent O
randomisation O
were O
included O
in O
analyses O
. O

1088 O
patients O
underwent O
randomisation O
: O
546 O
were O
assigned O
to O
abiraterone O
plus O
prednisone O
and O
542 O
to O
placebo O
plus O
prednisone O
. O

At O
the O
time O
of O
the O
second O
prespecified O
interim O
analysis O
, O
median O
follow O
- O
up O
was O
22 O
Â· O
2 O
months O
( O
IQR O
20 O
Â· O
2 O
- O
24 O
Â· O
8 O
) O
. O

Median B-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
mean I-Premise
pain I-Premise
intensity I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
26 I-Premise
Â· I-Premise
7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
19 I-Premise
Â· I-Premise
3 I-Premise
- I-Premise
not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
than I-Premise
in I-Premise
those I-Premise
assigned I-Premise
to I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
18 I-Premise
Â· I-Premise
4 I-Premise
months I-Premise
[ I-Premise
14 I-Premise
Â· I-Premise
9 I-Premise
- I-Premise
not I-Premise
estimable I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
0 I-Premise
Â· I-Premise
82 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0 I-Premise
Â· I-Premise
67 I-Premise
- I-Premise
1 I-Premise
Â· I-Premise
00 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
Â· I-Premise
0490 I-Premise
) I-Premise
, I-Premise
as I-Premise
was I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
pain I-Premise
interference I-Premise
with I-Premise
daily I-Premise
activities I-Premise
( I-Premise
10 I-Premise
Â· I-Premise
3 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
9 I-Premise
Â· I-Premise
3 I-Premise
- I-Premise
13 I-Premise
Â· I-Premise
0 I-Premise
] I-Premise
vs I-Premise
7 I-Premise
Â· I-Premise
4 I-Premise
months I-Premise
[ I-Premise
6 I-Premise
Â· I-Premise
4 I-Premise
- I-Premise
8 I-Premise
Â· I-Premise
6 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
HR I-Premise
0 I-Premise
Â· I-Premise
79 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0 I-Premise
Â· I-Premise
67 I-Premise
- I-Premise
0 I-Premise
Â· I-Premise
93 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
Â· I-Premise
005 I-Premise
) I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
worst I-Premise
pain I-Premise
was I-Premise
also I-Premise
longer I-Premise
with I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
26 I-Premise
Â· I-Premise
7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
19 I-Premise
Â· I-Premise
4 I-Premise
- I-Premise
not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
than I-Premise
with I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
19 I-Premise
Â· I-Premise
4 I-Premise
months I-Premise
[ I-Premise
16 I-Premise
Â· I-Premise
6 I-Premise
- I-Premise
not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
, I-Premise
but I-Premise
the I-Premise
difference I-Premise
was I-Premise
not I-Premise
significant I-Premise
( I-Premise
HR I-Premise
0 I-Premise
Â· I-Premise
85 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0 I-Premise
Â· I-Premise
69 I-Premise
- I-Premise
1 I-Premise
Â· I-Premise
04 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
Â· I-Premise
109 I-Premise
) I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
HRQoL I-Premise
deterioration I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
than I-Premise
in I-Premise
those I-Premise
assigned I-Premise
to I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
FACT I-Premise
- I-Premise
P I-Premise
total I-Premise
score I-Premise
( I-Premise
12 I-Premise
Â· I-Premise
7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
11 I-Premise
Â· I-Premise
1 I-Premise
- I-Premise
14 I-Premise
Â· I-Premise
0 I-Premise
] I-Premise
vs I-Premise
8 I-Premise
Â· I-Premise
3 I-Premise
months I-Premise
[ I-Premise
7 I-Premise
Â· I-Premise
4 I-Premise
- I-Premise
10 I-Premise
Â· I-Premise
6 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
HR I-Premise
0 I-Premise
Â· I-Premise
78 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0 I-Premise
Â· I-Premise
66 I-Premise
- I-Premise
0 I-Premise
Â· I-Premise
92 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
Â· I-Premise
003 I-Premise
) I-Premise
and I-Premise
by I-Premise
the I-Premise
score I-Premise
on I-Premise
its I-Premise
prostate I-Premise
- I-Premise
cancer I-Premise
- I-Premise
specific I-Premise
subscale I-Premise
( I-Premise
11 I-Premise
Â· I-Premise
1 I-Premise
months I-Premise
[ I-Premise
8 I-Premise
Â· I-Premise
6 I-Premise
- I-Premise
13 I-Premise
Â· I-Premise
8 I-Premise
] I-Premise
vs I-Premise
5 I-Premise
Â· I-Premise
8 I-Premise
months I-Premise
[ I-Premise
5 I-Premise
Â· I-Premise
5 I-Premise
- I-Premise
8 I-Premise
Â· I-Premise
3 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
HR I-Premise
0 I-Premise
Â· I-Premise
70 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0 I-Premise
Â· I-Premise
60 I-Premise
- I-Premise
0 I-Premise
Â· I-Premise
83 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
Â· I-Premise
0001 I-Premise
) I-Premise
. I-Premise

Abiraterone B-Claim
plus I-Claim
prednisone I-Claim
delays I-Claim
patient I-Claim
- I-Claim
reported I-Claim
pain I-Claim
progression I-Claim
and I-Claim
HRQoL I-Claim
deterioration I-Claim
in I-Claim
chemotherapy I-Claim
- I-Claim
naive I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
castration I-Claim
- I-Claim
resistant I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim

These B-Claim
results I-Claim
provide I-Claim
further I-Claim
support I-Claim
for I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
abiraterone I-Claim
in I-Claim
this I-Claim
population I-Claim
. I-Claim

Postoperative B-Claim
adjuvant I-Claim
chemoradiation I-Claim
treatment I-Claim
after I-Claim
curative I-Claim
resection I-Claim
for I-Claim
rectal I-Claim
cancer I-Claim
was I-Claim
needed I-Claim
to I-Claim
reduce I-Claim
recurrence I-Claim
and I-Claim
improve I-Claim
a I-Claim
survival I-Claim
rate I-Claim
. I-Claim

Intravenous B-Claim
5 I-Claim
- I-Claim
fluorouracil I-Claim
( I-Claim
5 I-Claim
- I-Claim
FU I-Claim
) I-Claim
and I-Claim
leucovorin I-Claim
has I-Claim
been I-Claim
a I-Claim
mainstay I-Claim
of I-Claim
chemotherapy I-Claim
, I-Claim
but O
oral B-Claim
5 I-Claim
- I-Claim
FU I-Claim
derivatives I-Claim
have I-Claim
been I-Claim
shown I-Claim
a I-Claim
comparable I-Claim
antitumor I-Claim
activity I-Claim
. I-Claim

Intravenous O
5 O
- O
FU O
and O
oral O
doxifluridine O
were O
compared O
with O
respect O
to O
therapeutic O
efficacy O
, O
drug O
toxicity O
, O
and O
quality O
of O
life O
. O

A O
total O
of O
166 O
patients O
were O
randomized O
to O
receive O
intravenous O
5 O
- O
FU O
( O
450 O
mg O
/ O
m2 O
/ O
day O
) O
or O
oral O
doxifluridine O
( O
900 O
mg O
/ O
m2 O
/ O
day O
) O
in O
combination O
with O
leucovorin O
( O
20 O
mg O
/ O
m2 O
/ O
day O
) O
for O
depth O
of O
invasion O
, O
nodal O
status O
, O
metastasis O
( O
TNM O
) O
stage O
II O
and O
III O
patients O
between O
October O
1997 O
and O
February O
1999 O
. O

Consecutive O
daily O
intravenous O
infusion O
for O
5 O
days O
per O
every O
month O
for O
a O
total O
of O
12 O
cycles O
( O
IV O
arm O
, O
n O
= O
74 O
) O
and O
oral O
doxifluridine O
daily O
for O
3 O
weeks O
and O
1 O
week O
rest O
for O
a O
total O
of O
12 O
cycles O
( O
oral O
arm O
, O
n O
= O
92 O
) O
. O

Drug O
toxicity O
and O
quality O
of O
life O
were O
observed O
. O

Quality O
of O
life O
was O
scored O
according O
to O
22 O
daily O
activity O
items O
( O
good O
, O
> O
or O
71 O
"""" O
; O
"""" O
fair O
, O
< O
70 O
"""" O
; O
"""" O
poor O
, O
< O
52 O
) O
. O

There O
was O
no O
difference O
of O
sex O
between O
two O
groups O
( O
IV O
arm O
: O
male O
/ O
female O
= O
45 O
/ O
29 O
, O
oral O
arm O
: O
male O
/ O
female O
= O
59 O
/ O
33 O
) O
. O

The O
mean O
age O
was O
52 O
. O
3 O
vs O
. O
59 O
. O
5 O
, O
respectively O
. O

There O
was O
also O
no O
difference O
of O
TNM O
stage O
distribution O
and O
type O
of O
operation O
between O
groups O
( O
P O
> O
. O
05 O
) O
. O

Mean B-Premise
numbers I-Premise
of I-Premise
chemotherapy I-Premise
cycles I-Premise
were I-Premise
6 I-Premise
. I-Premise
5 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
3 I-Premise
. I-Premise
7 I-Premise
( I-Premise
IV I-Premise
arm I-Premise
) I-Premise
vs I-Premise
. I-Premise
7 I-Premise
. I-Premise
2 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
4 I-Premise
. I-Premise
3 I-Premise
( I-Premise
oral I-Premise
arm I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
recurrence I-Premise
was I-Premise
9 I-Premise
/ I-Premise
74 I-Premise
( I-Premise
12 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
6 I-Premise
/ I-Premise
92 I-Premise
( I-Premise
6 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
937 I-Premise
) I-Premise
. I-Premise

Local B-Premise
recurrence I-Premise
was I-Premise
2 I-Premise
/ I-Premise
74 I-Premise
( I-Premise
stage I-Premise
III I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
2 I-Premise
. I-Premise
7 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
1 I-Premise
/ I-Premise
92 I-Premise
( I-Premise
stage I-Premise
II I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
1 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Systemic B-Premise
recurrence I-Premise
was I-Premise
7 I-Premise
/ I-Premise
74 I-Premise
( I-Premise
stage I-Premise
III I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
9 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
5 I-Premise
/ I-Premise
92 I-Premise
( I-Premise
stage I-Premise
III I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
5 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
site I-Premise
of I-Premise
systemic I-Premise
recurrence I-Premise
was I-Premise
the I-Premise
liver I-Premise
. I-Premise

Toxicity B-Premise
profile I-Premise
was I-Premise
as I-Premise
follows I-Premise
: I-Premise
leukopenia I-Premise
( I-Premise
30 I-Premise
/ I-Premise
74 I-Premise
vs I-Premise
. I-Premise
17 I-Premise
/ I-Premise
92 I-Premise
) I-Premise
and I-Premise
alopecia I-Premise
( I-Premise
21 I-Premise
/ I-Premise
74 I-Premise
vs I-Premise
. I-Premise
13 I-Premise
/ I-Premise
92 I-Premise
) I-Premise
were I-Premise
statistically I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
. I-Premise

Diarrhea B-Premise
was I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
. I-Premise

Poor B-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
between I-Premise
two I-Premise
groups I-Premise
was I-Premise
observed I-Premise
at I-Premise
1 I-Premise
month I-Premise
( I-Premise
23 I-Premise
. I-Premise
9 I-Premise
% I-Premise
vs I-Premise
. I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
months I-Premise
( I-Premise
15 I-Premise
. I-Premise
8 I-Premise
% I-Premise
vs I-Premise
. I-Premise
3 I-Premise
. I-Premise
7 I-Premise
% I-Premise
) I-Premise
after I-Premise
chemotherapy I-Premise
. I-Premise

Good B-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
was I-Premise
observed I-Premise
at I-Premise
1 I-Premise
month I-Premise
( I-Premise
19 I-Premise
. I-Premise
5 I-Premise
% I-Premise
vs I-Premise
. I-Premise
49 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
months I-Premise
( I-Premise
47 I-Premise
% I-Premise
vs I-Premise
. I-Premise
72 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

Oral B-Claim
doxifluridine I-Claim
with I-Claim
leucovorin I-Claim
shows I-Claim
a I-Claim
comparable I-Claim
therapeutic I-Claim
efficacy I-Claim
to I-Claim
intravenous I-Claim
5 I-Claim
- I-Claim
FU I-Claim
regimen I-Claim
with I-Claim
high I-Claim
quality I-Claim
of I-Claim
life I-Claim
as I-Claim
postoperative I-Claim
adjuvant I-Claim
therapy I-Claim
. I-Claim

The B-Claim
oral I-Claim
regimen I-Claim
also I-Claim
can I-Claim
be I-Claim
safely I-Claim
given I-Claim
with I-Claim
appropriate I-Claim
toxicity I-Claim
and I-Claim
tolerability I-Claim
. I-Claim

This O
phase O
III O
randomized O
trial O
compared O
two O
chemotherapy O
regimens O
, O
gemcitabine O
plus O
carboplatin O
and O
mitomycin O
, O
ifosfamide O
, O
and O
cisplatin O
, O
in O
chemotherapy O
- O
naive O
patients O
with O
advanced O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
NSCLC O
) O
. O

The O
regimens O
were O
compared O
with O
regard O
to O
effects O
on O
survival O
, O
response O
rates O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

Eligible O
patients O
had O
previously O
untreated O
stage O
IIIB O
or O
IV O
NSCLC O
suitable O
for O
cisplatin O
- O
based O
chemotherapy O
. O

Randomly O
assigned O
patients O
were O
to O
receive O
four O
cycles O
, O
each O
at O
3 O
- O
week O
intervals O
, O
of O
carboplatin O
area O
under O
the O
curve O
of O
5 O
on O
day O
1 O
plus O
gemcitabine O
1 O
, O
200 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
( O
GCa O
) O
or O
mitomycin O
6 O
mg O
/ O
m O
( O
2 O
) O
, O
ifosfamide O
3g O
/ O
m O
( O
2 O
) O
, O
and O
cisplatin O
50 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
( O
MIC O
) O
. O

Between O
February O
1999 O
and O
August O
2001 O
, O
422 O
patients O
( O
GCa O
, O
n O
= O
212 O
"""" O
; O
"""" O
MIC O
, O
n O
= O
210 O
) O
were O
randomly O
assigned O
in O
the O
United O
Kingdom O
. O

The O
majority O
of O
patients O
received O
the O
intended O
four O
cycles O
( O
GCa O
, O
64 O
% O
"""" O
; O
"""" O
MIC O
, O
61 O
% O
) O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
GCa I-Premise
compared I-Premise
with I-Premise
MIC I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0 I-Premise
. I-Premise
76 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
61 I-Premise
to I-Premise
0 I-Premise
. I-Premise
93 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
008 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
10 I-Premise
months I-Premise
with I-Premise
GCa I-Premise
and I-Premise
7 I-Premise
. I-Premise
6 I-Premise
months I-Premise
with I-Premise
MIC I-Premise
( I-Premise
difference I-Premise
, I-Premise
2 I-Premise
. I-Premise
4 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1 I-Premise
. I-Premise
0 I-Premise
to I-Premise
4 I-Premise
. I-Premise
0 I-Premise
) I-Premise
, I-Premise
and I-Premise
1 I-Premise
- I-Premise
year I-Premise
survival I-Premise
was I-Premise
40 I-Premise
% I-Premise
with I-Premise
GCa I-Premise
and I-Premise
30 I-Premise
% I-Premise
with I-Premise
MIC I-Premise
( I-Premise
difference I-Premise
, I-Premise
10 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3 I-Premise
% I-Premise
to I-Premise
18 I-Premise
% I-Premise
) I-Premise
. I-Premise

Overall B-Premise
response I-Premise
rates I-Premise
were I-Premise
similar I-Premise
( I-Premise
42 I-Premise
% I-Premise
for I-Premise
GCa I-Premise
v I-Premise
41 I-Premise
% I-Premise
for I-Premise
MIC I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
84 I-Premise
) I-Premise
. I-Premise

More B-Premise
thrombocytopenia I-Premise
occurred I-Premise
with I-Premise
GCa I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
was I-Premise
not I-Premise
associated I-Premise
with I-Premise
increased I-Premise
hospital I-Premise
admission I-Premise
or I-Premise
fatality I-Premise
. I-Premise

GCa B-Premise
caused I-Premise
less I-Premise
nausea I-Premise
, I-Premise
vomiting I-Premise
, I-Premise
constipation I-Premise
, I-Premise
and I-Premise
alopecia I-Premise
and I-Premise
was I-Premise
associated I-Premise
with I-Premise
fewer I-Premise
admissions I-Premise
for I-Premise
administration I-Premise
and I-Premise
better I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

In B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
, I-Claim
GCa I-Claim
chemotherapy I-Claim
was I-Claim
shown I-Claim
to I-Claim
be I-Claim
a I-Claim
better I-Claim
- I-Claim
tolerated I-Claim
treatment I-Claim
that I-Claim
conferred I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
MIC I-Claim
. I-Claim

To O
perform O
a O
randomized O
trial O
comparing O
70 O
and O
80 O
Gy O
radiotherapy O
for O
prostate O
cancer O
. O

A O
total O
of O
306 O
patients O
with O
localized O
prostate O
cancer O
were O
randomized O
. O

No O
androgen O
deprivation O
was O
allowed O
. O

The O
primary O
endpoint O
was O
biochemical O
relapse O
according O
to O
the O
modified O
1997 O
- O
American O
Society O
for O
Therapeutic O
Radiology O
and O
Oncology O
and O
Phoenix O
definitions O
. O

Toxicity O
was O
graded O
using O
the O
Radiation O
Therapy O
Oncology O
Group O
1991 O
criteria O
and O
the O
late O
effects O
on O
normal O
tissues O
- O
subjective O
, O
objective O
, O
management O
, O
analytic O
scales O
( O
LENT O
- O
SOMA O
) O
scales O
. O

The O
patients O
' O
quality O
of O
life O
was O
scored O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
30 O
- O
item O
cancer O
- O
specific O
and O
25 O
- O
item O
prostate O
- O
specific O
modules O
. O

The O
median O
follow O
- O
up O
was O
61 O
months O
. O

According O
to O
the O
1997 O
- O
American O
Society O
for O
Therapeutic O
Radiology O
and O
Oncology O
definition O
, O
the O
5 O
- O
year O
biochemical O
relapse O
rate O
was O
39 O
% O
and O
28 O
% O
in O
the O
- O
70 O
and O
80 O
- O
Gy O
arms O
, O
respectively O
( O
p O
= O
. O
036 O
) O
. O

Using O
the O
Phoenix O
definition O
, O
the O
5 O
- O
year O
biochemical O
relapse O
rate O
was O
32 O
% O
and O
23 O
. O
5 O
% O
, O
respectively O
( O
p O
= O
. O
09 O
) O
. O

The O
subgroup O
analysis O
showed O
a O
better O
biochemical O
outcome O
for O
the O
higher O
dose O
group O
with O
an O
initial O
prostate O
- O
specific O
antigen O
level O
> O
15 O
ng O
/ O
mL O
. O

At O
the O
last O
follow O
- O
up O
date O
, O
26 O
patients O
had O
died O
, O
10 O
of O
their O
disease O
and O
none O
of O
toxicity O
, O
with O
no O
differences O
between O
the O
two O
arms O
. O

According B-Premise
to I-Premise
the I-Premise
Radiation I-Premise
Therapy I-Premise
Oncology I-Premise
Group I-Premise
scale I-Premise
, I-Premise
the I-Premise
Grade I-Premise
2 I-Premise
or I-Premise
greater I-Premise
rectal I-Premise
toxicity I-Premise
rate I-Premise
was I-Premise
14 I-Premise
% I-Premise
and I-Premise
19 I-Premise
. I-Premise
5 I-Premise
% I-Premise
for I-Premise
the I-Premise
- I-Premise
70 I-Premise
and I-Premise
80 I-Premise
- I-Premise
Gy I-Premise
arms I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
22 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
Grade I-Premise
2 I-Premise
or I-Premise
greater I-Premise
urinary I-Premise
toxicity I-Premise
was I-Premise
10 I-Premise
% I-Premise
at I-Premise
70 I-Premise
Gy I-Premise
and I-Premise
17 I-Premise
. I-Premise
5 I-Premise
% I-Premise
at I-Premise
80 I-Premise
Gy I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
046 I-Premise
) I-Premise
. I-Premise

Similar B-Premise
results I-Premise
were I-Premise
observed I-Premise
using I-Premise
the I-Premise
LENT I-Premise
- I-Premise
SOMA I-Premise
scale I-Premise
. I-Premise

Bladder B-Premise
toxicity I-Premise
was I-Premise
more I-Premise
frequent I-Premise
at I-Premise
80 I-Premise
Gy I-Premise
than I-Premise
at I-Premise
70 I-Premise
Gy I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
039 I-Premise
) I-Premise
. I-Premise

The B-Premise
quality I-Premise
- I-Premise
of I-Premise
- I-Premise
life I-Premise
questionnaire I-Premise
results I-Premise
before I-Premise
and I-Premise
5 I-Premise
years I-Premise
after I-Premise
treatment I-Premise
were I-Premise
available I-Premise
for I-Premise
103 I-Premise
patients I-Premise
with I-Premise
no I-Premise
differences I-Premise
found I-Premise
between I-Premise
the I-Premise
- I-Premise
70 I-Premise
and I-Premise
80 I-Premise
- I-Premise
Gy I-Premise
arms I-Premise
. I-Premise

High B-Claim
- B-Claim
dose B-Claim
radiotherapy I-Claim
provided I-Claim
a I-Claim
better I-Claim
5 I-Claim
- I-Claim
year I-Claim
biochemical I-Claim
outcome I-Claim
with I-Claim
slightly I-Claim
greater I-Claim
toxicity I-Claim
. I-Claim

Several O
multicomponent O
regimens O
have O
been O
reported O
to O
be O
useful O
in O
advanced O
androgen O
- O
independent O
prostate O
cancer O
. O

We O
used O
a O
randomized O
phase O
II O
design O
to O
evaluate O
and O
compare O
two O
such O
regimens O
. O

Patients O
were O
accrued O
primarily O
in O
the O
community O
setting O
. O

Patients O
with O
progressive O
, O
androgen O
- O
independent O
prostate O
cancer O
were O
randomly O
assigned O
to O
one O
of O
two O
treatments O
: O
either O
ketoconazole O
/ O
doxorubicin O
alternating O
with O
vinblastine O
/ O
estramustine O
( O
KA O
/ O
VE O
) O
or O
paclitaxel O
, O
estramustine O
, O
and O
oral O
etoposide O
( O
TEE O
) O
. O

Patients O
were O
prospectively O
stratified O
on O
the O
basis O
of O
disease O
volume O
. O

The O
primary O
end O
points O
were O
response O
and O
overall O
survival O
time O
. O

A O
total O
of O
75 O
patients O
were O
registered O
"""" O
; O
"""" O
71 O
are O
included O
in O
the O
analysis O
. O

By O
the O
criterion O
of O
an O
80 O
% O
prostate O
- O
specific O
antigen O
reduction O
maintained O
for O
at O
least O
8 O
weeks O
, O
11 O
( O
30 O
% O
) O
of O
37 O
patients O
in O
the O
TEE O
arm O
responded O
, O
whereas O
11 O
( O
32 O
% O
) O
of O
34 O
assigned O
to O
KA O
/ O
VE O
responded O
. O

Median B-Premise
survival I-Premise
was I-Premise
16 I-Premise
. I-Premise
9 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
10 I-Premise
. I-Premise
5 I-Premise
to I-Premise
21 I-Premise
. I-Premise
2 I-Premise
months I-Premise
) I-Premise
in I-Premise
the I-Premise
TEE I-Premise
arm I-Premise
and I-Premise
23 I-Premise
. I-Premise
4 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
12 I-Premise
. I-Premise
9 I-Premise
to I-Premise
30 I-Premise
. I-Premise
6 I-Premise
months I-Premise
) I-Premise
for I-Premise
patients I-Premise
treated I-Premise
with I-Premise
KA I-Premise
/ I-Premise
VE I-Premise
. I-Premise

Many B-Premise
patients I-Premise
( I-Premise
24 I-Premise
% I-Premise
) I-Premise
failed I-Premise
to I-Premise
complete I-Premise
at I-Premise
least I-Premise
6 I-Premise
weeks I-Premise
of I-Premise
therapy I-Premise
, I-Premise
including I-Premise
five I-Premise
( I-Premise
8 I-Premise
% I-Premise
) I-Premise
treatment I-Premise
- I-Premise
related I-Premise
early I-Premise
deaths I-Premise
. I-Premise

Each B-Claim
of I-Claim
these I-Claim
regimens I-Claim
produced I-Claim
clinically I-Claim
significant I-Claim
responses I-Claim
, I-Claim
and O
the B-Claim
observed I-Claim
median I-Claim
survival I-Claim
( I-Claim
18 I-Claim
. I-Claim
9 I-Claim
months I-Claim
for I-Claim
all I-Claim
71 I-Claim
patients I-Claim
) I-Claim
compares I-Claim
favorably I-Claim
with I-Claim
previously I-Claim
published I-Claim
results I-Claim
, I-Claim
especially I-Claim
in I-Claim
the I-Claim
community I-Claim
setting I-Claim
. I-Claim

Nonetheless B-Claim
, I-Claim
it I-Claim
is I-Claim
apparent I-Claim
that I-Claim
these I-Claim
first I-Claim
- I-Claim
generation I-Claim
regimens I-Claim
must I-Claim
be I-Claim
applied I-Claim
judiciously I-Claim
, I-Claim
and O
thus B-Claim
we I-Claim
view I-Claim
efforts I-Claim
at I-Claim
better I-Claim
patient I-Claim
selection I-Claim
and I-Claim
the I-Claim
development I-Claim
of I-Claim
more I-Claim
tolerable I-Claim
therapies I-Claim
as I-Claim
higher I-Claim
priorities I-Claim
than I-Claim
carrying I-Claim
either I-Claim
of I-Claim
these I-Claim
regimens I-Claim
to I-Claim
phase I-Claim
III I-Claim
evaluation I-Claim
in I-Claim
the I-Claim
cooperative I-Claim
group I-Claim
setting I-Claim
. I-Claim

Systematic B-Claim
assessment I-Claim
is I-Claim
vital I-Claim
to I-Claim
palliative I-Claim
care I-Claim
, O
but O
documentation O
confirming O
completion O
of O
systematic O
assessment O
in O
hospice O
settings O
is O
often O
inadequate O
or O
absent O
. O

The O
objective O
of O
the O
study O
was O
to O
determine O
the O
efficacy O
of O
systematic O
feedback O
from O
standardized O
assessment O
tools O
for O
hospice O
patient O
- O
caregiver O
dyads O
in O
improving O
hospice O
outcomes O
compared O
with O
the O
usual O
clinical O
practice O
. O

The O
sample O
of O
patients O
( O
n O
= O
709 O
) O
newly O
admitted O
to O
hospice O
home O
care O
in O
2 O
hospices O
had O
designated O
family O
caregivers O
. O

The O
interdisciplinary O
teams O
( O
IDTs O
) O
caring O
for O
these O
dyads O
were O
randomly O
assigned O
to O
either O
experimental O
( O
n O
= O
338 O
) O
or O
control O
( O
n O
= O
371 O
) O
conditions O
. O

Data O
were O
collected O
from O
both O
groups O
of O
dyads O
using O
standardized O
assessments O
on O
admission O
and O
1 O
week O
after O
each O
of O
the O
first O
2 O
IDT O
meetings O
in O
which O
these O
dyads O
were O
discussed O
. O

The O
experimental O
intervention O
consisted O
of O
reporting O
data O
from O
the O
standardized O
assessments O
to O
the O
IDTs O
. O

Results B-Premise
showed I-Premise
improved I-Premise
patient I-Premise
depression I-Premise
( I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
the I-Premise
intervention I-Premise
and I-Premise
improvement I-Premise
in I-Premise
both I-Premise
groups I-Premise
in I-Premise
patients I-Premise
' I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

No B-Premise
other I-Premise
patient I-Premise
outcomes I-Premise
( I-Premise
symptom I-Premise
distress I-Premise
, I-Premise
spiritual I-Premise
needs I-Premise
) I-Premise
or I-Premise
caregiver I-Premise
outcomes I-Premise
( I-Premise
depression I-Premise
, I-Premise
support I-Premise
, I-Premise
spiritual I-Premise
needs I-Premise
) I-Premise
were I-Premise
significantly I-Premise
different I-Premise
. I-Premise

Assessment O
of O
depression O
added O
to O
usual O
care O
probably O
had O
an O
effect O
because O
it O
is O
not O
normally O
a O
focus O
of O
hospice O
staff O
. O

Hospice B-Premise
care I-Premise
was I-Premise
so I-Premise
good I-Premise
during I-Premise
the I-Premise
study I-Premise
that I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
improved I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
standard I-Premise
care I-Premise
and I-Premise
left I-Premise
little I-Premise
room I-Premise
for I-Premise
improvement I-Premise
in I-Premise
other I-Premise
variables I-Premise
. I-Premise

Systematic B-Claim
assessment I-Claim
of I-Claim
depression I-Claim
is I-Claim
needed I-Claim
in I-Claim
hospice I-Claim
patients I-Claim
. I-Claim

No O
caregiver O
variables O
changed O
, O
which O
may O
indicate O
a O
need O
for O
a O
focus O
on O
caregivers O
. O

This O
study O
aims O
to O
examine O
the O
effectiveness O
of O
a O
self O
- O
management O
multimodal O
comprehensive O
coping O
strategy O
program O
( O
CCSP O
) O
on O
quality O
of O
life O
( O
QOL O
) O
among O
breast O
cancer O
patients O
1 O
year O
after O
treatment O
. O

Patients O
( O
n O
= O
110 O
) O
with O
stage O
II O
, O
III O
, O
or O
IV O
breast O
cancer O
scheduled O
to O
receive O
high O
dose O
chemotherapy O
and O
autologous O
hematopoietic O
stem O
cell O
transplantation O
were O
randomized O
to O
either O
CCSP O
treatment O
or O
control O
group O
. O

The O
CCSP O
intervention O
was O
taught O
2 O
week O
before O
hospital O
admission O
with O
reinforcement O
at O
specified O
times O
during O
treatment O
and O
3 O
months O
after O
discharge O
. O

The O
CCSP O
components O
included O
educational O
information O
, O
cognitive O
restructuring O
, O
coping O
skills O
enhancement O
, O
and O
relaxation O
with O
guided O
imagery O
. O

Instruments O
administered O
at O
baseline O
included O
the O
following O
: O
Quality O
of O
Life O
Index O
- O
Cancer O
Version O
( O
QOLI O
- O
CV O
) O
, O
State O
- O
Trait O
Anxiety O
Inventory O
, O
Beck O
Depression O
Inventory O
, O
and O
Coping O
Strategies O
Questionnaire O
. O

At O
1 O
- O
year O
follow O
- O
up O
, O
patients O
( O
n O
= O
73 O
) O
completed O
and O
returned O
the O
follow O
- O
up O
QOLI O
- O
CV O
. O

Patients O
were O
mainly O
â‰¥ O
40 O
years O
of O
age O
, O
married O
, O
Caucasian O
, O
and O
diagnosed O
with O
advanced O
breast O
cancer O
. O

A B-Premise
model I-Premise
measuring I-Premise
effectiveness I-Premise
of I-Premise
CCSP I-Premise
on I-Premise
QOL I-Premise
( I-Premise
total I-Premise
and I-Premise
subscale I-Premise
) I-Premise
at I-Premise
1 I-Premise
- I-Premise
year I-Premise
follow I-Premise
- I-Premise
up I-Premise
showed I-Premise
that I-Premise
the I-Premise
CCSP I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
38 I-Premise
) I-Premise
had I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
health I-Premise
and I-Premise
functioning I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
and I-Premise
socioeconomic I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
and I-Premise
psychological I-Premise
/ I-Premise
spiritual I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
35 I-Premise
) I-Premise
. I-Premise

The B-Premise
CCSP I-Premise
patients I-Premise
frequently I-Premise
used I-Premise
the I-Premise
CCSP I-Premise
to I-Premise
manage I-Premise
psychological I-Premise
( I-Premise
51 I-Premise
% I-Premise
) I-Premise
and I-Premise
sleep I-Premise
problems I-Premise
( I-Premise
60 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
CCSP I-Premise
improved I-Premise
QOL I-Premise
for I-Premise
patients I-Premise
at I-Premise
1 I-Premise
- I-Premise
year I-Premise
follow I-Premise
- I-Premise
up I-Premise
. I-Premise

Patients B-Premise
overwhelmingly I-Premise
reported I-Premise
that I-Premise
CCSP I-Premise
was I-Premise
beneficial I-Premise
. I-Premise

The B-Claim
CCSP I-Claim
as I-Claim
an I-Claim
effective I-Claim
coping I-Claim
intervention I-Claim
has I-Claim
potential I-Claim
as I-Claim
a I-Claim
self I-Claim
- I-Claim
management I-Claim
program I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
etoposide I-Claim
plus I-Claim
cisplatin I-Claim
( I-Claim
EP I-Claim
) I-Claim
is I-Claim
considered I-Claim
to I-Claim
be I-Claim
standard I-Claim
therapy I-Claim
for I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
SCLC I-Claim
) I-Claim
. I-Claim

To O
determine O
whether O
drug O
intensification O
improves O
survival O
of O
patients O
with O
extensive O
SCLC O
, O
we O
compared O
this O
treatment O
with O
a O
four O
- O
drug O
regimen O
containing O
EP O
plus O
cyclophosphamide O
and O
4 O
' O
- O
epidoxorubicin O
( O
PCDE O
) O
. O

In O
a O
phase O
III O
clinical O
trial O
organized O
by O
the O
French O
Federation O
of O
Cancer O
Institutes O
, O
patients O
were O
randomly O
assigned O
to O
receive O
either O
EP O
( O
n O
= O
109 O
"""" O
; O
"""" O
etoposide O
at O
a O
dose O
of O
100 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
- O
3 O
plus O
cisplatin O
at O
100 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
2 O
) O
or O
PCDE O
( O
n O
= O
117 O
"""" O
; O
"""" O
etoposide O
and O
cisplatin O
given O
as O
in O
EP O
plus O
cyclophosphamide O
at O
400 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
- O
3 O
and O
4 O
' O
- O
epidoxorubicin O
at O
40 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
) O
every O
4 O
weeks O
. O

Both O
groups O
received O
a O
total O
of O
six O
cycles O
. O

Survival O
differences O
were O
analyzed O
by O
Wilcoxon O
and O
log O
- O
rank O
tests O
. O

Associations O
of O
treatment O
group O
and O
putative O
prognostic O
variables O
with O
survival O
were O
tested O
in O
the O
Cox O
proportional O
hazards O
model O
. O

Quality O
of O
life O
was O
assessed O
from O
the O
responses O
to O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
quality O
- O
of O
- O
life O
questionnaire O
( O
C30 O
, O
health O
status O
and O
lung O
cancer O
module O
13 O
) O
. O

All O
statistical O
tests O
were O
two O
- O
sided O
. O

Patients B-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
had I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
higher I-Premise
frequency I-Premise
of I-Premise
combined I-Premise
complete I-Premise
plus I-Premise
partial I-Premise
responses I-Premise
compared I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
( I-Premise
21 I-Premise
% I-Premise
plus I-Premise
55 I-Premise
% I-Premise
versus I-Premise
13 I-Premise
% I-Premise
plus I-Premise
48 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
02 I-Premise
for I-Premise
difference I-Premise
in I-Premise
combined I-Premise
objective I-Premise
responses I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
survived I-Premise
longer I-Premise
than I-Premise
those I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
( I-Premise
1 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rate I-Premise
: I-Premise
40 I-Premise
% I-Premise
and I-Premise
29 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
median I-Premise
survival I-Premise
: I-Premise
10 I-Premise
. I-Premise
5 I-Premise
and I-Premise
9 I-Premise
. I-Premise
3 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
log I-Premise
- I-Premise
rank I-Premise
P I-Premise
= I-Premise
. I-Premise
0067 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
Cox I-Premise
model I-Premise
, I-Premise
the I-Premise
relative I-Premise
risk I-Premise
of I-Premise
death I-Premise
for I-Premise
patients I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
compared I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
was I-Premise
0 I-Premise
. I-Premise
70 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
= I-Premise
0 I-Premise
. I-Premise
51 I-Premise
to I-Premise
0 I-Premise
. I-Premise
95 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
the B-Premise
disease I-Premise
also I-Premise
progressed I-Premise
more I-Premise
slowly I-Premise
in I-Premise
patients I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
. I-Premise

Hematologic B-Premise
toxicity I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
( I-Premise
22 I-Premise
% I-Premise
with I-Premise
documented I-Premise
infections I-Premise
compared I-Premise
with I-Premise
8 I-Premise
% I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
0038 I-Premise
) I-Premise
, I-Premise
and O
the B-Premise
toxicity I-Premise
- I-Premise
related I-Premise
death I-Premise
rate I-Premise
was I-Premise
9 I-Premise
% I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
versus I-Premise
5 I-Premise
. I-Premise
5 I-Premise
% I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
22 I-Premise
) I-Premise
. I-Premise

The B-Claim
global I-Claim
health I-Claim
status I-Claim
showed I-Claim
similar I-Claim
improvement I-Claim
in I-Claim
both I-Claim
arms I-Claim
during I-Claim
treatment I-Claim
. I-Claim

Compared B-Claim
with I-Claim
the I-Claim
EP I-Claim
regimen I-Claim
, I-Claim
the I-Claim
PCDE I-Claim
regimen I-Claim
yielded I-Claim
higher I-Claim
response I-Claim
rates I-Claim
and I-Claim
better I-Claim
survival I-Claim
rates I-Claim
in I-Claim
patients I-Claim
with I-Claim
extensive I-Claim
SCLC I-Claim
without I-Claim
affecting I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
of I-Claim
the I-Claim
patients I-Claim
during I-Claim
chemotherapy I-Claim
. I-Claim

Although O
many O
drug O
combination O
therapies O
have O
been O
proposed O
, O
there B-Claim
is I-Claim
no I-Claim
standard I-Claim
therapy I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
carcinoma I-Claim
. I-Claim

The B-Claim
superiority I-Claim
of I-Claim
combination I-Claim
therapy I-Claim
over I-Claim
monochemotherapy I-Claim
has I-Claim
not I-Claim
been I-Claim
demonstrated I-Claim
convincingly I-Claim
. I-Claim

To O
explore O
the O
role O
of O
monochemotherapy O
, O
the O
authors O
evaluated O
5 O
- O
fluorouracil O
( O
5 O
- O
FU O
) O
, O
modulated O
by O
6S O
- O
leucovorin O
( O
6S O
- O
LV O
) O
and O
a O
cisplatin O
- O
containing O
regimen O
, O
which O
was O
comprised O
of O
epirubicin O
, O
etoposide O
, O
and O
cisplatin O
with O
the O
addition O
of O
the O
reversal O
agent O
lonidamine O
( O
EEP O
- O
L O
) O
. O

After O
stratification O
according O
to O
performance O
status O
( O
PS O
) O
and O
resection O
of O
the O
primary O
tumor O
, O
72 O
patients O
with O
advanced O
gastric O
carcinoma O
were O
randomized O
to O
2 O
parallel O
Phase O
II O
trials O
with O
5 O
- O
FU O
/ O
6S O
- O
LV O
and O
EEP O
- O
L O
, O
respectively O
. O

Thirty O
- O
six O
patients O
in O
Study O
A O
received O
bolus O
6S O
- O
LV O
, O
100 O
mg O
/ O
m2 O
, O
followed O
by O
bolus O
5 O
- O
FU O
, O
370 O
mg O
/ O
m2 O
, O
on O
Days O
1 O
- O
5 O
and O
36 O
others O
in O
Study O
B O
received O
epirubicin O
, O
30 O
mg O
/ O
m2 O
, O
on O
Days O
1 O
and O
5 O
"""" O
; O
"""" O
etoposide O
, O
100 O
mg O
/ O
m2 O
, O
on O
Days O
1 O
, O
3 O
, O
and O
5 O
"""" O
; O
"""" O
cisplatin O
, O
30 O
mg O
/ O
m2 O
, O
on O
Days O
2 O
and O
4 O
"""" O
; O
"""" O
and O
lonidamine O
, O
150 O
mg O
/ O
day O
. O

There O
were O
6 O
partial O
responses O
( O
18 O
. O
2 O
% O
) O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
+ O
/ O
- O
13 O
. O
2 O
) O
in O
Study O
A O
and O
7 O
partial O
responses O
( O
21 O
. O
9 O
% O
) O
( O
95 O
% O
CI O
+ O
/ O
- O
14 O
. O
3 O
) O
in O
Study O
B O
. O

Partial O
responses O
were O
more O
frequent O
in O
patients O
with O
resected O
tumors O
or O
with O
an O
Eastern O
Cooperative O
Oncology O
Group O
PS O
of O
0 O
- O
1 O
. O

The B-Premise
median I-Premise
duration I-Premise
of I-Premise
response I-Premise
was I-Premise
8 I-Premise
. I-Premise
8 I-Premise
and I-Premise
8 I-Premise
. I-Premise
3 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
Study I-Premise
A I-Premise
and I-Premise
Study I-Premise
B I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
reached I-Premise
8 I-Premise
months I-Premise
in I-Premise
Study I-Premise
A I-Premise
and I-Premise
9 I-Premise
months I-Premise
in I-Premise
Study I-Premise
B I-Premise
. I-Premise

In B-Premise
the I-Premise
whole I-Premise
population I-Premise
of I-Premise
patients I-Premise
survival I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
patients I-Premise
with I-Premise
a I-Premise
PS I-Premise
of I-Premise
0 I-Premise
- I-Premise
1 I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
with I-Premise
a I-Premise
PS I-Premise
of I-Premise
0 I-Premise
- I-Premise
1 I-Premise
and I-Premise
a I-Premise
resected I-Premise
tumor I-Premise
had I-Premise
the I-Premise
significantly I-Premise
longest I-Premise
survival I-Premise
both I-Premise
in I-Premise
EEP I-Premise
- I-Premise
L I-Premise
treated I-Premise
patients I-Premise
and I-Premise
in I-Premise
all I-Premise
evaluable I-Premise
patients I-Premise
in I-Premise
the I-Premise
two I-Premise
studies I-Premise
. I-Premise

The B-Premise
most I-Premise
frequent I-Premise
World I-Premise
Health I-Premise
Organization I-Premise
Grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
toxic I-Premise
effects I-Premise
were I-Premise
gastrointestinal I-Premise
in I-Premise
Study I-Premise
A I-Premise
and I-Premise
hematologic I-Premise
in I-Premise
Study I-Premise
B I-Premise
. I-Premise

No B-Premise
treatment I-Premise
- I-Premise
related I-Premise
death I-Premise
was I-Premise
observed I-Premise
. I-Premise

The B-Claim
efficacy I-Claim
of I-Claim
5 I-Claim
- I-Claim
FU I-Claim
, I-Claim
modulated I-Claim
with I-Claim
6S I-Claim
- I-Claim
LV I-Claim
, I-Claim
is I-Claim
moderate I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
carcinoma I-Claim
, I-Claim
similar I-Claim
to I-Claim
cisplatin I-Claim
- I-Claim
containing I-Claim
regimens I-Claim
. I-Claim

PS B-Claim
and I-Claim
other I-Claim
prognostic I-Claim
factors I-Claim
could I-Claim
influence I-Claim
the I-Claim
response I-Claim
rate I-Claim
, I-Claim
which I-Claim
does I-Claim
not I-Claim
appear I-Claim
to I-Claim
be I-Claim
a I-Claim
reliable I-Claim
parameter I-Claim
for I-Claim
evaluating I-Claim
the I-Claim
outcome I-Claim
of I-Claim
chemotherapy I-Claim
trials I-Claim
. I-Claim

To O
assess O
the O
effects O
of O
an O
expressive O
writing O
( O
EW O
) O
intervention O
on O
perceptions O
of O
emotional O
support O
in O
women O
completing O
treatment O
for O
early O
stage O
breast O
cancer O
. O

Women O
were O
recruited O
to O
the O
study O
during O
their O
final O
week O
of O
treatment O
. O

Of O
260 O
eligible O
patients O
, O
104 O
( O
40 O
% O
) O
agreed O
to O
participate O
, O
and O
93 O
were O
randomised O
. O

Women O
in O
the O
writing O
group O
wrote O
for O
20 O
min O
on O
four O
consecutive O
days O
. O

The O
control O
group O
received O
normal O
care O
. O

Women O
' O
s O
perceptions O
of O
emotional O
support O
, O
quality O
of O
life O
( O
QOL O
) O
, O
mood O
, O
and O
healthcare O
utilisation O
were O
assessed O
at O
baseline O
, O
1 O
month O
, O
3 O
months O
and O
6 O
months O
. O

Interviews O
were O
conducted O
to O
explore O
women O
' O
s O
experience O
of O
writing O
. O

Eighty O
participants O
completed O
all O
follow O
- O
ups O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
effect I-Premise
of I-Premise
group I-Premise
on I-Premise
women I-Premise
' I-Premise
s I-Premise
perceptions I-Premise
of I-Premise
social I-Premise
support I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
being I-Premise
more I-Premise
satisfied I-Premise
with I-Premise
the I-Premise
emotional I-Premise
support I-Premise
they I-Premise
received I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

Satisfaction B-Premise
with I-Premise
emotional I-Premise
support I-Premise
was I-Premise
negatively I-Premise
correlated I-Premise
with I-Premise
depression I-Premise
/ I-Premise
dejection I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
and I-Premise
anger I-Premise
/ I-Premise
hostility I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
and I-Premise
positively I-Premise
correlated I-Premise
with I-Premise
social I-Premise
and I-Premise
family I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
6 I-Premise
months I-Premise
post I-Premise
intervention I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
effects I-Premise
of I-Premise
the I-Premise
intervention I-Premise
on I-Premise
mood I-Premise
, I-Premise
QOL I-Premise
or I-Premise
healthcare I-Premise
utilisation I-Premise
. I-Premise

Most B-Premise
participants I-Premise
found I-Premise
writing I-Premise
valuable I-Premise
and I-Premise
did I-Premise
not I-Premise
report I-Premise
any I-Premise
long I-Premise
- I-Premise
term I-Premise
negative I-Premise
effects I-Premise
. I-Premise

EW B-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
higher I-Claim
level I-Claim
of I-Claim
satisfaction I-Claim
with I-Claim
emotional I-Claim
support I-Claim
compared I-Claim
with I-Claim
controls I-Claim
. I-Claim

Given O
the O
existing O
evidence O
supporting O
the O
importance O
of O
social O
support O
in O
adjustment O
to O
breast O
cancer O
, O
it B-Claim
seems I-Claim
feasible I-Claim
to I-Claim
suggest I-Claim
that I-Claim
EW I-Claim
may I-Claim
be I-Claim
a I-Claim
cost I-Claim
effective I-Claim
accessible I-Claim
treatment I-Claim
that I-Claim
could I-Claim
be I-Claim
incorporated I-Claim
into I-Claim
the I-Claim
ongoing I-Claim
care I-Claim
of I-Claim
women I-Claim
. I-Claim

This O
study O
tested O
hyperbaric O
oxygen O
( O
HBO O
) O
as O
an O
adjunct O
to O
surgery O
and O
antibiotics O
in O
the O
treatment O
of O
bisphosphonate O
- O
related O
osteonecrosis O
of O
the O
jaw O
( O
ONJ O
) O
and O
evaluated O
its O
effects O
on O
gingival O
healing O
, O
pain O
, O
and O
quality O
of O
life O
. O

The O
investigators O
implemented O
a O
randomized O
controlled O
trial O
and O
enrolled O
a O
sample O
composed O
of O
patients O
with O
ONJ O
, O
where O
the O
predictor O
variable O
was O
HBO O
administered O
at O
2 O
atm O
twice O
a O
day O
for O
40 O
treatments O
as O
an O
adjunct O
to O
conventional O
therapy O
of O
surgery O
and O
antibiotics O
versus O
conventional O
therapy O
alone O
. O

Over O
the O
next O
24 O
months O
, O
oral O
lesion O
size O
and O
number O
, O
pain O
, O
and O
quality O
of O
life O
were O
assessed O
. O

Forty O
- O
six O
patients O
( O
mean O
age O
, O
66 O
yrs O
"""" O
; O
"""" O
57 O
% O
women O
) O
contributed O
data O
to O
the O
trial O
. O

There O
were O
no O
statistically O
significant O
differences O
in O
the O
distribution O
of O
variables O
used O
to O
assess O
randomization O
success O
between O
the O
HBO O
and O
standard O
treatment O
groups O
. O

Seventeen B-Premise
of I-Premise
25 I-Premise
HBO I-Premise
- I-Premise
treated I-Premise
patients I-Premise
( I-Premise
68 I-Premise
% I-Premise
) I-Premise
improved I-Premise
versus I-Premise
8 I-Premise
of I-Premise
21 I-Premise
controls I-Premise
( I-Premise
38 I-Premise
. I-Premise
1 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
043 I-Premise
, I-Premise
Ï‡ I-Premise
( I-Premise
2 I-Premise
) I-Premise
test I-Premise
) I-Premise
. I-Premise

Mean B-Premise
time I-Premise
to I-Premise
improvement I-Premise
was I-Premise
39 I-Premise
. I-Premise
7 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
22 I-Premise
. I-Premise
4 I-Premise
to I-Premise
57 I-Premise
. I-Premise
0 I-Premise
weeks I-Premise
) I-Premise
for I-Premise
HBO I-Premise
- I-Premise
treated I-Premise
patients I-Premise
versus I-Premise
67 I-Premise
. I-Premise
9 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
CI I-Premise
, I-Premise
48 I-Premise
. I-Premise
4 I-Premise
to I-Premise
87 I-Premise
. I-Premise
5 I-Premise
weeks I-Premise
) I-Premise
for I-Premise
controls I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
03 I-Premise
, I-Premise
log I-Premise
- I-Premise
rank I-Premise
test I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
complete I-Premise
gingival I-Premise
healing I-Premise
occurred I-Premise
in I-Premise
only I-Premise
14 I-Premise
of I-Premise
25 I-Premise
HBO I-Premise
- I-Premise
treated I-Premise
patients I-Premise
( I-Premise
52 I-Premise
% I-Premise
) I-Premise
versus I-Premise
7 I-Premise
of I-Premise
21 I-Premise
controls I-Premise
( I-Premise
33 I-Premise
. I-Premise
3 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
203 I-Premise
, I-Premise
Ï‡ I-Premise
( I-Premise
2 I-Premise
) I-Premise
test I-Premise
) I-Premise
, I-Premise
and I-Premise
time I-Premise
to I-Premise
healing I-Premise
was I-Premise
59 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
42 I-Premise
. I-Premise
8 I-Premise
% I-Premise
to I-Premise
75 I-Premise
. I-Premise
8 I-Premise
% I-Premise
) I-Premise
for I-Premise
HBO I-Premise
- I-Premise
treated I-Premise
patients I-Premise
versus I-Premise
70 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
CI I-Premise
, I-Premise
52 I-Premise
. I-Premise
2 I-Premise
% I-Premise
to I-Premise
88 I-Premise
. I-Premise
36 I-Premise
% I-Premise
) I-Premise
for I-Premise
controls I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
32 I-Premise
, I-Premise
log I-Premise
- I-Premise
rank I-Premise
test I-Premise
) I-Premise
. I-Premise

Pain B-Premise
decreased I-Premise
faster I-Premise
for I-Premise
HBO I-Premise
- I-Premise
treated I-Premise
subjects I-Premise
( I-Premise
P I-Premise
< I-Premise
. I-Premise
01 I-Premise
, I-Premise
linear I-Premise
regression I-Premise
) I-Premise
. I-Premise

Quality B-Premise
- B-Premise
of B-Premise
- B-Premise
life B-Premise
scores I-Premise
for I-Premise
physical I-Premise
health I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
and I-Premise
perceived I-Premise
health I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
043 I-Premise
) I-Premise
decreased I-Premise
at I-Premise
6 I-Premise
months I-Premise
for I-Premise
control I-Premise
group I-Premise
but I-Premise
for I-Premise
not I-Premise
the I-Premise
HBO I-Premise
group I-Premise
. I-Premise

ONJ B-Claim
is I-Claim
multifactorial I-Claim
and I-Claim
no I-Claim
single I-Claim
treatment I-Claim
modality I-Claim
is I-Claim
likely I-Claim
to I-Claim
reverse I-Claim
it I-Claim
"""" I-Claim
; I-Claim
"""" I-Claim
however B-Claim
, I-Claim
it I-Claim
is I-Claim
treatable I-Claim
and I-Claim
even I-Claim
advanced I-Claim
presentations I-Claim
can I-Claim
improve I-Claim
with I-Claim
intensive I-Claim
multimodal I-Claim
therapy I-Claim
. I-Claim

Clinically B-Claim
, I-Claim
HBO I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
useful I-Claim
adjunct I-Claim
to I-Claim
ONJ I-Claim
treatment I-Claim
, I-Claim
particularly I-Claim
for I-Claim
more I-Claim
severe I-Claim
cases I-Claim
, I-Claim
although I-Claim
this I-Claim
study I-Claim
was I-Claim
underpowered I-Claim
to I-Claim
fully I-Claim
support I-Claim
this I-Claim
claim I-Claim
. I-Claim

Therapy O
for O
polycystic O
liver O
is O
invasive O
, O
expensive O
, O
and O
has O
disappointing O
long O
- O
term O
results O
. O

Treatment O
with O
somatostatin O
analogues O
slowed O
kidney O
growth O
in O
patients O
with O
polycystic O
kidney O
disease O
( O
PKD O
) O
and O
reduced O
liver O
and O
kidney O
volume O
in O
a O
PKD O
rodent O
model O
. O

We O
evaluated O
the O
effects O
of O
lanreotide O
, O
a O
somatostatin O
analogue O
, O
in O
patients O
with O
polycystic O
liver O
because O
of O
autosomal O
- O
dominant O
( O
AD O
) O
PKD O
or O
autosomal O
- O
dominant O
polycystic O
liver O
disease O
( O
PCLD O
) O
. O

We O
performed O
a O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
in O
2 O
tertiary O
referral O
centers O
. O

Patients O
with O
polycystic O
liver O
( O
n O
= O
54 O
) O
were O
randomly O
assigned O
to O
groups O
given O
lanreotide O
( O
120 O
mg O
) O
or O
placebo O
, O
administered O
every O
28 O
days O
for O
24 O
weeks O
. O

The O
primary O
end O
point O
was O
the O
difference O
in O
total O
liver O
volume O
, O
measured O
by O
computerized O
tomography O
at O
weeks O
0 O
and O
24 O
. O

Analyses O
were O
performed O
on O
an O
intention O
- O
to O
- O
treat O
basis O
. O

Baseline B-Premise
characteristics I-Premise
were I-Premise
comparable I-Premise
for I-Premise
both I-Premise
groups I-Premise
, I-Premise
except B-Premise
that I-Premise
more I-Premise
patients I-Premise
with I-Premise
ADPKD I-Premise
were I-Premise
assigned I-Premise
to I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
liver I-Premise
volume I-Premise
decreased I-Premise
2 I-Premise
. I-Premise
9 I-Premise
% I-Premise
, I-Premise
from I-Premise
4606 I-Premise
mL I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
: I-Premise
547 I-Premise
- I-Premise
8665 I-Premise
) I-Premise
to I-Premise
4471 I-Premise
mL I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
542 I-Premise
- I-Premise
8401 I-Premise
mL I-Premise
) I-Premise
, I-Premise
in I-Premise
patients I-Premise
given I-Premise
lanreotide I-Premise
. I-Premise

In B-Premise
the I-Premise
placebo I-Premise
group I-Premise
, I-Premise
the I-Premise
mean I-Premise
liver I-Premise
volume I-Premise
increased I-Premise
1 I-Premise
. I-Premise
6 I-Premise
% I-Premise
, I-Premise
from I-Premise
4689 I-Premise
mL I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
613 I-Premise
- I-Premise
8765 I-Premise
mL I-Premise
) I-Premise
to I-Premise
4895 I-Premise
mL I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
739 I-Premise
- I-Premise
9053 I-Premise
mL I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise

Post B-Premise
hoc I-Premise
stratification I-Premise
for I-Premise
patients I-Premise
with I-Premise
ADPKD I-Premise
or I-Premise
PCLD I-Premise
revealed I-Premise
similar I-Premise
changes I-Premise
in I-Premise
liver I-Premise
volume I-Premise
, I-Premise
with I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
patients I-Premise
given I-Premise
lanreotide I-Premise
( I-Premise
P I-Premise
< I-Premise
. I-Premise
01 I-Premise
for I-Premise
both I-Premise
diseases I-Premise
) I-Premise
. I-Premise

In B-Claim
patients I-Claim
with I-Claim
polycystic I-Claim
liver I-Claim
, I-Claim
6 I-Claim
months I-Claim
of I-Claim
treatment I-Claim
with I-Claim
lanreotide I-Claim
reduces I-Claim
liver I-Claim
volume I-Claim
. I-Claim

A B-Claim
combination I-Claim
of I-Claim
mitoxantrone I-Claim
plus I-Claim
prednisone I-Claim
is I-Claim
preferable I-Claim
to I-Claim
prednisone I-Claim
alone I-Claim
for I-Claim
reduction I-Claim
of I-Claim
pain I-Claim
in I-Claim
men I-Claim
with I-Claim
metastatic I-Claim
, I-Claim
hormone I-Claim
- I-Claim
resistant I-Claim
, I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
these O
treatments O
on O
health O
- O
related O
quality O
of O
life O
( O
HQL O
) O
. O

Men O
with O
metastatic O
prostate O
cancer O
( O
n O
= O
161 O
) O
were O
randomized O
to O
receive O
either O
daily O
prednisone O
alone O
or O
mitoxantrone O
( O
every O
3 O
weeks O
) O
plus O
prednisone O
. O

Those O
who O
received O
prednisone O
alone O
could O
have O
mitoxantrone O
added O
after O
6 O
weeks O
if O
there O
was O
no O
improvement O
in O
pain O
. O

HQL O
was O
assessed O
before O
treatment O
initiation O
and O
then O
every O
3 O
weeks O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
- O
of O
- O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ O
- O
C30 O
) O
and O
the O
Quality O
of O
Life O
Module O
- O
Prostate O
14 O
( O
QOLM O
- O
P14 O
) O
, O
a O
trial O
- O
specific O
module O
developed O
for O
this O
study O
. O

An O
intent O
- O
to O
- O
treat O
analysis O
was O
used O
to O
determine O
the O
mean O
duration O
of O
HQL O
improvement O
and O
differences O
in O
improvement O
duration O
between O
groups O
of O
patients O
. O

At B-Premise
6 I-Premise
weeks I-Premise
, I-Premise
both I-Premise
groups I-Premise
showed I-Premise
improvement I-Premise
in I-Premise
several I-Premise
HQL I-Premise
domains I-Premise
, I-Premise
and O
only B-Premise
physical I-Premise
functioning I-Premise
and I-Premise
pain I-Premise
were I-Premise
better I-Premise
in I-Premise
the I-Premise
mitoxantrone I-Premise
- I-Premise
plus I-Premise
- I-Premise
prednisone I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
prednisone I-Premise
- I-Premise
alone I-Premise
group I-Premise
. I-Premise

After B-Premise
6 I-Premise
weeks I-Premise
, I-Premise
patients I-Premise
taking I-Premise
prednisone I-Premise
showed I-Premise
no I-Premise
improvement I-Premise
in I-Premise
HQL I-Premise
scores I-Premise
, I-Premise
whereas I-Premise
those I-Premise
taking I-Premise
mitoxantrone I-Premise
plus I-Premise
prednisone I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
009 I-Premise
) I-Premise
, I-Premise
four I-Premise
functioning I-Premise
domains I-Premise
, I-Premise
and I-Premise
nine I-Premise
symptoms I-Premise
( I-Premise
. I-Premise
001 I-Premise
< I-Premise
P I-Premise
< I-Premise
. I-Premise
1 I-Premise
) I-Premise
, I-Premise
and O
the B-Premise
improvement I-Premise
( I-Premise
> I-Premise
10 I-Premise
units I-Premise
on I-Premise
a I-Premise
scale I-Premise
of I-Premise
0 I-Premise
to100 I-Premise
) I-Premise
lasted I-Premise
longer I-Premise
than I-Premise
in I-Premise
the I-Premise
prednisone I-Premise
- I-Premise
alone I-Premise
group I-Premise
( I-Premise
. I-Premise
004 I-Premise
< I-Premise
P I-Premise
< I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

The B-Premise
addition I-Premise
of I-Premise
mitoxantrone I-Premise
to I-Premise
prednisone I-Premise
after I-Premise
failure I-Premise
of I-Premise
prednisone I-Premise
alone I-Premise
was I-Premise
associated I-Premise
with I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
pain I-Premise
impact I-Premise
, I-Premise
pain I-Premise
relief I-Premise
, I-Premise
insomnia I-Premise
, I-Premise
and I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
. I-Premise
001 I-Premise
< I-Premise
P I-Premise
< I-Premise
. I-Premise
003 I-Premise
) I-Premise
. I-Premise

Treatment B-Claim
with I-Claim
mitoxantrone I-Claim
plus I-Claim
prednisone I-Claim
was I-Claim
associated I-Claim
with I-Claim
greater I-Claim
and I-Claim
longer I-Claim
- I-Claim
lasting I-Claim
improvement I-Claim
in I-Claim
several I-Claim
HQL I-Claim
domains I-Claim
and I-Claim
symptoms I-Claim
than I-Claim
treatment I-Claim
with I-Claim
prednisone I-Claim
alone I-Claim
. I-Claim

Studies O
on O
quality O
of O
life O
( O
QOL O
) O
among O
women O
with O
endometrial O
cancer O
have O
shown O
that O
patients O
who O
undergo O
pelvic O
radiotherapy O
report O
lower O
role O
functioning O
and O
more O
diarrhea O
and O
fatigue O
. O

In O
the O
Post O
Operative O
Radiation O
Therapy O
in O
Endometrial O
Cancer O
( O
PORTEC O
) O
trial O
, O
patients O
with O
endometrial O
carcinoma O
were O
randomly O
assigned O
to O
receive O
external O
- O
beam O
radiotherapy O
( O
EBRT O
) O
or O
vaginal O
brachytherapy O
( O
VBT O
) O
. O

QOL O
was O
evaluated O
by O
using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
and O
subscales O
from O
the O
prostate O
cancer O
module O
, O
PR O
- O
25 O
, O
and O
the O
ovarian O
cancer O
module O
, O
OV O
- O
28 O
. O

PORTEC O
- O
2 O
accrued O
427 O
patients O
between O
2002 O
and O
2006 O
, O
of O
whom O
214 O
were O
randomly O
assigned O
to O
EBRT O
, O
and O
213 O
were O
randomly O
assigned O
to O
VBT O
. O

Three O
- O
hundred O
forty O
- O
eight O
patients O
( O
81 O
% O
) O
were O
evaluable O
for O
QOL O
. O

QOL O
outcomes O
were O
analyzed O
at O
a O
median O
follow O
- O
up O
of O
2 O
years O
. O

At O
baseline O
after O
surgery O
, O
patient O
functioning O
was O
at O
the O
lowest O
level O
, O
and O
it O
increased O
during O
and O
after O
radiotherapy O
to O
reach O
a O
plateau O
after O
12 O
months O
. O

Patients B-Premise
in I-Premise
the I-Premise
VBT I-Premise
group I-Premise
reported I-Premise
better I-Premise
social I-Premise
functioning I-Premise
( I-Premise
P I-Premise
< I-Premise
. I-Premise
002 I-Premise
) I-Premise
and I-Premise
lower I-Premise
symptom I-Premise
scores I-Premise
for I-Premise
diarrhea I-Premise
, I-Premise
fecal I-Premise
leakage I-Premise
, I-Premise
the I-Premise
need I-Premise
to I-Premise
stay I-Premise
close I-Premise
to I-Premise
the I-Premise
toilet I-Premise
, I-Premise
and I-Premise
limitation I-Premise
in I-Premise
daily I-Premise
activities I-Premise
because I-Premise
of I-Premise
bowel I-Premise
symptoms I-Premise
( I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

At O
baseline O
, O
15 O
% O
of O
patients O
were O
sexually O
active O
"""" O
; O
"""" O
this O
increased O
significantly O
to O
39 O
% O
during O
the O
first O
year O
( O
P O
< O
. O
001 O
) O
. O

Sexual B-Premise
functioning I-Premise
and I-Premise
symptoms I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

Patients B-Premise
who I-Premise
received I-Premise
EBRT I-Premise
reported I-Premise
significantly I-Premise
higher I-Premise
levels I-Premise
of I-Premise
diarrhea I-Premise
and I-Premise
bowel I-Premise
symptoms I-Premise
. I-Premise

This O
resulted O
in O
a O
higher O
need O
to O
remain O
close O
to O
a O
toilet O
and O
, O
as O
a O
consequence O
, O
more O
limitation O
of O
daily O
activities O
because O
of O
bowel O
symptoms O
and O
decreased O
social O
functioning O
. O

Vaginal B-Claim
brachytherapy I-Claim
provides I-Claim
a I-Claim
better I-Claim
QOL I-Claim
, I-Claim
and I-Claim
should I-Claim
be I-Claim
the I-Claim
preferred I-Claim
treatment I-Claim
from I-Claim
a I-Claim
QOL I-Claim
perspective I-Claim
. I-Claim

To O
assess O
the O
safety O
and O
health O
- O
related O
quality O
of O
life O
( O
HRQOL O
) O
of O
continuous O
combined O
hormone O
replacement O
therapy O
( O
ccHRT O
) O
with O
estradiol O
valerate O
/ O
medroxyprogesterone O
acetate O
( O
E O
( O
2 O
) O
V O
/ O
MPA O
) O
over O
nine O
years O
and O
at O
follow O
- O
up O
one O
year O
after O
discontinuation O
. O

A O
total O
of O
419 O
women O
were O
randomized O
to O
one O
of O
four O
treatments O
: O
once O
- O
daily O
1 O
mg O
E2V O
/ O
2 O
. O
5 O
mg O
MPA O
( O
1 O
+ O
2 O
. O
5 O
group O
) O
"""" O
; O
"""" O
1 O
mg O
E2V O
/ O
5 O
mg O
MPA O
daily O
( O
1 O
+ O
5 O
group O
) O
"""" O
; O
"""" O
2 O
mg O
E2V O
/ O
2 O
. O
5 O
mg O
MPA O
daily O
( O
2 O
+ O
2 O
. O
5 O
group O
) O
"""" O
; O
"""" O
2 O
mg O
E2V O
/ O
5 O
mg O
MPA O
daily O
( O
2 O
+ O
5 O
group O
) O
( O
Indivina O
, O
Orion O
Pharma O
) O
. O

For O
the O
last O
six O
months O
, O
all O
received O
the O
1 O
+ O
2 O
. O
5 O
dosage O
. O

The O
2 O
+ O
2 O
. O
5 O
dosage O
was O
discontinued O
at O
the O
end O
of O
year O
7 O
. O

A O
total O
of O
198 O
women O
continued O
after O
year O
7 O
. O

Annualized O
percentage O
rates O
for O
cardiovascular O
events O
[ O
corrected O
] O
and O
endometrial O
cancers O
[ O
corrected O
] O
were O
below O
national O
rates O
for O
Finland O
and O
those O
reported O
for O
the O
Women O
' O
s O
Health O
Initiative O
. O

There B-Premise
were I-Premise
no I-Premise
serious I-Premise
events I-Premise
with I-Premise
the I-Premise
1 I-Premise
+ I-Premise
2 I-Premise
. I-Premise
5 I-Premise
dosage I-Premise
or I-Premise
after I-Premise
ccHRT I-Premise
discontinuation I-Premise
. I-Premise

Climacteric B-Premise
symptoms I-Premise
remained I-Premise
significantly I-Premise
below I-Premise
baseline I-Premise
values I-Premise
after I-Premise
dosage I-Premise
reduction I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
some B-Premise
symptoms I-Premise
recurred I-Premise
after I-Premise
discontinuation I-Premise
of I-Premise
ccHRT I-Premise
. I-Premise

HRQOL B-Premise
ratings I-Premise
improved I-Premise
with I-Premise
ccHRT I-Premise
, I-Premise
irrespective I-Premise
of I-Premise
dosage I-Premise
, I-Premise
including I-Premise
depressed I-Premise
mood I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
health I-Premise
perception I-Premise
and I-Premise
sexual I-Premise
interest I-Premise
. I-Premise

Scores B-Premise
on I-Premise
a I-Premise
scale I-Premise
assessing I-Premise
daily I-Premise
functioning I-Premise
and I-Premise
enjoyment I-Premise
( I-Premise
Q I-Premise
- I-Premise
LES I-Premise
- I-Premise
Q I-Premise
) I-Premise
improved I-Premise
from I-Premise
year I-Premise
7 I-Premise
to I-Premise
year I-Premise
9 I-Premise
. I-Premise

They B-Premise
deteriorated I-Premise
during I-Premise
follow I-Premise
- I-Premise
up I-Premise
in I-Premise
women I-Premise
not I-Premise
continuing I-Premise
ccHRT I-Premise
. I-Premise

Lower B-Claim
dosages I-Claim
of I-Claim
HRT I-Claim
were I-Claim
as I-Claim
effective I-Claim
as I-Claim
higher I-Claim
doses I-Claim
in I-Claim
improving I-Claim
climacteric I-Claim
symptoms I-Claim
and I-Claim
HRQOL I-Claim
ratings I-Claim
and I-Claim
had I-Claim
fewer I-Claim
safety I-Claim
concerns I-Claim
. I-Claim

Following B-Premise
discontinuation I-Premise
of I-Premise
ccHRT I-Premise
, I-Premise
patient I-Premise
satisfaction I-Premise
was I-Premise
variable I-Premise
, I-Premise
with I-Premise
15 I-Premise
% I-Premise
electing I-Premise
to I-Premise
continue I-Premise
or I-Premise
restart I-Premise
HRT I-Premise
and I-Premise
7 I-Premise
% I-Premise
resuming I-Premise
at I-Premise
follow I-Premise
- I-Premise
up I-Premise
. I-Premise

This B-Claim
supports I-Claim
the I-Claim
need I-Claim
for I-Claim
an I-Claim
individualized I-Claim
approach I-Claim
to I-Claim
therapy I-Claim
recommendations I-Claim
. I-Claim

Few O
randomized O
trials O
have O
compared O
the O
survival O
benefit O
of O
interferon O
- O
alfa O
over O
controls O
in O
metastatic O
renal O
cell O
carcinoma O
, O
and O
none O
has O
been O
performed O
using O
interleukin O
- O
2 O
. O

The O
Programme O
Etude O
Rein O
Cytokines O
( O
PERCY O
) O
Quattro O
trial O
was O
designed O
to O
evaluate O
both O
cytokines O
for O
their O
survival O
benefit O
to O
intermediate O
prognosis O
patients O
, O
who O
represent O
the O
majority O
of O
candidates O
for O
these O
treatments O
. O

Patients O
were O
randomized O
in O
a O
2 O
- O
by O
- O
2 O
factorial O
design O
to O
medroxyprogesterone O
acetate O
200 O
mg O
daily O
, O
interferon O
- O
alfa O
9 O
million O
IU O
3 O
times O
a O
week O
, O
subcutaneous O
interleukin O
- O
2 O
9 O
million O
IU O
daily O
, O
or O
a O
combination O
of O
both O
cytokines O
. O

Tumor O
response O
was O
evaluated O
at O
Week O
12 O
and O
Month O
6 O
"""" O
; O
"""" O
progression O
- O
free O
patients O
received O
further O
identical O
treatment O
for O
a O
maximum O
of O
3 O
additional O
months O
. O

Primary O
endpoint O
was O
overall O
survival O
"""" O
; O
"""" O
secondary O
endpoints O
were O
disease O
- O
free O
survival O
, O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

Survival O
was O
analyzed O
on O
an O
intent O
- O
to O
- O
treat O
basis O
. O

From O
January O
2000 O
to O
July O
2004 O
, O
492 O
patients O
were O
enrolled O
. O

Analysis O
was O
performed O
after O
a O
29 O
. O
2 O
- O
month O
median O
follow O
- O
up O
( O
range O
, O
0 O
months O
to O
54 O
. O
6 O
months O
) O
. O

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
survival I-Premise
differences I-Premise
between I-Premise
the I-Premise
244 I-Premise
interferon I-Premise
- I-Premise
alfa I-Premise
- I-Premise
treated I-Premise
patients I-Premise
and I-Premise
248 I-Premise
noninterferon I-Premise
- I-Premise
alfa I-Premise
patients I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1 I-Premise
. I-Premise
00 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
81 I-Premise
- I-Premise
1 I-Premise
. I-Premise
24 I-Premise
) I-Premise
or I-Premise
between I-Premise
the I-Premise
247 I-Premise
interleukin I-Premise
- I-Premise
2 I-Premise
and I-Premise
245 I-Premise
noninterleukin I-Premise
- I-Premise
2 I-Premise
- I-Premise
treated I-Premise
patients I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1 I-Premise
. I-Premise
07 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
87 I-Premise
- I-Premise
1 I-Premise
. I-Premise
33 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
log I-Premise
rank I-Premise
, I-Premise
0 I-Premise
. I-Premise
99 I-Premise
and I-Premise
0 I-Premise
. I-Premise
52 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
- I-Premise
4 I-Premise
toxicities I-Premise
were I-Premise
significantly I-Premise
more I-Premise
frequent I-Premise
in I-Premise
cytokine I-Premise
- I-Premise
treated I-Premise
patients I-Premise
than I-Premise
in I-Premise
medroxyprogesterone I-Premise
- I-Premise
treated I-Premise
patients I-Premise
. I-Premise

Subcutaneous B-Claim
interleukin I-Claim
- I-Claim
2 I-Claim
and I-Claim
/ I-Claim
or I-Claim
interferon I-Claim
- I-Claim
alfa I-Claim
provide I-Claim
no I-Claim
survival I-Claim
benefit I-Claim
in I-Claim
metastatic I-Claim
renal I-Claim
cancers I-Claim
of I-Claim
intermediate I-Claim
prognosis I-Claim
, I-Claim
and I-Claim
they I-Claim
induce I-Claim
a I-Claim
significant I-Claim
risk I-Claim
of I-Claim
toxicity I-Claim
. I-Claim

Newly B-Claim
available I-Claim
angiogenesis I-Claim
inhibitors I-Claim
should I-Claim
be I-Claim
preferred I-Claim
for I-Claim
these I-Claim
patients I-Claim
. I-Claim

To O
investigate O
whether O
the O
effect O
of O
hypofractionated O
thoracic O
radiotherapy O
( O
TRT O
) O
is O
comparable O
to O
more O
standard O
fractionated O
radiotherapy O
( O
RT O
) O
in O
advanced O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
NSCLC O
) O
. O

A O
total O
of O
421 O
patients O
with O
locally O
advanced O
stage O
III O
or O
stage O
IV O
NSCLC O
tumors O
were O
included O
. O

Inclusion O
criteria O
were O
inoperable O
, O
disease O
too O
advanced O
for O
curative O
radiotherapy O
, O
and O
chest O
symptoms O
or O
central O
tumor O
threatening O
the O
airways O
. O

Patients O
were O
randomly O
assigned O
to O
three O
arms O
: O
A O
, O
17 O
Gy O
per O
two O
fractions O
( O
n O
= O
146 O
) O
"""" O
; O
"""" O
B O
, O
42 O
Gy O
per O
15 O
fractions O
( O
n O
= O
145 O
) O
"""" O
; O
"""" O
and O
C O
, O
50 O
Gy O
per O
25 O
fractions O
( O
n O
= O
130 O
) O
. O

Four O
hundred O
seven O
patients O
were O
eligible O
for O
the O
study O
"""" O
; O
"""" O
395 O
patients O
( O
97 O
% O
) O
participated O
in O
the O
health O
- O
related O
quality O
- O
of O
- O
life O
( O
HRQOL O
) O
study O
. O

The O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
( O
QLQ O
) O
- O
C30 O
and O
EORTC O
QLQ O
- O
lung O
cancer O
- O
specific O
module O
( O
LC13 O
) O
were O
used O
to O
investigate O
airway O
symptom O
relief O
and O
changes O
in O
HRQOL O
. O

Assessments O
were O
performed O
before O
TRT O
and O
until O
week O
54 O
. O

Clinicians O
' O
assessments O
of O
symptom O
improvement O
were O
at O
2 O
, O
6 O
, O
and O
14 O
weeks O
after O
completion O
of O
TRT O
. O

The O
patients O
were O
observed O
for O
a O
minimum O
of O
3 O
years O
. O

Results O
Baseline O
prognostic O
data O
were O
equally O
distributed O
in O
the O
treatment O
groups O
. O

Patient O
compliance O
with O
respect O
to O
the O
HRQOL O
investigation O
was O
minimum O
74 O
% O
. O

HRQOL B-Premise
and I-Premise
symptom I-Premise
relief I-Premise
were I-Premise
equivalent I-Premise
in I-Premise
the I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

No B-Premise
significant I-Premise
difference I-Premise
in I-Premise
survival I-Premise
among I-Premise
arms I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
and I-Premise
C I-Premise
was I-Premise
found I-Premise
, I-Premise
with I-Premise
median I-Premise
survival I-Premise
8 I-Premise
. I-Premise
2 I-Premise
, I-Premise
7 I-Premise
. I-Premise
0 I-Premise
, I-Premise
and I-Premise
6 I-Premise
. I-Premise
8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Our B-Claim
data I-Claim
indicate I-Claim
that I-Claim
protracted I-Claim
palliative I-Claim
TRT I-Claim
renders I-Claim
no I-Claim
improvement I-Claim
in I-Claim
symptom I-Claim
relief I-Claim
, I-Claim
HRQOL I-Claim
, I-Claim
or I-Claim
survival I-Claim
when I-Claim
compared I-Claim
with I-Claim
short I-Claim
- I-Claim
term I-Claim
hypofractionated I-Claim
treatment I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Cisplatin B-Claim
reduces I-Claim
plasma I-Claim
ghrelin I-Claim
levels I-Claim
through I-Claim
the I-Claim
5 I-Claim
- I-Claim
hydroxytryptamine I-Claim
( I-Claim
5 I-Claim
- I-Claim
HT I-Claim
) I-Claim
receptor I-Claim
. I-Claim

This O
may O
cause O
cisplatin O
- O
induced O
gastrointestinal O
disorders O
and O
hinders O
the O
continuation O
of O
chemotherapy O
. O

The O
authors O
of O
this O
report O
conducted O
a O
prospective O
, O
randomized O
phase O
2 O
trial O
to O
evaluate O
the O
effects O
of O
exogenous O
ghrelin O
during O
cisplatin O
- O
based O
chemotherapy O
. O

Forty O
- O
two O
patients O
with O
esophageal O
cancer O
who O
were O
receiving O
cisplatin O
- O
based O
neoadjuvant O
chemotherapy O
were O
assigned O
to O
either O
a O
ghrelin O
group O
( O
n O
= O
21 O
) O
or O
a O
placebo O
group O
( O
n O
= O
21 O
) O
. O

They O
received O
either O
intravenous O
infusions O
of O
synthetic O
human O
ghrelin O
( O
3 O
Î¼g O
/ O
kg O
) O
or O
saline O
twice O
daily O
for O
1 O
week O
with O
cisplatin O
administration O
. O

The O
primary O
endpoint O
was O
changes O
in O
oral O
calorie O
intake O
, O
and O
the O
secondary O
endpoints O
were O
chemotherapy O
- O
related O
adverse O
events O
"""" O
; O
"""" O
appetite O
visual O
analog O
scale O
( O
VAS O
) O
scores O
"""" O
; O
"""" O
changes O
in O
gastrointestinal O
hormones O
and O
nutritional O
status O
, O
including O
rapid O
turnover O
proteins O
, O
and O
quality O
of O
life O
( O
QoL O
) O
estimated O
with O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QoL O
core O
questionnaire O
( O
QLQ O
- O
C30 O
) O
. O

Two O
patients O
were O
excluded O
from O
the O
final O
analysis O
: O
One O
patient O
suspended O
ghrelin O
administration O
because O
of O
excessive O
diaphoresis O
, O
and O
another O
patient O
in O
the O
placebo O
group O
failed O
to O
monitor O
the O
self O
- O
questionnaire O
. O

Food B-Premise
intake I-Premise
and I-Premise
appetite I-Premise
VAS I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
ghrelin I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
18 I-Premise
. I-Premise
2 I-Premise
Â± I-Premise
5 I-Premise
. I-Premise
2 I-Premise
kcal I-Premise
/ I-Premise
kg I-Premise
/ I-Premise
day I-Premise
vs I-Premise
12 I-Premise
. I-Premise
7 I-Premise
Â± I-Premise
3 I-Premise
. I-Premise
4 I-Premise
kcal I-Premise
/ I-Premise
kg I-Premise
/ I-Premise
day I-Premise
[ I-Premise
P I-Premise
= I-Premise
. I-Premise
001 I-Premise
] I-Premise
and I-Premise
6 I-Premise
. I-Premise
2 I-Premise
Â± I-Premise
0 I-Premise
. I-Premise
9 I-Premise
vs I-Premise
4 I-Premise
. I-Premise
1 I-Premise
Â± I-Premise
0 I-Premise
. I-Premise
9 I-Premise
[ I-Premise
P I-Premise
< I-Premise
. I-Premise
0001 I-Premise
] I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
ghrelin I-Premise
group I-Premise
had I-Premise
fewer I-Premise
adverse I-Premise
events I-Premise
during I-Premise
chemotherapy I-Premise
related I-Premise
to I-Premise
anorexia I-Premise
and I-Premise
nausea I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Significant B-Premise
deterioration I-Premise
was I-Premise
noted I-Premise
after I-Premise
chemotherapy I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
in I-Premise
QoL I-Premise
scores I-Premise
, I-Premise
appetite I-Premise
, I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
and I-Premise
global I-Premise
health I-Premise
status I-Premise
. I-Premise

Short B-Claim
- B-Claim
term B-Claim
administration I-Claim
of I-Claim
exogenous I-Claim
ghrelin I-Claim
at I-Claim
the I-Claim
start I-Claim
of I-Claim
cisplatin I-Claim
- I-Claim
based I-Claim
chemotherapy I-Claim
stimulated I-Claim
food I-Claim
intake I-Claim
and I-Claim
minimized I-Claim
adverse I-Claim
events I-Claim
. I-Claim

Chemoradiotherapy O
( O
CRT O
) O
- O
induced O
oral O
mucositis O
( O
OM O
) O
adversely O
affects O
a O
patient O
' O
s O
oral O
functions O
and O
quality O
of O
life O
( O
QOL O
) O
. O

Low O
- O
level O
laser O
therapy O
( O
LLLT O
) O
showed O
some O
preventive O
and O
curative O
effects O
against O
clinically O
reported O
objective O
measures O
of O
OM O
in O
few O
trials O
including O
our O
recently O
published O
study O
. O

There O
is O
dearth O
of O
evidence O
regarding O
the O
effects O
of O
LLLT O
on O
patient O
' O
s O
subjective O
experience O
of O
OM O
and O
QOL O
. O

Hence O
, O
we O
did O
this O
study O
to O
evaluate O
the O
effects O
of O
LLLT O
on O
a O
patient O
' O
s O
reported O
measures O
of O
OM O
and O
QOL O
in O
head O
and O
neck O
cancer O
( O
HNC O
) O
patients O
receiving O
CRT O
. O

This O
triple O
blinded O
study O
randomized O
220 O
HNC O
patients O
scheduled O
for O
CRT O
( O
three O
weekly O
Cisplatin O
+ O
RT O
= O
66 O
Gray O
( O
2 O
Gy O
/ O
session O
) O
, O
five O
fractions O
/ O
week O
for O
6 O
. O
5 O
weeks O
, O
total O
33 O
fractions O
) O
into O
laser O
( O
110 O
) O
and O
placebo O
( O
110 O
) O
groups O
. O

The O
laser O
group O
received O
LLLT O
( O
Technomed O
Electronics O
Advanced O
Laser O
Therapy O
1000 O
, O
He O
- O
Ne O
, O
Î» O
= O
632 O
. O
8 O
nm O
, O
power O
density O
= O
24 O
mW O
/ O
cm O
( O
2 O
) O
, O
dosage O
= O
3 O
. O
0 O
J O
at O
each O
point O
, O
total O
dose O
/ O
session O
= O
36 O
- O
40 O
J O
, O
spot O
size O
1 O
cm O
( O
2 O
) O
, O
irradiation O
time O
/ O
point O
125 O
s O
) O
before O
each O
radiation O
session O
, O
while O
the O
placebo O
group O
did O
not O
receive O
laser O
therapy O
. O

Methodology O
was O
similar O
to O
our O
recently O
published O
study O
( O
Gautam O
et O
al O
. O

Radiother O
Oncol O
104 O
: O
349 O
- O
354 O
, O
2012 O
) O
. O

In O
this O
part O
of O
our O
study O
, O
a O
blinded O
assessor O
collected O
subjective O
outcomes O
of O
the O
patient O
' O
s O
reported O
measures O
of O
OM O
using O
Oral O
Mucositis O
Weekly O
Questionnaire O
- O
Head O
and O
Neck O
( O
OMWQ O
- O
HN O
) O
and O
QOL O
using O
Functional O
Assessment O
of O
Cancer O
Treatment O
- O
Head O
and O
Neck O
( O
FACT O
- O
HN O
) O
Questionnaire O
. O

Data O
were O
analyzed O
using O
repeated O
measure O
ANOVA O
through O
general O
linear O
model O
. O

Statistical O
significance O
was O
kept O
at O
p O
< O
0 O
. O
05 O
. O

Results B-Premise
analysis I-Premise
revealed I-Premise
that I-Premise
OMWQ I-Premise
- I-Premise
HN I-Premise
( I-Premise
F I-Premise
= I-Premise
12 I-Premise
. I-Premise
199 I-Premise
, I-Premise
df I-Premise
= I-Premise
6 I-Premise
, I-Premise
1314 I-Premise
, I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
FACT I-Premise
- I-Premise
HN I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
LLLT I-Premise
than I-Premise
placebo I-Premise
group I-Premise
patients I-Premise
. I-Premise

Also O
, O
a B-Premise
significant I-Premise
reduction I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
in I-Premise
incidence I-Premise
of I-Premise
severe I-Premise
OM I-Premise
, I-Premise
need I-Premise
for I-Premise
opioid I-Premise
analgesics I-Premise
, I-Premise
and I-Premise
total I-Premise
parenteral I-Premise
nutrition I-Premise
was I-Premise
observed I-Premise
. I-Premise

LLLT B-Claim
was I-Claim
effective I-Claim
in I-Claim
improving I-Claim
the I-Claim
patient I-Claim
' I-Claim
s I-Claim
subjective I-Claim
experience I-Claim
of I-Claim
OM I-Claim
and I-Claim
QOL I-Claim
in I-Claim
HNC I-Claim
patients I-Claim
receiving I-Claim
CRT I-Claim
. I-Claim

Due O
to O
concerns O
of O
fragility O
fracture O
, O
exercise O
is O
a O
perceived O
contraindication O
for O
prostate O
cancer O
patients O
with O
bone O
metastases O
. O

These O
patients O
experience O
significant O
functional O
impairment O
and O
muscle O
atrophy O
, O
which O
may O
lead O
to O
an O
increased O
likelihood O
of O
skeletal O
complicaTIOns O
( O
i O
. O
e O
. O
, O
pathological O
fracture O
, O
bone O
pain O
) O
and O
/ O
or O
falls O
. O

Safe O
resistance O
exercise O
prescription O
may O
counteract O
this O
effect O
. O

The O
aim O
of O
this O
feasibility O
trial O
was O
to O
determine O
the O
safety O
and O
efficacy O
of O
resistance O
exercise O
by O
prostate O
cancer O
survivors O
with O
bone O
metastatic O
disease O
. O

Twenty O
men O
with O
established O
bone O
metastases O
secondary O
to O
prostate O
cancer O
were O
randomly O
assigned O
to O
a O
12 O
- O
week O
resistance O
exercise O
program O
in O
which O
exercise O
prescription O
was O
based O
on O
the O
location O
of O
bone O
lesions O
( O
n O
= O
10 O
) O
or O
usual O
care O
( O
n O
= O
10 O
) O
. O

Outcomes O
included O
safety O
and O
tolerance O
of O
the O
exercise O
program O
, O
physical O
function O
, O
physical O
activity O
level O
, O
body O
composition O
, O
fatigue O
, O
quality O
of O
life O
and O
psychological O
distress O
. O

Outcomes O
were O
compared O
between O
groups O
using O
analysis O
of O
covariance O
adjusted O
for O
baseline O
values O
. O

Participants O
had O
significant O
disease O
load O
with O
65 O
% O
of O
participants O
presenting O
with O
two O
or O
more O
regions O
affected O
by O
bone O
metastases O
and O
an O
average O
Gleason O
score O
of O
8 O
. O
2Â±0 O
. O
9 O
. O

Five O
participants O
( O
exercise O
= O
2 O
"""" O
; O
"""" O
usual O
care O
= O
3 O
) O
did O
not O
complete O
the O
intervention O
, O
three O
of O
which O
were O
due O
to O
advancing O
disease O
( O
exercise O
= O
2 O
"""" O
; O
"""" O
usual O
care O
= O
1 O
) O
. O

No B-Premise
adverse I-Premise
events I-Premise
or I-Premise
skeletal I-Premise
complications I-Premise
occurred I-Premise
during I-Premise
the I-Premise
supervised I-Premise
exercise I-Premise
sessions I-Premise
. I-Premise

The B-Premise
exercise I-Premise
program I-Premise
was I-Premise
well I-Premise
tolerated I-Premise
as I-Premise
evidenced I-Premise
by I-Premise
high I-Premise
attendance I-Premise
( I-Premise
83 I-Premise
% I-Premise
) I-Premise
and I-Premise
compliance I-Premise
rates I-Premise
( I-Premise
93 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
ability I-Premise
of I-Premise
the I-Premise
participants I-Premise
to I-Premise
exercise I-Premise
at I-Premise
an I-Premise
intensity I-Premise
within I-Premise
the I-Premise
target I-Premise
range I-Premise
for I-Premise
cancer I-Premise
survivors I-Premise
( I-Premise
rating I-Premise
of I-Premise
perceived I-Premise
exertion I-Premise
= I-Premise
13 I-Premise
. I-Premise
8Â±1 I-Premise
. I-Premise
5 I-Premise
) I-Premise
. I-Premise

The B-Premise
change I-Premise
in I-Premise
physical I-Premise
function I-Premise
( I-Premise
muscle I-Premise
strength I-Premise
âˆ¼11 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
submaximal I-Premise
aerobic I-Premise
exercise I-Premise
capacity I-Premise
âˆ¼5 I-Premise
% I-Premise
and I-Premise
ambulation I-Premise
âˆ¼12 I-Premise
% I-Premise
) I-Premise
, I-Premise
physical I-Premise
activity I-Premise
level I-Premise
( I-Premise
âˆ¼24 I-Premise
% I-Premise
) I-Premise
and I-Premise
lean I-Premise
mass I-Premise
( I-Premise
âˆ¼3 I-Premise
% I-Premise
) I-Premise
differed I-Premise
significantly I-Premise
between I-Premise
groups I-Premise
following I-Premise
the I-Premise
intervention I-Premise
, I-Premise
with I-Premise
favorable I-Premise
changes I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
. I-Premise

No B-Premise
significant I-Premise
between I-Premise
- I-Premise
group I-Premise
differences I-Premise
were I-Premise
observed I-Premise
for I-Premise
fatigue I-Premise
, I-Premise
quality I-Premise
of I-Premise
life I-Premise
or I-Premise
psychological I-Premise
distress I-Premise
. I-Premise

This B-Claim
initial I-Claim
evidence I-Claim
involving I-Claim
a I-Claim
small I-Claim
sample I-Claim
size I-Claim
suggests I-Claim
that I-Claim
appropriately I-Claim
designed I-Claim
and I-Claim
supervised I-Claim
resistance I-Claim
exercise I-Claim
may I-Claim
be I-Claim
safe I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
by I-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
bone I-Claim
metastatic I-Claim
disease I-Claim
and I-Claim
can I-Claim
lead I-Claim
to I-Claim
improvements I-Claim
in I-Claim
physical I-Claim
function I-Claim
, I-Claim
physical I-Claim
activity I-Claim
levels I-Claim
and I-Claim
lean I-Claim
mass I-Claim
. I-Claim

Future B-Claim
trials I-Claim
involving I-Claim
larger I-Claim
sample I-Claim
sizes I-Claim
are I-Claim
required I-Claim
to I-Claim
expand I-Claim
these I-Claim
preliminary I-Claim
findings I-Claim
. I-Claim

A O
recent O
randomized O
trial O
to O
compare O
external O
beam O
radiation O
therapy O
( O
EBRT O
) O
to O
cryoablation O
for O
localized O
disease O
showed O
cryoablation O
to O
be O
noninferior O
to O
external O
beam O
EBRT O
in O
disease O
progression O
and O
overall O
and O
disease O
- O
specific O
survival O
. O

We O
report O
on O
the O
quality O
of O
life O
( O
QOL O
) O
outcomes O
for O
this O
trial O
. O

From O
December O
1997 O
through O
February O
2003 O
, O
244 O
men O
with O
newly O
diagnosed O
localized O
prostate O
cancer O
were O
randomly O
assigned O
to O
cryoablation O
or O
EBRT O
( O
median O
dose O
68 O
Gy O
) O
. O

All O
patients O
received O
neoadjuvant O
antiandrogen O
therapy O
. O

Patients O
completed O
the O
EORTC O
QLQ O
C30 O
and O
the O
Prostate O
Cancer O
Index O
( O
PCI O
) O
before O
treatment O
and O
at O
1 O
. O
5 O
, O
3 O
, O
6 O
, O
12 O
, O
18 O
, O
24 O
, O
and O
36 O
months O
post O
- O
treatment O
. O

Regardless B-Premise
of I-Premise
treatment I-Premise
arm I-Premise
, I-Premise
participants I-Premise
reported I-Premise
high I-Premise
levels I-Premise
of I-Premise
QOL I-Premise
with I-Premise
few I-Premise
exceptions I-Premise
. I-Premise

cryoablation B-Premise
was I-Premise
associated I-Premise
with I-Premise
more I-Premise
acute I-Premise
urinary I-Premise
dysfunction I-Premise
( I-Premise
mean I-Premise
PCI I-Premise
urinary I-Premise
function I-Premise
cryoablation I-Premise
= I-Premise
69 I-Premise
. I-Premise
4 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
mean I-Premise
EBRT I-Premise
= I-Premise
90 I-Premise
. I-Premise
7 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
which I-Premise
resolved I-Premise
over I-Premise
time I-Premise
. I-Premise

No B-Premise
late I-Premise
arising I-Premise
QOL I-Premise
issues I-Premise
were I-Premise
observed I-Premise
. I-Premise

Both B-Premise
EBRT I-Premise
and I-Premise
cryoablation I-Premise
participants I-Premise
reported I-Premise
decreases I-Premise
in I-Premise
sexual I-Premise
function I-Premise
at I-Premise
3 I-Premise
months I-Premise
with I-Premise
the I-Premise
cryoablation I-Premise
patients I-Premise
reporting I-Premise
poorer I-Premise
functioning I-Premise
( I-Premise
mean I-Premise
cryoablation I-Premise
= I-Premise
7 I-Premise
. I-Premise
2 I-Premise
: I-Premise
mean I-Premise
EBRT I-Premise
= I-Premise
32 I-Premise
. I-Premise
9 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
sexual I-Premise
function I-Premise
score I-Premise
was I-Premise
15 I-Premise
points I-Premise
lower I-Premise
at I-Premise
3 I-Premise
years I-Premise
for I-Premise
the I-Premise
cryoablation I-Premise
group I-Premise
and I-Premise
13 I-Premise
% I-Premise
more I-Premise
of I-Premise
the I-Premise
cryoablation I-Premise
men I-Premise
said I-Premise
that I-Premise
sexuality I-Premise
was I-Premise
a I-Premise
moderate I-Premise
or I-Premise
big I-Premise
problem I-Premise
. I-Premise

In B-Claim
this I-Claim
randomized I-Claim
trial I-Claim
, I-Claim
no I-Claim
long I-Claim
- I-Claim
term I-Claim
QOL I-Claim
advantage I-Claim
for I-Claim
either I-Claim
treatment I-Claim
was I-Claim
apparent I-Claim
with B-Claim
the I-Claim
exception I-Claim
of I-Claim
poorer I-Claim
sexual I-Claim
function I-Claim
reported I-Claim
by I-Claim
those I-Claim
treated I-Claim
with I-Claim
cryoablation I-Claim
. I-Claim

Men O
who O
wish O
to O
increase O
their O
odds O
of O
retaining O
sexual O
function O
might O
be O
counseled O
to O
choose O
EBRT O
over O
cryoablation O
. O

It B-Claim
has I-Claim
been I-Claim
shown I-Claim
that I-Claim
nonpharmacologic I-Claim
interventions I-Claim
are I-Claim
effective I-Claim
management I-Claim
techniques I-Claim
for I-Claim
cancer I-Claim
- I-Claim
related I-Claim
fatigue I-Claim
( I-Claim
CRF I-Claim
) I-Claim
in I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

However O
, O
few O
studies O
have O
investigated O
their O
effectiveness O
in O
patients O
who O
are O
receiving O
chemotherapy O
. O

In O
this O
study O
, O
the O
authors O
tested O
the O
effectiveness O
of O
a O
brief O
behaviorally O
oriented O
intervention O
in O
reducing O
CRF O
and O
improving O
physical O
function O
and O
associated O
distress O
in O
individuals O
who O
were O
receiving O
chemotherapy O
. O

For O
this O
randomized O
controlled O
trial O
, O
60 O
patients O
with O
cancer O
were O
recruited O
and O
received O
either O
usual O
care O
or O
the O
intervention O
. O

The O
intervention O
was O
delivered O
on O
an O
individual O
basis O
on O
3 O
occasions O
over O
a O
period O
from O
9 O
weeks O
to O
12 O
weeks O
, O
and O
the O
objective O
of O
the O
intervention O
was O
to O
alter O
fatigue O
- O
related O
thoughts O
and O
behavior O
. O

Primary O
outcomes O
were O
assessed O
as O
follows O
: O
CRF O
using O
the O
Visual O
Analogue O
Scale O
- O
Global O
Fatigue O
"""" O
; O
"""" O
physical O
functioning O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
- O
of O
- O
Life O
Core O
30 O
Questionnaire O
, O
and O
CRF O
- O
associated O
distress O
using O
the O
Fatigue O
Outcome O
Measure O
. O

Assessments O
were O
made O
on O
4 O
occasions O
: O
at O
baseline O
( O
T0 O
) O
, O
at O
the O
end O
of O
chemotherapy O
( O
T1 O
) O
, O
1 O
month O
after O
chemotherapy O
( O
T2 O
) O
, O
and O
9 O
months O
after O
recruitment O
( O
T3 O
) O
. O

Normally O
distributed O
data O
were O
analyzed O
using O
t O
tests O
and O
random O
- O
slope O
/ O
random O
- O
intercept O
mixed O
models O
. O

The B-Premise
intervention I-Premise
demonstrated I-Premise
a I-Premise
trend I-Premise
toward I-Premise
improved I-Premise
CRF I-Premise
, I-Premise
although B-Premise
this I-Premise
effect I-Premise
was I-Premise
reduced I-Premise
once I-Premise
confounders I-Premise
had I-Premise
been I-Premise
controlled I-Premise
statistically I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
coefficient I-Premise
, I-Premise
10 I-Premise
. I-Premise
0 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
2 I-Premise
. I-Premise
5 I-Premise
- I-Premise
17 I-Premise
. I-Premise
5 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
009 I-Premise
) I-Premise
, I-Premise
and I-Premise
this I-Premise
effect I-Premise
remained I-Premise
once I-Premise
the I-Premise
confounding I-Premise
effects I-Premise
of I-Premise
mood I-Premise
disturbance I-Premise
and I-Premise
comorbid I-Premise
disorders I-Premise
were I-Premise
controlled I-Premise
statistically I-Premise
. I-Premise

No B-Premise
decrease I-Premise
in I-Premise
fatigue I-Premise
- I-Premise
related I-Premise
distress I-Premise
was I-Premise
detected I-Premise
. I-Premise

The B-Claim
behaviorally I-Claim
oriented I-Claim
intervention I-Claim
brought I-Claim
about I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
indicated I-Claim
a I-Claim
trend I-Claim
toward I-Claim
improved I-Claim
CRF I-Claim
, I-Claim
but I-Claim
detected I-Claim
no I-Claim
effect I-Claim
for I-Claim
fatigue I-Claim
- I-Claim
related I-Claim
distress I-Claim
. I-Claim

Radiotherapy B-Claim
is I-Claim
an I-Claim
effective I-Claim
palliative I-Claim
treatment I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
painful I-Claim
bone I-Claim
metastases I-Claim
. I-Claim

Although O
single O
- O
and O
multiple O
- O
fraction O
radiotherapy O
are O
thought O
to O
provide O
equal O
palliation O
, O
which O
treatment O
schedule O
provides O
better O
value O
for O
the O
money O
is O
unknown O
. O

We O
compared O
quality O
- O
adjusted O
life O
expectancy O
( O
the O
overall O
valuation O
of O
the O
health O
of O
the O
patients O
) O
and O
societal O
costs O
for O
patients O
receiving O
either O
single O
- O
or O
multiple O
- O
fraction O
radiotherapy O
. O

A O
societal O
cost O
- O
utility O
analysis O
was O
performed O
on O
a O
Dutch O
randomized O
, O
controlled O
trial O
of O
1157 O
patients O
with O
painful O
bone O
metastases O
that O
compared O
pain O
responses O
and O
quality O
of O
life O
from O
a O
single O
- O
fraction O
treatment O
schedule O
of O
8 O
Gy O
with O
a O
treatment O
schedule O
of O
six O
fractions O
of O
4 O
Gy O
each O
. O

The O
societal O
values O
of O
life O
expectancies O
were O
assessed O
with O
the O
EuroQol O
classification O
system O
( O
EQ O
- O
5D O
) O
questionnaire O
. O

A O
subset O
of O
166 O
patients O
also O
answered O
additional O
questionnaires O
to O
estimate O
nonradiotherapy O
and O
nonmedical O
costs O
. O

Statistical O
tests O
were O
two O
- O
sided O
. O

Comparing B-Premise
the I-Premise
single I-Premise
- I-Premise
and I-Premise
multiple I-Premise
- I-Premise
fraction I-Premise
radiotherapy I-Premise
schedules I-Premise
, I-Premise
no I-Premise
differences I-Premise
were I-Premise
found I-Premise
in I-Premise
life I-Premise
expectancy I-Premise
( I-Premise
43 I-Premise
. I-Premise
0 I-Premise
versus I-Premise
40 I-Premise
. I-Premise
4 I-Premise
weeks I-Premise
, I-Premise
P I-Premise
= I-Premise
. I-Premise
20 I-Premise
) I-Premise
or I-Premise
quality I-Premise
- I-Premise
adjusted I-Premise
life I-Premise
expectancy I-Premise
( I-Premise
17 I-Premise
. I-Premise
7 I-Premise
versus I-Premise
16 I-Premise
. I-Premise
0 I-Premise
weeks I-Premise
, I-Premise
P I-Premise
= I-Premise
. I-Premise
21 I-Premise
) I-Premise
. I-Premise

The B-Premise
estimated I-Premise
cost I-Premise
of I-Premise
radiotherapy I-Premise
, I-Premise
including I-Premise
retreatments I-Premise
and I-Premise
nonmedical I-Premise
costs I-Premise
, I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
lower I-Premise
for I-Premise
the I-Premise
single I-Premise
- I-Premise
fraction I-Premise
schedule I-Premise
than I-Premise
for I-Premise
the I-Premise
multiple I-Premise
- I-Premise
fraction I-Premise
schedule I-Premise
( I-Premise
$ I-Premise
2438 I-Premise
versus I-Premise
$ I-Premise
3311 I-Premise
, I-Premise
difference I-Premise
= I-Premise
$ I-Premise
873 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
on I-Premise
the I-Premise
difference I-Premise
= I-Premise
$ I-Premise
449 I-Premise
to I-Premise
$ I-Premise
1297 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

The B-Premise
estimated I-Premise
difference I-Premise
in I-Premise
total I-Premise
societal I-Premise
costs I-Premise
was I-Premise
larger I-Premise
, I-Premise
also I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
single I-Premise
- I-Premise
fraction I-Premise
schedule I-Premise
, I-Premise
but B-Premise
it I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
$ I-Premise
4700 I-Premise
versus I-Premise
$ I-Premise
6453 I-Premise
, I-Premise
difference I-Premise
= I-Premise
$ I-Premise
1753 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
on I-Premise
the I-Premise
difference I-Premise
= I-Premise
- I-Premise
$ I-Premise
99 I-Premise
to I-Premise
$ I-Premise
3604 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
06 I-Premise
) I-Premise
. I-Premise

For B-Premise
willingness I-Premise
- I-Premise
to I-Premise
- I-Premise
pay I-Premise
between I-Premise
$ I-Premise
5000 I-Premise
and I-Premise
$ I-Premise
40 I-Premise
0 I-Premise
per I-Premise
quality I-Premise
- I-Premise
adjusted I-Premise
life I-Premise
year I-Premise
, I-Premise
the I-Premise
single I-Premise
- I-Premise
fraction I-Premise
schedule I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
more I-Premise
cost I-Premise
- I-Premise
effective I-Premise
than I-Premise
the I-Premise
multiple I-Premise
- I-Premise
fraction I-Premise
schedule I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

Compared B-Claim
with I-Claim
multiple I-Claim
- I-Claim
fraction I-Claim
radiotherapy I-Claim
, I-Claim
single I-Claim
- I-Claim
fraction I-Claim
radiotherapy I-Claim
provides I-Claim
equal I-Claim
palliation I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
has I-Claim
lower I-Claim
medical I-Claim
and I-Claim
societal I-Claim
costs I-Claim
, I-Claim
at I-Claim
least I-Claim
in I-Claim
The I-Claim
Netherlands I-Claim
. I-Claim

Therefore B-Claim
, I-Claim
single I-Claim
- I-Claim
fraction I-Claim
radiotherapy I-Claim
should I-Claim
be I-Claim
considered I-Claim
as I-Claim
the I-Claim
palliative I-Claim
treatment I-Claim
of I-Claim
choice I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
painful I-Claim
bone I-Claim
metastases I-Claim
. I-Claim

For B-Claim
malignant I-Claim
pleural I-Claim
mesothelioma I-Claim
( I-Claim
MPM I-Claim
) I-Claim
patients I-Claim
with I-Claim
a I-Claim
poor I-Claim
prognosis I-Claim
, I-Claim
maintaining I-Claim
health I-Claim
- I-Claim
related I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
HRQOL I-Claim
) I-Claim
is I-Claim
important I-Claim
. I-Claim

This O
article O
compares O
the O
impact O
on O
HRQOL O
of O
first O
- O
line O
treatment O
with O
cisplatin O
versus O
raltitrexed O
and O
cisplatin O
. O

Patients O
with O
histologically O
- O
proven O
unresectable O
MPM O
, O
not O
pretreated O
with O
chemotherapy O
were O
randomly O
assigned O
to O
receive O
cisplatin O
80 O
mg O
/ O
m2 O
intravenously O
on O
day O
1 O
, O
with O
or O
without O
preceding O
infusion O
of O
raltitrexed O
3 O
mg O
/ O
m2 O
. O

HRQOL O
was O
assessed O
with O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Core O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ O
- O
C30 O
) O
and O
EORTC O
Lung O
Cancer O
Module O
( O
QLQ O
- O
LC13 O
) O
tools O
. O

Assessments O
were O
conducted O
at O
baseline O
, O
immediately O
before O
every O
treatment O
cycle O
, O
at O
the O
end O
of O
treatment O
, O
and O
every O
six O
weeks O
for O
12 O
months O
. O

Two O
hundred O
fifty O
patients O
were O
randomly O
assigned O
, O
80 O
% O
were O
male O
with O
a O
median O
age O
of O
58 O
years O
, O
WHO O
performance O
status O
0 O
, O
1 O
, O
and O
2 O
, O
in O
25 O
% O
, O
62 O
% O
, O
and O
13 O
% O
of O
cases O
. O

The B-Premise
clinical I-Premise
results I-Premise
found I-Premise
raltitrexed I-Premise
and I-Premise
cisplatin I-Premise
to I-Premise
be I-Premise
superior I-Premise
to I-Premise
cisplatin I-Premise
with I-Premise
regard I-Premise
to I-Premise
overall I-Premise
survival I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
048 I-Premise
) I-Premise
. I-Premise

The B-Premise
global I-Premise
HRQOL I-Premise
scale I-Premise
was I-Premise
comparable I-Premise
at I-Premise
baseline I-Premise
on I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
848 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
at B-Premise
no I-Premise
point I-Premise
was I-Premise
any I-Premise
significant I-Premise
difference I-Premise
apparent I-Premise
on I-Premise
this I-Premise
end I-Premise
point I-Premise
. I-Premise

Both B-Premise
treatments I-Premise
led I-Premise
to I-Premise
an I-Premise
improvement I-Premise
, I-Premise
over I-Premise
time I-Premise
, I-Premise
in I-Premise
dyspnoea I-Premise
. I-Premise

This B-Claim
effect I-Claim
is I-Claim
an I-Claim
important I-Claim
clinically I-Claim
meaningful I-Claim
reduction I-Claim
from I-Claim
baseline I-Claim
in I-Claim
the I-Claim
cisplatin I-Claim
/ I-Claim
raltitrexed I-Claim
arm I-Claim
. I-Claim

However B-Premise
, I-Premise
the I-Premise
majority I-Premise
of I-Premise
scales I-Premise
of I-Premise
the I-Premise
EORTC I-Premise
QLQ I-Premise
- I-Premise
C30 I-Premise
or I-Premise
LC13 I-Premise
showed I-Premise
stabilization I-Premise
of I-Premise
HRQOL I-Premise
with I-Premise
few I-Premise
clinically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

This B-Claim
study I-Claim
provides I-Claim
important I-Claim
information I-Claim
about I-Claim
the I-Claim
HRQOL I-Claim
of I-Claim
chemotherapy I-Claim
- I-Claim
treated I-Claim
MPM I-Claim
patients I-Claim
. I-Claim

The O
physiological O
and O
psychological O
stress O
that O
brain O
tumor O
patients O
undergo O
during O
the O
entire O
surgical O
experience O
can O
considerably O
affect O
several O
aspects O
of O
their O
hospitalization O
. O

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
live O
music O
therapy O
on O
quality O
of O
life O
indicators O
, O
amount O
of O
medications O
administered O
and O
length O
of O
stay O
for O
persons O
receiving O
elective O
surgical O
procedures O
of O
the O
brain O
. O

Subjects O
( O
N O
= O
27 O
) O
were O
patients O
admitted O
for O
some O
type O
of O
surgical O
procedure O
of O
the O
brain O
. O

Subjects O
were O
randomly O
assigned O
to O
either O
the O
control O
group O
receiving O
no O
music O
intervention O
( O
n O
= O
13 O
) O
or O
the O
experimental O
group O
receiving O
pre O
and O
postoperative O
live O
music O
therapy O
sessions O
( O
n O
= O
14 O
) O
. O

Anxiety O
, O
mood O
, O
pain O
, O
perception O
of O
hospitalization O
or O
procedure O
, O
relaxation O
, O
and O
stress O
were O
measured O
using O
a O
self O
- O
report O
Visual O
Analog O
Scale O
( O
VAS O
) O
for O
each O
of O
the O
variables O
. O

The O
documented O
administration O
of O
postoperative O
pain O
medications O
"""" O
; O
"""" O
the O
frequency O
, O
dosage O
, O
type O
, O
and O
how O
it O
was O
given O
was O
also O
compared O
between O
groups O
. O

Experimental O
subjects O
live O
and O
interactive O
music O
therapy O
sessions O
, O
including O
a O
pre O
- O
operative O
session O
and O
continuing O
with O
daily O
sessions O
until O
the O
patient O
was O
discharged O
home O
. O

Control O
subjects O
received O
routine O
hospital O
care O
without O
any O
music O
therapy O
intervention O
. O

Differences O
in O
experimental O
pretest O
and O
posttest O
scores O
were O
analyzed O
using O
a O
Wilcoxon O
Matched O
- O
Pairs O
Signed O
- O
Rank O
test O
. O

Results B-Premise
indicated I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
for I-Premise
4 I-Premise
of I-Premise
the I-Premise
6 I-Premise
quality I-Premise
of I-Premise
life I-Premise
measures I-Premise
: I-Premise
anxiety I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
perception I-Premise
of I-Premise
hospitalization I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
relaxation I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
and I-Premise
stress I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
were I-Premise
found I-Premise
for I-Premise
mood I-Premise
( I-Premise
p I-Premise
> I-Premise
. I-Premise
05 I-Premise
) I-Premise
or I-Premise
pain I-Premise
( I-Premise
p I-Premise
> I-Premise
. I-Premise
05 I-Premise
) I-Premise
levels I-Premise
. I-Premise

Administration O
amounts O
of O
nausea O
and O
pain O
medications O
were O
compared O
with O
a O
Two O
- O
Way O
ANOVA O
with O
One O
Repeated O
Measure O
resulting O
in O
no O
significant O
differences O
between O
groups O
and O
medications O
, O
F O
( O
1 O
, O
51 O
) O
= O
0 O
. O
03 O
"""" O
; O
"""" O
p O
> O
. O
05 O
. O

Results O
indicate O
no O
significant O
differences O
between O
groups O
for O
length O
of O
stay O
( O
t O
= O
. O
97 O
, O
df O
= O
25 O
, O
p O
> O
. O
05 O
) O
. O

This B-Claim
research I-Claim
study I-Claim
indicates I-Claim
that I-Claim
live I-Claim
music I-Claim
therapy I-Claim
using I-Claim
patient I-Claim
- I-Claim
preferred I-Claim
music I-Claim
can I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
improving I-Claim
quality I-Claim
of I-Claim
life I-Claim
indicators I-Claim
such I-Claim
as I-Claim
anxiety I-Claim
, I-Claim
perception I-Claim
of I-Claim
the I-Claim
hospitalization I-Claim
or I-Claim
procedure I-Claim
, I-Claim
relaxation I-Claim
, I-Claim
and I-Claim
stress I-Claim
in I-Claim
patients I-Claim
undergoing I-Claim
surgical I-Claim
procedures I-Claim
of I-Claim
the I-Claim
brain I-Claim
. I-Claim

Spiritual O
well O
- O
being O
and O
sense O
of O
meaning O
are O
important O
concerns O
for O
clinicians O
who O
care O
for O
patients O
with O
cancer O
. O

We O
developed O
Individual O
Meaning O
- O
Centered O
Psychotherapy O
( O
IMCP O
) O
to O
address O
the O
need O
for O
brief O
interventions O
targeting O
spiritual O
well O
- O
being O
and O
meaning O
for O
patients O
with O
advanced O
cancer O
. O

Patients O
with O
stage O
III O
or O
IV O
cancer O
( O
N O
= O
120 O
) O
were O
randomly O
assigned O
to O
seven O
sessions O
of O
either O
IMCP O
or O
therapeutic O
massage O
( O
TM O
) O
. O

Patients O
were O
assessed O
before O
and O
after O
completing O
the O
intervention O
and O
2 O
months O
postintervention O
. O

Primary O
outcome O
measures O
assessed O
spiritual O
well O
- O
being O
and O
quality O
of O
life O
"""" O
; O
"""" O
secondary O
outcomes O
included O
anxiety O
, O
depression O
, O
hopelessness O
, O
symptom O
burden O
, O
and O
symptom O
- O
related O
distress O
. O

Of O
the O
120 O
participants O
randomly O
assigned O
, O
78 O
( O
65 O
% O
) O
completed O
the O
post O
- O
treatment O
assessment O
and O
67 O
( O
56 O
% O
) O
completed O
the O
2 O
- O
month O
follow O
- O
up O
. O

At B-Premise
the I-Premise
post I-Premise
- I-Premise
treatment I-Premise
assessment I-Premise
, I-Premise
IMCP I-Premise
participants I-Premise
demonstrated I-Premise
significantly I-Premise
greater I-Premise
improvement I-Premise
than I-Premise
the I-Premise
control I-Premise
condition I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcomes I-Premise
of I-Premise
spiritual I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
b I-Premise
= I-Premise
0 I-Premise
. I-Premise
39 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
, I-Premise
including I-Premise
both I-Premise
components I-Premise
of I-Premise
spiritual I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
sense I-Premise
of I-Premise
meaning I-Premise
: I-Premise
b I-Premise
= I-Premise
0 I-Premise
. I-Premise
34 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
003 I-Premise
and I-Premise
faith I-Premise
: I-Premise
b I-Premise
= I-Premise
0 I-Premise
. I-Premise
42 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
b I-Premise
= I-Premise
0 I-Premise
. I-Premise
76 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
013 I-Premise
) I-Premise
. I-Premise

Significantly B-Premise
greater I-Premise
improvements I-Premise
for I-Premise
IMCP I-Premise
patients I-Premise
were I-Premise
also I-Premise
observed I-Premise
for I-Premise
the I-Premise
secondary I-Premise
outcomes I-Premise
of I-Premise
symptom I-Premise
burden I-Premise
( I-Premise
b I-Premise
= I-Premise
- I-Premise
6 I-Premise
. I-Premise
56 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
symptom I-Premise
- I-Premise
related I-Premise
distress I-Premise
( I-Premise
b I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
47 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
but I-Premise
not I-Premise
for I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
or I-Premise
hopelessness I-Premise
. I-Premise

At B-Premise
the I-Premise
2 I-Premise
- I-Premise
month I-Premise
follow I-Premise
- I-Premise
up I-Premise
assessment I-Premise
, I-Premise
the I-Premise
improvements I-Premise
observed I-Premise
for I-Premise
the I-Premise
IMCP I-Premise
group I-Premise
were I-Premise
no I-Premise
longer I-Premise
significantly I-Premise
greater I-Premise
than I-Premise
those I-Premise
observed I-Premise
for I-Premise
the I-Premise
TM I-Premise
group I-Premise
. I-Premise

IMCP B-Claim
has I-Claim
clear I-Claim
short I-Claim
- I-Claim
term I-Claim
benefits I-Claim
for I-Claim
spiritual I-Claim
suffering I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
. I-Claim

Clinicians O
working O
with O
patients O
who O
have O
advanced O
cancer O
should O
consider O
IMCP O
as O
an O
approach O
to O
enhance O
quality O
of O
life O
and O
spiritual O
well O
- O
being O
. O

Recently B-Claim
, I-Claim
the I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
gastric I-Claim
cancer I-Claim
by I-Claim
continuous I-Claim
infusion I-Claim
of I-Claim
5 I-Claim
- I-Claim
fluorouracil I-Claim
( I-Claim
5 I-Claim
- I-Claim
FU I-Claim
) I-Claim
with I-Claim
low I-Claim
- I-Claim
dose I-Claim
cisplatin I-Claim
( I-Claim
CDDP I-Claim
) I-Claim
has I-Claim
improved I-Claim
efficacy I-Claim
without I-Claim
severe I-Claim
toxicities I-Claim
. I-Claim

The B-Claim
possible I-Claim
effectiveness I-Claim
of I-Claim
5 I-Claim
- I-Claim
FU I-Claim
+ I-Claim
low I-Claim
- I-Claim
dose I-Claim
CDDP I-Claim
for I-Claim
colorectal I-Claim
cancer I-Claim
( I-Claim
CRC I-Claim
) I-Claim
is I-Claim
intriguing I-Claim
. I-Claim

One O
hundred O
fifty O
- O
five O
patients O
with O
far O
- O
advanced O
CRC O
including O
at O
least O
one O
measurable O
lesion O
were O
enrolled O
in O
a O
prospective O
randomized O
clinical O
trial O
funded O
by O
the O
Japanese O
Foundation O
for O
Multidisciplinary O
Treatment O
of O
Cancer O
. O

These O
patients O
were O
assigned O
to O
the O
two O
arms O
to O
assess O
the O
value O
of O
low O
- O
dose O
CDDP O
when O
added O
to O
a O
continuous O
intravenous O
infusion O
of O
5 O
- O
FU O
at O
a O
dose O
of O
300 O
mg O
/ O
m O
( O
2 O
) O
/ O
24 O
hrs O
in O
a O
one O
- O
week O
cycle O
consisting O
of O
5 O
days O
of O
treatment O
and O
2 O
days O
of O
rest O
for O
at O
least O
12 O
weeks O
. O

CD O
- O
DP O
was O
given O
intravenously O
at O
a O
dose O
of O
3 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
- O
5 O
and O
days O
8 O
- O
12 O
, O
and O
then O
at O
a O
dose O
of O
7 O
mg O
/ O
m O
( O
2 O
) O
twice O
a O
week O
. O

Three O
patients O
were O
excluded O
from O
the O
trial O
. O

The B-Premise
response I-Premise
rate I-Premise
in I-Premise
the I-Premise
5 I-Premise
- I-Premise
FU I-Premise
+ I-Premise
low I-Premise
- I-Premise
dose I-Premise
CDDP I-Premise
arm I-Premise
( I-Premise
n I-Premise
= I-Premise
75 I-Premise
) I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
5 I-Premise
- I-Premise
FU I-Premise
arm I-Premise
( I-Premise
n I-Premise
= I-Premise
77 I-Premise
) I-Premise
( I-Premise
25 I-Premise
. I-Premise
3 I-Premise
% I-Premise
vs I-Premise
. I-Premise
11 I-Premise
. I-Premise
7 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
037 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
median I-Premise
overall I-Premise
survival I-Premise
time I-Premise
between I-Premise
the I-Premise
5 I-Premise
- I-Premise
FU I-Premise
+ I-Premise
low I-Premise
- I-Premise
dose I-Premise
CDDP I-Premise
arm I-Premise
and I-Premise
the I-Premise
5 I-Premise
- I-Premise
FU I-Premise
arm I-Premise
( I-Premise
479 I-Premise
and I-Premise
491 I-Premise
days I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Grades B-Premise
3 I-Premise
/ I-Premise
4 I-Premise
toxicities I-Premise
occurred I-Premise
infrequently I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

The B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
almost I-Premise
the I-Premise
same I-Premise
between I-Premise
the I-Premise
arms I-Premise
. O

Low B-Claim
- B-Claim
dose B-Claim
CDDP I-Claim
improved I-Claim
the I-Claim
response I-Claim
rate I-Claim
while I-Claim
keeping I-Claim
toxicities I-Claim
within I-Claim
clinically I-Claim
acceptable I-Claim
limits I-Claim
. I-Claim

However B-Claim
, I-Claim
this I-Claim
combined I-Claim
treatment I-Claim
did I-Claim
not I-Claim
confer I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
treatment I-Claim
with I-Claim
continuous I-Claim
infusion I-Claim
of I-Claim
5 I-Claim
- I-Claim
FU I-Claim
alone I-Claim
for I-Claim
patients I-Claim
with I-Claim
far I-Claim
- I-Claim
advanced I-Claim
CRC I-Claim
"""" I-Claim
; I-Claim
"""" I-Claim
that I-Claim
might I-Claim
be I-Claim
attributable I-Claim
to I-Claim
the I-Claim
short I-Claim
CDDP I-Claim
administration I-Claim
setting I-Claim
of I-Claim
12 I-Claim
weeks I-Claim
. I-Claim

Recent B-Claim
studies I-Claim
have I-Claim
shown I-Claim
that I-Claim
administering I-Claim
the I-Claim
aromatase I-Claim
inhibitor I-Claim
exemestane I-Claim
after I-Claim
2 I-Claim
- I-Claim
3 I-Claim
years I-Claim
of I-Claim
tamoxifen I-Claim
therapy I-Claim
significantly I-Claim
improves I-Claim
disease I-Claim
- I-Claim
free I-Claim
survival I-Claim
in I-Claim
postmenopausal I-Claim
women I-Claim
with I-Claim
primary I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
comparison I-Claim
with I-Claim
standard I-Claim
5 I-Claim
- I-Claim
year I-Claim
tamoxifen I-Claim
treatment I-Claim
. I-Claim

Although O
many O
of O
the O
adverse O
effects O
associated O
with O
exemestane O
and O
tamoxifen O
have O
been O
analysed O
, O
there O
are O
no O
comparative O
data O
concerning O
body O
weight O
and O
body O
composition O
. O

The O
aim O
of O
this O
randomised O
study O
was O
to O
evaluate O
the O
longitudinal O
changes O
in O
body O
composition O
and O
lipid O
profiles O
in O
postmenopausal O
women O
switched O
from O
tamoxifen O
to O
exemestane O
. O

In O
total O
, O
60 O
overweight O
or O
obese O
postmenopausal O
patients O
were O
enrolled O
. O

Their O
anthropometric O
data O
, O
body O
composition O
, O
including O
fat O
mass O
( O
FM O
) O
and O
fat O
- O
free O
mass O
( O
FFM O
) O
, O
and O
lipid O
profiles O
, O
caloric O
intake O
and O
physical O
activity O
were O
assessed O
1 O
week O
before O
randomisation O
, O
and O
6 O
and O
12 O
months O
later O
. O

In O
all O
, O
55 O
patients O
( O
27 O
on O
tamoxifen O
and O
28 O
on O
exemestane O
) O
completed O
the O
1 O
- O
year O
study O
period O
. O

Fat B-Premise
mass I-Premise
had I-Premise
significantly I-Premise
decreased I-Premise
by I-Premise
month I-Premise
12 I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
, I-Premise
but I-Premise
not I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
the B-Premise
between I-Premise
- I-Premise
group I-Premise
difference I-Premise
was I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise

The B-Premise
FFM I-Premise
/ I-Premise
FM I-Premise
ratio I-Premise
had I-Premise
significantly I-Premise
increased I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
, I-Premise
but I-Premise
not I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
the B-Premise
between I-Premise
- I-Premise
group I-Premise
difference I-Premise
was I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

Triglycerides B-Premise
and I-Premise
high I-Premise
- I-Premise
density I-Premise
lipoprotein I-Premise
cholesterol I-Premise
significantly I-Premise
decreased I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
and O
low B-Premise
- B-Premise
density B-Premise
lipoprotein I-Premise
cholesterol I-Premise
significantly I-Premise
increased I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
1 I-Premise
- I-Premise
year I-Premise
study I-Premise
period I-Premise
. I-Premise

Our B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
switching I-Claim
patients I-Claim
to I-Claim
adjuvant I-Claim
exemestane I-Claim
treatment I-Claim
after I-Claim
at I-Claim
least I-Claim
2 I-Claim
years I-Claim
of I-Claim
tamoxifen I-Claim
therapy I-Claim
may I-Claim
be I-Claim
associated I-Claim
with I-Claim
an I-Claim
advantage I-Claim
over I-Claim
continuing I-Claim
adjuvant I-Claim
tamoxifen I-Claim
treatment I-Claim
in I-Claim
terms I-Claim
of I-Claim
body I-Claim
composition I-Claim
. I-Claim

Anti B-Claim
- B-Claim
aromatase B-Claim
therapy I-Claim
is I-Claim
important I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
postmenopausal I-Claim
women I-Claim
but O
they O
have O
effects O
on O
the O
bone O
mineral O
density O
( O
BMD O
) O
and O
osteoporosis O
. O

Cyclooxygenase B-Claim
- B-Claim
2 B-Claim
( I-Claim
COX I-Claim
- I-Claim
2 I-Claim
) I-Claim
inhibitors I-Claim
have I-Claim
been I-Claim
shown I-Claim
to I-Claim
be I-Claim
effective I-Claim
in I-Claim
chemoprevention I-Claim
in I-Claim
animal I-Claim
and I-Claim
clinical I-Claim
studies I-Claim
. I-Claim

A O
proof O
of O
principle O
study O
was O
performed O
to O
investigate O
the O
efficacy O
of O
combing O
anti O
- O
aromatase O
therapy O
( O
exemestane O
) O
and O
COX O
- O
2 O
inhibitors O
neoadjuvantly O
. O

The O
changes O
in O
the O
BMD O
, O
bone O
turnover O
proteins O
and O
quality O
- O
of O
- O
life O
( O
QoL O
) O
were O
analyzed O
and O
presented O
here O
. O

82 O
postmenopausal O
patients O
with O
histologically O
confirmed O
invasive O
hormone O
- O
sensitive O
breast O
cancers O
were O
included O
for O
the O
neoadjuvant O
therapy O
( O
NHT O
) O
. O

30 O
patients O
received O
exemestane O
( O
EXE O
) O
25 O
mg O
daily O
and O
celecoxib O
( O
CXB O
) O
400 O
mg O
twice O
daily O
( O
group O
A O
) O
, O
24 O
patients O
received O
EXE O
25 O
mg O
daily O
( O
group O
B O
) O
and O
28 O
patients O
received O
letrozole O
( O
LET O
) O
2 O
. O
5 O
mg O
daily O
( O
group O
C O
) O
. O

The O
same O
assigned O
treatment O
was O
intended O
to O
continue O
for O
2 O
years O
to O
study O
the O
changes O
in O
the O
bone O
metabolism O
. O

BMD O
of O
48 O
patients O
were O
analyzed O
"""" O
; O
"""" O
23 O
belongs O
to O
group O
A O
, O
10 O
to O
group O
B O
and O
15 O
to O
group O
C O
. O
The O
serum O
bone O
turnover O
proteins O
bone O
- O
specific O
alkaline O
phosphatase O
( O
BAP O
) O
and O
carboxyterminal O
crosslinked O
telopeptide O
of O
type O
I O
collagen O
( O
ICTP O
) O
, O
were O
measured O
with O
commercially O
available O
test O
kits O
before O
treatment O
, O
3 O
months O
and O
15 O
months O
after O
treatment O
. O

Functional O
Assessment O
of O
Cancer O
Therapy O
core O
questionnaire O
( O
FACT O
- O
G O
) O
with O
its O
additional O
breast O
cancer O
subscale O
were O
performed O
at O
baseline O
, O
4 O
, O
8 O
, O
and O
12 O
weeks O
after O
NHT O
. O

Difference B-Premise
between I-Premise
groups I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
007 I-Premise
) I-Premise
for I-Premise
BMD I-Premise
at I-Premise
femur I-Premise
was I-Premise
significant I-Premise
. I-Premise

The B-Premise
changes I-Premise
of I-Premise
BMD I-Premise
in I-Premise
group I-Premise
B I-Premise
patients I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
than I-Premise
patients I-Premise
in I-Premise
group I-Premise
A I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
011 I-Premise
, I-Premise
CI I-Premise
= I-Premise
0 I-Premise
. I-Premise
063 I-Premise
- I-Premise
0 I-Premise
. I-Premise
437 I-Premise
) I-Premise
, I-Premise
and I-Premise
group I-Premise
C I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
003 I-Premise
, I-Premise
CI I-Premise
= I-Premise
0 I-Premise
. I-Premise
146 I-Premise
- I-Premise
0 I-Premise
. I-Premise
620 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
BAP I-Premise
increased I-Premise
from I-Premise
baseline I-Premise
in I-Premise
group I-Premise
B I-Premise
patients I-Premise
but I-Premise
decreased I-Premise
from I-Premise
baseline I-Premise
in I-Premise
group I-Premise
C I-Premise
patients I-Premise
at I-Premise
3 I-Premise
months I-Premise
and I-Premise
15 I-Premise
months I-Premise
. I-Premise

No B-Premise
statistical I-Premise
significance I-Premise
was I-Premise
found I-Premise
in I-Premise
the I-Premise
FACT I-Premise
- I-Premise
G I-Premise
scores I-Premise
and I-Premise
FACT I-Premise
- I-Premise
B I-Premise
scores I-Premise
among I-Premise
different I-Premise
groups I-Premise
at I-Premise
baseline I-Premise
, I-Premise
week I-Premise
4 I-Premise
, I-Premise
week I-Premise
8 I-Premise
and I-Premise
week I-Premise
12 I-Premise
after I-Premise
NHT I-Premise
. I-Premise

The B-Premise
Breast I-Premise
Cancer I-Premise
Subscale I-Premise
scores I-Premise
in I-Premise
group I-Premise
A I-Premise
patients I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
of I-Premise
group I-Premise
C I-Premise
patients I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
021 I-Premise
) I-Premise
. I-Premise

After B-Premise
4 I-Premise
weeks I-Premise
of I-Premise
NHT I-Premise
, I-Premise
negative I-Premise
changes I-Premise
of I-Premise
FACT I-Premise
- I-Premise
B I-Premise
and I-Premise
FACT I-Premise
- I-Premise
G I-Premise
scores I-Premise
were I-Premise
found I-Premise
in I-Premise
group I-Premise
B I-Premise
and I-Premise
C I-Premise
patients I-Premise
, I-Premise
but B-Premise
there I-Premise
were I-Premise
positive I-Premise
changes I-Premise
in I-Premise
group I-Premise
A I-Premise
patients I-Premise
. I-Premise

Significant B-Premise
differences I-Premise
of I-Premise
FACT I-Premise
- I-Premise
B I-Premise
score I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
008 I-Premise
) I-Premise
and I-Premise
FACT I-Premise
- I-Premise
G I-Premise
score I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
019 I-Premise
) I-Premise
were I-Premise
observed I-Premise
at I-Premise
that I-Premise
time I-Premise
point I-Premise
. I-Premise

Article O
from O
the O
Special O
issue O
on O
Targeted O
Inhibitors O
. O

Hot O
flushes O
and O
night O
sweats O
( O
HFNS O
) O
affect O
65 O
- O
85 O
% O
of O
women O
after O
breast O
cancer O
treatment O
"""" O
; O
"""" O
they O
are O
distressing O
, O
causing O
sleep O
problems O
and O
decreased O
quality O
of O
life O
. O

Hormone B-Claim
replacement I-Claim
therapy I-Claim
is I-Claim
often I-Claim
either I-Claim
undesirable I-Claim
or I-Claim
contraindicated I-Claim
. I-Claim

Safe B-Claim
, I-Claim
effective I-Claim
non I-Claim
- I-Claim
hormonal I-Claim
treatments I-Claim
are I-Claim
needed I-Claim
. I-Claim

We O
investigated O
whether O
cognitive O
behavioural O
therapy O
( O
CBT O
) O
can O
help O
breast O
cancer O
survivors O
to O
effectively O
manage O
HFNS O
. O

In O
this O
randomised O
controlled O
trial O
, O
we O
recruited O
women O
from O
breast O
clinics O
in O
London O
, O
UK O
, O
who O
had O
problematic O
HFNS O
( O
minimum O
ten O
problematic O
episodes O
a O
week O
) O
after O
breast O
- O
cancer O
treatment O
. O

Participants O
were O
randomly O
allocated O
to O
receive O
either O
usual O
care O
or O
usual O
care O
plus O
group O
CBT O
( O
1 O
: O
1 O
) O
. O

Randomisation O
was O
done O
in O
blocks O
of O
12 O
- O
20 O
participants O
, O
stratifying O
by O
age O
( O
younger O
than O
50 O
years O
, O
50 O
years O
or O
older O
) O
, O
and O
was O
done O
with O
a O
computer O
- O
generated O
sequence O
. O

The O
trial O
statistician O
and O
researchers O
collecting O
outcome O
measures O
were O
masked O
to O
group O
allocation O
. O

Group O
CBT O
comprised O
one O
90 O
min O
session O
a O
week O
for O
6 O
weeks O
, O
and O
included O
psycho O
- O
education O
, O
paced O
breathing O
, O
and O
cognitive O
and O
behavioural O
strategies O
to O
manage O
HFNS O
. O

Assessments O
were O
done O
at O
baseline O
, O
9 O
weeks O
, O
and O
26 O
weeks O
after O
randomisation O
. O

The O
primary O
outcome O
was O
the O
adjusted O
mean O
difference O
in O
HFNS O
problem O
rating O
( O
1 O
- O
10 O
) O
between O
CBT O
and O
usual O
care O
groups O
at O
9 O
weeks O
after O
randomisation O
. O

Analysis O
of O
the O
primary O
endpoint O
was O
done O
by O
modified O
intention O
to O
treat O
. O

The O
trial O
is O
registered O
, O
ISRCTN13771934 O
, O
and O
was O
closed O
March O
15 O
, O
2011 O
. O

Between O
May O
5 O
, O
2009 O
, O
and O
Aug O
27 O
, O
2010 O
, O
96 O
women O
were O
randomly O
allocated O
to O
group O
CBT O
( O
n O
= O
47 O
) O
or O
usual O
care O
( O
n O
= O
49 O
) O
. O

Group B-Premise
CBT I-Premise
significantly I-Premise
reduced I-Premise
HFNS I-Premise
problem I-Premise
rating I-Premise
at I-Premise
9 I-Premise
weeks I-Premise
after I-Premise
randomisation I-Premise
compared I-Premise
with I-Premise
usual I-Premise
care I-Premise
( I-Premise
mean I-Premise
difference I-Premise
- I-Premise
1 I-Premise
Â· I-Premise
67 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
- I-Premise
2 I-Premise
Â· I-Premise
43 I-Premise
to I-Premise
- I-Premise
0 I-Premise
Â· I-Premise
91 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
Â· I-Premise
0001 I-Premise
) I-Premise
and I-Premise
improvements I-Premise
were I-Premise
maintained I-Premise
at I-Premise
26 I-Premise
weeks I-Premise
( I-Premise
mean I-Premise
difference I-Premise
- I-Premise
1 I-Premise
Â· I-Premise
76 I-Premise
, I-Premise
- I-Premise
2 I-Premise
Â· I-Premise
54 I-Premise
to I-Premise
- I-Premise
0 I-Premise
Â· I-Premise
99 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
Â· I-Premise
0001 I-Premise
) I-Premise
. I-Premise

We B-Premise
recorded I-Premise
no I-Premise
CBT I-Premise
- I-Premise
related I-Premise
adverse I-Premise
events I-Premise
. I-Premise

Group B-Claim
CBT I-Claim
seems I-Claim
to I-Claim
be I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
treatment I-Claim
for I-Claim
women I-Claim
who I-Claim
have I-Claim
problematic I-Claim
HFNS I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
with I-Claim
additional I-Claim
benefits I-Claim
to I-Claim
mood I-Claim
, I-Claim
sleep I-Claim
, I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

The O
treatment O
could O
be O
incorporated O
into O
breast O
cancer O
survivorship O
programmes O
and O
delivered O
by O
trained O
breast O
cancer O
nurses O
. O

Most B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
develop I-Claim
recurrent I-Claim
disease I-Claim
. I-Claim

For B-Claim
those I-Claim
patients I-Claim
who I-Claim
recur I-Claim
at I-Claim
least I-Claim
6 I-Claim
months I-Claim
after I-Claim
initial I-Claim
therapy I-Claim
, I-Claim
paclitaxel I-Claim
platinum I-Claim
has I-Claim
shown I-Claim
a I-Claim
modest I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
platinum I-Claim
without I-Claim
paclitaxel I-Claim
"""" I-Claim
; I-Claim
"""" I-Claim
however B-Premise
, I-Premise
many I-Premise
patients I-Premise
develop I-Premise
clinically I-Premise
relevant I-Premise
neurotoxicity I-Premise
, I-Premise
frequently I-Premise
resulting I-Premise
in I-Premise
treatment I-Premise
discontinuation I-Premise
. O

Thus O
, O
an O
alternative O
regimen O
without O
significant O
neurotoxicity O
was O
evaluated O
by O
comparing O
gemcitabine O
plus O
carboplatin O
with O
single O
- O
agent O
carboplatin O
in O
platinum O
- O
sensitive O
recurrent O
ovarian O
cancer O
patients O
. O

Patients O
with O
platinum O
- O
sensitive O
recurrent O
ovarian O
cancer O
were O
randomly O
assigned O
to O
receive O
either O
gemcitabine O
plus O
carboplatin O
or O
carboplatin O
alone O
, O
every O
21 O
days O
. O

The O
primary O
objective O
was O
to O
compare O
progression O
- O
free O
survival O
( O
PFS O
) O
. O

Three O
hundred O
fifty O
- O
six O
patients O
( O
178 O
gemcitabine O
plus O
carboplatin O
"""" O
; O
"""" O
178 O
carboplatin O
) O
were O
randomly O
assigned O
. O

Patients O
received O
a O
median O
of O
six O
cycles O
in O
both O
arms O
. O

With B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
17 I-Premise
months I-Premise
, I-Premise
median I-Premise
PFS I-Premise
was I-Premise
8 I-Premise
. I-Premise
6 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
7 I-Premise
. I-Premise
9 I-Premise
to I-Premise
9 I-Premise
. I-Premise
7 I-Premise
months I-Premise
) I-Premise
for I-Premise
gemcitabine I-Premise
plus I-Premise
carboplatin I-Premise
and I-Premise
5 I-Premise
. I-Premise
8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
5 I-Premise
. I-Premise
2 I-Premise
to I-Premise
7 I-Premise
. I-Premise
1 I-Premise
months I-Premise
) I-Premise
for I-Premise
carboplatin I-Premise
. I-Premise

The B-Premise
hazard I-Premise
ration I-Premise
( I-Premise
HR I-Premise
) I-Premise
for I-Premise
PFS I-Premise
was I-Premise
0 I-Premise
. I-Premise
72 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
58 I-Premise
to I-Premise
0 I-Premise
. I-Premise
90 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
0031 I-Premise
) I-Premise
. I-Premise

Response B-Premise
rate I-Premise
was I-Premise
47 I-Premise
. I-Premise
2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
39 I-Premise
. I-Premise
9 I-Premise
% I-Premise
to I-Premise
54 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
for I-Premise
gemcitabine I-Premise
plus I-Premise
carboplatin I-Premise
and I-Premise
30 I-Premise
. I-Premise
9 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
24 I-Premise
. I-Premise
1 I-Premise
% I-Premise
to I-Premise
37 I-Premise
. I-Premise
7 I-Premise
% I-Premise
) I-Premise
for I-Premise
carboplatin I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
0016 I-Premise
) I-Premise
. I-Premise

The B-Premise
HR I-Premise
for I-Premise
overall I-Premise
survival I-Premise
was I-Premise
0 I-Premise
. I-Premise
96 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
75 I-Premise
to1 I-Premise
. I-Premise
23 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
7349 I-Premise
) I-Premise
. I-Premise

While B-Premise
myelosuppression I-Premise
was I-Premise
significantly I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
combination I-Premise
, I-Premise
sequelae I-Premise
such I-Premise
as I-Premise
febrile I-Premise
neutropenia I-Premise
or I-Premise
infections I-Premise
were I-Premise
uncommon I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
between I-Premise
arms I-Premise
were I-Premise
noted I-Premise
. I-Premise

Gemcitabine B-Claim
plus I-Claim
carboplatin I-Claim
significantly I-Claim
improves I-Claim
PFS I-Claim
and I-Claim
response I-Claim
rate I-Claim
without I-Claim
worsening I-Claim
quality I-Claim
of I-Claim
life I-Claim
for I-Claim
patients I-Claim
with I-Claim
platinum I-Claim
- I-Claim
sensitive I-Claim
recurrent I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

There O
are O
very O
few O
randomized O
controlled O
studies O
on O
exercise O
in O
cancer O
patients O
. O

Consequently O
, O
there O
are O
no O
guidelines O
available O
with O
regard O
to O
the O
exercises O
that O
can O
be O
recommended O
and O
difficulties O
are O
encountered O
in O
the O
clinical O
practice O
as O
to O
which O
exercise O
is O
more O
suitable O
to O
the O
patients O
. O

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
impact O
of O
pilates O
exercises O
on O
physical O
performance O
, O
flexibility O
, O
fatigue O
, O
depression O
and O
quality O
of O
life O
in O
women O
who O
had O
been O
treated O
for O
breast O
cancer O
. O

Randomized O
controlled O
trial O
. O

Out O
patient O
group O
, O
Department O
of O
Physical O
Medicine O
and O
Rehabilitation O
and O
Medical O
Oncology O
Department O
, O
University O
Hospital O
. O

Fifty O
- O
two O
patients O
with O
breast O
cancer O
were O
divided O
into O
either O
pilates O
exercise O
( O
group O
1 O
) O
and O
control O
group O
( O
group O
2 O
) O
. O

Patients O
in O
Group O
1 O
performed O
pilates O
and O
home O
exercises O
and O
patients O
in O
group O
2 O
performed O
only O
home O
exercises O
. O

Pilates O
exercise O
sessions O
were O
performed O
three O
times O
a O
week O
for O
a O
period O
of O
eight O
weeks O
in O
the O
rehabilitation O
unit O
. O

Subjects O
were O
assessed O
before O
and O
after O
rehabilitation O
program O
, O
with O
respect O
to O
, O
6 O
- O
min O
walk O
test O
( O
6MWT O
) O
, O
modified O
sit O
and O
reach O
test O
, O
Brief O
Fatigue O
Inventory O
( O
BFI O
) O
, O
Beck O
Depression O
Index O
( O
BDI O
) O
and O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
C30 O
( O
EORTC O
QLQ O
- O
C30 O
) O
and O
EORTC O
QLQ O
BR23 O
. O

After B-Premise
the I-Premise
exercise I-Premise
program I-Premise
, I-Premise
improvements I-Premise
were I-Premise
observed I-Premise
in I-Premise
Group I-Premise
1 I-Premise
in I-Premise
6 I-Premise
- I-Premise
minute I-Premise
walk I-Premise
test I-Premise
, I-Premise
BDI I-Premise
, I-Premise
EORTC I-Premise
QLQ I-Premise
- I-Premise
C30 I-Premise
functional I-Premise
, I-Premise
and I-Premise
EORTC I-Premise
QLQ I-Premise
- I-Premise
C30 I-Premise
BR23 I-Premise
functional I-Premise
scores I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

In O
contrast O
, O
no B-Premise
significant I-Premise
improvement I-Premise
was I-Premise
observed I-Premise
in I-Premise
Group I-Premise
2 I-Premise
after I-Premise
the I-Premise
exercise I-Premise
program I-Premise
in I-Premise
any I-Premise
of I-Premise
parameters I-Premise
in I-Premise
comparison I-Premise
to I-Premise
the I-Premise
pre I-Premise
- I-Premise
exercise I-Premise
period I-Premise
( I-Premise
P I-Premise
> I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

When B-Premise
the I-Premise
two I-Premise
exercise I-Premise
groups I-Premise
were I-Premise
compared I-Premise
, I-Premise
there I-Premise
were I-Premise
significant I-Premise
differences I-Premise
in I-Premise
6MWT I-Premise
in I-Premise
pilates I-Premise
- I-Premise
exercise I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

Pilates B-Claim
exercises I-Claim
are I-Claim
effective I-Claim
and I-Claim
safe I-Claim
in I-Claim
female I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

There B-Claim
is I-Claim
a I-Claim
need I-Claim
for I-Claim
further I-Claim
studies I-Claim
so I-Claim
that I-Claim
its I-Claim
effect I-Claim
can I-Claim
be I-Claim
confirmed I-Claim
. I-Claim

This O
study O
addressed O
the O
effects O
of O
pilates O
exercise O
, O
as O
a O
new O
approach O
, O
on O
functional O
capacity O
, O
fatigue O
, O
depression O
and O
quality O
of O
life O
in O
breast O
cancer O
patients O
in O
whom O
there O
are O
doubts O
regarding O
the O
efficacy O
and O
usefulness O
of O
the O
exercise O
. O

Treatment O
- O
induced O
arm O
lymphoedema O
is O
a O
common O
and O
distressing O
complication O
of O
curative O
surgery O
and O
radiotherapy O
for O
early O
breast O
cancer O
. O

A O
number O
of O
studies O
testing O
alpha O
- O
tocopherol O
( O
vitamin O
E O
) O
and O
pentoxifylline O
suggest O
evidence O
of O
clinical O
regression O
of O
superficial O
radiation O
- O
induced O
fibrosis O
but O
there O
is O
only O
very O
limited O
evidence O
from O
randomised O
trials O
. O

Arm O
lymphoedema O
after O
lymphatic O
radiotherapy O
and O
surgery O
has O
been O
used O
in O
the O
present O
study O
as O
a O
clinical O
system O
for O
testing O
these O
drugs O
in O
a O
double O
- O
blind O
placebo O
- O
controlled O
randomised O
phase O
II O
trial O
. O

Sixty O
- O
eight O
eligible O
research O
volunteers O
with O
a O
minimum O
20 O
% O
increase O
in O
arm O
volume O
at O
a O
median O
15 O
. O
5 O
years O
( O
range O
2 O
- O
41 O
) O
after O
axillary O
/ O
supraclavicular O
radiotherapy O
( O
plus O
axillary O
surgery O
in O
51 O
/ O
68 O
( O
75 O
% O
) O
cases O
) O
were O
randomised O
to O
active O
drugs O
or O
placebo O
. O

All O
volunteers O
were O
given O
dl O
- O
alpha O
tocopheryl O
acetate O
500 O
mg O
twice O
a O
day O
orally O
plus O
pentoxifylline O
400 O
mg O
twice O
a O
day O
orally O
, O
or O
corresponding O
placebos O
, O
for O
6 O
months O
. O

The O
primary O
endpoint O
was O
volume O
of O
the O
ipsilateral O
limb O
measured O
opto O
- O
electronically O
using O
a O
perometer O
and O
expressed O
as O
a O
percentage O
of O
the O
contralateral O
limb O
volume O
. O

At B-Premise
12 I-Premise
months I-Premise
post I-Premise
- I-Premise
randomisation I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
treatment I-Premise
and I-Premise
control I-Premise
groups I-Premise
in I-Premise
terms I-Premise
of I-Premise
arm I-Premise
volume I-Premise
. I-Premise

Absolute B-Premise
change I-Premise
in I-Premise
arm I-Premise
volume I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
2 I-Premise
. I-Premise
5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
- I-Premise
0 I-Premise
. I-Premise
40 I-Premise
to I-Premise
5 I-Premise
. I-Premise
3 I-Premise
) I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
compared I-Premise
to I-Premise
1 I-Premise
. I-Premise
2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
- I-Premise
2 I-Premise
. I-Premise
8 I-Premise
to I-Premise
5 I-Premise
. I-Premise
1 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

The B-Premise
difference I-Premise
in I-Premise
mean I-Premise
volume I-Premise
change I-Premise
between I-Premise
randomisation I-Premise
groups I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
6 I-Premise
) I-Premise
, I-Premise
- I-Premise
1 I-Premise
. I-Premise
3 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
- I-Premise
6 I-Premise
. I-Premise
1 I-Premise
to I-Premise
3 I-Premise
. I-Premise
5 I-Premise
) I-Premise
, I-Premise
nor I-Premise
was I-Premise
there I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
response I-Premise
at I-Premise
6 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
7 I-Premise
) I-Premise
, I-Premise
where I-Premise
mean I-Premise
change I-Premise
in I-Premise
arm I-Premise
volume I-Premise
from I-Premise
baseline I-Premise
in I-Premise
the I-Premise
treatment I-Premise
and I-Premise
placebo I-Premise
groups I-Premise
was I-Premise
- I-Premise
2 I-Premise
. I-Premise
3 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
- I-Premise
7 I-Premise
. I-Premise
9 I-Premise
to I-Premise
3 I-Premise
. I-Premise
4 I-Premise
) I-Premise
and I-Premise
- I-Premise
1 I-Premise
. I-Premise
1 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
- I-Premise
3 I-Premise
. I-Premise
9 I-Premise
to I-Premise
1 I-Premise
. I-Premise
7 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
randomised I-Premise
groups I-Premise
in I-Premise
terms I-Premise
of I-Premise
secondary I-Premise
endpoints I-Premise
, I-Premise
including I-Premise
tissue I-Premise
induration I-Premise
( I-Premise
fibrosis I-Premise
) I-Premise
in I-Premise
the I-Premise
irradiated I-Premise
breast I-Premise
or I-Premise
chest I-Premise
wall I-Premise
, I-Premise
pectoral I-Premise
fold I-Premise
or I-Premise
supraclavicular I-Premise
fossa I-Premise
, I-Premise
change I-Premise
in I-Premise
photographic I-Premise
breast I-Premise
/ I-Premise
chest I-Premise
wall I-Premise
appearance I-Premise
or I-Premise
patient I-Premise
self I-Premise
- I-Premise
assessment I-Premise
of I-Premise
function I-Premise
and I-Premise
Quality I-Premise
of I-Premise
Life I-Premise
at I-Premise
either I-Premise
6 I-Premise
or I-Premise
12 I-Premise
months I-Premise
. I-Premise

The B-Claim
study I-Claim
fails I-Claim
to I-Claim
demonstrate I-Claim
efficacy I-Claim
of I-Claim
dl I-Claim
- I-Claim
alpha I-Claim
tocopheryl I-Claim
acetate I-Claim
plus I-Claim
pentoxifylline I-Claim
in I-Claim
patients I-Claim
with I-Claim
arm I-Claim
lymphoedema I-Claim
following I-Claim
axillary I-Claim
surgery I-Claim
and I-Claim
lymphatic I-Claim
radiotherapy I-Claim
, I-Claim
nor I-Claim
does I-Claim
it I-Claim
suggest I-Claim
any I-Claim
benefits I-Claim
of I-Claim
these I-Claim
drugs I-Claim
in I-Claim
radiation I-Claim
- I-Claim
induced I-Claim
induration I-Claim
( I-Claim
fibrosis I-Claim
) I-Claim
in I-Claim
the I-Claim
breast I-Claim
, I-Claim
chest I-Claim
wall I-Claim
, I-Claim
pectoral I-Claim
fold I-Claim
, I-Claim
axilla I-Claim
or I-Claim
supraclavicular I-Claim
fossa I-Claim
. I-Claim

Many O
patients O
with O
advanced O
ovarian O
cancer O
will O
develop O
recurrent O
disease O
. O

For B-Premise
those I-Premise
patients I-Premise
who I-Premise
have I-Premise
recurrence I-Premise
of I-Premise
disease I-Premise
at I-Premise
least I-Premise
6 I-Premise
months I-Premise
after I-Premise
initial I-Premise
therapy I-Premise
, I-Premise
the I-Premise
paclitaxel I-Premise
- I-Premise
platinum I-Premise
combination I-Premise
has I-Premise
been I-Premise
shown I-Premise
to I-Premise
be I-Premise
a I-Premise
superior I-Premise
treatment I-Premise
to I-Premise
platinum I-Premise
monotherapy I-Premise
. I-Premise

However B-Claim
, I-Claim
many I-Claim
patients I-Claim
develop I-Claim
clinically I-Claim
relevant I-Claim
neurotoxicity I-Claim
, I-Claim
frequently I-Claim
resulting I-Claim
in I-Claim
treatment I-Claim
discontinuation I-Claim
. I-Claim

The O
efficacy O
and O
safety O
of O
an O
alternative O
regimen O
that O
does O
not O
show O
significant O
neurotoxicity O
were O
evaluated O
by O
comparing O
gemcitabine O
- O
carboplatin O
with O
carboplatin O
in O
platinum O
- O
sensitive O
recurrent O
ovarian O
cancer O
patients O
in O
a O
Gynecologic O
Cancer O
InterGroup O
trial O
of O
the O
Arbeitsgemeinschaft O
Gynakologische O
Onkologie O
Ovarian O
Cancer O
Study O
Group O
, O
the O
National O
Cancer O
Institute O
of O
Canada O
Clinical O
Trials O
Group O
, O
and O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Gynaecological O
Cancer O
Group O
. O

Participants O
with O
recurrent O
platinum O
- O
sensitive O
ovarian O
cancer O
were O
randomly O
assigned O
to O
receive O
either O
gemcitabine O
- O
carboplatin O
or O
carboplatin O
every O
21 O
days O
. O

The O
primary O
objective O
was O
to O
compare O
progression O
- O
free O
survival O
( O
PFS O
) O
between O
the O
groups O
. O

From O
September O
1999 O
to O
April O
2002 O
, O
356 O
patients O
( O
178 O
participants O
received O
gemcitabine O
- O
carboplatin O
, O
178 O
received O
carboplatin O
only O
) O
were O
randomized O
to O
treatment O
. O

Patients O
received O
six O
cycles O
of O
either O
gemcitabine O
- O
carboplatin O
or O
carboplatin O
. O

With B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
17 I-Premise
months I-Premise
, I-Premise
median I-Premise
PFS I-Premise
was I-Premise
8 I-Premise
. I-Premise
6 I-Premise
months I-Premise
for I-Premise
gemcitabine I-Premise
- I-Premise
carboplatin I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
7 I-Premise
. I-Premise
9 I-Premise
- I-Premise
9 I-Premise
. I-Premise
7 I-Premise
months I-Premise
) I-Premise
and I-Premise
5 I-Premise
. I-Premise
8 I-Premise
months I-Premise
for I-Premise
carboplatin I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
5 I-Premise
. I-Premise
2 I-Premise
- I-Premise
7 I-Premise
. I-Premise
1 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
0 I-Premise
. I-Premise
72 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0 I-Premise
. I-Premise
58 I-Premise
- I-Premise
0 I-Premise
. I-Premise
90 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
0032 I-Premise
] I-Premise
) I-Premise
. I-Premise

The B-Premise
response I-Premise
rate I-Premise
for I-Premise
the I-Premise
gemcitabine I-Premise
- I-Premise
carboplatin I-Premise
group I-Premise
was I-Premise
47 I-Premise
. I-Premise
2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
39 I-Premise
. I-Premise
9 I-Premise
- I-Premise
54 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
and I-Premise
30 I-Premise
. I-Premise
9 I-Premise
% I-Premise
for I-Premise
carboplatin I-Premise
group I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
24 I-Premise
. I-Premise
1 I-Premise
- I-Premise
37 I-Premise
. I-Premise
7 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
0016 I-Premise
) I-Premise
. I-Premise

The B-Premise
HR I-Premise
for I-Premise
overall I-Premise
survival I-Premise
was I-Premise
0 I-Premise
. I-Premise
96 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0 I-Premise
. I-Premise
75 I-Premise
- I-Premise
1 I-Premise
. I-Premise
23 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
7349 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
gemcitabine I-Premise
- I-Premise
carboplatin I-Premise
reported I-Premise
significantly I-Premise
faster I-Premise
palliation I-Premise
of I-Premise
abdominal I-Premise
symptoms I-Premise
and I-Premise
a I-Premise
significantly I-Premise
improved I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Gemcitabine B-Claim
- B-Claim
carboplatin B-Claim
treatment I-Claim
significantly I-Claim
improves I-Claim
the I-Claim
PFS I-Claim
of I-Claim
patients I-Claim
with I-Claim
platinum I-Claim
- I-Claim
sensitive I-Claim
recurrent I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

The O
combination O
of O
cisplatin O
and O
etoposide O
( O
PE O
) O
has O
been O
a O
standard O
treatment O
for O
patients O
with O
poor O
- O
prognosis O
small O
cell O
lung O
cancer O
( O
SCLC O
) O
. O

This O
non O
- O
inferiority O
design O
trial O
aimed O
to O
determine O
whether O
the O
combination O
of O
gemcitabine O
and O
carboplatin O
( O
GC O
) O
results O
in O
similar O
survival O
but O
is O
less O
toxic O
with O
better O
quality O
of O
life O
. O

Previously O
untreated O
patients O
with O
SCLC O
with O
extensive O
disease O
or O
limited O
stage O
with O
poor O
prognostic O
factors O
were O
randomly O
assigned O
to O
six O
3 O
- O
weekly O
cycles O
of O
GC O
or O
PE O
. O

241 O
patients O
( O
121 O
GC O
, O
120 O
PE O
) O
were O
recruited O
, O
of O
which O
216 O
( O
90 O
% O
) O
had O
died O
. O

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HR I-Premise
1 I-Premise
. I-Premise
01 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0 I-Premise
. I-Premise
77 I-Premise
to I-Premise
1 I-Premise
. I-Premise
32 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
with I-Premise
GC I-Premise
and I-Premise
PE I-Premise
was I-Premise
8 I-Premise
. I-Premise
0 I-Premise
and I-Premise
8 I-Premise
. I-Premise
1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Median B-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
was I-Premise
5 I-Premise
. I-Premise
9 I-Premise
months I-Premise
with I-Premise
GC I-Premise
and I-Premise
6 I-Premise
. I-Premise
3 I-Premise
months I-Premise
with I-Premise
PE I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
myelosuppressions I-Premise
were I-Premise
more I-Premise
frequent I-Premise
with I-Premise
GC I-Premise
( I-Premise
anaemia I-Premise
: I-Premise
14 I-Premise
% I-Premise
GC I-Premise
vs I-Premise
2 I-Premise
% I-Premise
PE I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
leucopenia I-Premise
: I-Premise
32 I-Premise
% I-Premise
GC I-Premise
vs I-Premise
13 I-Premise
% I-Premise
PE I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
thrombocytopenia I-Premise
: I-Premise
22 I-Premise
% I-Premise
GC I-Premise
vs I-Premise
4 I-Premise
% I-Premise
PE I-Premise
) I-Premise
, I-Premise
but B-Premise
these I-Premise
were I-Premise
not I-Premise
associated I-Premise
with I-Premise
increased I-Premise
hospital I-Premise
admissions I-Premise
, I-Premise
infections I-Premise
or I-Premise
fatalities I-Premise
. I-Premise

Grade B-Premise
2 I-Premise
- I-Premise
3 I-Premise
alopecia I-Premise
( I-Premise
68 I-Premise
% I-Premise
PE I-Premise
vs I-Premise
17 I-Premise
% I-Premise
GC I-Premise
) I-Premise
and I-Premise
nausea I-Premise
( I-Premise
43 I-Premise
% I-Premise
PE I-Premise
vs I-Premise
26 I-Premise
% I-Premise
GC I-Premise
) I-Premise
were I-Premise
more I-Premise
frequent I-Premise
with I-Premise
PE I-Premise
. I-Premise

Patients O
given O
GC O
received O
more O
chemotherapy O
as O
outpatients O
( O
89 O
% O
GC O
vs O
66 O
% O
PE O
of O
treatment O
cycles O
) O
. O

In B-Premise
QoL I-Premise
questionnaires I-Premise
, I-Premise
more I-Premise
patients I-Premise
receiving I-Premise
PE I-Premise
reported I-Premise
being I-Premise
upset I-Premise
by I-Premise
hair I-Premise
loss I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
004 I-Premise
) I-Premise
and I-Premise
impaired I-Premise
cognitive I-Premise
functioning I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
) I-Premise
. I-Premise

GC B-Claim
is I-Claim
as I-Claim
effective I-Claim
as I-Claim
PE I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
survival I-Claim
and I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
and I-Claim
has I-Claim
a I-Claim
toxicity I-Claim
profile I-Claim
more I-Claim
acceptable I-Claim
to I-Claim
patients I-Claim
. I-Claim

To O
assess O
the O
efficacy O
of O
a O
novel O
coloplasty O
colonic O
pouch O
design O
in O
optimizing O
bowel O
function O
after O
ultralow O
anterior O
resection O
. O

A B-Claim
colonic I-Claim
J I-Claim
- I-Claim
pouch I-Claim
may I-Claim
reduce I-Claim
excessive I-Claim
stool I-Claim
frequency I-Claim
and I-Claim
incontinence I-Claim
after I-Claim
anterior I-Claim
resection I-Claim
, I-Claim
but I-Claim
at I-Claim
the I-Claim
risk I-Claim
of I-Claim
evacuation I-Claim
problems I-Claim
. I-Claim

Experimental B-Claim
surgery I-Claim
on I-Claim
pigs I-Claim
has I-Claim
suggested I-Claim
that I-Claim
a I-Claim
coloplasty I-Claim
pouch I-Claim
( I-Claim
CP I-Claim
) I-Claim
may I-Claim
be I-Claim
a I-Claim
useful I-Claim
alternative I-Claim
. O

Although O
CP O
has O
recently O
been O
shown O
to O
be O
feasible O
in O
patients O
, O
there O
is O
no O
randomized O
controlled O
trial O
comparing O
bowel O
function O
with O
the O
J O
- O
pouch O
. O

After O
anterior O
resection O
for O
cancer O
, O
patients O
were O
allocated O
to O
either O
J O
- O
pouch O
or O
CP O
- O
anal O
anastomoses O
. O

Continence O
scoring O
, O
anorectal O
manometry O
, O
and O
endoanal O
ultrasound O
assessments O
were O
made O
before O
surgery O
. O

All O
complications O
were O
recorded O
, O
and O
these O
preoperative O
assessments O
were O
repeated O
at O
4 O
months O
. O

The O
assessments O
were O
repeated O
again O
at O
1 O
year O
, O
and O
a O
quality O
of O
life O
questionnaire O
was O
added O
. O

Eighty O
- O
eight O
patients O
were O
recruited O
from O
October O
1998 O
to O
April O
2000 O
. O

Both O
groups O
were O
well O
matched O
for O
age O
, O
gender O
, O
staging O
, O
adjuvant O
therapy O
, O
and O
mean O
follow O
- O
up O
. O

There O
were O
no O
differences O
in O
the O
intraoperative O
time O
and O
hospital O
stay O
. O

CP B-Premise
resulted I-Premise
in I-Premise
more I-Premise
anastomotic I-Premise
leaks I-Premise
. I-Premise

At B-Premise
4 I-Premise
months I-Premise
, I-Premise
J I-Premise
- I-Premise
pouch I-Premise
patients I-Premise
had I-Premise
10 I-Premise
. I-Premise
3 I-Premise
% I-Premise
less I-Premise
stool I-Premise
fragmentation I-Premise
but I-Premise
poorer I-Premise
stool I-Premise
deferment I-Premise
and I-Premise
more I-Premise
nocturnal I-Premise
leakage I-Premise
. I-Premise

However O
, O
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
bowel I-Premise
function I-Premise
, I-Premise
continence I-Premise
score I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
anorectal I-Premise
manometry I-Premise
and I-Premise
endoanal I-Premise
ultrasound I-Premise
findings I-Premise
. I-Premise

Coloplasty B-Claim
pouches I-Claim
resulted I-Claim
in I-Claim
more I-Claim
anastomotic I-Claim
leaks I-Claim
and I-Claim
minimal I-Claim
differences I-Claim
in I-Claim
bowel I-Claim
function I-Claim
. I-Claim

At O
present O
, O
the B-Claim
J I-Claim
- I-Claim
pouch I-Claim
remains I-Claim
the I-Claim
benchmark I-Claim
for I-Claim
routine I-Claim
clinical I-Claim
practice I-Claim
, I-Claim
and O
due B-Claim
care I-Claim
( I-Claim
including I-Claim
defunctioning I-Claim
stoma I-Claim
) I-Claim
should I-Claim
be I-Claim
exercised I-Claim
in I-Claim
situations I-Claim
requiring I-Claim
CP I-Claim
. I-Claim

From O
1984 O
to O
1989 O
, O
the O
Swiss O
Group O
for O
Clinical O
Cancer O
Research O
( O
SAKK O
) O
performed O
a O
randomized O
phase O
III O
trial O
comparing O
early O
versus O
late O
alternating O
chemotherapy O
in O
patients O
with O
small O
- O
cell O
lung O
cancer O
. O

406 O
eligible O
patients O
were O
entered O
into O
the O
trial O
. O

Regimen O
A O
consisted O
of O
PAV O
( O
cisPlatin O
, O
Adriamycin O
, O
VP O
16 O
- O
213 O
, O
and O
Regimen O
B O
of O
CyMOC O
( O
Cyclophosphamide O
, O
Methotrexate O
, O
Oncovin O
, O
CCNU O
) O
. O

Cycles O
were O
repeated O
as O
rapidly O
as O
possible O
. O

patients O
were O
randomized O
to O
receive O
either O
ABABAB O
( O
early O
alternating O
chemotherapy O
) O
or O
AAABBB O
( O
late O
alternating O
chemotherapy O
) O
. O

After O
six O
cycles O
patients O
with O
limited O
disease O
in O
complete O
or O
partial O
remission O
and O
those O
with O
extensive O
disease O
in O
complete O
remission O
received O
irradiation O
to O
the O
primary O
( O
45 O
Gy O
) O
and O
the O
CNS O
( O
36 O
Gy O
) O
. O

The B-Premise
overall I-Premise
remission I-Premise
rate I-Premise
was I-Premise
87 I-Premise
% I-Premise
with I-Premise
31 I-Premise
% I-Premise
complete I-Premise
remissions I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
of I-Premise
all I-Premise
406 I-Premise
eligible I-Premise
patients I-Premise
was I-Premise
346 I-Premise
days I-Premise
with I-Premise
15 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
alive I-Premise
at I-Premise
two I-Premise
years I-Premise
. I-Premise

The B-Premise
overall I-Premise
remission I-Premise
rate I-Premise
, I-Premise
the I-Premise
rate I-Premise
of I-Premise
complete I-Premise
remission I-Premise
, I-Premise
the I-Premise
median I-Premise
survival I-Premise
and I-Premise
the I-Premise
rate I-Premise
of I-Premise
long I-Premise
- I-Premise
term I-Premise
survival I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
in I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

In B-Premise
limited I-Premise
disease I-Premise
the I-Premise
estimated I-Premise
percentages I-Premise
of I-Premise
survival I-Premise
at I-Premise
2 I-Premise
years I-Premise
were I-Premise
33 I-Premise
% I-Premise
in I-Premise
the I-Premise
early I-Premise
and I-Premise
24 I-Premise
% I-Premise
in I-Premise
the I-Premise
late I-Premise
alternating I-Premise
chemotherapy I-Premise
arms I-Premise
. I-Premise

Patients B-Premise
with I-Premise
extensive I-Premise
disease I-Premise
survived I-Premise
significantly I-Premise
longer I-Premise
with I-Premise
late I-Premise
alternating I-Premise
chemotherapy I-Premise
than I-Premise
on I-Premise
the I-Premise
early I-Premise
alternation I-Premise
regimen I-Premise
( I-Premise
median I-Premise
survival I-Premise
336 I-Premise
days I-Premise
versus I-Premise
301 I-Premise
days I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
latter I-Premise
patients I-Premise
the I-Premise
received I-Premise
dose I-Premise
intensities I-Premise
( I-Premise
RDI I-Premise
) I-Premise
of I-Premise
cisplatin I-Premise
, I-Premise
adriamycin I-Premise
and I-Premise
etoposide I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
late I-Premise
- I-Premise
alternation I-Premise
arm I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
early I-Premise
alternating I-Premise
chemotherapy I-Premise
rated I-Premise
their I-Premise
tumor I-Premise
symptoms I-Premise
, I-Premise
functional I-Premise
states I-Premise
, I-Premise
fatigue I-Premise
/ I-Premise
malaise I-Premise
and I-Premise
restriction I-Premise
of I-Premise
social I-Premise
activity I-Premise
significantly I-Premise
better I-Premise
, I-Premise
reflecting I-Premise
an I-Premise
improved I-Premise
subjective I-Premise
adjustment I-Premise
. I-Premise

Alternating B-Claim
chemotherapy I-Claim
with I-Claim
PAV I-Claim
- I-Claim
CyMOC I-Claim
plus I-Claim
consolidating I-Claim
radiotherapy I-Claim
is I-Claim
a I-Claim
feasible I-Claim
and I-Claim
effective I-Claim
treatment I-Claim
for I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
, I-Claim
with I-Claim
acceptable I-Claim
toxicity I-Claim
. I-Claim

Whereas O
patients B-Claim
with I-Claim
early I-Claim
alternating I-Claim
chemotherapy I-Claim
achieve I-Claim
a I-Claim
better I-Claim
subjective I-Claim
adjustment I-Claim
, I-Claim
late B-Claim
alternating I-Claim
chemotherapy I-Claim
allows I-Claim
for I-Claim
a I-Claim
higher I-Claim
RDI I-Claim
of I-Claim
cisplatin I-Claim
, I-Claim
adriamycin I-Claim
and I-Claim
etoposide I-Claim
, I-Claim
which I-Claim
results I-Claim
in I-Claim
a I-Claim
significantly I-Claim
longer I-Claim
median I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
extensive I-Claim
disease I-Claim
. I-Claim

Assess O
toxicity O
and O
efficacy O
of O
cisplatin O
( O
Cis O
) O
doublet O
combinations O
in O
advanced O
and O
recurrent O
cervical O
carcinoma O
. O

Patients O
were O
randomly O
assigned O
to O
paclitaxel O
135 O
mg O
/ O
m O
( O
2 O
) O
over O
24 O
hours O
plus O
Cis O
50 O
mg O
/ O
m O
( O
2 O
) O
day O
2 O
every O
3 O
weeks O
( O
PC O
, O
reference O
arm O
) O
"""" O
; O
"""" O
vinorelbine O
30 O
mg O
/ O
m O
( O
2 O
) O
days O
1 O
and O
8 O
plus O
Cis O
50 O
mg O
/ O
m O
( O
2 O
) O
day O
1 O
every O
3 O
weeks O
( O
VC O
) O
"""" O
; O
"""" O
gemcitabine O
1 O
, O
000 O
mg O
/ O
m O
( O
2 O
) O
day O
1 O
and O
8 O
plus O
Cis O
50 O
mg O
/ O
m O
( O
2 O
) O
day O
1 O
every O
3 O
weeks O
( O
GC O
) O
"""" O
; O
"""" O
or O
topotecan O
0 O
. O
75 O
mg O
/ O
m O
( O
2 O
) O
days O
1 O
, O
2 O
, O
and O
3 O
plus O
Cis O
50 O
mg O
/ O
m O
( O
2 O
) O
day O
1 O
every O
3 O
weeks O
( O
TC O
) O
. O

Survival O
was O
the O
primary O
end O
point O
with O
a O
33 O
% O
improvement O
relative O
to O
PC O
considered O
important O
( O
85 O
% O
power O
, O
alpha O
= O
5 O
% O
) O
. O

Quality O
- O
of O
- O
life O
data O
were O
prospectively O
collected O
. O

A O
total O
of O
513 O
patients O
were O
enrolled O
when O
a O
planned O
interim O
analysis O
recommended O
early O
closure O
for O
futility O
. O

The B-Premise
experimental I-Premise
- I-Premise
to I-Premise
- I-Premise
PC I-Premise
hazard I-Premise
ratios I-Premise
of I-Premise
death I-Premise
were I-Premise
1 I-Premise
. I-Premise
15 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
79 I-Premise
to I-Premise
1 I-Premise
. I-Premise
67 I-Premise
) I-Premise
for I-Premise
VC I-Premise
, I-Premise
1 I-Premise
. I-Premise
32 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
91 I-Premise
to I-Premise
1 I-Premise
. I-Premise
92 I-Premise
) I-Premise
for I-Premise
GC I-Premise
, I-Premise
and I-Premise
1 I-Premise
. I-Premise
26 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
86 I-Premise
to I-Premise
1 I-Premise
. I-Premise
82 I-Premise
) I-Premise
for I-Premise
TC I-Premise
. I-Premise

The B-Premise
hazard I-Premise
ratios I-Premise
for I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
were I-Premise
1 I-Premise
. I-Premise
36 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
97 I-Premise
to I-Premise
1 I-Premise
. I-Premise
90 I-Premise
) I-Premise
for I-Premise
VC I-Premise
, I-Premise
1 I-Premise
. I-Premise
39 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
99 I-Premise
to I-Premise
1 I-Premise
. I-Premise
96 I-Premise
) I-Premise
for I-Premise
GC I-Premise
, I-Premise
and I-Premise
1 I-Premise
. I-Premise
27 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
90 I-Premise
to I-Premise
1 I-Premise
. I-Premise
78 I-Premise
) I-Premise
for I-Premise
TC I-Premise
. I-Premise

Response B-Premise
rates I-Premise
( I-Premise
RRs I-Premise
) I-Premise
for I-Premise
PC I-Premise
, I-Premise
VC I-Premise
, I-Premise
GC I-Premise
, I-Premise
and I-Premise
TC I-Premise
were I-Premise
29 I-Premise
. I-Premise
1 I-Premise
% I-Premise
, I-Premise
25 I-Premise
. I-Premise
9 I-Premise
% I-Premise
, I-Premise
22 I-Premise
. I-Premise
3 I-Premise
% I-Premise
, I-Premise
and I-Premise
23 I-Premise
. I-Premise
4 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
arms I-Premise
were I-Premise
comparable I-Premise
with I-Premise
respect I-Premise
to I-Premise
toxicity I-Premise
except I-Premise
for I-Premise
leucopenia I-Premise
, I-Premise
neutropenia I-Premise
, I-Premise
infection I-Premise
, I-Premise
and I-Premise
alopecia I-Premise
. I-Premise

VC B-Claim
, I-Claim
GC I-Claim
, I-Claim
and I-Claim
TC I-Claim
are I-Claim
not I-Claim
superior I-Claim
to I-Claim
PC I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
survival I-Claim
( I-Claim
OS I-Claim
) I-Claim
. I-Claim

However B-Claim
, I-Claim
the I-Claim
trend I-Claim
in I-Claim
RR I-Claim
, I-Claim
PFS I-Claim
, I-Claim
and I-Claim
OS I-Claim
favors I-Claim
PC I-Claim
. I-Claim

Differences B-Claim
in I-Claim
chemotherapy I-Claim
scheduling I-Claim
, I-Claim
pre I-Claim
- I-Claim
existing I-Claim
morbidity I-Claim
, I-Claim
and I-Claim
toxicity I-Claim
are I-Claim
important I-Claim
in I-Claim
individualizing I-Claim
therapy I-Claim
. I-Claim

To O
report O
5 O
- O
year O
contrast O
- O
enhanced O
magnetic O
resonance O
imaging O
findings O
of O
the O
REST O
trial O
recruits O
who O
underwent O
either O
uterine O
artery O
embolization O
( O
UAE O
) O
or O
myomectomy O
. O

A O
total O
of O
157 O
patients O
were O
randomized O
to O
UAE O
or O
surgery O
( O
hysterectomy O
or O
myomectomy O
) O
. O

Ninety O
- O
nine O
patients O
who O
had O
UAE O
and O
eight O
patients O
who O
had O
myomectomy O
were O
analyzed O
. O

MRI O
scans O
at O
baseline O
, O
6 O
months O
, O
and O
5 O
years O
were O
independently O
interpreted O
by O
two O
radiologists O
. O

Dominant O
fibroid O
diameter O
, O
uterine O
volume O
, O
total O
fibroid O
infarction O
( O
complete O
100 O
% O
, O
almost O
complete O
90 O
- O
99 O
% O
, O
partial O
< O
90 O
% O
) O
, O
and O
new O
fibroid O
formation O
were O
the O
main O
parameters O
assessed O
and O
related O
to O
the O
need O
for O
reintervention O
. O

In B-Premise
the I-Premise
UAE I-Premise
group I-Premise
, I-Premise
mean I-Premise
Â± I-Premise
standard I-Premise
deviation I-Premise
uterine I-Premise
volume I-Premise
was I-Premise
670 I-Premise
Â± I-Premise
503 I-Premise
, I-Premise
422 I-Premise
Â± I-Premise
353 I-Premise
, I-Premise
and I-Premise
292 I-Premise
Â± I-Premise
287 I-Premise
mL I-Premise
at I-Premise
baseline I-Premise
, I-Premise
6 I-Premise
months I-Premise
, I-Premise
and I-Premise
5 I-Premise
years I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Mean B-Premise
dominant I-Premise
fibroid I-Premise
diameter I-Premise
was I-Premise
7 I-Premise
. I-Premise
6 I-Premise
Â± I-Premise
3 I-Premise
. I-Premise
0 I-Premise
, I-Premise
5 I-Premise
. I-Premise
8 I-Premise
Â± I-Premise
2 I-Premise
. I-Premise
9 I-Premise
, I-Premise
and I-Premise
5 I-Premise
Â± I-Premise
2 I-Premise
. I-Premise
9 I-Premise
cm I-Premise
at I-Premise
baseline I-Premise
, I-Premise
6 I-Premise
months I-Premise
, I-Premise
and I-Premise
5 I-Premise
years I-Premise
. I-Premise

Fibroid B-Premise
infarction I-Premise
at I-Premise
6 I-Premise
months I-Premise
was I-Premise
complete I-Premise
in I-Premise
35 I-Premise
% I-Premise
of I-Premise
women I-Premise
, I-Premise
almost I-Premise
complete I-Premise
in I-Premise
29 I-Premise
% I-Premise
, I-Premise
and I-Premise
partial I-Premise
in I-Premise
36 I-Premise
% I-Premise
. I-Premise

Need B-Premise
for I-Premise
reintervention I-Premise
was I-Premise
19 I-Premise
, I-Premise
10 I-Premise
, I-Premise
and I-Premise
33 I-Premise
% I-Premise
in I-Premise
these I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
123 I-Premise
) I-Premise
. I-Premise

No B-Premise
myomectomy I-Premise
cases I-Premise
had I-Premise
further I-Premise
intervention I-Premise
. I-Premise

At B-Premise
5 I-Premise
years I-Premise
, I-Premise
the I-Premise
prevalence I-Premise
of I-Premise
new I-Premise
fibroid I-Premise
was I-Premise
60 I-Premise
% I-Premise
in I-Premise
the I-Premise
myomectomy I-Premise
group I-Premise
and I-Premise
7 I-Premise
% I-Premise
in I-Premise
the I-Premise
UAE I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
008 I-Premise
) I-Premise
. I-Premise

There B-Premise
is I-Premise
a I-Premise
further I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
both I-Premise
uterine I-Premise
volume I-Premise
and I-Premise
dominant I-Premise
fibroid I-Premise
diameter I-Premise
between I-Premise
6 I-Premise
months I-Premise
and I-Premise
5 I-Premise
years I-Premise
after I-Premise
UAE I-Premise
. I-Premise

Complete B-Claim
fibroid I-Claim
infarction I-Claim
does I-Claim
not I-Claim
translate I-Claim
into I-Claim
total I-Claim
freedom I-Claim
from I-Claim
a I-Claim
subsequent I-Claim
reintervention I-Claim
. I-Claim

New B-Claim
fibroid I-Claim
formation I-Claim
is I-Claim
significantly I-Claim
higher I-Claim
after I-Claim
myomectomy I-Claim
. I-Claim

The O
current O
study O
examined O
the O
effect O
of O
recombinant O
human O
deoxyribonuclease O
( O
rhDNase O
) O
on O
quality O
of O
life O
( O
QOL O
) O
measures O
, O
clinical O
improvement O
, O
and O
DNA O
content O
of O
thick O
oropharyngeal O
secretions O
( O
OPS O
) O
in O
patients O
with O
head O
- O
and O
- O
neck O
( O
H O
& O
N O
) O
cancers O
. O

Thirty O
- O
six O
patients O
with O
local O
- O
regional O
advanced O
H O
& O
amp O
"""" O
; O
"""" O
N O
cancer O
receiving O
chemoradiationtherapy O
( O
CRT O
) O
were O
randomized O
to O
receive O
either O
placebo O
or O
rhDNase O
. O

Endpoints O
included O
MD O
Anderson O
Symptom O
Inventory O
- O
Head O
and O
Neck O
( O
MDASI O
- O
HN O
) O
and O
Functional O
Assessment O
of O
Cancer O
Therapy O
- O
Head O
and O
Neck O
( O
FACT O
- O
NH O
) O
scores O
, O
along O
with O
clinical O
assessment O
and O
DNA O
concentration O
of O
OPS O
. O

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
patients I-Premise
' I-Premise
QOL I-Premise
outcomes I-Premise
over I-Premise
the I-Premise
study I-Premise
period I-Premise
. I-Premise

Both B-Premise
groups I-Premise
showed I-Premise
an I-Premise
increase I-Premise
in I-Premise
symptom I-Premise
and I-Premise
interference I-Premise
scores I-Premise
, I-Premise
although O
patients B-Premise
in I-Premise
the I-Premise
rhDNase I-Premise
group I-Premise
showed I-Premise
a I-Premise
greater I-Premise
decline I-Premise
in I-Premise
both I-Premise
scores I-Premise
during I-Premise
the I-Premise
3 I-Premise
months I-Premise
posttreatment I-Premise
. I-Premise

Similarly B-Premise
, I-Premise
both I-Premise
groups I-Premise
showed I-Premise
a I-Premise
decline I-Premise
in I-Premise
physical I-Premise
and I-Premise
functional I-Premise
well I-Premise
being I-Premise
but I-Premise
recovered I-Premise
in I-Premise
the I-Premise
3 I-Premise
months I-Premise
posttreatment I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
with I-Premise
the I-Premise
rhDNase I-Premise
group I-Premise
exhibiting I-Premise
speedier I-Premise
recovery I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
rhDNase I-Premise
group I-Premise
exhibited I-Premise
significant I-Premise
clinical I-Premise
improvement I-Premise
in I-Premise
OPS I-Premise
, I-Premise
blindly I-Premise
assessed I-Premise
by I-Premise
a I-Premise
physician I-Premise
, I-Premise
compared I-Premise
with I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
67 I-Premise
% I-Premise
vs I-Premise
27 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
046 I-Premise
) I-Premise
. I-Premise

The B-Premise
rhDNase I-Premise
group I-Premise
showed I-Premise
no I-Premise
change I-Premise
in I-Premise
OPS I-Premise
- I-Premise
DNA I-Premise
concentration I-Premise
, I-Premise
although O
the B-Premise
placebo I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
increase I-Premise
in I-Premise
DNA I-Premise
concentration I-Premise
during I-Premise
the I-Premise
drug I-Premise
trial I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
045 I-Premise
) I-Premise
. I-Premise

There B-Claim
was I-Claim
no I-Claim
differences I-Claim
in I-Claim
acute I-Claim
toxicities I-Claim
between I-Claim
the I-Claim
2 I-Claim
groups I-Claim
. I-Claim

Our B-Claim
preliminary I-Claim
data I-Claim
suggest I-Claim
that I-Claim
rhDNase I-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
study I-Claim
primary I-Claim
endpoints I-Claim
of I-Claim
QOL I-Claim
measures I-Claim
compared I-Claim
with I-Claim
the I-Claim
placebo I-Claim
group I-Claim
. I-Claim

However O
, O
there B-Claim
was I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
secondary I-Claim
endpoints I-Claim
of I-Claim
clinically I-Claim
assessed I-Claim
OPS I-Claim
and I-Claim
DNA I-Claim
concentration I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
in I-Claim
H I-Claim
& I-Claim
N I-Claim
cancer I-Claim
patients I-Claim
treated I-Claim
with I-Claim
CRT I-Claim
. I-Claim

Further O
investigation O
in O
larger O
numbers O
of O
patients O
is O
warranted O
. O

Thalidomide O
with O
melphalan O
/ O
prednisone O
( O
MPT O
) O
was O
defined O
as O
standard O
treatment O
in O
elderly O
patients O
with O
multiple O
myeloma O
( O
MM O
) O
based O
on O
five O
randomized O
trials O
. O

In O
one O
of O
these O
trials O
, O
HOVON49 O
, O
a O
prospective O
health O
- O
related O
quality O
- O
of O
- O
life O
( O
HRQoL O
) O
study O
was O
initiated O
in O
order O
to O
assess O
the O
impact O
of O
thalidomide O
on O
QoL O
. O

Patients O
aged O
> O
65 O
years O
with O
newly O
diagnosed O
MM O
were O
randomized O
to O
receive O
melphalan O
plus O
prednisone O
( O
MP O
) O
or O
MPT O
, O
followed O
by O
thalidomide O
maintenance O
in O
the O
MPT O
arm O
. O

Two O
hundred O
eighty O
- O
four O
patients O
were O
included O
in O
this O
side O
study O
( O
MP O
, O
n O
= O
149 O
"""" O
; O
"""" O
MPT O
n O
= O
135 O
) O
. O

HRQoL O
was O
assessed O
with O
the O
EORTC O
Core O
QoL O
Questionnaire O
( O
QLQ O
- O
C30 O
) O
and O
the O
myeloma O
- O
specific O
module O
( O
QLQ O
- O
MY24 O
) O
at O
baseline O
and O
at O
predetermined O
intervals O
during O
treatment O
. O

The B-Premise
QLQ I-Premise
- I-Premise
C30 I-Premise
subscales I-Premise
physical I-Premise
function I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
044 I-Premise
) I-Premise
and I-Premise
constipation I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
showed I-Premise
an I-Premise
improvement I-Premise
during I-Premise
induction I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
MP I-Premise
arm I-Premise
. I-Premise

During B-Premise
thalidomide I-Premise
maintenance I-Premise
, I-Premise
the I-Premise
scores I-Premise
for I-Premise
the I-Premise
QLQ I-Premise
- I-Premise
MY24 I-Premise
paraesthesia I-Premise
became I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
MPT I-Premise
arm I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

The B-Premise
QLQ I-Premise
- I-Premise
C30 I-Premise
subscales I-Premise
pain I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
12 I-Premise
) I-Premise
, I-Premise
insomnia I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
068 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
loss I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
074 I-Premise
) I-Premise
and I-Premise
the I-Premise
QLQ I-Premise
- I-Premise
MY24 I-Premise
item I-Premise
sick I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
086 I-Premise
) I-Premise
scored I-Premise
marginally I-Premise
better I-Premise
during I-Premise
thalidomide I-Premise
maintenance I-Premise
. I-Premise

The B-Premise
overall I-Premise
QoL I-Premise
- I-Premise
scale I-Premise
QLQ I-Premise
- I-Premise
C30 I-Premise
- I-Premise
HRQoL I-Premise
showed I-Premise
a I-Premise
significant I-Premise
time I-Premise
trend I-Premise
towards I-Premise
more I-Premise
favourable I-Premise
mean I-Premise
values I-Premise
during I-Premise
protocol I-Premise
treatment I-Premise
without I-Premise
differences I-Premise
between I-Premise
MP I-Premise
and I-Premise
MPT I-Premise
. I-Premise

For B-Premise
the I-Premise
QLQ I-Premise
- I-Premise
C30 I-Premise
subscales I-Premise
emotional I-Premise
function I-Premise
and I-Premise
future I-Premise
perspectives I-Premise
, I-Premise
difference I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
MPT I-Premise
arm I-Premise
from I-Premise
the I-Premise
start I-Premise
of I-Premise
treatment I-Premise
was I-Premise
observed I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
018 I-Premise
and I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
045 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
with I-Premise
no I-Premise
significant I-Premise
' I-Premise
time I-Premise
Ã— I-Premise
arm I-Premise
' I-Premise
interaction I-Premise
, I-Premise
indicating I-Premise
a I-Premise
persistent I-Premise
better I-Premise
patient I-Premise
perspective I-Premise
with I-Premise
MPT I-Premise
treatment I-Premise
. I-Premise

This B-Claim
study I-Claim
shows I-Claim
that I-Claim
the I-Claim
higher I-Claim
frequency I-Claim
of I-Claim
toxicity I-Claim
associated I-Claim
with I-Claim
MPT I-Claim
does I-Claim
not I-Claim
translate I-Claim
into I-Claim
a I-Claim
negative I-Claim
effect I-Claim
on I-Claim
HRQoL I-Claim
and I-Claim
that I-Claim
MPT I-Claim
holds I-Claim
a I-Claim
better I-Claim
patient I-Claim
perspective I-Claim
. I-Claim

Paclitaxel O
and O
pegylated O
liposomal O
doxorubicin O
( O
PLD O
) O
are O
active O
cytotoxic O
agents O
for O
the O
treatment O
of O
human O
immunodeficiency O
virus O
( O
HIV O
) O
- O
associated O
Kaposi O
sarcoma O
( O
KS O
) O
. O

A O
randomized O
trial O
comparing O
the O
efficacy O
and O
toxicity O
of O
paclitaxel O
and O
PLD O
was O
performed O
, O
and O
the O
effects O
of O
therapy O
on O
symptom O
palliation O
and O
quality O
of O
life O
were O
determined O
. O

Patients O
with O
advanced O
HIV O
- O
associated O
KS O
were O
randomly O
assigned O
to O
receive O
paclitaxel O
at O
a O
dose O
of O
100 O
mg O
/ O
m2 O
intravenously O
( O
iv O
) O
every O
2 O
weeks O
or O
PLD O
at O
a O
dose O
of O
20 O
mg O
/ O
m2 O
iv O
every O
3 O
weeks O
. O

The O
KS O
Functional O
Assessment O
of O
HIV O
( O
FAHI O
) O
quality O
of O
life O
instrument O
was O
used O
before O
and O
after O
every O
other O
treatment O
cycle O
. O

The O
study O
included O
73 O
analyzable O
patients O
enrolled O
between O
1998 O
and O
2002 O
, O
including O
36 O
in O
the O
paclitaxel O
arm O
and O
37 O
in O
the O
PLD O
arm O
"""" O
; O
"""" O
73 O
% O
of O
patients O
received O
highly O
active O
antiretroviral O
therapy O
( O
HAART O
) O
and O
32 O
% O
had O
an O
undetectable O
viral O
load O
( O
< O
400 O
copies O
/ O
mL O
) O
. O

Treatment B-Premise
was I-Premise
associated I-Premise
with I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
024 I-Premise
) I-Premise
and I-Premise
swelling I-Premise
( I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

Of B-Premise
the I-Premise
36 I-Premise
patients I-Premise
who I-Premise
reported I-Premise
that I-Premise
pain I-Premise
interfered I-Premise
with I-Premise
their I-Premise
normal I-Premise
work I-Premise
or I-Premise
activities I-Premise
at I-Premise
baseline I-Premise
, I-Premise
25 I-Premise
( I-Premise
69 I-Premise
% I-Premise
) I-Premise
improved I-Premise
. I-Premise

Of B-Premise
the I-Premise
41 I-Premise
patients I-Premise
who I-Premise
reported I-Premise
swelling I-Premise
at I-Premise
baseline I-Premise
, I-Premise
38 I-Premise
( I-Premise
93 I-Premise
% I-Premise
) I-Premise
improved I-Premise
. I-Premise

Comparing B-Premise
the I-Premise
paclitaxel I-Premise
and I-Premise
PLD I-Premise
arms I-Premise
revealed I-Premise
comparable I-Premise
response I-Premise
rates I-Premise
( I-Premise
56 I-Premise
% I-Premise
vs I-Premise
46 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
49 I-Premise
) I-Premise
, I-Premise
median I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
17 I-Premise
. I-Premise
5 I-Premise
months I-Premise
vs I-Premise
12 I-Premise
. I-Premise
2 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
66 I-Premise
) I-Premise
, I-Premise
and I-Premise
2 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rates I-Premise
( I-Premise
79 I-Premise
% I-Premise
vs I-Premise
78 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
75 I-Premise
) I-Premise
, I-Premise
but B-Premise
somewhat I-Premise
more I-Premise
grade I-Premise
3 I-Premise
to I-Premise
5 I-Premise
toxicity I-Premise
for I-Premise
paclitaxel I-Premise
( I-Premise
84 I-Premise
% I-Premise
vs I-Premise
66 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
077 I-Premise
) I-Premise
. I-Premise

Treatment B-Claim
with I-Claim
either I-Claim
paclitaxel I-Claim
or I-Claim
PLD I-Claim
appears I-Claim
to I-Claim
produce I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
pain I-Claim
and I-Claim
swelling I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
, I-Claim
symptomatic I-Claim
, I-Claim
HIV I-Claim
- I-Claim
associated I-Claim
KS I-Claim
treated I-Claim
in I-Claim
the I-Claim
HAART I-Claim
era I-Claim
. I-Claim

The O
phase O
3 O
VISTA O
study O
in O
transplant O
- O
ineligible O
myeloma O
patients O
demonstrated O
superior O
efficacy O
with O
bortezomib O
- O
melphalan O
- O
prednisone O
( O
VMP O
"""" O
; O
"""" O
nine O
6 O
- O
wk O
cycles O
) O
vs O
. O
melphalan O
- O
prednisone O
( O
MP O
) O
but O
also O
increased O
toxicity O
. O

Health O
- O
related O
quality O
of O
life O
( O
HRQoL O
"""" O
; O
"""" O
exploratory O
endpoint O
) O
was O
evaluated O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
( O
QLQ O
- O
C30 O
) O
. O

The O
phase O
3 O
VISTA O
study O
in O
transplant O
- O
ineligible O
myeloma O
patients O
demonstrated O
superior O
efficacy O
with O
bortezomib O
- O
melphalan O
- O
prednisone O
( O
VMP O
"""" O
; O
"""" O
nine O
6 O
- O
wk O
cycles O
) O
vs O
. O
melphalan O
- O
prednisone O
( O
MP O
) O
but O
also O
increased O
toxicity O
. O

Health O
- O
related O
quality O
of O
life O
( O
HRQoL O
"""" O
; O
"""" O
exploratory O
endpoint O
) O
was O
evaluated O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
( O
QLQ O
- O
C30 O
) O
. O

EORTC O
QLQ O
- O
C30 O
was O
administered O
at O
screening O
, O
on O
day O
1 O
of O
each O
cycle O
, O
at O
the O
end O
- O
of O
- O
treatment O
visit O
, O
and O
every O
8 O
wk O
until O
progression O
. O

EORTC O
QLQ O
- O
C30 O
scores O
were O
evaluated O
among O
patients O
with O
a O
valid O
baseline O
and O
at O
least O
one O
post O
- O
baseline O
HRQoL O
assessment O
. O

At O
baseline O
, O
domain O
scores O
were O
similar O
between O
arms O
. O

By B-Premise
cycle I-Premise
4 I-Premise
, I-Premise
mean I-Premise
differences I-Premise
were I-Premise
clinically I-Premise
meaningful I-Premise
for I-Premise
most I-Premise
domains I-Premise
, I-Premise
indicating I-Premise
poorer I-Premise
health I-Premise
status I-Premise
with I-Premise
VMP I-Premise
. I-Premise

From B-Premise
cycle I-Premise
5 I-Premise
onwards I-Premise
, I-Premise
improvements I-Premise
relative I-Premise
to I-Premise
baseline I-Premise
/ I-Premise
MP I-Premise
were I-Premise
observed I-Premise
for I-Premise
all I-Premise
domains I-Premise
with I-Premise
VMP I-Premise
. I-Premise

Mean B-Premise
scores I-Premise
were I-Premise
generally I-Premise
improved I-Premise
by I-Premise
the I-Premise
end I-Premise
- I-Premise
of I-Premise
- I-Premise
treatment I-Premise
assessment I-Premise
vs I-Premise
. I-Premise
baseline I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

Among B-Premise
responding I-Premise
patients I-Premise
, I-Premise
mean I-Premise
scores I-Premise
generally I-Premise
improved I-Premise
from I-Premise
time I-Premise
of I-Premise
response I-Premise
to I-Premise
end I-Premise
- I-Premise
of I-Premise
- I-Premise
treatment I-Premise
assessment I-Premise
, I-Premise
substantially I-Premise
driven I-Premise
by I-Premise
patients I-Premise
achieving I-Premise
complete I-Premise
response I-Premise
( I-Premise
CR I-Premise
) I-Premise
. I-Premise

Multivariate B-Premise
analysis I-Premise
showed I-Premise
a I-Premise
significant I-Premise
impact I-Premise
of I-Premise
duration I-Premise
of I-Premise
response I-Premise
/ I-Premise
CR I-Premise
on I-Premise
improving I-Premise
global I-Premise
health I-Premise
status I-Premise
, I-Premise
pain I-Premise
, I-Premise
and I-Premise
appetite I-Premise
loss I-Premise
scores I-Premise
. I-Premise

Analyses B-Claim
by I-Claim
bortezomib I-Claim
dose I-Claim
intensity I-Claim
indicated I-Claim
better I-Claim
HRQoL I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
lower I-Claim
dose I-Claim
intensity I-Claim
. I-Claim

These B-Claim
findings I-Claim
demonstrate I-Claim
clinically I-Claim
meaningful I-Claim
, I-Claim
transitory I-Claim
HRQoL I-Claim
decrements I-Claim
with I-Claim
VMP I-Claim
and I-Claim
relatively I-Claim
lower I-Claim
HRQoL I-Claim
vs I-Claim
. I-Claim
MP I-Claim
during I-Claim
early I-Claim
treatment I-Claim
cycles I-Claim
, I-Claim
associated I-Claim
with I-Claim
the I-Claim
expected I-Claim
additional I-Claim
toxicities I-Claim
. I-Claim

However B-Claim
, I-Claim
HRQoL I-Claim
is I-Claim
not I-Claim
compromised I-Claim
in I-Claim
the I-Claim
long I-Claim
term I-Claim
, I-Claim
recovering I-Claim
by I-Claim
the I-Claim
end I-Claim
- I-Claim
of I-Claim
- I-Claim
treatment I-Claim
visit I-Claim
to I-Claim
be I-Claim
comparable I-Claim
vs I-Claim
. I-Claim
MP I-Claim
. I-Claim

Chemotherapy B-Claim
prolongs I-Claim
survival I-Claim
and I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
for I-Claim
good I-Claim
performance I-Claim
status I-Claim
( I-Claim
PS I-Claim
) I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non I-Claim
- I-Claim
small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

Targeted B-Claim
therapies I-Claim
may I-Claim
improve I-Claim
chemotherapy I-Claim
effectiveness I-Claim
without I-Claim
worsening I-Claim
toxicity I-Claim
. I-Claim

SGN O
- O
15 O
is O
an O
antibody O
- O
drug O
conjugate O
( O
ADC O
) O
, O
consisting O
of O
a O
chimeric O
murine O
monoclonal O
antibody O
recognizing O
the O
Lewis O
Y O
( O
Le O
( O
y O
) O
) O
antigen O
, O
conjugated O
to O
doxorubicin O
. O

Le B-Claim
( I-Claim
y I-Claim
) I-Claim
is I-Claim
an I-Claim
attractive I-Claim
target I-Claim
since I-Claim
it I-Claim
is I-Claim
expressed I-Claim
by I-Claim
most I-Claim
NSCLC I-Claim
. I-Claim

SGN B-Premise
- B-Premise
15 B-Premise
was I-Premise
active I-Premise
against I-Premise
Le I-Premise
( I-Premise
y I-Premise
) I-Premise
- I-Premise
positive I-Premise
tumors I-Premise
in I-Premise
early I-Premise
phase I-Premise
clinical I-Premise
trials I-Premise
and I-Premise
was I-Premise
synergistic I-Premise
with I-Premise
docetaxel I-Premise
in I-Premise
preclinical I-Premise
experiments I-Premise
. I-Premise

This O
Phase O
II O
, O
open O
- O
label O
study O
was O
conducted O
to O
confirm O
the O
activity O
of O
SGN O
- O
15 O
plus O
docetaxel O
in O
previously O
treated O
NSCLC O
patients O
. O

Sixty O
- O
two O
patients O
with O
recurrent O
or O
metastatic O
NSCLC O
expressing O
Le O
( O
y O
) O
, O
one O
or O
two O
prior O
chemotherapy O
regimens O
, O
and O
PS O
< O
or O
2 O
were O
randomized O
2 O
: O
1 O
to O
receive O
SGN O
- O
15 O
200 O
mg O
/ O
m2 O
/ O
week O
with O
docetaxel O
35 O
mg O
/ O
m2 O
/ O
week O
( O
Arm O
A O
) O
or O
docetaxel O
35 O
mg O
/ O
m2 O
/ O
week O
alone O
( O
Arm O
B O
) O
for O
6 O
of O
8 O
weeks O
. O

Intrapatient O
dose O
- O
escalation O
of O
SGN O
- O
15 O
to O
350 O
mg O
/ O
m2 O
was O
permitted O
in O
the O
second O
half O
of O
the O
study O
. O

Endpoints O
were O
survival O
, O
safety O
, O
efficacy O
, O
and O
quality O
of O
life O
. O

Forty O
patients O
on O
Arm O
A O
and O
19 O
on O
Arm O
B O
received O
at O
least O
one O
treatment O
. O

Patients B-Premise
on I-Premise
Arms I-Premise
A I-Premise
and I-Premise
B I-Premise
had I-Premise
median I-Premise
survivals I-Premise
of I-Premise
31 I-Premise
. I-Premise
4 I-Premise
and I-Premise
25 I-Premise
. I-Premise
3 I-Premise
weeks I-Premise
, I-Premise
12 I-Premise
- I-Premise
month I-Premise
survivals I-Premise
of I-Premise
29 I-Premise
% I-Premise
and I-Premise
24 I-Premise
% I-Premise
, I-Premise
and I-Premise
18 I-Premise
- I-Premise
month I-Premise
survivals I-Premise
of I-Premise
18 I-Premise
% I-Premise
and I-Premise
8 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. O

Toxicity B-Premise
was I-Premise
mild I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

QOL B-Premise
analyses I-Premise
favored I-Premise
Arm I-Premise
A I-Premise
. I-Premise
SGN B-Claim
- B-Claim
15 B-Claim
plus I-Claim
docetaxel I-Claim
is I-Claim
a I-Claim
well I-Claim
- I-Claim
tolerated I-Claim
and I-Claim
active I-Claim
second I-Claim
and I-Claim
third I-Claim
line I-Claim
treatment I-Claim
for I-Claim
NSCLC I-Claim
patients I-Claim
. O

Ongoing O
studies O
are O
exploring O
alternate O
schedules O
to O
maximize O
synergy O
between O
these O
agents O
. O

The O
combination O
of O
radiotherapy O
plus O
long O
- O
term O
medical O
suppression O
of O
androgens O
( O
> O
or O
= O
2 O
years O
) O
improves O
overall O
survival O
in O
patients O
with O
locally O
advanced O
prostate O
cancer O
. O

We O
compared O
the O
use O
of O
radiotherapy O
plus O
short O
- O
term O
androgen O
suppression O
with O
the O
use O
of O
radiotherapy O
plus O
long O
- O
term O
androgen O
suppression O
in O
the O
treatment O
of O
locally O
advanced O
prostate O
cancer O
. O

We O
randomly O
assigned O
patients O
with O
locally O
advanced O
prostate O
cancer O
who O
had O
received O
external O
- O
beam O
radiotherapy O
plus O
6 O
months O
of O
androgen O
suppression O
to O
two O
groups O
, O
one O
to O
receive O
no O
further O
treatment O
( O
short O
- O
term O
suppression O
) O
and O
the O
other O
to O
receive O
2 O
. O
5 O
years O
of O
further O
treatment O
with O
a O
luteinizing O
hormone O
- O
releasing O
hormone O
agonist O
( O
long O
- O
term O
suppression O
) O
. O

An O
outcome O
of O
noninferiority O
of O
short O
- O
term O
androgen O
suppression O
as O
compared O
with O
long O
- O
term O
suppression O
required O
a O
hazard O
ratio O
of O
more O
than O
1 O
. O
35 O
for O
overall O
survival O
, O
with O
a O
one O
- O
sided O
alpha O
level O
of O
0 O
. O
05 O
. O

An O
interim O
analysis O
showed O
futility O
, O
and O
the O
results O
are O
presented O
with O
an O
adjusted O
one O
- O
sided O
alpha O
level O
of O
0 O
. O
0429 O
. O

A O
total O
of O
1113 O
men O
were O
registered O
, O
of O
whom O
970 O
were O
randomly O
assigned O
, O
483 O
to O
short O
- O
term O
suppression O
and O
487 O
to O
long O
- O
term O
suppression O
. O

After B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
6 I-Premise
. I-Premise
4 I-Premise
years I-Premise
, I-Premise
132 I-Premise
patients I-Premise
in I-Premise
the I-Premise
short I-Premise
- I-Premise
term I-Premise
group I-Premise
and I-Premise
98 I-Premise
in I-Premise
the I-Premise
long I-Premise
- I-Premise
term I-Premise
group I-Premise
had I-Premise
died I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
the B-Premise
number I-Premise
of I-Premise
deaths I-Premise
due I-Premise
to I-Premise
prostate I-Premise
cancer I-Premise
was I-Premise
47 I-Premise
in I-Premise
the I-Premise
short I-Premise
- I-Premise
term I-Premise
group I-Premise
and I-Premise
29 I-Premise
in I-Premise
the I-Premise
long I-Premise
- I-Premise
term I-Premise
group I-Premise
. I-Premise

The B-Premise
5 I-Premise
- I-Premise
year I-Premise
overall I-Premise
mortality I-Premise
for I-Premise
short I-Premise
- I-Premise
term I-Premise
and I-Premise
long I-Premise
- I-Premise
term I-Premise
suppression I-Premise
was I-Premise
19 I-Premise
. I-Premise
0 I-Premise
% I-Premise
and I-Premise
15 I-Premise
. I-Premise
2 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
the O
observed O
hazard O
ratio O
was O
1 O
. O
42 O
( O
upper O
95 O
. O
71 O
% O
confidence O
limit O
, O
1 O
. O
79 O
"""" O
; O
"""" O
P O
= O
0 O
. O
65 O
for O
noninferiority O
) O
. O

Adverse B-Premise
events I-Premise
in I-Premise
both I-Premise
groups I-Premise
included I-Premise
fatigue I-Premise
, I-Premise
diminished I-Premise
sexual I-Premise
function I-Premise
, I-Premise
and I-Premise
hot I-Premise
flushes I-Premise
. I-Premise

The B-Claim
combination I-Claim
of I-Claim
radiotherapy I-Claim
plus I-Claim
6 I-Claim
months I-Claim
of I-Claim
androgen I-Claim
suppression I-Claim
provides I-Claim
inferior I-Claim
survival I-Claim
as I-Claim
compared I-Claim
with I-Claim
radiotherapy I-Claim
plus I-Claim
3 I-Claim
years I-Claim
of I-Claim
androgen I-Claim
suppression I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
locally I-Claim
advanced I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim

Cancer O
cachexia O
is O
a O
common O
problem O
among O
advanced O
cancer O
patients O
. O

A O
mixture O
of O
beta O
- O
hydroxyl O
beta O
- O
methyl O
butyrate O
, O
glutamine O
, O
and O
arginine O
( O
HMB O
/ O
Arg O
/ O
Gln O
) O
previously O
showed O
activity O
for O
increasing O
lean O
body O
mass O
( O
LBM O
) O
among O
patients O
with O
cancer O
cachexia O
. O

Therefore O
a O
phase O
III O
trial O
was O
implemented O
to O
confirm O
this O
activity O
. O

Four O
hundred O
seventy O
- O
two O
advanced O
cancer O
patients O
with O
between O
2 O
% O
and O
10 O
% O
weight O
loss O
were O
randomized O
to O
a O
mixture O
of O
beta O
- O
hydroxyl O
beta O
- O
methyl O
butyrate O
, O
glutamine O
, O
and O
arginine O
or O
an O
isonitrogenous O
, O
isocaloric O
control O
mixture O
taken O
twice O
a O
day O
for O
8 O
weeks O
. O

Lean O
body O
mass O
was O
estimated O
by O
bioimpedance O
and O
skin O
- O
fold O
measurements O
. O

Body O
plethysmography O
was O
used O
when O
available O
. O

Weight O
, O
the O
Schwartz O
Fatigue O
Scale O
, O
and O
the O
Spitzer O
Quality O
of O
Life O
Scale O
were O
also O
measured O
. O

Only O
37 O
% O
of O
the O
patients O
completed O
protocol O
treatment O
. O

The O
majority O
of O
the O
patient O
loss O
was O
because O
of O
patient O
preference O
( O
45 O
% O
of O
enrolled O
patients O
) O
. O

However O
, O
loss O
of O
power O
was O
not O
an O
issue O
because O
of O
the O
planned O
large O
target O
sample O
size O
. O

Based O
on O
an O
intention O
to O
treat O
analysis O
, O
there O
was O
no O
statistically O
significant O
difference O
in O
the O
8 O
- O
week O
lean O
body O
mass O
between O
the O
two O
arms O
. O

The O
secondary O
endpoints O
were O
also O
not O
significantly O
different O
between O
the O
arms O
. O

Based B-Premise
on I-Premise
the I-Premise
results I-Premise
of I-Premise
the I-Premise
area I-Premise
under I-Premise
the I-Premise
curve I-Premise
( I-Premise
AUC I-Premise
) I-Premise
analysis I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
HMB I-Premise
/ I-Premise
Arg I-Premise
/ I-Premise
Gln I-Premise
had I-Premise
a I-Premise
strong I-Premise
trend I-Premise
higher I-Premise
LBM I-Premise
throughout I-Premise
the I-Premise
study I-Premise
as I-Premise
measured I-Premise
by I-Premise
both I-Premise
bioimpedance I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
08 I-Premise
) I-Premise
and I-Premise
skin I-Premise
- I-Premise
fold I-Premise
measurements I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
08 I-Premise
) I-Premise
. I-Premise

Among B-Premise
the I-Premise
subset I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
concurrent I-Premise
chemotherapy I-Premise
, I-Premise
there I-Premise
were I-Premise
again I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
the I-Premise
endpoints I-Premise
. I-Premise

The O
secondary O
endpoints O
were O
also O
not O
significantly O
different O
between O
the O
arms O
. O

This B-Claim
trial I-Claim
was I-Claim
unable I-Claim
to I-Claim
adequately I-Claim
test I-Claim
the I-Claim
ability I-Claim
of I-Claim
beta I-Claim
- I-Claim
hydroxy I-Claim
beta I-Claim
- I-Claim
methylbutyrate I-Claim
, I-Claim
glutamine I-Claim
, I-Claim
and I-Claim
arginine I-Claim
to I-Claim
reverse I-Claim
or I-Claim
prevent I-Claim
lean I-Claim
body I-Claim
mass I-Claim
wasting I-Claim
among I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Possible O
contributing O
factors O
beyond O
the O
efficacy O
of O
the O
intervention O
were O
the O
inability O
of O
patients O
to O
complete O
an O
8 O
- O
week O
course O
of O
treatment O
and O
return O
in O
a O
timely O
fashion O
for O
follow O
- O
up O
assessment O
, O
and O
because O
the O
patients O
may O
have O
only O
had O
weight O
loss O
possible O
not O
related O
to O
cachexia O
, O
but O
other O
causes O
of O
weight O
loss O
, O
such O
as O
decreased O
appetite O
. O

However O
, O
there O
was O
a O
strong O
trend O
towards O
an O
increased O
body O
mass O
among O
patients O
taking O
the O
Juven O
compound O
using O
the O
secondary O
endpoint O
of O
AUC O
. O

To O
assess O
the O
safety O
, O
tolerability O
and O
efficacy O
of O
abatacept O
in O
patients O
with O
rheumatoid O
arthritis O
( O
RA O
) O
who O
had O
failed O
anti O
- O
tumour O
necrosis O
factor O
( O
TNF O
) O
therapy O
and O
were O
switched O
to O
abatacept O
directly O
or O
after O
completing O
washout O
. O

In O
this O
international O
, O
6 O
- O
month O
, O
open O
- O
label O
trial O
, O
patients O
had O
active O
RA O
, O
an O
inadequate O
response O
to O
anti O
- O
TNF O
therapy O
for O
3 O
months O
or O
longer O
and O
a O
disease O
activity O
score O
in O
28 O
joints O
( O
DAS28 O
( O
C O
- O
reactive O
protein O
"""" O
; O
"""" O
CRP O
) O
of O
5 O
. O
1 O
or O
greater O
. O

"""" O
Washout O
"""" O
patients O
discontinued O
anti O
- O
TNF O
therapy O
2 O
months O
or O
longer O
pre O
- O
screening O
"""" O
; O
"""" O
"""" O
direct O
- O
switch O
100 O
"""" O
patients O
began O
abatacept O
( O
approximately O
10 O
mg O
/ O
kg O
) O
at O
their O
next O
scheduled O
anti O
- O
TNF O
therapy O
dose O
. O

1046 O
patients O
were O
treated O
( O
449 O
washout O
, O
597 O
direct O
- O
switch O
"""" O
; O
"""" O
baseline O
characteristics O
were O
similar O
between O
groups O
) O
. O

At B-Premise
6 I-Premise
months I-Premise
, I-Premise
adverse I-Premise
events I-Premise
( I-Premise
AE I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
78 I-Premise
. I-Premise
0 I-Premise
% I-Premise
vs I-Premise
79 I-Premise
. I-Premise
2 I-Premise
% I-Premise
) I-Premise
, I-Premise
serious I-Premise
AE I-Premise
( I-Premise
11 I-Premise
. I-Premise
1 I-Premise
% I-Premise
vs I-Premise
9 I-Premise
. I-Premise
9 I-Premise
% I-Premise
) I-Premise
and I-Premise
discontinuations I-Premise
due I-Premise
to I-Premise
AE I-Premise
( I-Premise
3 I-Premise
. I-Premise
8 I-Premise
% I-Premise
vs I-Premise
4 I-Premise
. I-Premise
0 I-Premise
% I-Premise
) I-Premise
and I-Premise
serious I-Premise
AE I-Premise
( I-Premise
2 I-Premise
. I-Premise
0 I-Premise
% I-Premise
vs I-Premise
1 I-Premise
. I-Premise
3 I-Premise
% I-Premise
) I-Premise
were I-Premise
comparable I-Premise
in I-Premise
washout I-Premise
versus I-Premise
direct I-Premise
- I-Premise
switch I-Premise
patients I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
opportunistic I-Premise
infections I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
, I-Premise
in I-Premise
washout I-Premise
versus I-Premise
direct I-Premise
- I-Premise
switch I-Premise
patients I-Premise
, I-Premise
similar I-Premise
clinically I-Premise
meaningful I-Premise
improvements I-Premise
were I-Premise
seen I-Premise
in I-Premise
DAS28 I-Premise
( I-Premise
CRP I-Premise
) I-Premise
( I-Premise
> I-Premise
or I-Premise
= I-Premise
1 I-Premise
. I-Premise
2 I-Premise
unit I-Premise
improvement I-Premise
, I-Premise
59 I-Premise
. I-Premise
5 I-Premise
% I-Premise
vs I-Premise
53 I-Premise
. I-Premise
6 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
low I-Premise
disease I-Premise
activity I-Premise
state I-Premise
, I-Premise
22 I-Premise
. I-Premise
5 I-Premise
% I-Premise
vs I-Premise
22 I-Premise
. I-Premise
3 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
DAS28 I-Premise
- I-Premise
defined I-Premise
remission I-Premise
, I-Premise
12 I-Premise
. I-Premise
0 I-Premise
% I-Premise
vs I-Premise
13 I-Premise
. I-Premise
7 I-Premise
% I-Premise
) I-Premise
, I-Premise
physical I-Premise
function I-Premise
( I-Premise
health I-Premise
assessment I-Premise
questionnaire I-Premise
disability I-Premise
index I-Premise
> I-Premise
or I-Premise
= I-Premise
0 I-Premise
. I-Premise
22 I-Premise
improvement I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
46 I-Premise
. I-Premise
3 I-Premise
% I-Premise
vs I-Premise
47 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
and I-Premise
health I-Premise
- I-Premise
related I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
mean I-Premise
change I-Premise
in I-Premise
short I-Premise
- I-Premise
form I-Premise
36 I-Premise
scores I-Premise
: I-Premise
physical I-Premise
component I-Premise
summary I-Premise
, I-Premise
5 I-Premise
. I-Premise
5 I-Premise
vs I-Premise
6 I-Premise
. I-Premise
1 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
mental I-Premise
component I-Premise
summary I-Premise
, I-Premise
4 I-Premise
. I-Premise
8 I-Premise
vs I-Premise
5 I-Premise
. I-Premise
4 I-Premise
) I-Premise
. I-Premise

Abatacept B-Claim
demonstrated I-Claim
acceptable I-Claim
safety I-Claim
and I-Claim
tolerability I-Claim
and I-Claim
clinically I-Claim
meaningful I-Claim
efficacy I-Claim
over I-Claim
6 I-Claim
months I-Claim
in I-Claim
patients I-Claim
with I-Claim
inadequate I-Claim
response I-Claim
to I-Claim
anti I-Claim
- I-Claim
TNF I-Claim
therapy I-Claim
. I-Claim

Results B-Claim
were I-Claim
comparable I-Claim
with I-Claim
or I-Claim
without I-Claim
a I-Claim
washout I-Claim
, I-Claim
supporting I-Claim
direct I-Claim
switching I-Claim
from I-Claim
anti I-Claim
- I-Claim
TNF I-Claim
therapy I-Claim
to I-Claim
abatacept I-Claim
as I-Claim
an I-Claim
option I-Claim
in I-Claim
clinical I-Claim
practice I-Claim
. I-Claim

To O
assess O
patient O
- O
reported O
prostate O
cancer O
- O
specific O
quality O
of O
life O
2 O
and O
3 O
years O
after O
radiotherapy O
to O
the O
prostate O
in O
a O
randomized O
dose O
- O
escalation O
trial O
of O
70 O
versus O
78 O
Gy O
conducted O
from O
1993 O
to O
1998 O
. O

Two O
years O
after O
completing O
radiotherapy O
, O
a O
questionnaire O
that O
assessed O
bladder O
, O
rectal O
, O
and O
sexual O
function O
was O
sent O
to O
301 O
patients O
in O
the O
study O
. O

Three O
years O
after O
treatment O
, O
a O
second O
questionnaire O
was O
sent O
to O
the O
175 O
patients O
with O
adequate O
follow O
- O
up O
. O

Three B-Premise
years I-Premise
after I-Premise
radiotherapy I-Premise
, I-Premise
urinary I-Premise
incontinence I-Premise
was I-Premise
reported I-Premise
by I-Premise
35 I-Premise
% I-Premise
of I-Premise
patients I-Premise
, I-Premise
but I-Premise
only I-Premise
6 I-Premise
% I-Premise
required I-Premise
the I-Premise
use I-Premise
of I-Premise
a I-Premise
pad I-Premise
or I-Premise
other I-Premise
protective I-Premise
device I-Premise
. I-Premise

Patients B-Premise
reported I-Premise
increased I-Premise
leakage I-Premise
with I-Premise
a I-Premise
full I-Premise
bladder I-Premise
( I-Premise
urge I-Premise
incontinence I-Premise
) I-Premise
between I-Premise
the I-Premise
2 I-Premise
and I-Premise
3 I-Premise
- I-Premise
year I-Premise
questionnaires I-Premise
( I-Premise
42 I-Premise
% I-Premise
versus I-Premise
50 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
03 I-Premise
) I-Premise
. I-Premise

At B-Premise
3 I-Premise
years I-Premise
, I-Premise
33 I-Premise
% I-Premise
of I-Premise
patients I-Premise
reported I-Premise
rectal I-Premise
bleeding I-Premise
compared I-Premise
with I-Premise
47 I-Premise
% I-Premise
at I-Premise
2 I-Premise
years I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
006 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
78 I-Premise
- I-Premise
Gy I-Premise
arm I-Premise
reported I-Premise
more I-Premise
frequent I-Premise
bowel I-Premise
movements I-Premise
at I-Premise
3 I-Premise
years I-Premise
and I-Premise
less I-Premise
change I-Premise
in I-Premise
bowel I-Premise
function I-Premise
at I-Premise
2 I-Premise
years I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
70 I-Premise
- I-Premise
Gy I-Premise
arm I-Premise
. I-Premise

Before B-Premise
radiotherapy I-Premise
, I-Premise
84 I-Premise
% I-Premise
of I-Premise
patients I-Premise
reported I-Premise
erections I-Premise
adequate I-Premise
for I-Premise
intercourse I-Premise
at I-Premise
least I-Premise
a I-Premise
few I-Premise
times I-Premise
during I-Premise
the I-Premise
previous I-Premise
year I-Premise
. I-Premise

After B-Premise
2 I-Premise
and I-Premise
3 I-Premise
years I-Premise
, I-Premise
this I-Premise
had I-Premise
decreased I-Premise
to I-Premise
49 I-Premise
% I-Premise
and I-Premise
41 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise

By B-Claim
patient I-Claim
- I-Claim
reported I-Claim
questionnaire I-Claim
, I-Claim
78 I-Claim
Gy I-Claim
produced I-Claim
an I-Claim
increase I-Claim
in I-Claim
bowel I-Claim
movement I-Claim
frequency I-Claim
and I-Claim
no I-Claim
increase I-Claim
in I-Claim
bladder I-Claim
or I-Claim
sexual I-Claim
side I-Claim
effects I-Claim
at I-Claim
3 I-Claim
years I-Claim
compared I-Claim
with I-Claim
70 I-Claim
Gy I-Claim
. I-Claim

Comparing B-Claim
the I-Claim
results I-Claim
2 I-Claim
and I-Claim
3 I-Claim
years I-Claim
after I-Claim
radiotherapy I-Claim
, I-Claim
the I-Claim
symptoms I-Claim
of I-Claim
rectal I-Claim
bleeding I-Claim
had I-Claim
improved I-Claim
, I-Claim
erectile I-Claim
function I-Claim
had I-Claim
decreased I-Claim
, I-Claim
and I-Claim
urinary I-Claim
urge I-Claim
incontinence I-Claim
had I-Claim
increased I-Claim
. I-Claim

Due O
to O
the O
various O
inter O
- O
individual O
differences O
in O
the O
biological O
characteristics O
of O
tumor O
cells O
, O
as O
well O
as O
issues O
on O
the O
efficacy O
, O
adverse O
reactions O
, O
and O
defects O
of O
existing O
drugs O
, O
we O
compared O
the O
clinical O
efficacy O
and O
toxicity O
of O
pemetrexed O
and O
gemcitabine O
combined O
with O
cisplatin O
for O
the O
treatment O
of O
previously O
untreated O
advanced O
non O
- O
small O
cell O
lung O
cancer O
( O
NSCLC O
) O
. O

251 O
patients O
were O
randomly O
divided O
into O
pemetrexed O
combined O
with O
cisplatin O
group O
( O
PP O
group O
) O
with O
127 O
cases O
and O
gemcitabine O
combined O
with O
cisplatin O
group O
( O
GP O
group O
) O
with O
124 O
cases O
. O

PP O
group O
received O
pemetrexed O
500 O
mg O
/ O
mÂ² O
iv O
infusion O
d1 O
and O
cisplatin O
75 O
mg O
/ O
mÂ² O
iv O
infusion O
d1 O
, O
whereas O
GP O
group O
received O
gemcitabine O
1 O
, O
000 O
mg O
/ O
mÂ² O
iv O
infusion O
d1 O
, O
8 O
and O
cisplatin O
75 O
mg O
/ O
mÂ² O
iv O
infusion O
d1 O
. O

The O
treatment O
cycle O
was O
once O
every O
three O
weeks O
. O

In O
addition O
, O
folic O
acid O
, O
vitamin O
B12 O
, O
and O
dexamethasone O
were O
administered O
in O
both O
groups O
. O

The B-Premise
total I-Premise
clinical I-Premise
effective I-Premise
rates I-Premise
in I-Premise
PP I-Premise
group I-Premise
and I-Premise
GP I-Premise
group I-Premise
were I-Premise
25 I-Premise
. I-Premise
20 I-Premise
% I-Premise
and I-Premise
17 I-Premise
. I-Premise
74 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
total I-Premise
efficiencies I-Premise
of I-Premise
non I-Premise
- I-Premise
squamous I-Premise
cell I-Premise
carcinoma I-Premise
were I-Premise
27 I-Premise
. I-Premise
62 I-Premise
% I-Premise
and I-Premise
16 I-Premise
. I-Premise
00 I-Premise
% I-Premise
. I-Premise

The B-Premise
tumor I-Premise
progression I-Premise
duration I-Premise
in I-Premise
these I-Premise
two I-Premise
groups I-Premise
was I-Premise
6 I-Premise
. I-Premise
5 I-Premise
and I-Premise
5 I-Premise
. I-Premise
6 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
time I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
was I-Premise
16 I-Premise
. I-Premise
9 I-Premise
and I-Premise
17 I-Premise
. I-Premise
0 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
with I-Premise
59 I-Premise
. I-Premise
62 I-Premise
% I-Premise
and I-Premise
65 I-Premise
. I-Premise
87 I-Premise
% I-Premise
survival I-Premise
rates I-Premise
of I-Premise
1 I-Premise
year I-Premise
and I-Premise
27 I-Premise
. I-Premise
28 I-Premise
% I-Premise
and I-Premise
27 I-Premise
. I-Premise
93 I-Premise
% I-Premise
survival I-Premise
rates I-Premise
of I-Premise
2 I-Premise
years I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
total I-Premise
efficacy I-Premise
of I-Premise
non I-Premise
- I-Premise
squamous I-Premise
cell I-Premise
carcinoma I-Premise
in I-Premise
the I-Premise
PP I-Premise
group I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
in I-Premise
GP I-Premise
group I-Premise
. I-Premise

The B-Premise
results I-Premise
were I-Premise
statistically I-Premise
significant I-Premise
. I-Premise

However O
, O
there O
were O
no O
significant O
differences O
in O
total O
response O
rates O
, O
tumor O
progression O
duration O
, O
and O
median O
survival O
rates O
of O
1 O
and O
2 O
years O
. O

The B-Premise
rate I-Premise
of I-Premise
adverse I-Premise
reactions I-Premise
, I-Premise
including I-Premise
white I-Premise
blood I-Premise
cell I-Premise
reduction I-Premise
, I-Premise
lower I-Premise
platelet I-Premise
count I-Premise
, I-Premise
lower I-Premise
hemoglobin I-Premise
, I-Premise
and I-Premise
hair I-Premise
loss I-Premise
in I-Premise
the I-Premise
PP I-Premise
group I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
GP I-Premise
group I-Premise
. I-Premise

The O
results O
were O
statistically O
significant O
. O

The B-Claim
clinical I-Claim
efficacy I-Claim
of I-Claim
pemetrexed I-Claim
and I-Claim
gemcitabine I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
previously I-Claim
untreated I-Claim
advanced I-Claim
NSCLC I-Claim
was I-Claim
roughly I-Claim
the I-Claim
same I-Claim
, I-Claim
but B-Claim
the I-Claim
adverse I-Claim
reactions I-Claim
decreased I-Claim
significantly I-Claim
in I-Claim
the I-Claim
PP I-Claim
group I-Claim
compared I-Claim
with I-Claim
those I-Claim
in I-Claim
the I-Claim
GP I-Claim
group I-Claim
. I-Claim

Therefore B-Claim
, I-Claim
pemetrexed I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
can I-Claim
be I-Claim
used I-Claim
as I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
drug I-Claim
for I-Claim
clinical I-Claim
first I-Claim
- I-Claim
line I-Claim
treatment I-Claim
for I-Claim
previously I-Claim
untreated I-Claim
NSCLC I-Claim
. I-Claim

This O
randomised O
multicentre O
trial O
was O
conducted O
to O
establish O
the O
optimal O
duration O
of O
palliative O
chemotherapy O
in O
advanced O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
NSCLC O
) O
. O

We O
compared O
a O
policy O
of O
three O
vs O
six O
courses O
of O
new O
- O
generation O
platinum O
- O
based O
combination O
chemotherapy O
with O
regard O
to O
effects O
on O
quality O
of O
life O
( O
QoL O
) O
and O
survival O
. O

Patients O
with O
stage O
IIIB O
or O
IV O
NSCLC O
and O
WHO O
performance O
status O
( O
PS O
) O
0 O
- O
2 O
were O
randomised O
to O
receive O
three O
( O
C3 O
) O
or O
six O
( O
C6 O
) O
courses O
of O
carboplatin O
( O
area O
under O
the O
curve O
( O
AUC O
) O
4 O
, O
Chatelut O
' O
s O
formula O
, O
equivalent O
to O
Calvert O
' O
s O
AUC O
5 O
) O
on O
day O
1 O
and O
vinorelbine O
25 O
mg O
m O
( O
- O
2 O
) O
on O
days O
1 O
and O
8 O
of O
a O
3 O
- O
week O
cycle O
. O

Key O
end O
points O
were O
QoL O
at O
18 O
weeks O
, O
measured O
with O
EORTC O
Quality O
of O
Life O
Questionnaire O
( O
QLQ O
) O
- O
C30 O
and O
QLQ O
- O
LC13 O
, O
and O
overall O
survival O
. O

Secondary O
end O
points O
were O
progression O
- O
free O
survival O
and O
need O
of O
palliative O
radiotherapy O
. O

Two O
hundred O
and O
ninety O
- O
seven O
patients O
were O
randomised O
( O
C3 O
150 O
, O
C6 O
147 O
) O
. O

Their O
median O
age O
was O
65 O
years O
, O
30 O
% O
had O
PS O
2 O
and O
76 O
% O
stage O
IV O
disease O
. O

Seventy O
- O
eight O
and O
54 O
% O
of O
C3 O
and O
C6 O
patients O
, O
respectively O
, O
completed O
all O
scheduled O
chemotherapy O
courses O
. O

Compliance O
with O
QoL O
questionnaires O
was O
88 O
% O
. O

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
group I-Premise
differences I-Premise
in I-Premise
global I-Premise
QoL I-Premise
, I-Premise
pain I-Premise
or I-Premise
fatigue I-Premise
up I-Premise
to I-Premise
26 I-Premise
weeks I-Premise
. I-Premise

The B-Premise
dyspnoea I-Premise
palliation I-Premise
rate I-Premise
was I-Premise
lower I-Premise
in I-Premise
the I-Premise
C3 I-Premise
arm I-Premise
at I-Premise
18 I-Premise
and I-Premise
26 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
finding I-Premise
was I-Premise
inconsistent I-Premise
across I-Premise
different I-Premise
methods I-Premise
of I-Premise
analysis I-Premise
. I-Premise

Median B-Premise
survival I-Premise
in I-Premise
the I-Premise
C3 I-Premise
group I-Premise
was I-Premise
28 I-Premise
vs I-Premise
32 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
C6 I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
75 I-Premise
, I-Premise
HR I-Premise
1 I-Premise
. I-Premise
04 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0 I-Premise
. I-Premise
82 I-Premise
- I-Premise
1 I-Premise
. I-Premise
31 I-Premise
) I-Premise
. I-Premise

One B-Premise
- B-Premise
and I-Premise
2 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
25 I-Premise
and I-Premise
9 I-Premise
% I-Premise
vs I-Premise
25 I-Premise
and I-Premise
5 I-Premise
% I-Premise
in I-Premise
the I-Premise
C3 I-Premise
and I-Premise
C6 I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Median B-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
was I-Premise
16 I-Premise
and I-Premise
21 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
C3 I-Premise
and I-Premise
C6 I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
21 I-Premise
, I-Premise
HR I-Premise
0 I-Premise
. I-Premise
86 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0 I-Premise
. I-Premise
68 I-Premise
- I-Premise
1 I-Premise
. I-Premise
08 I-Premise
) I-Premise
. I-Premise

In B-Claim
conclusion I-Claim
, I-Claim
palliative I-Claim
chemotherapy I-Claim
with I-Claim
carboplatin I-Claim
and I-Claim
vinorelbine I-Claim
beyond I-Claim
three I-Claim
courses I-Claim
conveys I-Claim
no I-Claim
survival I-Claim
or I-Claim
consistent I-Claim
QoL I-Claim
benefits I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

To O
determine O
the O
efficacy O
, O
impact O
on O
quality O
- O
of O
- O
life O
( O
QoL O
) O
and O
tolerability O
of O
two O
different O
irinotecan O
administration O
schedules O
in O
combination O
with O
capecitabine O
as O
first O
- O
line O
treatment O
of O
metastatic O
colorectal O
cancer O
. O

We O
carried O
out O
a O
randomized O
phase O
II O
trial O
to O
select O
one O
of O
the O
following O
treatment O
regimens O
for O
further O
investigation O
: O
weekly O
irinotecan O
at O
a O
dose O
of O
70 O
mg O
/ O
m O
( O
2 O
) O
days O
1 O
, O
8 O
, O
15 O
, O
22 O
, O
29 O
( O
arm O
A O
) O
or O
3 O
- O
weekly O
irinotecan O
at O
a O
dose O
of O
300 O
/ O
240 O
mg O
/ O
m O
( O
2 O
) O
day O
1 O
and O
days O
22 O
( O
arm O
B O
) O
in O
combination O
with O
capecitabine O
1000 O
mg O
/ O
m O
( O
2 O
) O
twice O
daily O
days O
1 O
- O
14 O
and O
days O
22 O
- O
35 O
every O
6 O
weeks O
. O

Seventy O
- O
five O
patients O
with O
good O
performance O
status O
entered O
the O
trial O
. O

The O
two O
arms O
were O
well O
balanced O
for O
relevant O
patient O
and O
disease O
characteristics O
. O

The B-Premise
most I-Premise
frequent I-Premise
toxic I-Premise
effects I-Premise
were I-Premise
grade I-Premise
3 I-Premise
/ I-Premise
4 I-Premise
diarrhea I-Premise
( I-Premise
arm I-Premise
A I-Premise
: I-Premise
34 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
19 I-Premise
% I-Premise
) I-Premise
, I-Premise
grade I-Premise
3 I-Premise
/ I-Premise
4 I-Premise
neutropenia I-Premise
( I-Premise
A I-Premise
: I-Premise
5 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
19 I-Premise
% I-Premise
) I-Premise
and I-Premise
grade I-Premise
2 I-Premise
/ I-Premise
3 I-Premise
alopecia I-Premise
( I-Premise
A I-Premise
: I-Premise
26 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
65 I-Premise
% I-Premise
) I-Premise
. I-Premise

Other B-Premise
grade I-Premise
3 I-Premise
/ I-Premise
4 I-Premise
toxic I-Premise
effects I-Premise
were I-Premise
rare I-Premise
( I-Premise
< I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Response B-Premise
rates I-Premise
were I-Premise
34 I-Premise
% I-Premise
[ I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
20 I-Premise
% I-Premise
to I-Premise
51 I-Premise
% I-Premise
] I-Premise
in I-Premise
arm I-Premise
A I-Premise
and I-Premise
35 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
20 I-Premise
% I-Premise
to I-Premise
53 I-Premise
% I-Premise
) I-Premise
in I-Premise
arm I-Premise
B I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
6 I-Premise
. I-Premise
9 I-Premise
( I-Premise
4 I-Premise
. I-Premise
6 I-Premise
- I-Premise
10 I-Premise
. I-Premise
1 I-Premise
) I-Premise
and I-Premise
9 I-Premise
. I-Premise
2 I-Premise
( I-Premise
7 I-Premise
. I-Premise
9 I-Premise
- I-Premise
11 I-Premise
. I-Premise
5 I-Premise
) I-Premise
months I-Premise
and I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
17 I-Premise
. I-Premise
4 I-Premise
( I-Premise
12 I-Premise
. I-Premise
6 I-Premise
- I-Premise
23 I-Premise
. I-Premise
0 I-Premise
+ I-Premise
) I-Premise
and I-Premise
24 I-Premise
. I-Premise
7 I-Premise
( I-Premise
16 I-Premise
. I-Premise
3 I-Premise
- I-Premise
26 I-Premise
. I-Premise
4 I-Premise
+ I-Premise
) I-Premise
months I-Premise
. I-Premise

Patients B-Premise
with I-Premise
an I-Premise
objective I-Premise
tumor I-Premise
response I-Premise
reported I-Premise
better I-Premise
physical I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
mood I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
functional I-Premise
performance I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
and I-Premise
less I-Premise
effort I-Premise
to I-Premise
cope I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
non I-Premise
- I-Premise
responders I-Premise
and I-Premise
stable I-Premise
disease I-Premise
patients I-Premise
. I-Premise

The O
primary O
end O
point O
of O
this O
study O
was O
the O
objective O
response O
rate O
and O
based O
on O
the O
statistical O
design O
of O
the O
trial O
, O
the O
3 O
- O
weekly O
irinotecan O
schedule O
was O
selected O
over O
weekly O
irinotecan O
administration O
. O

The B-Claim
3 I-Claim
- I-Claim
weekly I-Claim
irinotecan I-Claim
schedule I-Claim
also I-Claim
seemed I-Claim
advantageous I-Claim
in I-Claim
terms I-Claim
of I-Claim
grade I-Claim
3 I-Claim
/ I-Claim
4 I-Claim
diarrhea I-Claim
, I-Claim
time I-Claim
to I-Claim
progression I-Claim
, I-Claim
overall I-Claim
survival I-Claim
and I-Claim
patient I-Claim
convenience I-Claim
, I-Claim
but B-Claim
the I-Claim
study I-Claim
was I-Claim
not I-Claim
designed I-Claim
to I-Claim
detect I-Claim
differences I-Claim
in I-Claim
these I-Claim
parameters I-Claim
. I-Claim

In O
addition O
, O
tumor B-Claim
response I-Claim
was I-Claim
shown I-Claim
to I-Claim
have I-Claim
a I-Claim
beneficial I-Claim
effect I-Claim
on I-Claim
QoL I-Claim
indicators I-Claim
. I-Claim

To O
compare O
protracted O
venous O
infusion O
( O
PVI O
) O
5 O
- O
fluorouracil O
( O
5 O
- O
FU O
) O
with O
and O
without O
mitomycin O
C O
( O
MMC O
) O
in O
a O
prospectively O
randomised O
study O
and O
analyse O
for O
tumour O
response O
, O
survival O
, O
toxicity O
and O
quality O
of O
life O
( O
QL O
) O
. O

Two O
hundred O
patients O
with O
advanced O
colorectal O
cancer O
received O
PVI O
5 O
- O
FU O
300 O
mg O
/ O
m2 O
/ O
day O
for O
a O
maximum O
of O
24 O
weeks O
and O
were O
randomised O
to O
PVI O
5 O
- O
FU O
alone O
or O
PVI O
5 O
- O
FU O
+ O
MMC O
10 O
mg O
/ O
m2 O
( O
7 O
mg O
/ O
m2 O
from O
June O
1995 O
) O
6 O
weekly O
for O
4 O
courses O
. O

Overall B-Premise
response I-Premise
was I-Premise
54 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
44 I-Premise
. I-Premise
1 I-Premise
% I-Premise
- I-Premise
63 I-Premise
. I-Premise
9 I-Premise
% I-Premise
) I-Premise
with I-Premise
PVI I-Premise
5 I-Premise
- I-Premise
FU I-Premise
+ I-Premise
MMC I-Premise
compared I-Premise
to I-Premise
38 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
28 I-Premise
. I-Premise
3 I-Premise
% I-Premise
- I-Premise
47 I-Premise
. I-Premise
7 I-Premise
% I-Premise
) I-Premise
for I-Premise
PVI I-Premise
5 I-Premise
- I-Premise
FU I-Premise
alone I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
024 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
failure I-Premise
free I-Premise
survival I-Premise
was I-Premise
7 I-Premise
. I-Premise
9 I-Premise
months I-Premise
in I-Premise
PVI I-Premise
5 I-Premise
- I-Premise
FU I-Premise
plus I-Premise
MMC I-Premise
and I-Premise
5 I-Premise
. I-Premise
4 I-Premise
months I-Premise
with I-Premise
PVI I-Premise
5 I-Premise
- I-Premise
FU I-Premise
alone I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
033 I-Premise
) I-Premise
and I-Premise
at I-Premise
one I-Premise
year I-Premise
31 I-Premise
. I-Premise
9 I-Premise
% I-Premise
for I-Premise
the I-Premise
combination I-Premise
compared I-Premise
to I-Premise
17 I-Premise
. I-Premise
7 I-Premise
% I-Premise
for I-Premise
PVI I-Premise
5 I-Premise
- I-Premise
FU I-Premise
alone I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
14 I-Premise
months I-Premise
with I-Premise
MMC I-Premise
and I-Premise
15 I-Premise
months I-Premise
in I-Premise
5 I-Premise
- I-Premise
FU I-Premise
alone I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
one I-Premise
- I-Premise
year I-Premise
survival I-Premise
51 I-Premise
. I-Premise
7 I-Premise
% I-Premise
vs I-Premise
. I-Premise
57 I-Premise
. I-Premise
2 I-Premise
% I-Premise
. I-Premise

PVI B-Premise
5 I-Premise
- I-Premise
FU I-Premise
+ I-Premise
MMC I-Premise
caused I-Premise
more I-Premise
overall I-Premise
haematological I-Premise
toxicity I-Premise
but I-Premise
CTC I-Premise
grades I-Premise
3 I-Premise
/ I-Premise
4 I-Premise
was I-Premise
increased I-Premise
only I-Premise
for I-Premise
thrombocytopaenia I-Premise
. I-Premise

Two B-Premise
patients I-Premise
treated I-Premise
with I-Premise
a I-Premise
cumulative I-Premise
dose I-Premise
of I-Premise
MMC I-Premise
of I-Premise
40 I-Premise
mg I-Premise
/ I-Premise
m2 I-Premise
developed I-Premise
haemolytic I-Premise
uraemic I-Premise
syndrome I-Premise
warranting I-Premise
the I-Premise
reduction I-Premise
in I-Premise
cumulative I-Premise
MMC I-Premise
dose I-Premise
to I-Premise
28 I-Premise
mg I-Premise
/ I-Premise
m2 I-Premise
. I-Premise

The B-Premise
global I-Premise
QL I-Premise
scores I-Premise
were I-Premise
better I-Premise
for I-Premise
PVI I-Premise
5 I-Premise
- I-Premise
FU I-Premise
+ I-Premise
MMC I-Premise
arm I-Premise
at I-Premise
24 I-Premise
weeks I-Premise
, I-Premise
but B-Premise
the I-Premise
remaining I-Premise
QL I-Premise
data I-Premise
showed I-Premise
no I-Premise
differences I-Premise
. I-Premise

PVI B-Claim
5 I-Claim
- I-Claim
FU I-Claim
+ I-Claim
MMC I-Claim
results I-Claim
in I-Claim
failure I-Claim
- I-Claim
free I-Claim
survival I-Claim
and I-Claim
response I-Claim
advantage I-Claim
, I-Claim
tolerable I-Claim
toxicity I-Claim
and I-Claim
better I-Claim
QL I-Claim
when I-Claim
compared I-Claim
to I-Claim
PVI I-Claim
5 I-Claim
- I-Claim
FU I-Claim
alone I-Claim
but I-Claim
no I-Claim
overall I-Claim
survival I-Claim
advantage I-Claim
. I-Claim

There B-Premise
is I-Premise
no I-Premise
irreversible I-Premise
toxicity I-Premise
with I-Premise
MMC I-Premise
at I-Premise
a I-Premise
cumulative I-Premise
dose I-Premise
of I-Premise
28 I-Premise
mg I-Premise
/ I-Premise
m2 I-Premise
. I-Premise

To O
compare O
in O
a O
phase O
III O
study O
the O
safety O
and O
efficacy O
of O
fludarabine O
to O
that O
of O
cyclophosphamide O
, O
vincristine O
, O
and O
prednisone O
( O
CVP O
) O
in O
recurrent O
, O
low O
- O
grade O
, O
non O
- O
Hodgkin O
' O
s O
lymphoma O
after O
previous O
response O
to O
systemic O
treatment O
. O

Patients O
were O
randomized O
to O
fludarabine O
( O
25 O
mg O
/ O
m O
( O
2 O
) O
intravenously O
on O
days O
1 O
to O
5 O
, O
every O
28 O
days O
) O
or O
CVP O
( O
cyclophosphamide O
750 O
mg O
/ O
m O
( O
2 O
) O
and O
vincristine O
1 O
. O
2 O
mg O
/ O
m O
( O
2 O
) O
both O
intravenously O
on O
day O
1 O
and O
prednisone O
40 O
mg O
/ O
m O
( O
2 O
) O
orally O
on O
days O
1 O
to O
5 O
, O
every O
21 O
days O
) O
. O

The O
primary O
outcome O
assessed O
was O
progression O
- O
free O
survival O
( O
PFS O
) O
"""" O
; O
"""" O
secondary O
outcomes O
included O
treatment O
- O
free O
survival O
( O
TFS O
) O
, O
overall O
survival O
( O
OS O
) O
, O
treatment O
- O
related O
toxicity O
, O
and O
quality O
of O
life O
( O
QoL O
) O
according O
to O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
' O
s O
Quality O
of O
Life O
Questionnaire O
C O
- O
30 O
version O
1 O
. O
0 O
instrument O
. O

Ninety O
- O
one O
patients O
were O
randomized O
, O
47 O
to O
fludarabine O
and O
44 O
to O
CVP O
. O

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
response I-Premise
rates I-Premise
, I-Premise
with I-Premise
64 I-Premise
% I-Premise
( I-Premise
complete I-Premise
response I-Premise
[ I-Premise
CR I-Premise
] I-Premise
, I-Premise
9 I-Premise
% I-Premise
) I-Premise
for I-Premise
fludarabine I-Premise
versus I-Premise
52 I-Premise
% I-Premise
( I-Premise
CR I-Premise
, I-Premise
7 I-Premise
% I-Premise
) I-Premise
for I-Premise
CVP I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
72 I-Premise
) I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
42 I-Premise
months I-Premise
, I-Premise
median I-Premise
PFS I-Premise
( I-Premise
11 I-Premise
months I-Premise
v I-Premise
9 I-Premise
. I-Premise
1 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
and I-Premise
TFS I-Premise
( I-Premise
15 I-Premise
months I-Premise
v I-Premise
11 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
were I-Premise
superior I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
fludarabine I-Premise
. I-Premise

No B-Premise
difference I-Premise
in I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
detected I-Premise
( I-Premise
57 I-Premise
months I-Premise
for I-Premise
fludarabine I-Premise
v I-Premise
44 I-Premise
months I-Premise
for I-Premise
CVP I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
95 I-Premise
) I-Premise
. I-Premise

Three B-Premise
patients I-Premise
receiving I-Premise
fludarabine I-Premise
died I-Premise
of I-Premise
treatment I-Premise
- I-Premise
related I-Premise
toxicity I-Premise
compared I-Premise
with I-Premise
none I-Premise
of I-Premise
the I-Premise
patients I-Premise
receiving I-Premise
CVP I-Premise
. I-Premise

Peripheral B-Premise
neuropathy I-Premise
and I-Premise
alopecia I-Premise
were I-Premise
more I-Premise
common I-Premise
with I-Premise
CVP I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
fludarabine I-Premise
had I-Premise
higher I-Premise
scores I-Premise
for I-Premise
social I-Premise
function I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
008 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
no B-Premise
other I-Premise
differences I-Premise
in I-Premise
QoL I-Premise
were I-Premise
detected I-Premise
. I-Premise

In B-Claim
recurrent I-Claim
low I-Claim
- I-Claim
grade I-Claim
lymphoma I-Claim
, I-Claim
fludarabine I-Claim
improves I-Claim
PFS I-Claim
, I-Claim
TFS I-Claim
, I-Claim
and I-Claim
social I-Claim
function I-Claim
scores I-Claim
in I-Claim
comparison I-Claim
with I-Claim
CVP I-Claim
but I-Claim
does I-Claim
not I-Claim
improve I-Claim
OS I-Claim
. I-Claim

For B-Claim
patients I-Claim
with I-Claim
anthracycline I-Claim
- I-Claim
pretreated I-Claim
metastatic I-Claim
breast I-Claim
carcinoma I-Claim
, I-Claim
capecitabine I-Claim
plus I-Claim
docetaxel I-Claim
significantly I-Claim
increased I-Claim
overall I-Claim
survival I-Claim
compared I-Claim
with I-Claim
docetaxel I-Claim
alone I-Claim
. I-Claim

The O
current O
study O
evaluated O
the O
cost O
- O
effectiveness O
of O
the O
capecitabine O
/ O
docetaxel O
combination O
versus O
docetaxel O
monotherapy O
, O
comparing O
the O
gain O
in O
quality O
- O
adjusted O
survival O
with O
associated O
health O
care O
costs O
. O

Patients O
were O
randomized O
to O
receive O
21 O
- O
day O
cycles O
of O
oral O
capecitabine O
1250 O
mg O
/ O
m2 O
twice O
daily O
, O
on O
Days O
1 O
- O
14 O
, O
plus O
docetaxel O
75 O
mg O
/ O
m2 O
Day O
1 O
( O
n O
= O
255 O
) O
, O
or O
docetaxel O
100 O
mg O
/ O
m2 O
on O
Day O
1 O
( O
n O
= O
256 O
) O
. O

Health O
and O
cost O
outcomes O
in O
the O
two O
arms O
were O
compared O
, O
and O
cost O
- O
effectiveness O
was O
estimated O
. O

Data O
on O
survival O
time O
and O
medical O
care O
resource O
use O
were O
prospectively O
collected O
in O
the O
trial O
. O

Costs O
associated O
with O
medical O
care O
resource O
use O
and O
quality O
- O
of O
- O
life O
adjustments O
were O
obtained O
from O
the O
published O
literature O
. O

The O
incremental O
cost O
- O
effectiveness O
ratio O
was O
calculated O
as O
the O
cost O
per O
quality O
- O
adjusted O
life O
year O
( O
QALY O
) O
gained O
. O

Capecitabine B-Premise
/ B-Premise
docetaxel B-Premise
increased I-Premise
the I-Premise
median I-Premise
overall I-Premise
survival I-Premise
by I-Premise
3 I-Premise
months I-Premise
compared I-Premise
with I-Premise
docetaxel I-Premise
alone I-Premise
( I-Premise
14 I-Premise
. I-Premise
5 I-Premise
vs I-Premise
. I-Premise
11 I-Premise
. I-Premise
5 I-Premise
months I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
quality I-Premise
- I-Premise
adjusted I-Premise
survival I-Premise
was I-Premise
increased I-Premise
by I-Premise
1 I-Premise
. I-Premise
8 I-Premise
months I-Premise
in I-Premise
the I-Premise
capecitabine I-Premise
/ I-Premise
docetaxel I-Premise
group I-Premise
. I-Premise

The B-Premise
total I-Premise
medical I-Premise
- I-Premise
resource I-Premise
utilization I-Premise
cost I-Premise
per I-Premise
patient I-Premise
was I-Premise
8 I-Premise
. I-Premise
9 I-Premise
% I-Premise
higher I-Premise
with I-Premise
the I-Premise
combination I-Premise
: I-Premise
24 I-Premise
, I-Premise
475 I-Premise
dollars I-Premise
for I-Premise
combination I-Premise
therapy I-Premise
versus I-Premise
22 I-Premise
, I-Premise
477 I-Premise
dollars I-Premise
for I-Premise
single I-Premise
- I-Premise
agent I-Premise
docetaxel I-Premise
. I-Premise

The B-Premise
mean I-Premise
cost I-Premise
per I-Premise
QALY I-Premise
gained I-Premise
with I-Premise
combination I-Premise
therapy I-Premise
was I-Premise
13 I-Premise
, I-Premise
558 I-Premise
dollars I-Premise
( I-Premise
standard I-Premise
deviation I-Premise
, I-Premise
6742 I-Premise
dollars I-Premise
) I-Premise
. I-Premise

Cost B-Premise
savings I-Premise
due I-Premise
to I-Premise
reduced I-Premise
docetaxel I-Premise
dose I-Premise
and I-Premise
hospital I-Premise
use I-Premise
were I-Premise
the I-Premise
major I-Premise
cost I-Premise
offsets I-Premise
with I-Premise
the I-Premise
combination I-Premise
. I-Premise

Sensitivity B-Premise
analyses I-Premise
showed I-Premise
that I-Premise
varying I-Premise
the I-Premise
mean I-Premise
hospital I-Premise
cost I-Premise
per I-Premise
day I-Premise
from I-Premise
the I-Premise
5th I-Premise
to I-Premise
the I-Premise
95th I-Premise
percentile I-Premise
resulted I-Premise
in I-Premise
cost I-Premise
- I-Premise
utility I-Premise
ratios I-Premise
ranging I-Premise
from I-Premise
20 I-Premise
, I-Premise
326 I-Premise
dollars I-Premise
to I-Premise
as I-Premise
low I-Premise
as I-Premise
6360 I-Premise
dollars I-Premise
. I-Premise

Capecitabine B-Claim
/ B-Claim
docetaxel B-Claim
was I-Claim
a I-Claim
cost I-Claim
- I-Claim
effective I-Claim
treatment I-Claim
in I-Claim
patients I-Claim
with I-Claim
anthracycline I-Claim
- I-Claim
pretreated I-Claim
advanced I-Claim
breast I-Claim
carcinoma I-Claim
, I-Claim
and I-Claim
had I-Claim
an I-Claim
incremental I-Claim
cost I-Claim
- I-Claim
effectiveness I-Claim
ratio I-Claim
that I-Claim
compares I-Claim
very I-Claim
favorably I-Claim
with I-Claim
that I-Claim
of I-Claim
many I-Claim
other I-Claim
oncology I-Claim
therapies I-Claim
. I-Claim

Epoetin B-Claim
alfa I-Claim
administered I-Claim
at I-Claim
40 I-Claim
, I-Claim
000 I-Claim
U I-Claim
once I-Claim
weekly I-Claim
( I-Claim
qw I-Claim
) I-Claim
to I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
receiving I-Claim
chemotherapy I-Claim
increases I-Claim
hemoglobin I-Claim
levels I-Claim
, I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
, I-Claim
and I-Claim
reduces I-Claim
transfusions I-Claim
. I-Claim

The O
benefit O
of O
epoetin O
alfa O
in O
maintaining O
hemoglobin O
levels O
in O
cancer O
patients O
with O
hemoglobin O
less O
than O
12 O
g O
/ O
dL O
has O
not O
been O
evaluated O
. O

Breast O
cancer O
patients O
( O
N O
= O
354 O
) O
receiving O
chemotherapy O
were O
randomly O
assigned O
in O
1 O
: O
1 O
ratio O
to O
epoetin O
alfa O
( O
40 O
, O
000 O
U O
qw O
) O
or O
standard O
of O
care O
( O
SOC O
) O
. O

QOL O
was O
assessed O
at O
baseline O
and O
week O
12 O
. O

Hemoglobin O
responses O
, O
transfusion O
requirements O
, O
and O
prognostic O
factors O
for O
responses O
were O
measured O
. O

At B-Premise
week I-Premise
12 I-Premise
, I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy I-Premise
- I-Premise
Anemia I-Premise
( I-Premise
FACT I-Premise
- I-Premise
An I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
mean I-Premise
, I-Premise
2 I-Premise
. I-Premise
16 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
12 I-Premise
. I-Premise
84 I-Premise
for I-Premise
epoetin I-Premise
alfa I-Premise
v I-Premise
- I-Premise
4 I-Premise
. I-Premise
43 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
13 I-Premise
. I-Premise
42 I-Premise
for I-Premise
SOC I-Premise
) I-Premise
and I-Premise
FACT I-Premise
- I-Premise
An I-Premise
fatigue I-Premise
( I-Premise
mean I-Premise
, I-Premise
1 I-Premise
. I-Premise
85 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
10 I-Premise
. I-Premise
52 I-Premise
for I-Premise
epoetin I-Premise
alfa I-Premise
v I-Premise
- I-Premise
3 I-Premise
. I-Premise
55 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
11 I-Premise
. I-Premise
14 I-Premise
for I-Premise
SOC I-Premise
) I-Premise
change I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise

Hemoglobin B-Premise
responses I-Premise
defined I-Premise
as I-Premise
mean I-Premise
hemoglobin I-Premise
> I-Premise
or I-Premise
= I-Premise
12 I-Premise
g I-Premise
/ I-Premise
dL I-Premise
or I-Premise
a I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
g I-Premise
/ I-Premise
dL I-Premise
increase I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
SOC I-Premise
: I-Premise
52 I-Premise
. I-Premise
0 I-Premise
% I-Premise
v I-Premise
5 I-Premise
. I-Premise
1 I-Premise
% I-Premise
and I-Premise
65 I-Premise
. I-Premise
7 I-Premise
% I-Premise
v I-Premise
6 I-Premise
. I-Premise
3 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
. I-Premise
0001 I-Premise
for I-Premise
both I-Premise
comparisons I-Premise
) I-Premise
. I-Premise

Percentage B-Premise
transfused I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
compared I-Premise
with I-Premise
SOC I-Premise
( I-Premise
8 I-Premise
. I-Premise
6 I-Premise
% I-Premise
v I-Premise
22 I-Premise
. I-Premise
9 I-Premise
% I-Premise
) I-Premise
. I-Premise

More B-Premise
than I-Premise
90 I-Premise
% I-Premise
of I-Premise
patients I-Premise
did I-Premise
not I-Premise
require I-Premise
a I-Premise
dose I-Premise
increase I-Premise
and I-Premise
28 I-Premise
. I-Premise
7 I-Premise
% I-Premise
had I-Premise
a I-Premise
dose I-Premise
reduction I-Premise
. I-Premise

Epoetin B-Claim
alfa I-Claim
administered I-Claim
at I-Claim
40 I-Claim
, I-Claim
000 I-Claim
U I-Claim
qw I-Claim
is I-Claim
effective I-Claim
in I-Claim
improving I-Claim
QOL I-Claim
, I-Claim
maintaining I-Claim
hemoglobin I-Claim
level I-Claim
, I-Claim
and I-Claim
reducing I-Claim
transfusion I-Claim
requirements I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

The B-Claim
high I-Claim
effectiveness I-Claim
observed I-Claim
could I-Claim
be I-Claim
attributed I-Claim
in I-Claim
part I-Claim
to I-Claim
early I-Claim
treatment I-Claim
with I-Claim
epoetin I-Claim
alfa I-Claim
. I-Claim

During B-Premise
the I-Premise
last I-Premise
decade I-Premise
, I-Premise
survival I-Premise
rates I-Premise
for I-Premise
breast I-Premise
cancer I-Premise
have I-Premise
increased I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
earlier I-Premise
detection I-Premise
and I-Premise
increased I-Premise
use I-Premise
of I-Premise
adjuvant I-Premise
therapy I-Premise
. I-Premise

Limited O
data O
exist O
on O
the O
psychosocial O
aspects O
of O
the O
transitional O
period O
between O
the O
end O
of O
primary O
treatment O
and O
survivorship O
. O

We O
investigated O
the O
baseline O
psychosocial O
status O
of O
women O
enrolled O
in O
a O
randomized O
trial O
testing O
two O
psychosocial O
interventions O
for O
women O
at O
the O
end O
of O
primary O
treatment O
. O

Participants O
, O
identified O
within O
1 O
month O
after O
surgery O
( O
registration O
) O
, O
provided O
demographic O
information O
and O
limited O
measures O
of O
quality O
of O
life O
. O

They O
were O
followed O
until O
they O
finished O
primary O
treatment O
( O
enrollment O
) O
, O
at O
which O
time O
they O
completed O
a O
mailed O
baseline O
survey O
that O
included O
standardized O
measures O
of O
quality O
of O
life O
( O
including O
standardized O
scales O
of O
physical O
and O
emotional O
functioning O
) O
, O
mood O
, O
symptoms O
, O
and O
sexual O
functioning O
. O

A O
total O
of O
558 O
patients O
( O
mean O
age O
= O
56 O
. O
9 O
years O
) O
were O
enrolled O
in O
the O
study O
between O
July O
1 O
, O
1999 O
, O
and O
June O
30 O
, O
2002 O
. O

Health O
outcomes O
were O
examined O
according O
to O
treatment O
received O
: O
mastectomy O
with O
and O
without O
chemotherapy O
, O
and O
lumpectomy O
with O
and O
without O
chemotherapy O
. O

All O
statistical O
tests O
were O
two O
- O
sided O
. O

Among B-Premise
all I-Premise
treatment I-Premise
groups I-Premise
, I-Premise
patients I-Premise
who I-Premise
had I-Premise
a I-Premise
mastectomy I-Premise
had I-Premise
the I-Premise
poorest I-Premise
physical I-Premise
functioning I-Premise
at I-Premise
registration I-Premise
( I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
at I-Premise
enrollment I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

At B-Premise
enrollment I-Premise
, I-Premise
mood I-Premise
and I-Premise
emotional I-Premise
functioning I-Premise
were I-Premise
similar I-Premise
among I-Premise
all I-Premise
patients I-Premise
, I-Premise
with I-Premise
no I-Premise
differences I-Premise
by I-Premise
type I-Premise
of I-Premise
treatment I-Premise
received I-Premise
. I-Premise

At B-Premise
enrollment I-Premise
, I-Premise
symptoms I-Premise
, I-Premise
including I-Premise
muscle I-Premise
stiffness I-Premise
, I-Premise
breast I-Premise
sensitivity I-Premise
, I-Premise
aches I-Premise
and I-Premise
pains I-Premise
, I-Premise
tendency I-Premise
to I-Premise
take I-Premise
naps I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
concentrating I-Premise
, I-Premise
were I-Premise
common I-Premise
among I-Premise
patients I-Premise
in I-Premise
all I-Premise
groups I-Premise
and I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
poor I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
emotional I-Premise
well I-Premise
- I-Premise
being I-Premise
. I-Premise

Sexual B-Premise
functioning I-Premise
was I-Premise
worse I-Premise
for I-Premise
women I-Premise
who I-Premise
received I-Premise
chemotherapy I-Premise
than I-Premise
for I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
, I-Premise
regardless I-Premise
of I-Premise
type I-Premise
of I-Premise
surgery I-Premise
( I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

At B-Claim
the I-Claim
end I-Claim
of I-Claim
primary I-Claim
treatment I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
women I-Claim
in I-Claim
all I-Claim
treatment I-Claim
groups I-Claim
report I-Claim
good I-Claim
emotional I-Claim
functioning I-Claim
but I-Claim
report I-Claim
decreased I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
particularly I-Claim
among I-Claim
women I-Claim
who I-Claim
have I-Claim
a I-Claim
mastectomy I-Claim
or I-Claim
receive I-Claim
chemotherapy I-Claim
. I-Claim

Clinical B-Claim
interventions I-Claim
to I-Claim
address I-Claim
common I-Claim
symptoms I-Claim
associated I-Claim
with I-Claim
treatment I-Claim
should I-Claim
be I-Claim
considered I-Claim
to I-Claim
improve I-Claim
physical I-Claim
and I-Claim
emotional I-Claim
functioning I-Claim
at I-Claim
the I-Claim
end I-Claim
of I-Claim
primary I-Claim
treatment I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

In B-Premise
a I-Premise
multinational I-Premise
trial I-Premise
of I-Premise
anaemic I-Premise
patients I-Premise
with I-Premise
cancer I-Premise
receiving I-Premise
nonplatinum I-Premise
- I-Premise
containing I-Premise
chemotherapy I-Premise
, I-Premise
epoetin I-Premise
- I-Premise
alfa I-Premise
effectively I-Premise
increased I-Premise
haemoglobin I-Premise
levels I-Premise
, I-Premise
reduced I-Premise
red I-Premise
blood I-Premise
cell I-Premise
transfusion I-Premise
requirements I-Premise
, I-Premise
and I-Premise
improved I-Premise
QOL I-Premise
. I-Premise

Although O
the O
study O
was O
not O
designed O
or O
powered O
to O
evaluate O
survival O
, O
a B-Premise
survival I-Premise
trend I-Premise
was I-Premise
noted I-Premise
favouring I-Premise
epoetin I-Premise
- I-Premise
alfa I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
median I-Premise
survival I-Premise
17 I-Premise
vs I-Premise
11 I-Premise
months I-Premise
[ I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
126 I-Premise
] I-Premise
) I-Premise
. I-Premise

To O
determine O
the O
incremental O
cost O
utility O
of O
epoetin O
- O
alfa O
versus O
placebo O
in O
anaemic O
patients O
with O
stage O
IV O
breast O
cancer O
from O
a O
UK O
National O
Health O
Service O
perspective O
. O

Patient O
data O
regarding O
transfusions O
, O
epoetin O
- O
alfa O
usage O
, O
chemotherapy O
treatment O
cycles O
, O
and O
adverse O
events O
were O
recorded O
, O
with O
survival O
follow O
- O
up O
for O
12 O
- O
36 O
months O
post O
- O
study O
. O

Stage O
IV O
breast O
cancer O
therapy O
costs O
were O
collected O
by O
surveying O
UK O
oncologists O
, O
and O
utilities O
for O
associated O
health O
states O
were O
from O
published O
sources O
. O

Costs O
were O
in O
British O
pounds O
and O
year O
2000 O
values O
. O

Costs O
and O
benefits O
were O
jointly O
determined O
for O
the O
stage O
IV O
breast O
cancer O
subgroup O
( O
n O
= O
55 O
) O
. O

Incremental O
cost O
- O
utility O
ratios O
( O
ICURs O
) O
were O
calculated O
assuming O
a O
6 O
% O
annual O
discount O
rate O
for O
costs O
and O
a O
1 O
. O
5 O
% O
annual O
discount O
rate O
for O
benefits O
. O

Bootstrap O
simulations O
( O
10 O
, O
000 O
iterations O
) O
were O
conducted O
to O
account O
for O
uncertainty O
, O
and O
sensitivity O
analyses O
were O
conducted O
to O
establish O
robustness O
. O

The B-Premise
ICUR I-Premise
for I-Premise
epoetin I-Premise
- I-Premise
alfa I-Premise
treatment I-Premise
was I-Premise
pounds I-Premise
8 I-Premise
, I-Premise
851 I-Premise
per I-Premise
QALY I-Premise
, I-Premise
with I-Premise
a I-Premise
99 I-Premise
% I-Premise
probability I-Premise
of I-Premise
a I-Premise
positive I-Premise
net I-Premise
benefit I-Premise
in I-Premise
QALYs I-Premise
( I-Premise
net I-Premise
benefit I-Premise
= I-Premise
0 I-Premise
. I-Premise
4805 I-Premise
years I-Premise
of I-Premise
perfect I-Premise
life I-Premise
) I-Premise
and I-Premise
a I-Premise
94 I-Premise
% I-Premise
probability I-Premise
of I-Premise
being I-Premise
acceptable I-Premise
using I-Premise
a I-Premise
threshold I-Premise
ICUR I-Premise
of I-Premise
pounds I-Premise
30 I-Premise
, I-Premise
000 I-Premise
/ I-Premise
QALY I-Premise
. I-Premise

The B-Premise
main I-Premise
cost I-Premise
drivers I-Premise
distinguishing I-Premise
epoetin I-Premise
- I-Premise
alfa I-Premise
from I-Premise
placebo I-Premise
were I-Premise
the I-Premise
costs I-Premise
of I-Premise
drug I-Premise
and I-Premise
patient I-Premise
care I-Premise
due I-Premise
to I-Premise
increased I-Premise
survival I-Premise
. I-Premise

The B-Claim
available I-Claim
data I-Claim
suggest I-Claim
a I-Claim
high I-Claim
probability I-Claim
of I-Claim
favourable I-Claim
cost I-Claim
- I-Claim
utility I-Claim
outcomes I-Claim
with I-Claim
epoetin I-Claim
- I-Claim
alfa I-Claim
treatment I-Claim
for I-Claim
anaemia I-Claim
in I-Claim
patients I-Claim
with I-Claim
stage I-Claim
IV I-Claim
breast I-Claim
cancer I-Claim
receiving I-Claim
nonplatinum I-Claim
- I-Claim
containing I-Claim
chemotherapy I-Claim
. I-Claim

Additional B-Claim
studies I-Claim
are I-Claim
warranted I-Claim
. I-Claim

The O
EORTC O
24971 O
/ O
TAX O
323 O
, O
a O
phase O
III O
study O
of O
358 O
patients O
with O
unresectable O
locoregionally O
advanced O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
, O
showed O
an O
improved O
progression O
- O
free O
and O
overall O
survival O
( O
OS O
) O
with O
less O
toxicity O
when O
docetaxel O
( O
T O
) O
was O
added O
to O
cisplatin O
and O
5 O
- O
fluorouracil O
( O
PF O
) O
for O
induction O
and O
given O
before O
radiotherapy O
( O
RT O
) O
. O

The O
impact O
of O
the O
addition O
of O
docetaxel O
on O
patients O
' O
health O
- O
related O
quality O
of O
life O
( O
HRQOL O
) O
and O
symptoms O
was O
investigated O
. O

HRQOL O
was O
assessed O
at O
baseline O
, O
at O
end O
of O
cycle O
2 O
, O
and O
4 O
, O
6 O
, O
and O
9 O
months O
after O
completion O
of O
RT O
using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
QLQ O
- O
C30 O
) O
and O
the O
EORTC O
QLQ O
Head O
and O
Neck O
Cancer O
- O
Specific O
Module O
( O
EORTC O
QLQ O
- O
H O
& O
amp O
"""" O
; O
"""" O
N35 O
) O
. O

The O
primary O
HRQOL O
scale O
was O
global O
HRQOL O
per O
protocol O
. O

Compliance O
to O
HRQOL O
assessments O
was O
97 O
% O
at O
baseline O
, O
but O
dropped O
to O
54 O
% O
by O
6 O
months O
. O

Data O
were O
analysed O
up O
to O
6 O
months O
. O

There B-Premise
was I-Premise
a I-Premise
trend I-Premise
towards I-Premise
improved I-Premise
global I-Premise
HRQOL I-Premise
during I-Premise
the I-Premise
treatment I-Premise
period I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
after I-Premise
the I-Premise
end I-Premise
of I-Premise
RT I-Premise
, I-Premise
global I-Premise
HRQOL I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
TPF I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
PF I-Premise
arm I-Premise
, I-Premise
but B-Premise
the I-Premise
low I-Premise
compliance I-Premise
does I-Premise
not I-Premise
allow I-Premise
to I-Premise
draw I-Premise
definitive I-Premise
conclusions I-Premise
. I-Premise

Swallowing B-Premise
and I-Premise
coughing I-Premise
problems I-Premise
decreased I-Premise
more I-Premise
in I-Premise
the I-Premise
TPF I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
PF I-Premise
arm I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
cycle I-Premise
2 I-Premise
, I-Premise
but B-Premise
to I-Premise
a I-Premise
limited I-Premise
extent I-Premise
. I-Premise

Induction B-Claim
chemotherapy I-Claim
with I-Claim
TPF I-Claim
before I-Claim
RT I-Claim
not I-Claim
only I-Claim
improves I-Claim
survival I-Claim
and I-Claim
reduces I-Claim
toxicity I-Claim
compared I-Claim
with I-Claim
PF I-Claim
but I-Claim
also I-Claim
seems I-Claim
to I-Claim
improve I-Claim
global I-Claim
HRQOL I-Claim
in I-Claim
a I-Claim
more I-Claim
sustainable I-Claim
manner I-Claim
. I-Claim

A O
randomised O
controlled O
trial O
( O
RCT O
) O
demonstrated O
that O
cognitive O
behaviour O
therapy O
( O
CBT O
) O
for O
fatigue O
during O
curative O
cancer O
treatment O
was O
effective O
shortly O
after O
cancer O
treatment O
. O

This O
study O
aimed O
to O
identify O
which O
patient O
characteristics O
predict O
fatigue O
improvement O
after O
CBT O
. O

In O
addition O
, O
the O
long O
- O
term O
effectiveness O
was O
investigated O
. O

Patients O
with O
various O
malignancies O
participated O
in O
the O
RCT O
( O
n O
= O
210 O
) O
. O

Participants O
were O
assessed O
before O
cancer O
treatment O
( O
T1 O
) O
, O
postintervention O
( O
T2 O
) O
, O
which O
was O
at O
least O
2 O
months O
after O
cancer O
treatment O
, O
and O
after O
1 O
- O
year O
follow O
- O
up O
( O
T3 O
) O
. O

Monthly O
fatigue O
assessments O
were O
completed O
between O
T2 O
and O
T3 O
. O

A O
regression O
analysis O
with O
interactions O
was O
performed O
to O
determine O
if O
domains O
of O
quality O
of O
life O
( O
EORTC O
- O
QLQ O
- O
C30 O
) O
functioning O
( O
Health O
Survey O
Short O
Form O
- O
36 O
) O
or O
psychological O
distress O
( O
Symptom O
Checklist O
- O
90 O
) O
moderated O
the O
effect O
of O
CBT O
on O
fatigue O
. O

Analyses O
of O
covariance O
were O
used O
to O
study O
the O
long O
- O
term O
effectiveness O
of O
CBT O
. O

Fatigue B-Premise
at I-Premise
T2 I-Premise
was I-Premise
predicted I-Premise
by I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
between I-Premise
self I-Premise
- I-Premise
reported I-Premise
cognitive I-Premise
functioning I-Premise
and I-Premise
CBT I-Premise
. I-Premise

No B-Premise
interactions I-Premise
were I-Premise
found I-Premise
between I-Premise
other I-Premise
domains I-Premise
of I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
functioning I-Premise
, I-Premise
psychological I-Premise
distress I-Premise
and I-Premise
CBT I-Premise
. I-Premise

At B-Premise
T3 I-Premise
, I-Premise
no I-Premise
significant I-Premise
difference I-Premise
on I-Premise
fatigue I-Premise
was I-Premise
found I-Premise
between I-Premise
CBT I-Premise
and I-Premise
usual I-Premise
care I-Premise
. I-Premise

Exploratory B-Premise
analyses I-Premise
showed I-Premise
that I-Premise
the I-Premise
difference I-Premise
nearly I-Premise
reached I-Premise
significance I-Premise
until I-Premise
7 I-Premise
months I-Premise
postintervention I-Premise
. I-Premise

Patients B-Premise
who I-Premise
experienced I-Premise
more I-Premise
concentration I-Premise
and I-Premise
memory I-Premise
problems I-Premise
at I-Premise
T1 I-Premise
benefited I-Premise
more I-Premise
from I-Premise
CBT I-Premise
for I-Premise
fatigue I-Premise
and I-Premise
are I-Premise
indicators I-Premise
. I-Premise

After B-Premise
a I-Premise
year I-Premise
of I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
the I-Premise
effect I-Premise
of I-Premise
CBT I-Premise
for I-Premise
fatigue I-Premise
was I-Premise
no I-Premise
longer I-Premise
observed I-Premise
, I-Premise
and I-Premise
the I-Premise
effect I-Premise
on I-Premise
fatigue I-Premise
seemed I-Premise
to I-Premise
be I-Premise
diminished I-Premise
7 I-Premise
months I-Premise
postintervention I-Premise
. I-Premise

The B-Claim
implication I-Claim
is I-Claim
that I-Claim
CBT I-Claim
for I-Claim
fatigue I-Claim
should I-Claim
be I-Claim
offered I-Claim
to I-Claim
patients I-Claim
with I-Claim
cancer I-Claim
with I-Claim
the I-Claim
highest I-Claim
chance I-Claim
to I-Claim
benefit I-Claim
. I-Claim

A O
phase O
III O
randomized O
trial O
was O
carried O
out O
to O
compare O
two O
schedules O
of O
the O
vinorelbine O
( O
VNR O
) O
- O
cisplatin O
( O
CDDP O
) O
regimen O
in O
patients O
with O
locally O
advanced O
unresectable O
poor O
prognosis O
stage O
IIIB O
or O
metastatic O
stage O
IV O
non O
- O
small O
cell O
lung O
cancer O
. O

The O
primary O
endpoints O
were O
overall O
survival O
( O
OS O
) O
and O
analysis O
of O
toxicity O
, O
while O
secondary O
endpoints O
included O
response O
rates O
, O
time O
- O
to O
- O
progression O
( O
TTP O
) O
and O
quality O
of O
life O
( O
QoL O
) O
. O

Eligible O
patients O
were O
randomized O
to O
receive O
: O
( O
a O
) O
VNR O
25mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
, O
8 O
and O
15 O
plus O
CDDP O
100mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
every O
4 O
weeks O
or O
( O
b O
) O
VNR O
30 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
and O
8 O
plus O
CDDP O
80 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
every O
3 O
weeks O
. O

All O
patients O
were O
chemotherapy O
- O
naÃ¯ve O
and O
had O
an O
ECOG O
performance O
status O
( O
PS O
) O
of O
0 O
- O
1 O
. O

Overall O
278 O
patients O
were O
enrolled O
into O
the O
trial O
. O

Overall O
response O
rate O
was O
34 O
% O
( O
95 O
% O
CL O
26 O
- O
42 O
% O
) O
in O
the O
weekly O
VNR O
/ O
CDDP O
arm O
, O
and O
32 O
% O
( O
95 O
% O
CL O
24 O
- O
40 O
% O
) O
in O
patients O
treated O
with O
day O
1 O
- O
8 O
VNR O
/ O
CDDP O
without O
any O
statistically O
significant O
difference O
. O

Median B-Premise
TTP I-Premise
was I-Premise
4 I-Premise
. I-Premise
5 I-Premise
and I-Premise
4 I-Premise
. I-Premise
6 I-Premise
months I-Premise
respectively I-Premise
for I-Premise
weekly I-Premise
VNR I-Premise
/ I-Premise
CDDP I-Premise
arm I-Premise
and I-Premise
the I-Premise
day I-Premise
1 I-Premise
- I-Premise
8 I-Premise
VNR I-Premise
/ I-Premise
CDDP I-Premise
one I-Premise
. I-Premise

This B-Premise
difference I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
log I-Premise
- I-Premise
rank I-Premise
test I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
818 I-Premise
) I-Premise
. I-Premise

Median B-Premise
OS I-Premise
was I-Premise
9 I-Premise
. I-Premise
45 I-Premise
and I-Premise
10 I-Premise
months I-Premise
respectively I-Premise
for I-Premise
weekly I-Premise
VNR I-Premise
/ I-Premise
CDDP I-Premise
arm I-Premise
and I-Premise
the I-Premise
day I-Premise
1 I-Premise
- I-Premise
8 I-Premise
VNR I-Premise
/ I-Premise
CDDP I-Premise
one I-Premise
without I-Premise
statistically I-Premise
a I-Premise
significant I-Premise
difference I-Premise
( I-Premise
log I-Premise
- I-Premise
rank I-Premise
test I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
259 I-Premise
) I-Premise
. I-Premise

The B-Premise
- I-Premise
1 I-Premise
and I-Premise
2 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
31 I-Premise
and I-Premise
36 I-Premise
% I-Premise
, I-Premise
and I-Premise
10 I-Premise
and I-Premise
11 I-Premise
% I-Premise
respectively I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
severe I-Premise
neutropenia I-Premise
( I-Premise
34 I-Premise
% I-Premise
versus I-Premise
68 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
and I-Premise
of I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
5 I-Premise
% I-Premise
versus I-Premise
12 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
026 I-Premise
) I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
the I-Premise
rate I-Premise
of I-Premise
therapy I-Premise
omissions I-Premise
( I-Premise
10 I-Premise
% I-Premise
versus I-Premise
24 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0037 I-Premise
) I-Premise
were I-Premise
higher I-Premise
in I-Premise
the I-Premise
weekly I-Premise
VNR I-Premise
/ I-Premise
CDDP I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
day I-Premise
1 I-Premise
- I-Premise
8 I-Premise
VNR I-Premise
/ I-Premise
CDDP I-Premise
one I-Premise
. I-Premise

The B-Premise
weekly I-Premise
VNR I-Premise
/ I-Premise
CDDP I-Premise
regimen I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
lower I-Premise
received I-Premise
dose I-Premise
intensity I-Premise
in I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
fashion I-Premise
( I-Premise
9 I-Premise
% I-Premise
versus I-Premise
22 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
and I-Premise
with I-Premise
a I-Premise
lower I-Premise
non I-Premise
- I-Premise
statistically I-Premise
significant I-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
as I-Premise
compared I-Premise
to I-Premise
the I-Premise
day I-Premise
1 I-Premise
- I-Premise
8 I-Premise
VNR I-Premise
/ I-Premise
CDDP I-Premise
schedule I-Premise
. I-Premise

The B-Claim
combination I-Claim
of I-Claim
day I-Claim
1 I-Claim
- I-Claim
8 I-Claim
VNR I-Claim
plus I-Claim
CDDP I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
is I-Claim
less I-Claim
toxic I-Claim
and I-Claim
better I-Claim
tolerated I-Claim
than I-Claim
the I-Claim
regimen I-Claim
of I-Claim
weekly I-Claim
VNR I-Claim
plus I-Claim
CDDP I-Claim
every I-Claim
4 I-Claim
weeks I-Claim
. I-Claim

The B-Claim
two I-Claim
schedules I-Claim
are I-Claim
equivalent I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
response I-Claim
rate I-Claim
, I-Claim
median I-Claim
time I-Claim
- I-Claim
to I-Claim
- I-Claim
progression I-Claim
and I-Claim
overall I-Claim
survival I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
VNR I-Claim
on I-Claim
day I-Claim
1 I-Claim
- I-Claim
8 I-Claim
plus I-Claim
CDDP I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
may I-Claim
be I-Claim
considered I-Claim
as I-Claim
a I-Claim
reference I-Claim
regimen I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
disease I-Claim
and I-Claim
those I-Claim
who I-Claim
deserve I-Claim
a I-Claim
postoperative I-Claim
therapy I-Claim
, I-Claim
and I-Claim
for I-Claim
future I-Claim
studies I-Claim
. I-Claim

Cancer O
related O
fatigue O
( O
CRF O
) O
is O
a O
common O
problem O
for O
cancer O
patients O
across O
diagnoses O
during O
chemotherapy O
and O
is O
associated O
with O
physical O
inactivity O
, O
lower O
functional O
level O
and O
lack O
of O
energy O
. O

Few O
RCT O
exercise O
intervention O
studies O
have O
included O
cancer O
patients O
undergoing O
chemotherapy O
. O

The O
objective O
of O
this O
study O
is O
to O
evaluate O
whether O
a O
six O
- O
week O
supervised O
multimodal O
exercise O
intervention O
, O
adjunct O
to O
chemotherapy O
and O
standard O
care O
, O
can O
reduce O
the O
patient O
' O
s O
CRF O
level O
. O

Data O
is O
based O
on O
analyses O
of O
a O
prospective O
randomised O
controlled O
trial O
' O
The O
Body O
Cancer O
Trial O
' O
. O

213 O
cancer O
patients O
with O
different O
diagnoses O
were O
randomised O
into O
an O
intervention O
group O
or O
wait O
- O
list O
control O
group O
. O

The O
primary O
outcome O
, O
Fatigue O
score O
( O
CRF O
) O
, O
was O
evaluated O
by O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
- O
Anaemia O
Questionnaire O
( O
FACT O
- O
An O
- O
) O
( O
FACT O
- O
G O
score O
& O
FACT O
- O
An O
Anemia O
subscale O
) O
. O

Supervised O
exercise O
, O
comprising O
high O
- O
intensity O
cardiovascular O
and O
heavy O
resistance O
training O
, O
relaxation O
- O
and O
body O
awareness O
training O
and O
massage O
, O
9 O
h O
weekly O
for O
6 O
weeks O
. O

CRF B-Premise
was I-Premise
significantly I-Premise
reduced I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
corresponding I-Premise
to I-Premise
a I-Premise
Fatigue I-Premise
score I-Premise
reduction I-Premise
of I-Premise
3 I-Premise
. I-Premise
04 I-Premise
( I-Premise
effect I-Premise
size I-Premise
of I-Premise
0 I-Premise
. I-Premise
44 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0 I-Premise
. I-Premise
17 I-Premise
- I-Premise
0 I-Premise
. I-Premise
72 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
, I-Premise
the I-Premise
FACT I-Premise
- I-Premise
An I-Premise
score I-Premise
by I-Premise
5 I-Premise
. I-Premise
40 I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
015 I-Premise
) I-Premise
, I-Premise
the I-Premise
FACT I-Premise
- I-Premise
An I-Premise
Toi I-Premise
score I-Premise
by I-Premise
5 I-Premise
. I-Premise
22 I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
009 I-Premise
) I-Premise
and I-Premise
the I-Premise
Anaemia I-Premise
- I-Premise
ANS I-Premise
by I-Premise
3 I-Premise
. I-Premise
76 I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
effect I-Premise
on I-Premise
the I-Premise
General I-Premise
Quality I-Premise
of I-Premise
Life I-Premise
score I-Premise
( I-Premise
FACT I-Premise
- I-Premise
G I-Premise
) I-Premise
or I-Premise
on I-Premise
any I-Premise
of I-Premise
the I-Premise
individual I-Premise
wellbeing I-Premise
scores I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
Physical I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
13 I-Premise
) I-Premise
, I-Premise
Emotional I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
87 I-Premise
) I-Premise
, I-Premise
Social I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
83 I-Premise
) I-Premise
and I-Premise
Functional I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
26 I-Premise
) I-Premise
. I-Premise

In B-Claim
summary I-Claim
, I-Claim
this I-Claim
six I-Claim
- I-Claim
week I-Claim
supervised I-Claim
multimodal I-Claim
exercise I-Claim
intervention I-Claim
can I-Claim
lead I-Claim
to I-Claim
significant I-Claim
reduction I-Claim
in I-Claim
self I-Claim
- I-Claim
reported I-Claim
CRF I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
undergoing I-Claim
chemotherapy I-Claim
. I-Claim

Chemotherapy O
with O
a O
platinum O
agent O
and O
a O
taxane O
( O
paclitaxel O
) O
is O
considered O
the O
standard O
of O
care O
for O
treatment O
of O
ovarian O
carcinoma O
. O

We O
compared O
the O
combination O
of O
docetaxel O
- O
carboplatin O
with O
the O
combination O
of O
paclitaxel O
- O
carboplatin O
as O
first O
- O
line O
chemotherapy O
for O
stage O
Ic O
- O
IV O
epithelial O
ovarian O
or O
primary O
peritoneal O
cancer O
. O

We O
randomly O
assigned O
1077 O
patients O
to O
receive O
docetaxel O
at O
75 O
mg O
/ O
m2 O
of O
body O
surface O
area O
( O
1 O
- O
hour O
intravenous O
infusion O
) O
or O
paclitaxel O
at O
175 O
mg O
/ O
m2 O
( O
3 O
- O
hour O
intravenous O
infusion O
) O
. O

Both O
treatments O
then O
were O
followed O
by O
carboplatin O
to O
an O
area O
under O
the O
plasma O
concentration O
- O
time O
curve O
of O
5 O
. O

The O
treatments O
were O
repeated O
every O
3 O
weeks O
for O
six O
cycles O
"""" O
; O
"""" O
in O
responding O
patients O
, O
an O
additional O
three O
cycles O
of O
single O
- O
agent O
carboplatin O
was O
permitted O
. O

Survival O
curves O
were O
calculated O
by O
the O
Kaplan O
- O
Meier O
method O
, O
and O
hazard O
ratios O
were O
estimated O
with O
the O
Cox O
proportional O
hazards O
model O
. O

All O
statistical O
tests O
were O
two O
- O
sided O
. O

After B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
23 I-Premise
months I-Premise
, I-Premise
both I-Premise
groups I-Premise
had I-Premise
similar I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
medians I-Premise
of I-Premise
15 I-Premise
. I-Premise
0 I-Premise
months I-Premise
for I-Premise
docetaxel I-Premise
- I-Premise
carboplatin I-Premise
and I-Premise
14 I-Premise
. I-Premise
8 I-Premise
months I-Premise
for I-Premise
paclitaxel I-Premise
- I-Premise
carboplatin I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
docetaxel I-Premise
- I-Premise
paclitaxel I-Premise
= I-Premise
0 I-Premise
. I-Premise
97 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0 I-Premise
. I-Premise
83 I-Premise
to I-Premise
1 I-Premise
. I-Premise
13 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
707 I-Premise
) I-Premise
, I-Premise
overall I-Premise
survival I-Premise
rates I-Premise
at I-Premise
2 I-Premise
years I-Premise
( I-Premise
64 I-Premise
. I-Premise
2 I-Premise
% I-Premise
and I-Premise
68 I-Premise
. I-Premise
9 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
HR I-Premise
= I-Premise
1 I-Premise
. I-Premise
13 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0 I-Premise
. I-Premise
92 I-Premise
to I-Premise
1 I-Premise
. I-Premise
39 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
238 I-Premise
) I-Premise
, I-Premise
and I-Premise
objective I-Premise
tumor I-Premise
( I-Premise
58 I-Premise
. I-Premise
7 I-Premise
% I-Premise
and I-Premise
59 I-Premise
. I-Premise
5 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
difference I-Premise
between I-Premise
docetaxel I-Premise
and I-Premise
paclitaxel I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
8 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
- I-Premise
8 I-Premise
. I-Premise
6 I-Premise
% I-Premise
to I-Premise
7 I-Premise
. I-Premise
1 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
868 I-Premise
) I-Premise
and I-Premise
CA I-Premise
- I-Premise
125 I-Premise
( I-Premise
75 I-Premise
. I-Premise
8 I-Premise
% I-Premise
and I-Premise
76 I-Premise
. I-Premise
8 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
difference I-Premise
docetaxel I-Premise
- I-Premise
paclitaxel I-Premise
= I-Premise
- I-Premise
1 I-Premise
. I-Premise
0 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
- I-Premise
7 I-Premise
. I-Premise
2 I-Premise
% I-Premise
to I-Premise
5 I-Premise
. I-Premise
1 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
794 I-Premise
) I-Premise
response I-Premise
rates I-Premise
. I-Premise

However B-Premise
, I-Premise
docetaxel I-Premise
- I-Premise
carboplatin I-Premise
was I-Premise
associated I-Premise
with I-Premise
substantially I-Premise
less I-Premise
overall I-Premise
and I-Premise
grade I-Premise
2 I-Premise
or I-Premise
higher I-Premise
neurotoxicity I-Premise
than I-Premise
paclitaxel I-Premise
- I-Premise
carboplatin I-Premise
( I-Premise
grade I-Premise
> I-Premise
or I-Premise
2 I-Premise
neurosensory I-Premise
toxicity I-Premise
in I-Premise
11 I-Premise
% I-Premise
versus I-Premise
30 I-Premise
% I-Premise
, I-Premise
difference I-Premise
= I-Premise
19 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
15 I-Premise
% I-Premise
to I-Premise
24 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
grade I-Premise
> I-Premise
or I-Premise
2 I-Premise
neuromotor I-Premise
toxicity I-Premise
in I-Premise
3 I-Premise
% I-Premise
versus I-Premise
7 I-Premise
% I-Premise
, I-Premise
difference I-Premise
= I-Premise
4 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1 I-Premise
% I-Premise
to I-Premise
7 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

Treatment B-Premise
with I-Premise
docetaxel I-Premise
- I-Premise
carboplatin I-Premise
was I-Premise
associated I-Premise
with I-Premise
statistically I-Premise
significantly I-Premise
more I-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
neutropenia I-Premise
( I-Premise
94 I-Premise
% I-Premise
versus I-Premise
84 I-Premise
% I-Premise
, I-Premise
difference I-Premise
= I-Premise
11 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
7 I-Premise
% I-Premise
to I-Premise
14 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
neutropenic I-Premise
complications I-Premise
than I-Premise
treatment I-Premise
with I-Premise
paclitaxel I-Premise
- I-Premise
carboplatin I-Premise
, I-Premise
although B-Premise
myelosuppression I-Premise
did I-Premise
not I-Premise
influence I-Premise
dose I-Premise
delivery I-Premise
or I-Premise
patient I-Premise
safety I-Premise
. I-Premise

Global B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
similar I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
but B-Premise
substantive I-Premise
differences I-Premise
in I-Premise
many I-Premise
symptom I-Premise
scores I-Premise
favored I-Premise
docetaxel I-Premise
. I-Premise

Docetaxel B-Claim
- B-Claim
carboplatin B-Claim
appears I-Claim
to I-Claim
be I-Claim
similar I-Claim
to I-Claim
paclitaxel I-Claim
- I-Claim
carboplatin I-Claim
in I-Claim
terms I-Claim
of I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
and I-Claim
response I-Claim
, I-Claim
although B-Claim
longer I-Claim
follow I-Claim
- I-Claim
up I-Claim
is I-Claim
required I-Claim
for I-Claim
a I-Claim
definitive I-Claim
statement I-Claim
on I-Claim
survival I-Claim
. I-Claim

Thus B-Claim
, I-Claim
docetaxel I-Claim
- I-Claim
carboplatin I-Claim
represents I-Claim
an I-Claim
alternative I-Claim
first I-Claim
- I-Claim
line I-Claim
chemotherapy I-Claim
regimen I-Claim
for I-Claim
patients I-Claim
with I-Claim
newly I-Claim
diagnosed I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

Exercise O
for O
Health O
was O
a O
randomized O
, O
controlled O
trial O
designed O
to O
evaluate O
two O
modes O
of O
delivering O
( O
face O
- O
to O
- O
face O
[ O
FtF O
] O
and O
over O
- O
the O
- O
telephone O
[ O
Tel O
] O
) O
an O
8 O
- O
month O
translational O
exercise O
intervention O
, O
commencing O
6 O
- O
weeks O
post O
- O
breast O
cancer O
surgery O
( O
PS O
) O
. O

Outcomes O
included O
quality O
of O
life O
( O
QoL O
) O
, O
function O
( O
fitness O
and O
upper O
body O
) O
and O
treatment O
- O
related O
side O
effects O
( O
fatigue O
, O
lymphoedema O
, O
body O
mass O
index O
, O
menopausal O
symptoms O
, O
anxiety O
, O
depression O
and O
pain O
) O
. O

Generalised O
estimating O
equation O
modelling O
determined O
time O
( O
baseline O
[ O
5 O
weeks O
PS O
] O
, O
mid O
- O
intervention O
[ O
6 O
months O
PS O
] O
, O
post O
- O
intervention O
[ O
12 O
months O
PS O
] O
) O
, O
group O
( O
FtF O
, O
Tel O
, O
Usual O
Care O
[ O
UC O
] O
) O
and O
time O
- O
by O
- O
group O
effects O
. O

194 O
women O
representative O
of O
the O
breast O
cancer O
population O
were O
randomised O
to O
the O
FtF O
( O
n O
= O
67 O
) O
, O
Tel O
( O
n O
= O
67 O
) O
and O
UC O
( O
n O
= O
60 O
) O
groups O
. O

There B-Premise
were I-Premise
significant I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
interaction I-Premise
effects I-Premise
on I-Premise
QoL I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
with I-Premise
differences I-Premise
being I-Premise
observed I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
and I-Premise
the I-Premise
UC I-Premise
group I-Premise
. I-Premise

Trends B-Premise
observed I-Premise
for I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
were I-Premise
similar I-Premise
. I-Premise

The B-Premise
treatment I-Premise
groups I-Premise
reported I-Premise
improved I-Premise
QoL I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
over I-Premise
time I-Premise
and I-Premise
changes I-Premise
observed I-Premise
between I-Premise
baseline I-Premise
and I-Premise
post I-Premise
- I-Premise
intervention I-Premise
were I-Premise
clinically I-Premise
relevant I-Premise
. I-Premise

In B-Premise
contrast I-Premise
, I-Premise
the I-Premise
UC I-Premise
group I-Premise
experienced I-Premise
no I-Premise
change I-Premise
, I-Premise
or I-Premise
worsening I-Premise
QoL I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
, I-Premise
mid I-Premise
- I-Premise
intervention I-Premise
. I-Premise

Although B-Premise
improvements I-Premise
in I-Premise
the I-Premise
UC I-Premise
group I-Premise
occurred I-Premise
by I-Premise
12 I-Premise
- I-Premise
months I-Premise
post I-Premise
- I-Premise
surgery I-Premise
, I-Premise
the B-Premise
change I-Premise
did I-Premise
not I-Premise
meet I-Premise
the I-Premise
clinically I-Premise
relevant I-Premise
threshold I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
other I-Premise
treatment I-Premise
- I-Premise
related I-Premise
side I-Premise
effects I-Premise
between I-Premise
groups I-Premise
. I-Premise

This B-Claim
translational I-Claim
intervention I-Claim
trial I-Claim
, I-Claim
delivered I-Claim
either I-Claim
FtF I-Claim
or I-Claim
Tel I-Claim
, I-Claim
supports I-Claim
exercise I-Claim
as I-Claim
a I-Claim
form I-Claim
of I-Claim
adjuvant I-Claim
breast I-Claim
cancer I-Claim
therapy I-Claim
that I-Claim
can I-Claim
prevent I-Claim
declines I-Claim
in I-Claim
fitness I-Claim
and I-Claim
function I-Claim
during I-Claim
treatment I-Claim
and I-Claim
optimise I-Claim
recovery I-Claim
post I-Claim
- I-Claim
treatment I-Claim
. I-Claim

Malignant B-Claim
pleural I-Claim
effusion I-Claim
( I-Claim
MPE I-Claim
) I-Claim
is I-Claim
a I-Claim
common I-Claim
complication I-Claim
of I-Claim
advanced I-Claim
non I-Claim
- I-Claim
small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

Bevacizumab B-Claim
, I-Claim
a I-Claim
humanized I-Claim
monoclonal I-Claim
antibody I-Claim
against I-Claim
vascular I-Claim
endothelial I-Claim
growth I-Claim
factor I-Claim
( I-Claim
VEGF I-Claim
) I-Claim
, I-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
be I-Claim
efficient I-Claim
in I-Claim
suppressing I-Claim
the I-Claim
accumulation I-Claim
of I-Claim
pleural I-Claim
fluid I-Claim
. I-Claim

However O
, O
whether O
intrapleural O
delivery O
of O
bevacizumab O
can O
be O
used O
to O
treat O
MPE O
remains O
unknown O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
combined O
intrapleural O
therapy O
with O
bevacizumab O
and O
cisplatin O
, O
an O
antineoplastic O
agent O
, O
in O
controlling O
MPE O
. O

A O
total O
of O
72 O
NSCLC O
study O
subjects O
with O
MPE O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
. O

The O
first O
group O
received O
intrapleural O
bevacizumab O
( O
300 O
mg O
) O
with O
cisplatin O
( O
30 O
mg O
) O
therapy O
and O
the O
second O
group O
received O
intrapleural O
cisplatin O
( O
30 O
mg O
) O
therapy O
alone O
. O

Pleural O
fluid O
was O
collected O
from O
both O
groups O
prior O
to O
and O
following O
treatment O
. O

The O
levels O
of O
VEGF O
and O
carcinoembryonic O
antigen O
( O
CEA O
) O
in O
the O
pleural O
fluid O
were O
determined O
by O
ELISA O
. O

In B-Premise
70 I-Premise
evaluable I-Premise
study I-Premise
subjects I-Premise
, I-Premise
the I-Premise
curative I-Premise
efficacy I-Premise
in I-Premise
the I-Premise
bevacizumab I-Premise
group I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
found I-Premise
in I-Premise
the I-Premise
cisplatin I-Premise
group I-Premise
( I-Premise
83 I-Premise
. I-Premise
33 I-Premise
vs I-Premise
. I-Premise
50 I-Premise
. I-Premise
00 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

Therapy B-Premise
with I-Premise
combined I-Premise
bevacizumab I-Premise
plus I-Premise
cisplatin I-Premise
significantly I-Premise
reduced I-Premise
VEGF I-Premise
levels I-Premise
in I-Premise
the I-Premise
pleural I-Premise
fluid I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
bevacizumab I-Premise
group I-Premise
, I-Premise
the I-Premise
levels I-Premise
of I-Premise
VEGF I-Premise
in I-Premise
the I-Premise
pleural I-Premise
fluid I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
compared I-Premise
to I-Premise
those I-Premise
of I-Premise
the I-Premise
cisplatin I-Premise
group I-Premise
after I-Premise
treatment I-Premise
, I-Premise
which I-Premise
showed I-Premise
greater I-Premise
efficacy I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise

In B-Premise
addition I-Premise
, I-Premise
combination I-Premise
therapy I-Premise
showed I-Premise
greater I-Premise
efficacy I-Premise
in I-Premise
the I-Premise
patients I-Premise
with I-Premise
high I-Premise
levels I-Premise
of I-Premise
VEGF I-Premise
expression I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
grade I-Premise
III I-Premise
/ I-Premise
IV I-Premise
adverse I-Premise
events I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

All B-Premise
procedures I-Premise
were I-Premise
well I-Premise
tolerated I-Premise
by I-Premise
the I-Premise
patients I-Premise
. I-Premise

Combined B-Claim
intrapleural I-Claim
therapy I-Claim
with I-Claim
bevacizumab I-Claim
and I-Claim
cisplatin I-Claim
was I-Claim
effective I-Claim
and I-Claim
safe I-Claim
in I-Claim
managing I-Claim
NSCLC I-Claim
- I-Claim
mediated I-Claim
MPE I-Claim
. I-Claim

We B-Claim
propose I-Claim
that I-Claim
VEGF I-Claim
expression I-Claim
levels I-Claim
in I-Claim
MPE I-Claim
could I-Claim
serve I-Claim
as I-Claim
a I-Claim
prognostic I-Claim
marker I-Claim
for I-Claim
bevacizumab I-Claim
therapy I-Claim
. I-Claim

In B-Claim
endocrine I-Claim
therapy I-Claim
trials I-Claim
in I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
patients I-Claim
with I-Claim
response I-Claim
( I-Claim
complete I-Claim
response I-Claim
/ I-Claim
partial I-Claim
response I-Claim
[ I-Claim
CR I-Claim
/ I-Claim
PR I-Claim
] I-Claim
) I-Claim
and I-Claim
patients I-Claim
with I-Claim
stable I-Claim
disease I-Claim
for I-Claim
at I-Claim
least I-Claim
6 I-Claim
months I-Claim
( I-Claim
SD I-Claim
( I-Claim
6m I-Claim
) I-Claim
) I-Claim
have I-Claim
shown I-Claim
similar I-Claim
survival I-Claim
and I-Claim
therefore I-Claim
are I-Claim
often I-Claim
defined I-Claim
as I-Claim
a I-Claim
population I-Claim
with I-Claim
clinical I-Claim
benefit I-Claim
( I-Claim
patients I-Claim
with I-Claim
CR I-Claim
/ I-Claim
PR I-Claim
or I-Claim
SD I-Claim
( I-Claim
6m I-Claim
) I-Claim
) I-Claim
. I-Claim

We O
evaluated O
the O
impact O
of O
response O
and O
/ O
or O
clinical O
benefit O
on O
quality O
of O
life O
( O
QL O
) O
in O
postmenopausal O
patients O
under O
second O
- O
line O
endocrine O
treatment O
after O
failure O
of O
tamoxifen O
. O

One O
hundred O
twenty O
- O
eight O
of O
177 O
eligible O
patients O
of O
a O
randomized O
trial O
( O
Swiss O
Group O
for O
Clinical O
Cancer O
Research O
20 O
/ O
90 O
) O
receiving O
either O
formestane O
( O
250 O
mg O
intramuscularly O
biweekly O
) O
or O
megestrol O
acetate O
( O
160 O
mg O
orally O
daily O
) O
were O
analyzed O
. O

The O
baseline O
characteristics O
( O
with O
the O
exception O
of O
site O
of O
metastases O
) O
were O
balanced O
among O
patients O
with O
CR O
/ O
PR O
, O
SD O
( O
6m O
) O
, O
and O
progressive O
disease O
( O
PD O
) O
. O

Patients O
completed O
QL O
indicators O
at O
baseline O
and O
at O
1 O
, O
3 O
, O
5 O
, O
7 O
, O
9 O
, O
and O
11 O
months O
. O

Responders O
were O
separately O
compared O
with O
nonresponders O
( O
patients O
with O
SD O
( O
6m O
) O
or O
PD O
) O
and O
with O
patients O
with O
SD O
( O
6m O
) O
, O
and O
patients O
with O
clinical O
benefit O
were O
compared O
with O
patients O
with O
PD O
by O
analysis O
of O
covariance O
with O
adjustment O
for O
baseline O
scores O
. O

Overall O
, O
88 O
% O
( O
557 O
of O
634 O
) O
of O
expected O
QL O
forms O
were O
received O
. O

In O
the O
comparison O
of O
responders O
versus O
patients O
with O
both O
SD O
( O
6m O
) O
and O
PD O
, O
responders B-Premise
indicated I-Premise
better I-Premise
physical I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
4 I-Premise
) I-Premise
and I-Premise
mood I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
at I-Premise
month I-Premise
3 I-Premise
. I-Premise

Compared B-Premise
only I-Premise
with I-Premise
patients I-Premise
with I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
, I-Premise
responders I-Premise
showed I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
baseline I-Premise
QL I-Premise
and I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
( I-Premise
328 I-Premise
. I-Premise
5 I-Premise
v I-Premise
340 I-Premise
days I-Premise
) I-Premise
. I-Premise

While B-Premise
under I-Premise
treatment I-Premise
, I-Premise
responders I-Premise
reported I-Premise
significantly I-Premise
better I-Premise
physical I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
months I-Premise
3 I-Premise
to I-Premise
11 I-Premise
) I-Premise
, I-Premise
mood I-Premise
( I-Premise
months I-Premise
5 I-Premise
to I-Premise
11 I-Premise
) I-Premise
, I-Premise
coping I-Premise
( I-Premise
months I-Premise
5 I-Premise
to I-Premise
9 I-Premise
) I-Premise
, I-Premise
and I-Premise
appetite I-Premise
( I-Premise
months I-Premise
7 I-Premise
to I-Premise
11 I-Premise
) I-Premise
and I-Premise
less I-Premise
dizziness I-Premise
( I-Premise
month I-Premise
9 I-Premise
) I-Premise
than I-Premise
patients I-Premise
with I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
. I-Premise

The B-Premise
changes I-Premise
between I-Premise
baseline I-Premise
and I-Premise
months I-Premise
5 I-Premise
and I-Premise
7 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
indicated I-Premise
improvement I-Premise
in I-Premise
responders I-Premise
but I-Premise
heterogeneous I-Premise
patterns I-Premise
in I-Premise
patients I-Premise
with I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
. I-Premise

Although B-Premise
the I-Premise
CR I-Premise
/ I-Premise
PR I-Premise
and I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
groups I-Premise
had I-Premise
similar I-Premise
times I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
, I-Premise
patients B-Claim
with I-Claim
CR I-Claim
/ I-Claim
PR I-Claim
reported I-Claim
better I-Claim
QL I-Claim
, I-Claim
suggesting I-Claim
more I-Claim
beneficial I-Claim
response I-Claim
to I-Claim
second I-Claim
- I-Claim
line I-Claim
endocrine I-Claim
treatment I-Claim
. I-Claim

Patients O
' O
subjective O
perspective O
should O
be O
taken O
into O
account O
in O
this O
mainly O
palliative O
setting O
. O

Future O
trials O
should O
be O
designed O
so O
that O
the O
CR O
/ O
PR O
and O
SD O
( O
6m O
) O
groups O
are O
investigated O
separately O
. O

To O
describe O
the O
Food O
and O
Drug O
Administration O
( O
FDA O
) O
review O
and O
approval O
of O
erlotinib O
( O
Tarceva O
, O
OSI O
Pharmaceuticals O
, O
Melville O
, O
NY O
) O
for O
treatment O
of O
patients O
with O
locally O
advanced O
or O
metastatic O
non O
- O
small O
cell O
lung O
cancer O
( O
NSCLC O
) O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O

The O
FDA O
reviewed O
raw O
data O
in O
electronic O
format O
from O
a O
randomized O
controlled O
clinical O
trial O
comparing O
erlotinib O
with O
placebo O
in O
patients O
with O
locally O
advanced O
or O
metastatic O
NSCLC O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O

Patients O
were O
randomized O
in O
a O
2 O
: O
1 O
ratio O
( O
erlotinib O
, O
n O
= O
488 O
and O
placebo O
, O
n O
= O
243 O
) O
. O

Erlotinib B-Claim
was I-Claim
superior I-Claim
to I-Claim
placebo I-Claim
for I-Claim
survival I-Claim
, I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
, I-Claim
and I-Claim
tumor I-Claim
response I-Claim
rate I-Claim
. I-Claim

Exploratory B-Claim
analyses I-Claim
indicate I-Claim
that I-Claim
epidermal I-Claim
growth I-Claim
factor I-Claim
receptor I-Claim
status I-Claim
may I-Claim
be I-Claim
an I-Claim
important I-Claim
predictor I-Claim
of I-Claim
the I-Claim
erlotinib I-Claim
survival I-Claim
effect I-Claim
. I-Claim

Rash B-Premise
( I-Premise
75 I-Premise
% I-Premise
versus I-Premise
17 I-Premise
% I-Premise
) I-Premise
and I-Premise
diarrhea I-Premise
( I-Premise
54 I-Premise
% I-Premise
versus I-Premise
18 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
erlotnib I-Premise
and I-Premise
placebo I-Premise
group I-Premise
respectively I-Premise
were I-Premise
the I-Premise
most I-Premise
common I-Premise
adverse I-Premise
events I-Premise
. I-Premise

Severe B-Premise
rash I-Premise
occurred I-Premise
in I-Premise
9 I-Premise
% I-Premise
and I-Premise
severe I-Premise
diarrhea I-Premise
in I-Premise
6 I-Premise
% I-Premise
of I-Premise
erlotinib I-Premise
- I-Premise
treated I-Premise
patients I-Premise
and I-Premise
each I-Premise
resulted I-Premise
in I-Premise
study I-Premise
discontinuation I-Premise
in I-Premise
1 I-Premise
% I-Premise
of I-Premise
patients I-Premise
. I-Premise

Dose B-Premise
reductions I-Premise
were I-Premise
required I-Premise
for I-Premise
10 I-Premise
% I-Premise
of I-Premise
patients I-Premise
with I-Premise
rash I-Premise
and I-Premise
4 I-Premise
% I-Premise
of I-Premise
patients I-Premise
with I-Premise
diarrhea I-Premise
. I-Premise

On O
November O
18 O
, O
2004 O
, O
the O
FDA O
granted O
erlotinib O
regular O
approval O
for O
treatment O
of O
patients O
with O
locally O
advanced O
or O
metastatic O
NSCLC O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O

The O
applicant O
has O
committed O
to O
conduct O
post O
- O
marketing O
clinical O
trials O
to O
assess O
further O
the O
effect O
of O
epidermal O
growth O
factor O
receptor O
expression O
, O
measured O
with O
immunohistochemical O
staining O
, O
on O
erlotinib O
treatment O
effect O
. O

Gastrojejunostomy O
( O
GJJ O
) O
and O
stent O
placement O
are O
the O
most O
commonly O
used O
palliative O
treatments O
for O
malignant O
gastric O
outlet O
obstruction O
( O
GOO O
) O
. O

In O
a O
recent O
randomized O
trial O
, O
stent O
placement O
was O
preferred O
in O
patients O
with O
a O
relatively O
short O
survival O
and O
GJJ O
in O
patients O
with O
a O
longer O
survival O
. O

As O
health O
economic O
aspects O
have O
only O
been O
studied O
in O
general O
terms O
, O
we O
estimated O
the O
cost O
of O
GJJ O
and O
that O
of O
stent O
placement O
in O
such O
patients O
. O

In O
the O
SUSTENT O
study O
, O
patients O
were O
randomized O
to O
GJJ O
( O
n O
= O
18 O
) O
or O
stent O
placement O
( O
n O
= O
21 O
) O
. O

Pancreatic O
cancer O
was O
the O
most O
common O
cause O
of O
GOO O
. O

We O
compared O
initial O
costs O
and O
costs O
during O
follow O
- O
up O
. O

For O
cost O
- O
effectiveness O
, O
the O
incremental O
cost O
- O
effectiveness O
ratio O
was O
calculated O
. O

Food B-Premise
intake I-Premise
improved I-Premise
more I-Premise
rapidly I-Premise
after I-Premise
stent I-Premise
placement I-Premise
than I-Premise
after I-Premise
GJJ I-Premise
, I-Premise
but B-Premise
long I-Premise
- I-Premise
term I-Premise
relief I-Premise
of I-Premise
obstructive I-Premise
symptoms I-Premise
was I-Premise
better I-Premise
after I-Premise
GJJ I-Premise
. I-Premise

More B-Premise
major I-Premise
complications I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
occurred I-Premise
and I-Premise
more I-Premise
reinterventions I-Premise
were I-Premise
performed I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
after I-Premise
stent I-Premise
placement I-Premise
than I-Premise
after I-Premise
GJJ I-Premise
. I-Premise

Initial B-Premise
costs I-Premise
were I-Premise
higher I-Premise
for I-Premise
GJJ I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
( I-Premise
euro8315 I-Premise
vs I-Premise
. I-Premise
euro4820 I-Premise
, I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

We B-Premise
found I-Premise
no I-Premise
difference I-Premise
in I-Premise
follow I-Premise
- I-Premise
up I-Premise
costs I-Premise
. I-Premise

Total B-Premise
costs I-Premise
per I-Premise
patient I-Premise
were I-Premise
higher I-Premise
for I-Premise
GJJ I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
( I-Premise
euro12433 I-Premise
vs I-Premise
. I-Premise
euro8819 I-Premise
, I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
049 I-Premise
) I-Premise
. I-Premise

The B-Premise
incremental I-Premise
cost I-Premise
- I-Premise
effectiveness I-Premise
ratio I-Premise
of I-Premise
GJJ I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
was I-Premise
euro164 I-Premise
per I-Premise
extra I-Premise
day I-Premise
with I-Premise
a I-Premise
gastric I-Premise
outlet I-Premise
obstruction I-Premise
scoring I-Premise
system I-Premise
( I-Premise
GOOSS I-Premise
) I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
adjusted I-Premise
for I-Premise
survival I-Premise
. I-Premise

Medical B-Claim
effects I-Claim
were I-Claim
better I-Claim
after I-Claim
GJJ I-Claim
, O
although B-Claim
GJJ I-Claim
had I-Claim
higher I-Claim
total I-Claim
costs I-Claim
. I-Claim

Since B-Claim
the I-Claim
cost I-Claim
difference I-Claim
between I-Claim
the I-Claim
two I-Claim
treatments I-Claim
was I-Claim
only I-Claim
small I-Claim
, I-Claim
cost B-Claim
should I-Claim
not I-Claim
play I-Claim
a I-Claim
predominant I-Claim
role I-Claim
when I-Claim
deciding I-Claim
on I-Claim
the I-Claim
type I-Claim
of I-Claim
treatment I-Claim
assigned I-Claim
to I-Claim
patients I-Claim
with I-Claim
malignant I-Claim
GOO I-Claim
. I-Claim

We O
conducted O
a O
prospective O
, O
randomized O
, O
multicentre O
clinical O
trial O
comparing O
the O
effects O
and O
costs O
of O
GM O
- O
CSF O
as O
an O
adjunct O
to O
intensive O
chemotherapy O
in O
elderly O
patients O
with O
acute O
myeloid O
leukaemia O
( O
AML O
) O
. O

The O
patients O
were O
randomized O
to O
either O
daunomycin O
- O
cytosine O
arabinoside O
( O
control O
arm O
: O
n O
= O
161 O
) O
or O
daunomycin O
- O
cytosine O
arabinoside O
with O
GM O
- O
CSF O
( O
GM O
- O
CSF O
arm O
: O
n O
= O
157 O
) O
. O

The O
primary O
end O
- O
point O
was O
the O
effect O
of O
GM O
- O
CSF O
on O
the O
percentage O
of O
complete O
remissions O
( O
CR O
) O
. O

Survival O
duration O
, O
disease O
- O
free O
survival O
, O
quality O
of O
life O
and O
costs O
were O
evaluated O
separately O
. O

CR B-Premise
after I-Premise
remission I-Premise
induction I-Premise
treatment I-Premise
was I-Premise
achieved I-Premise
in I-Premise
55 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
in I-Premise
56 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
GM I-Premise
- I-Premise
CSF I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
NS I-Premise
) I-Premise
. I-Premise

The B-Premise
duration I-Premise
of I-Premise
survival I-Premise
and I-Premise
disease I-Premise
- I-Premise
free I-Premise
survival I-Premise
at I-Premise
2 I-Premise
years I-Premise
after I-Premise
randomization I-Premise
were I-Premise
estimated I-Premise
at I-Premise
22 I-Premise
% I-Premise
and I-Premise
19 I-Premise
% I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
22 I-Premise
% I-Premise
and I-Premise
14 I-Premise
% I-Premise
for I-Premise
the I-Premise
GM I-Premise
- I-Premise
CSF I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
NS I-Premise
) I-Premise
. I-Premise

Considering B-Premise
the I-Premise
short I-Premise
- I-Premise
term I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
the I-Premise
administration I-Premise
of I-Premise
GM I-Premise
- I-Premise
CSF I-Premise
resulted I-Premise
in I-Premise
more I-Premise
problems I-Premise
with I-Premise
regard I-Premise
to I-Premise
depressed I-Premise
mood I-Premise
, I-Premise
diarrhoea I-Premise
and I-Premise
rash I-Premise
/ I-Premise
eczema I-Premise
. I-Premise

With B-Premise
regard I-Premise
to I-Premise
the I-Premise
long I-Premise
- I-Premise
term I-Premise
quality I-Premise
of I-Premise
life I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

The B-Premise
average I-Premise
costs I-Premise
of I-Premise
the I-Premise
primary I-Premise
treatment I-Premise
were I-Premise
higher I-Premise
in I-Premise
GM I-Premise
- I-Premise
CSF I-Premise
- I-Premise
treated I-Premise
patients I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
i I-Premise
. I-Premise
e I-Premise
. I-Premise
US I-Premise
$ I-Premise
40782 I-Premise
and I-Premise
US I-Premise
$ I-Premise
34465 I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise

The B-Premise
costs I-Premise
during I-Premise
the I-Premise
follow I-Premise
- I-Premise
up I-Premise
period I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

The B-Claim
results I-Claim
of I-Claim
this I-Claim
randomized I-Claim
clinical I-Claim
trial I-Claim
indicate I-Claim
that I-Claim
daunomycin I-Claim
- I-Claim
cytosine I-Claim
arabinoside I-Claim
plus I-Claim
GM I-Claim
- I-Claim
CSF I-Claim
is I-Claim
not I-Claim
a I-Claim
cost I-Claim
- I-Claim
effective I-Claim
treatment I-Claim
strategy I-Claim
when I-Claim
compared I-Claim
with I-Claim
daunomycin I-Claim
- I-Claim
cytosine I-Claim
arabinoside I-Claim
alone I-Claim
. I-Claim

Androgen O
treatment O
for O
prostate O
cancer O
can O
adversely O
affect O
functional O
domains O
of O
quality O
of O
life O
. O

We O
aimed O
to O
assess O
quality O
of O
life O
in O
men O
with O
locally O
advanced O
prostate O
cancer O
in O
an O
open O
- O
label O
phase O
III O
randomised O
comparison O
between O
lifelong O
endocrine O
treatment O
with O
and O
without O
radiotherapy O
. O

We O
obtained O
quality O
- O
of O
- O
life O
information O
from O
872 O
( O
99 O
% O
) O
of O
875 O
eligible O
men O
with O
locally O
advanced O
prostate O
cancer O
( O
T3 O
"""" O
; O
"""" O
78 O
% O
) O
who O
were O
randomly O
assigned O
, O
between O
1996 O
and O
2002 O
, O
to O
3 O
months O
of O
total O
androgen O
blockade O
followed O
by O
continuous O
endocrine O
treatment O
( O
439 O
patients O
) O
or O
the O
same O
hormonal O
treatment O
with O
radiotherapy O
3 O
months O
after O
randomisation O
( O
436 O
patients O
) O
. O

Prospective O
outcomes O
included O
patient O
- O
reported O
symptoms O
and O
quality O
of O
life O
assessed O
with O
questionnaires O
from O
baseline O
to O
4 O
years O
after O
randomisation O
. O

Analysis O
was O
by O
intention O
to O
treat O
. O

This O
study O
is O
registered O
as O
an O
international O
standard O
randomised O
controlled O
trial O
, O
number O
ISRCTN01534787 O
. O

438 O
of O
439 O
men O
assigned O
endocrine O
treatment O
and O
434 O
of O
436 O
assigned O
endocrine O
plus O
radiotherapy O
completed O
at O
least O
one O
questionnaire O
. O

Missing O
data O
at O
baseline O
and O
during O
follow O
- O
up O
was O
equally O
distributed O
between O
groups O
. O

At B-Premise
4 I-Premise
years I-Premise
, I-Premise
64 I-Premise
( I-Premise
18 I-Premise
% I-Premise
) I-Premise
of I-Premise
353 I-Premise
patients I-Premise
on I-Premise
combined I-Premise
therapy I-Premise
and I-Premise
39 I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
of I-Premise
337 I-Premise
on I-Premise
endocrine I-Premise
- I-Premise
alone I-Premise
therapy I-Premise
had I-Premise
moderate I-Premise
to I-Premise
severe I-Premise
urinary I-Premise
bother I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
005 I-Premise
) I-Premise
, I-Premise
and I-Premise
16 I-Premise
( I-Premise
4 I-Premise
% I-Premise
) I-Premise
of I-Premise
355 I-Premise
on I-Premise
combined I-Premise
therapy I-Premise
and I-Premise
five I-Premise
( I-Premise
2 I-Premise
% I-Premise
) I-Premise
of I-Premise
338 I-Premise
on I-Premise
endocrine I-Premise
treatment I-Premise
alone I-Premise
had I-Premise
pain I-Premise
while I-Premise
urinating I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
024 I-Premise
) I-Premise
. I-Premise

37 B-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
of I-Premise
350 I-Premise
in I-Premise
the I-Premise
combined I-Premise
group I-Premise
and I-Premise
23 I-Premise
( I-Premise
7 I-Premise
% I-Premise
) I-Premise
of I-Premise
35 I-Premise
in I-Premise
the I-Premise
endocrine I-Premise
- I-Premise
only I-Premise
group I-Premise
had I-Premise
overall I-Premise
bother I-Premise
from I-Premise
all I-Premise
bowel I-Premise
symptoms I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
022 I-Premise
) I-Premise
. I-Premise

281 B-Premise
( I-Premise
85 I-Premise
% I-Premise
) I-Premise
of I-Premise
332 I-Premise
in I-Premise
the I-Premise
combined I-Premise
- I-Premise
treatment I-Premise
group I-Premise
and I-Premise
227 I-Premise
( I-Premise
72 I-Premise
% I-Premise
) I-Premise
of I-Premise
313 I-Premise
in I-Premise
the I-Premise
endocrine I-Premise
- I-Premise
only I-Premise
group I-Premise
had I-Premise
erectile I-Premise
dysfunction I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0002 I-Premise
) I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
at I-Premise
4 I-Premise
years I-Premise
was I-Premise
similar I-Premise
, I-Premise
with I-Premise
the I-Premise
exception I-Premise
of I-Premise
decreased I-Premise
social I-Premise
function I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
endocrine I-Premise
treatment I-Premise
plus I-Premise
radiotherapy I-Premise
. I-Premise

Although B-Claim
addition I-Claim
of I-Claim
radiotherapy I-Claim
to I-Claim
endocrine I-Claim
treatment I-Claim
significantly I-Claim
increased I-Claim
some I-Claim
treatment I-Claim
- I-Claim
related I-Claim
symptoms I-Claim
, I-Claim
none I-Claim
were I-Claim
serious I-Claim
. I-Claim

Given O
the O
substantial O
survival O
benefit O
of O
combined O
treatment O
, O
the B-Claim
increase I-Claim
of I-Claim
symptoms I-Claim
seems I-Claim
acceptable I-Claim
and I-Claim
has I-Claim
little I-Claim
extra I-Claim
effect I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
after I-Claim
4 I-Claim
years I-Claim
compared I-Claim
with I-Claim
endocrine I-Claim
treatment I-Claim
alone I-Claim
. I-Claim

The O
aim O
of O
this O
randomised O
trial O
was O
to O
evaluate O
the O
activity O
and O
toxicity O
of O
a O
biweekly O
regimen O
including O
6S O
- O
leucovorin O
- O
modulated O
5 O
- O
fluorouracil O
( O
LFA O
- O
5 O
- O
FU O
) O
, O
combined O
with O
either O
irinotecan O
( O
CPT O
- O
11 O
+ O
LFA O
5 O
- O
FU O
) O
or O
raltitrexed O
( O
Tomudex O
) O
( O
TOM O
+ O
LFA O
- O
5 O
- O
FU O
) O
, O
in O
advanced O
colorectal O
cancer O
patients O
, O
and O
to O
make O
a O
preliminary O
comparison O
of O
both O
these O
experimental O
regimens O
with O
a O
biweekly O
administration O
of O
LFA O
- O
5 O
- O
FU O
modulated O
by O
methotrexate O
( O
MTX O
+ O
LFA O
- O
5 O
- O
FU O
) O
. O

One O
hundred O
fifty O
- O
nine O
patients O
with O
advanced O
colorectal O
carcinoma O
previously O
untreated O
for O
the O
metastatic O
disease O
( O
34 O
of O
them O
previously O
exposed O
to O
adjuvant O
5 O
- O
FU O
) O
were O
randomly O
allocated O
to O
receive O
: O
CPT O
- O
11 O
, O
200 O
mg O
/ O
m2 O
i O
. O
v O
. O

on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
LFA O
, O
250 O
mg O
/ O
m2 O
i O
. O
v O
. O

infusion O
and O
5 O
- O
FU O
, O
850 O
mg O
/ O
m2 O
s O
i O
. O
v O
. O

bolus O
( O
arm O
A O
) O
"""" O
; O
"""" O
TOM O
, O
3 O
mg O
/ O
m2 O
i O
. O
v O
. O

on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
LFA O
, O
250 O
mg O
/ O
m2 O
i O
. O
v O
. O

infusion O
and O
5 O
- O
FU O
, O
1050 O
mg O
/ O
m2 O
i O
. O
v O
. O

bolus O
( O
arm O
B O
) O
"""" O
; O
"""" O
or O
MTX O
, O
750 O
mg O
/ O
m2 O
i O
. O
v O
. O

on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
LFA O
, O
250 O
mg O
/ O
m2 O
i O
. O
v O
. O

infusion O
and O
5 O
- O
FU O
, O
800 O
mg O
/ O
m2 O
i O
. O
v O
. O

bolus O
( O
arm O
C O
) O
. O

Courses O
were O
repeated O
every O
two O
weeks O
in O
all O
arms O
of O
the O
trial O
. O

Response O
rate O
( O
RR O
) O
was O
evaluated O
after O
every O
four O
courses O
. O

The O
sample O
size O
was O
defined O
to O
have O
an O
80 O
% O
power O
to O
detect O
a O
35 O
% O
RR O
for O
each O
experimental O
treatment O
, O
and O
to O
show O
a O
difference O
of O
at O
least O
4 O
% O
in O
RR O
with O
the O
standard O
treatment O
if O
the O
TRUE O
difference O
is O
15 O
% O
or O
more O
. O

The O
RRs O
were O
: O
34 O
% O
( O
95 O
% O
confidence O
interval O
( O
95 O
% O
, O
CI O
) O
: O
21 O
% O
- O
48 O
% O
) O
in O
arm O
A O
, O
including O
3 O
complete O
responses O
( O
CRs O
) O
and O
15 O
partial O
responses O
( O
PRs O
) O
, O
24 O
% O
( O
95 O
% O
CI O
: O
14 O
% O
- O
38 O
% O
) O
in O
arm O
B O
, O
including O
2 O
CRs O
and O
11 O
PRs O
, O
and O
24 O
% O
( O
95 O
% O
CI O
: O
14 O
% O
- O
38 O
% O
) O
, O
with O
2 O
CRs O
and O
11 O
PRs O
, O
in O
arm O
C O
. O
After B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
time I-Premise
of I-Premise
62 I-Premise
( I-Premise
range I-Premise
18 I-Premise
- I-Premise
108 I-Premise
) I-Premise
weeks I-Premise
, I-Premise
the I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
38 I-Premise
, I-Premise
25 I-Premise
, I-Premise
and I-Premise
27 I-Premise
weeks I-Premise
for I-Premise
arm I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
and I-Premise
C I-Premise
, I-Premise
respectively I-Premise
. I-Premise

With B-Premise
94 I-Premise
patients I-Premise
still I-Premise
alive I-Premise
, I-Premise
the I-Premise
one I-Premise
- I-Premise
year I-Premise
probability I-Premise
of I-Premise
survival I-Premise
was I-Premise
61 I-Premise
% I-Premise
, I-Premise
54 I-Premise
% I-Premise
, I-Premise
and I-Premise
59 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

WHO B-Premise
grade I-Premise
3 I-Premise
or I-Premise
4 I-Premise
neutropenia I-Premise
and I-Premise
diarrhoea I-Premise
affected I-Premise
46 I-Premise
% I-Premise
and I-Premise
16 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
CPT I-Premise
- I-Premise
11 I-Premise
+ I-Premise
LFA I-Premise
5 I-Premise
- I-Premise
FU I-Premise
. I-Premise

Median B-Premise
relative I-Premise
dose I-Premise
intensity I-Premise
over I-Premise
eight I-Premise
cycles I-Premise
( I-Premise
DI8 I-Premise
) I-Premise
was I-Premise
78 I-Premise
% I-Premise
for I-Premise
CPT I-Premise
- I-Premise
11 I-Premise
and I-Premise
82 I-Premise
% I-Premise
for I-Premise
5 I-Premise
- I-Premise
FU I-Premise
. I-Premise

Severe B-Premise
toxicities I-Premise
of I-Premise
TOM I-Premise
+ I-Premise
LFA I-Premise
- I-Premise
5 I-Premise
- I-Premise
FU I-Premise
were I-Premise
neutropenia I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
and I-Premise
diarrhoea I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
, I-Premise
but I-Premise
median I-Premise
relative I-Premise
DI8 I-Premise
was I-Premise
93 I-Premise
% I-Premise
for I-Premise
TOM I-Premise
, I-Premise
and I-Premise
82 I-Premise
% I-Premise
for I-Premise
5 I-Premise
- I-Premise
FU I-Premise
. I-Premise

CPT B-Premise
- B-Premise
11 B-Premise
+ I-Premise
LFA I-Premise
- I-Premise
5 I-Premise
- I-Premise
FU I-Premise
compares I-Premise
favorably I-Premise
in I-Premise
term I-Premise
of I-Premise
activity I-Premise
and I-Premise
toxicity I-Premise
with I-Premise
other I-Premise
combination I-Premise
regimens I-Premise
including I-Premise
CPT I-Premise
- I-Premise
11 I-Premise
and I-Premise
continuous I-Premise
infusional I-Premise
5 I-Premise
- I-Premise
FU I-Premise
. I-Premise

The B-Claim
hypothesis I-Claim
of I-Claim
a I-Claim
RR I-Claim
15 I-Claim
% I-Claim
higher I-Claim
than I-Claim
the I-Claim
MTX I-Claim
+ I-Claim
LFA I-Claim
- I-Claim
5 I-Claim
- I-Claim
FU I-Claim
treatment I-Claim
can I-Claim
not I-Claim
be I-Claim
ruled I-Claim
out I-Claim
after I-Claim
this I-Claim
interim I-Claim
analysis I-Claim
. I-Claim

The B-Claim
TOM I-Claim
+ I-Claim
LFA I-Claim
5 I-Claim
- I-Claim
FU I-Claim
regimen I-Claim
showed I-Claim
a I-Claim
RR I-Claim
and I-Claim
a I-Claim
toxicity I-Claim
profile I-Claim
very I-Claim
close I-Claim
to I-Claim
the I-Claim
MTX I-Claim
+ I-Claim
LFA I-Claim
5 I-Claim
- I-Claim
FU I-Claim
combination I-Claim
, I-Claim
and I-Claim
does I-Claim
not I-Claim
deserve I-Claim
further I-Claim
evaluation I-Claim
in I-Claim
advanced I-Claim
colorectal I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Adjuvant O
chemotherapy O
for O
early O
stage O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
NSCLC O
) O
is O
now O
the O
standard O
of O
care O
, O
but O
there O
is O
little O
information O
regarding O
its O
impact O
on O
quality O
of O
life O
( O
QOL O
) O
. O

We O
report O
the O
QOL O
results O
of O
JBR O
. O
10 O
, O
a O
North O
American O
, O
intergroup O
, O
randomized O
trial O
of O
adjuvant O
cisplatin O
and O
vinorelbine O
compared O
with O
observation O
in O
patients O
who O
have O
completely O
resected O
, O
stages O
IB O
to O
II O
NSCLC O
. O

QOL O
was O
assessed O
with O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
and O
a O
trial O
- O
specific O
checklist O
at O
baseline O
and O
at O
weeks O
5 O
and O
9 O
for O
those O
who O
received O
chemotherapy O
and O
at O
follow O
- O
up O
months O
3 O
, O
6 O
, O
9 O
, O
12 O
, O
18 O
, O
24 O
, O
30 O
and O
36 O
. O

A O
10 O
- O
point O
change O
in O
QOL O
scores O
from O
baseline O
was O
considered O
clinically O
significant O
. O

Four O
hundred O
eighty O
- O
two O
patients O
were O
randomly O
assigned O
on O
JBR O
. O
10 O
. O

A O
total O
of O
173 O
patients O
( O
82 O
% O
of O
the O
expected O
) O
in O
the O
observation O
arm O
and O
186 O
( O
85 O
% O
of O
expected O
) O
in O
the O
chemotherapy O
arm O
completed O
baseline O
QOL O
assessments O
. O

The B-Premise
two I-Premise
groups I-Premise
were I-Premise
comparable I-Premise
, I-Premise
with I-Premise
low I-Premise
global I-Premise
QOL I-Premise
scores I-Premise
and I-Premise
significant I-Premise
symptom I-Premise
burden I-Premise
, I-Premise
especially I-Premise
pain I-Premise
and I-Premise
fatigue I-Premise
, I-Premise
after I-Premise
thoracotomy I-Premise
. I-Premise

Changes O
in O
QOL O
during O
chemotherapy O
were O
relatively O
modest O
"""" O
; O
"""" O
fatigue B-Premise
, I-Premise
nausea I-Premise
, I-Premise
and I-Premise
vomiting I-Premise
worsened I-Premise
, I-Premise
but B-Premise
there I-Premise
was I-Premise
a I-Premise
reduction I-Premise
in I-Premise
pain I-Premise
and I-Premise
no I-Premise
change I-Premise
in I-Premise
global I-Premise
QOL I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
observation I-Premise
arm I-Premise
showed I-Premise
considerable I-Premise
improvements I-Premise
in I-Premise
QOL I-Premise
by I-Premise
3 I-Premise
months I-Premise
. I-Premise

QOL B-Premise
, I-Premise
except I-Premise
for I-Premise
symptoms I-Premise
of I-Premise
sensory I-Premise
neuropathy I-Premise
and I-Premise
hearing I-Premise
loss I-Premise
, I-Premise
in I-Premise
those I-Premise
treated I-Premise
with I-Premise
chemotherapy I-Premise
returned I-Premise
to I-Premise
baseline I-Premise
by I-Premise
9 I-Premise
months I-Premise
. I-Premise

The B-Claim
findings I-Claim
of I-Claim
this I-Claim
trial I-Claim
indicate I-Claim
that I-Claim
the I-Claim
negative I-Claim
effects I-Claim
of I-Claim
adjuvant I-Claim
chemotherapy I-Claim
on I-Claim
QOL I-Claim
appear I-Claim
to I-Claim
be I-Claim
temporary I-Claim
, I-Claim
and I-Claim
that I-Claim
improvements I-Claim
( I-Claim
with I-Claim
a I-Claim
return I-Claim
to I-Claim
baseline I-Claim
function I-Claim
) I-Claim
are I-Claim
likely I-Claim
in I-Claim
most I-Claim
patients I-Claim
. I-Claim

Promising O
results O
in O
a O
randomized O
phase O
II O
trial O
with O
the O
hypoxic O
cytotoxin O
tirapazamine O
( O
TPZ O
) O
combined O
with O
cisplatin O
( O
CIS O
) O
and O
radiation O
led O
to O
this O
phase O
III O
trial O
. O

Patients O
with O
previously O
untreated O
stage O
III O
or O
IV O
( O
excluding O
T1 O
- O
2N1 O
and O
M1 O
) O
squamous O
cell O
carcinoma O
of O
the O
oral O
cavity O
, O
oropharynx O
, O
hypopharynx O
, O
or O
larynx O
were O
randomly O
assigned O
to O
receive O
definitive O
radiotherapy O
( O
70 O
Gy O
in O
7 O
weeks O
) O
concurrently O
with O
either O
CIS O
( O
100 O
mg O
/ O
m O
( O
2 O
) O
) O
on O
day O
1 O
of O
weeks O
1 O
, O
4 O
, O
and O
7 O
or O
CIS O
( O
75 O
mg O
/ O
m O
( O
2 O
) O
) O
plus O
TPZ O
( O
290 O
mg O
/ O
m O
( O
2 O
) O
/ O
d O
) O
on O
day O
1 O
of O
weeks O
1 O
, O
4 O
, O
and O
7 O
and O
TPZ O
alone O
( O
160 O
mg O
/ O
m O
( O
2 O
) O
/ O
d O
) O
on O
days O
1 O
, O
3 O
, O
and O
5 O
of O
weeks O
2 O
and O
3 O
( O
TPZ O
/ O
CIS O
) O
. O

The O
primary O
end O
point O
was O
overall O
survival O
( O
OS O
) O
. O

The O
planned O
sample O
size O
was O
850 O
, O
estimated O
to O
result O
in O
334 O
deaths O
, O
which O
would O
provide O
90 O
% O
power O
to O
detect O
a O
difference O
in O
2 O
- O
year O
survival O
rates O
of O
60 O
% O
v O
70 O
% O
for O
CIS O
versus O
TPZ O
/ O
CIS O
, O
respectively O
( O
hazard O
ratio O
= O
0 O
. O
69 O
) O
. O

Eight O
hundred O
sixty O
- O
one O
patients O
were O
accrued O
from O
89 O
sites O
in O
16 O
countries O
. O

In B-Premise
an I-Premise
intent I-Premise
- I-Premise
to I-Premise
- I-Premise
treat I-Premise
analysis I-Premise
, I-Premise
the I-Premise
2 I-Premise
- I-Premise
year I-Premise
OS I-Premise
rates I-Premise
were I-Premise
65 I-Premise
. I-Premise
7 I-Premise
% I-Premise
for I-Premise
CIS I-Premise
and I-Premise
66 I-Premise
. I-Premise
2 I-Premise
% I-Premise
for I-Premise
TPZ I-Premise
/ I-Premise
CIS I-Premise
( I-Premise
TPZ I-Premise
/ I-Premise
CIS I-Premise
- I-Premise
- I-Premise
CIS I-Premise
: I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
- I-Premise
5 I-Premise
. I-Premise
9 I-Premise
% I-Premise
to I-Premise
6 I-Premise
. I-Premise
9 I-Premise
% I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
failure I-Premise
- I-Premise
free I-Premise
survival I-Premise
, I-Premise
time I-Premise
to I-Premise
locoregional I-Premise
failure I-Premise
, I-Premise
or I-Premise
quality I-Premise
of I-Premise
life I-Premise
as I-Premise
measured I-Premise
by I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy I-Premise
- I-Premise
Head I-Premise
and I-Premise
Neck I-Premise
. I-Premise

We B-Claim
found I-Claim
no I-Claim
evidence I-Claim
that I-Claim
the I-Claim
addition I-Claim
of I-Claim
TPZ I-Claim
to I-Claim
chemoradiotherapy I-Claim
, I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
not I-Claim
selected I-Claim
for I-Claim
the I-Claim
presence I-Claim
of I-Claim
hypoxia I-Claim
, I-Claim
improves I-Claim
OS I-Claim
. I-Claim

The O
combination O
of O
carboplatin O
and O
paclitaxel O
is O
the O
standard O
of O
care O
for O
the O
treatment O
of O
ovarian O
cancer O
, O
yet O
rates O
of O
recurrence O
and O
death O
remain O
high O
. O

We O
performed O
a O
prospective O
randomized O
phase O
III O
study O
to O
examine O
whether O
sequential O
administration O
of O
topotecan O
can O
improve O
the O
efficacy O
of O
carboplatin O
and O
paclitaxel O
in O
first O
- O
line O
treatment O
of O
advanced O
epithelial O
ovarian O
cancer O
. O

A O
total O
of O
1308 O
patients O
with O
previously O
untreated O
ovarian O
cancer O
( O
International O
Federation O
of O
Gynecology O
and O
Obstetrics O
stages O
IIB O
- O
IV O
) O
were O
randomly O
assigned O
to O
receive O
six O
cycles O
of O
paclitaxel O
and O
carboplatin O
followed O
by O
either O
four O
cycles O
of O
topotecan O
( O
TC O
- O
Top O
"""" O
; O
"""" O
658 O
patients O
) O
or O
surveillance O
( O
TC O
"""" O
; O
"""" O
650 O
patients O
) O
on O
a O
3 O
- O
week O
per O
cycle O
schedule O
. O

The O
primary O
endpoint O
was O
overall O
survival O
, O
and O
secondary O
endpoints O
were O
progression O
- O
free O
survival O
, O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

Time O
- O
to O
- O
event O
data O
were O
analyzed O
using O
the O
Kaplan O
- O
Meier O
method O
, O
and O
a O
stratified O
log O
- O
rank O
test O
was O
used O
to O
compare O
distributions O
between O
treatment O
groups O
. O

Hazard O
ratios O
( O
HRs O
) O
with O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
were O
estimated O
using O
a O
Cox O
proportional O
hazards O
model O
. O

Categorical O
data O
were O
compared O
using O
a O
stratified O
Cochran O
- O
Mantel O
- O
Haenszel O
test O
. O

All O
statistical O
tests O
were O
two O
- O
sided O
. O

Median B-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
was I-Premise
18 I-Premise
. I-Premise
2 I-Premise
months I-Premise
in I-Premise
the I-Premise
TC I-Premise
- I-Premise
Top I-Premise
arm I-Premise
versus I-Premise
18 I-Premise
. I-Premise
5 I-Premise
months I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
stratum I-Premise
- I-Premise
adjusted I-Premise
HR I-Premise
= I-Premise
0 I-Premise
. I-Premise
97 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0 I-Premise
. I-Premise
85 I-Premise
to I-Premise
1 I-Premise
. I-Premise
10 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
688 I-Premise
) I-Premise
. I-Premise

Median B-Premise
overall I-Premise
survival I-Premise
was I-Premise
43 I-Premise
. I-Premise
1 I-Premise
months I-Premise
for I-Premise
the I-Premise
TC I-Premise
- I-Premise
Top I-Premise
arm I-Premise
versus I-Premise
44 I-Premise
. I-Premise
5 I-Premise
months I-Premise
for I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
stratum I-Premise
- I-Premise
adjusted I-Premise
HR I-Premise
= I-Premise
1 I-Premise
. I-Premise
01 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0 I-Premise
. I-Premise
86 I-Premise
to I-Premise
1 I-Premise
. I-Premise
18 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
885 I-Premise
) I-Premise
. I-Premise

At B-Premise
3 I-Premise
years I-Premise
, I-Premise
overall I-Premise
survival I-Premise
in I-Premise
both I-Premise
arms I-Premise
was I-Premise
57 I-Premise
% I-Premise
( I-Premise
58 I-Premise
. I-Premise
5 I-Premise
% I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
and I-Premise
55 I-Premise
. I-Premise
7 I-Premise
% I-Premise
in I-Premise
the I-Premise
TC I-Premise
- I-Premise
Top I-Premise
arm I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
, I-Premise
patients I-Premise
in I-Premise
the I-Premise
TC I-Premise
- I-Premise
Top I-Premise
arm I-Premise
had I-Premise
more I-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
hematologic I-Premise
toxic I-Premise
effects I-Premise
( I-Premise
requiring I-Premise
more I-Premise
supportive I-Premise
care I-Premise
) I-Premise
and I-Premise
more I-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
infections I-Premise
( I-Premise
5 I-Premise
. I-Premise
1 I-Premise
% I-Premise
versus I-Premise
2 I-Premise
. I-Premise
7 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
034 I-Premise
) I-Premise
but I-Premise
did I-Premise
not I-Premise
have I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
increase I-Premise
in I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
3 I-Premise
. I-Premise
3 I-Premise
% I-Premise
versus I-Premise
3 I-Premise
. I-Premise
1 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
80 I-Premise
) I-Premise
. I-Premise

Among B-Premise
patients I-Premise
who I-Premise
had I-Premise
measurable I-Premise
disease I-Premise
( I-Premise
TC I-Premise
, I-Premise
n I-Premise
= I-Premise
147 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
TC I-Premise
- I-Premise
Top I-Premise
, I-Premise
n I-Premise
= I-Premise
145 I-Premise
) I-Premise
, I-Premise
overall I-Premise
( I-Premise
i I-Premise
. I-Premise
e I-Premise
. I-Premise
, I-Premise
complete I-Premise
or I-Premise
partial I-Premise
) I-Premise
response I-Premise
was I-Premise
69 I-Premise
. I-Premise
0 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
61 I-Premise
. I-Premise
4 I-Premise
% I-Premise
to I-Premise
76 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
TC I-Premise
- I-Premise
Top I-Premise
arm I-Premise
and I-Premise
76 I-Premise
. I-Premise
2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
69 I-Premise
. I-Premise
3 I-Premise
% I-Premise
to I-Premise
83 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
166 I-Premise
) I-Premise
. I-Premise

The B-Claim
sequential I-Claim
addition I-Claim
of I-Claim
topotecan I-Claim
to I-Claim
carboplatin I-Claim
- I-Claim
paclitaxel I-Claim
did I-Claim
not I-Claim
result I-Claim
in I-Claim
superior I-Claim
overall I-Claim
response I-Claim
or I-Claim
progression I-Claim
- I-Claim
free I-Claim
or I-Claim
overall I-Claim
survival I-Claim
. I-Claim

Therefore B-Claim
, I-Claim
this I-Claim
regimen I-Claim
is I-Claim
not I-Claim
recommended I-Claim
as I-Claim
standard I-Claim
of I-Claim
care I-Claim
treatment I-Claim
for I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

To O
examine O
health O
- O
related O
quality O
of O
life O
, O
we O
investigated O
the O
effect O
of O
adjuvant O
chemotherapy O
regimens O
on O
utility O
scores O
assessed O
by O
the O
EuroQoL O
- O
5D O
( O
EQ O
- O
5D O
) O
instrument O
in O
a O
randomized O
, O
controlled O
trial O
for O
breast O
cancer O
patients O
after O
surgery O
. O

We O
also O
investigated O
the O
relationship O
between O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT O
) O
scale O
scores O
and O
EQ O
- O
5D O
utilities O
. O

Patients O
were O
randomly O
assigned O
to O
the O
following O
four O
chemotherapy O
regimens O
: O
four O
cycles O
of O
anthracycline O
followed O
by O
paclitaxel O
( O
ACP O
) O
, O
four O
cycles O
of O
anthracycline O
- O
containing O
regimens O
followed O
by O
docetaxel O
( O
ACD O
) O
, O
eight O
cycles O
of O
paclitaxel O
( O
PTX O
) O
, O
and O
eight O
cycles O
of O
docetaxel O
( O
DTX O
) O
. O

Of O
1060 O
registered O
, O
the O
first O
300 O
consecutive O
patients O
were O
included O
in O
the O
current O
utility O
study O
. O

Utility O
scores O
were O
assessed O
using O
the O
EQ O
- O
5D O
instrument O
at O
baseline O
"""" O
; O
"""" O
cycles O
3 O
, O
5 O
, O
and O
7 O
"""" O
; O
"""" O
7 O
months O
"""" O
; O
"""" O
and O
1 O
year O
. O

We O
also O
evaluated O
the O
correlation O
between O
these O
scores O
and O
FACT O
- O
G O
, O
- O
B O
, O
and O
- O
Taxane O
scores O
at O
each O
time O
point O
. O

Utility B-Premise
scores I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
DTX I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
ACP I-Premise
and I-Premise
ACD I-Premise
groups I-Premise
. I-Premise

Mean B-Premise
utility I-Premise
scores I-Premise
in I-Premise
the I-Premise
DTX I-Premise
group I-Premise
were I-Premise
lowest I-Premise
at I-Premise
7 I-Premise
months I-Premise
and I-Premise
tended I-Premise
to I-Premise
remain I-Premise
low I-Premise
for I-Premise
a I-Premise
long I-Premise
time I-Premise
. I-Premise

The B-Premise
combined I-Premise
anthracycline I-Premise
followed I-Premise
by I-Premise
taxane I-Premise
group I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
utility I-Premise
scores I-Premise
that I-Premise
the I-Premise
taxane I-Premise
- I-Premise
alone I-Premise
group I-Premise
, I-Premise
with I-Premise
no I-Premise
significant I-Premise
difference I-Premise
depending I-Premise
on I-Premise
the I-Premise
type I-Premise
of I-Premise
taxane I-Premise
. I-Premise

Only B-Premise
the I-Premise
FACT I-Premise
- I-Premise
G I-Premise
social I-Premise
/ I-Premise
family I-Premise
well I-Premise
- I-Premise
being I-Premise
subscale I-Premise
had I-Premise
no I-Premise
relationship I-Premise
with I-Premise
EQ I-Premise
- I-Premise
5D I-Premise
responses I-Premise
and I-Premise
utility I-Premise
scores I-Premise
. I-Premise

Although B-Claim
the I-Claim
regimens I-Claim
in I-Claim
this I-Claim
study I-Claim
were I-Claim
similar I-Claim
in I-Claim
that I-Claim
they I-Claim
included I-Claim
taxane I-Claim
, I-Claim
the I-Claim
mean I-Claim
utility I-Claim
scores I-Claim
and I-Claim
longitudinal I-Claim
patterns I-Claim
of I-Claim
utility I-Claim
scores I-Claim
were I-Claim
different I-Claim
among I-Claim
regimens I-Claim
. I-Claim

Topical O
photodynamic O
therapy O
( O
PDT O
) O
with O
aminolevulinic O
acid O
( O
ALA O
) O
and O
5 O
% O
imiquimod O
cream O
are O
effective O
therapies O
for O
the O
treatment O
of O
actinic O
keratoses O
( O
AKs O
) O
, O
but O
no O
split O
- O
face O
studies O
directly O
comparing O
these O
treatment O
options O
are O
available O
in O
the O
literature O
. O

To O
compare O
the O
efficacy O
and O
tolerability O
of O
ALA O
- O
PDT O
and O
imiquimod O
5 O
% O
cream O
for O
the O
treatment O
of O
AKs O
. O

Sixty O
- O
one O
patients O
were O
enrolled O
from O
the O
Salt O
Lake O
City O
Veterans O
Affairs O
Hospital O
"""" O
; O
"""" O
51 O
completed O
the O
study O
and O
were O
included O
in O
the O
analysis O
. O

All O
patients O
were O
randomized O
to O
receive O
half O
of O
a O
sachet O
of O
imiquimod O
5 O
% O
cream O
twice O
weekly O
on O
half O
of O
their O
face O
and O
two O
sessions O
of O
PDT O
with O
20 O
% O
solution O
of O
ALA O
applied O
for O
1 O
hour O
to O
the O
other O
side O
of O
the O
face O
. O

The B-Premise
75 I-Premise
% I-Premise
AK I-Premise
clearance I-Premise
rate I-Premise
was I-Premise
34 I-Premise
. I-Premise
6 I-Premise
% I-Premise
for I-Premise
ALA I-Premise
- I-Premise
PDT I-Premise
and I-Premise
25 I-Premise
% I-Premise
for I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
30 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
reduction I-Premise
in I-Premise
AK I-Premise
count I-Premise
was I-Premise
59 I-Premise
. I-Premise
2 I-Premise
% I-Premise
for I-Premise
ALA I-Premise
- I-Premise
PDT I-Premise
and I-Premise
41 I-Premise
. I-Premise
4 I-Premise
% I-Premise
for I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
. I-Premise

Dermatology B-Premise
Life I-Premise
Quality I-Premise
Index I-Premise
( I-Premise
DLQI I-Premise
) I-Premise
scores I-Premise
were I-Premise
assessed I-Premise
for I-Premise
each I-Premise
treatment I-Premise
modality I-Premise
at I-Premise
week I-Premise
4 I-Premise
and I-Premise
were I-Premise
1 I-Premise
. I-Premise
95 I-Premise
and I-Premise
1 I-Premise
. I-Premise
38 I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
20 I-Premise
) I-Premise
. I-Premise

The B-Premise
sample I-Premise
size I-Premise
was I-Premise
small I-Premise
, I-Premise
and I-Premise
patients I-Premise
applied I-Premise
a I-Premise
small I-Premise
amount I-Premise
of I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
half I-Premise
a I-Premise
sachet I-Premise
) I-Premise
to I-Premise
a I-Premise
large I-Premise
surface I-Premise
area I-Premise
. I-Premise

There B-Claim
was I-Claim
no I-Claim
statistically I-Claim
significant I-Claim
difference I-Claim
in I-Claim
treatment I-Claim
response I-Claim
when I-Claim
the I-Claim
100 I-Claim
% I-Claim
or I-Claim
75 I-Claim
% I-Claim
clearance I-Claim
rate I-Claim
cutoff I-Claim
was I-Claim
used I-Claim
, I-Claim
but B-Claim
our I-Claim
secondary I-Claim
outcome I-Claim
suggests I-Claim
that I-Claim
two I-Claim
sessions I-Claim
of I-Claim
ALA I-Claim
- I-Claim
PDT I-Claim
is I-Claim
superior I-Claim
to I-Claim
imiquimod I-Claim
5 I-Claim
% I-Claim
cream I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
AKs I-Claim
. I-Claim

There B-Claim
was I-Claim
no I-Claim
statistically I-Claim
significant I-Claim
difference I-Claim
in I-Claim
effect I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
as I-Claim
assessed I-Claim
using I-Claim
the I-Claim
DLQI I-Claim
. I-Claim

We O
aimed O
at O
investigating O
the O
efficacy O
, O
tolerability O
, O
and O
quality O
of O
life O
( O
QOL O
) O
of O
gemcitabine O
( O
GEM O
) O
compared O
with O
pegylated O
liposomal O
doxorubicin O
( O
PLD O
) O
in O
the O
salvage O
treatment O
of O
recurrent O
ovarian O
cancer O
. O

A O
phase O
III O
randomized O
multicenter O
trial O
was O
planned O
to O
compare O
GEM O
( O
1 O
, O
000 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
, O
8 O
, O
and O
15 O
every O
28 O
days O
) O
with O
PLD O
( O
40 O
mg O
/ O
m O
( O
2 O
) O
every O
28 O
days O
) O
in O
ovarian O
cancer O
patients O
who O
experienced O
treatment O
failure O
with O
only O
one O
platinum O
/ O
paclitaxel O
regimen O
and O
who O
experienced O
recurrence O
or O
progression O
within O
12 O
months O
after O
completion O
of O
primary O
treatment O
. O

One O
hundred O
fifty O
- O
three O
patients O
were O
randomly O
assigned O
to O
PLD O
( O
n O
= O
76 O
) O
or O
GEM O
( O
n O
= O
77 O
) O
. O

Treatment O
arms O
were O
well O
balanced O
for O
clinicopathologic O
characteristics O
. O

Grade O
3 O
or O
4 O
neutropenia O
was O
more O
frequent O
in O
GEM O
- O
treated O
patients O
versus O
PLD O
- O
treated O
patients O
( O
P O
= O
. O
007 O
) O
. O

Grade O
3 O
or O
4 O
palmar O
- O
plantar O
erythrodysesthesia O
was O
documented O
in O
a O
higher O
proportion O
of O
PLD O
patients O
( O
6 O
% O
) O
versus O
GEM O
patients O
( O
0 O
% O
"""" O
; O
"""" O
P O
= O
. O
061 O
) O
. O

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
16 I-Premise
% I-Premise
in I-Premise
the I-Premise
PLD I-Premise
arm I-Premise
compared I-Premise
with I-Premise
29 I-Premise
% I-Premise
in I-Premise
the I-Premise
GEM I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
056 I-Premise
) I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
time I-Premise
to I-Premise
progression I-Premise
( I-Premise
TTP I-Premise
) I-Premise
curves I-Premise
according I-Premise
to I-Premise
treatment I-Premise
allocation I-Premise
was I-Premise
documented I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
411 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
a I-Premise
trend I-Premise
for I-Premise
more I-Premise
favorable I-Premise
overall I-Premise
survival I-Premise
was I-Premise
documented I-Premise
in I-Premise
the I-Premise
PLD I-Premise
arm I-Premise
compared I-Premise
with I-Premise
the I-Premise
GEM I-Premise
arm I-Premise
, I-Premise
although B-Premise
the I-Premise
P I-Premise
value I-Premise
was I-Premise
of I-Premise
borderline I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
048 I-Premise
) I-Premise
. I-Premise

Statistically B-Premise
significantly I-Premise
higher I-Premise
global I-Premise
QOL I-Premise
scores I-Premise
were I-Premise
found I-Premise
in I-Premise
PLD I-Premise
- I-Premise
treated I-Premise
patients I-Premise
at I-Premise
the I-Premise
first I-Premise
and I-Premise
second I-Premise
postbaseline I-Premise
QOL I-Premise
assessments I-Premise
. I-Premise

GEM B-Claim
does I-Claim
not I-Claim
provide I-Claim
an I-Claim
advantage I-Claim
compared I-Claim
with I-Claim
PLD I-Claim
in I-Claim
terms I-Claim
of I-Claim
TTP I-Claim
in I-Claim
ovarian I-Claim
cancer I-Claim
patients I-Claim
who I-Claim
experience I-Claim
recurrence I-Claim
within I-Claim
12 I-Claim
months I-Claim
after I-Claim
primary I-Claim
treatment I-Claim
but I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
spectrum I-Claim
of I-Claim
drugs I-Claim
to I-Claim
be I-Claim
possibly I-Claim
used I-Claim
in I-Claim
the I-Claim
salvage I-Claim
setting I-Claim
. I-Claim

The O
aim O
of O
this O
multicenter O
randomized O
trial O
was O
to O
assess O
the O
efficacy O
and O
safety O
of O
sentinel O
lymph O
node O
( O
SLN O
) O
biopsy O
compared O
with O
axillary O
lymph O
node O
dissection O
( O
ALND O
) O
. O

All O
studies O
on O
SLN O
biopsy O
in O
breast O
cancer O
report O
a O
variable O
FALSE O
negative O
rate O
, O
whose O
prognostic O
consequences O
are O
still O
unclear O
. O

From O
May O
1999 O
to O
December O
2004 O
, O
patients O
with O
breast O
cancer O
< O
or O
3 O
cm O
were O
randomly O
assigned O
to O
receive O
SLN O
biopsy O
associated O
with O
ALND O
( O
ALND O
arm O
) O
or O
SLN O
biopsy O
followed O
by O
ALND O
only O
if O
the O
SLN O
was O
metastatic O
( O
SLN O
arm O
) O
. O

The O
main O
aim O
was O
the O
comparison O
of O
disease O
- O
free O
survival O
in O
the O
2 O
arms O
. O

A O
total O
of O
749 O
patients O
were O
randomized O
and O
697 O
were O
available O
for O
analysis O
. O

SLNs O
were O
identified O
in O
662 O
of O
697 O
patients O
( O
95 O
% O
) O
and O
positive O
SLNs O
were O
found O
in O
189 O
of O
662 O
patients O
( O
28 O
. O
5 O
% O
) O
. O

In O
the O
ALND O
group O
, O
positive O
non O
- O
SLNs O
were O
found O
in O
18 O
patients O
with O
negative O
SLN O
, O
giving O
a O
FALSE O
negative O
rate O
of O
16 O
. O
7 O
% O
( O
18 O
of O
108 O
) O
. O

Postoperative B-Premise
side I-Premise
effects I-Premise
were I-Premise
significantly I-Premise
less I-Premise
in I-Premise
the I-Premise
SLN I-Premise
group I-Premise
and I-Premise
there I-Premise
was I-Premise
no I-Premise
negative I-Premise
impact I-Premise
of I-Premise
the I-Premise
SLN I-Premise
procedure I-Premise
on I-Premise
psychologic I-Premise
well I-Premise
being I-Premise
. I-Premise

At O
a O
median O
follow O
- O
up O
of O
56 O
months O
, O
there O
were O
more O
locoregional O
recurrences O
in O
the O
SLN O
arm O
, O
and O
the O
5 O
- O
year O
disease O
- O
free O
survival O
was O
89 O
. O
9 O
% O
in O
the O
ALND O
arm O
and O
87 O
. O
6 O
% O
in O
the O
SLN O
arm O
, O
with O
a O
difference O
of O
2 O
. O
3 O
% O
( O
95 O
% O
confidence O
interval O
: O
- O
3 O
. O
1 O
% O
to O
7 O
. O
6 O
% O
) O
. O

However B-Premise
, I-Premise
the I-Premise
number I-Premise
of I-Premise
enrolled I-Premise
patients I-Premise
was I-Premise
not I-Premise
sufficient I-Premise
to I-Premise
draw I-Premise
definitive I-Premise
conclusions I-Premise
. I-Premise

SLN B-Claim
biopsy I-Claim
is I-Claim
an I-Claim
effective I-Claim
and I-Claim
well I-Claim
- I-Claim
tolerated I-Claim
procedure I-Claim
. I-Claim

However B-Claim
, I-Claim
its I-Claim
safety I-Claim
should I-Claim
be I-Claim
confirmed I-Claim
by I-Claim
the I-Claim
results I-Claim
of I-Claim
larger I-Claim
randomized I-Claim
trials I-Claim
and I-Claim
meta I-Claim
- I-Claim
analyses I-Claim
. I-Claim

Nocturnal O
administration O
of O
branched O
- O
chain O
amino O
acid O
( O
BCAA O
) O
granules O
improves O
serum O
albumin O
levels O
in O
patients O
with O
cirrhosis O
. O

However O
, O
it O
is O
unclear O
whether O
or O
not O
this O
administration O
method O
can O
improve O
the O
patients O
' O
quality O
of O
life O
( O
QOL O
) O
. O

In O
this O
study O
, O
we O
aimed O
to O
investigate O
the O
efficacy O
of O
BCAA O
granules O
, O
given O
nocturnally O
, O
in O
improving O
QOL O
in O
these O
patients O
. O

We O
performed O
a O
multicenter O
, O
randomized O
controlled O
trial O
examining O
the O
comparative O
effects O
of O
BCAA O
granules O
given O
orally O
for O
3 O
months O
with O
daytime O
or O
nocturnal O
administration O
in O
patients O
with O
compensated O
cirrhosis O
. O

Health O
- O
related O
QOL O
was O
measured O
by O
a O
Japanese O
version O
of O
the O
questionnaire O
on O
subjective O
and O
objective O
symptoms O
, O
and O
the O
Short O
Form O
- O
8 O
( O
SF O
- O
8 O
) O
questionnaire O
. O

Twenty O
- O
one O
patients O
received O
BCAA O
granules O
three O
times O
a O
day O
( O
one O
sachet O
after O
each O
meal O
: O
the O
daytime O
group O
) O
, O
and O
16 O
patients O
received O
the O
granules O
twice O
a O
day O
( O
one O
sachet O
after O
breakfast O
, O
and O
two O
sachets O
before O
bedtime O
: O
the O
nocturnal O
group O
) O
. O

Baseline O
characteristics O
did O
not O
differ O
between O
the O
groups O
( O
whole O
cohort O
: O
Child O
- O
Pugh O
grade O
A O
/ O
B O
, O
21 O
/ O
16 O
"""" O
; O
"""" O
mean O
age O
, O
68 O
. O
2 O
years O
) O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
subjects I-Premise
revealed I-Premise
by I-Premise
the I-Premise
questionnaire I-Premise
regarding I-Premise
subjective I-Premise
or I-Premise
objective I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
by I-Premise
the I-Premise
SF I-Premise
- I-Premise
8 I-Premise
between I-Premise
the I-Premise
daytime I-Premise
group I-Premise
and I-Premise
the I-Premise
nocturnal I-Premise
group I-Premise
after I-Premise
3 I-Premise
months I-Premise
of I-Premise
treatment I-Premise
. I-Premise

The B-Premise
daytime I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
effect I-Premise
on I-Premise
general I-Premise
health I-Premise
, I-Premise
vitality I-Premise
, I-Premise
social I-Premise
functioning I-Premise
, I-Premise
mental I-Premise
health I-Premise
, I-Premise
and I-Premise
role I-Premise
emotional I-Premise
as I-Premise
revealed I-Premise
on I-Premise
the I-Premise
SF I-Premise
- I-Premise
8 I-Premise
. I-Premise

Conversely B-Premise
, I-Premise
the I-Premise
nocturnal I-Premise
group I-Premise
exhibited I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
muscle I-Premise
cramps I-Premise
in I-Premise
the I-Premise
legs I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
014 I-Premise
) I-Premise
and I-Premise
significantly I-Premise
improved I-Premise
Fisher I-Premise
' I-Premise
s I-Premise
ratio I-Premise
after I-Premise
3 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
) I-Premise
. I-Premise

Nocturnal B-Claim
administration I-Claim
of I-Claim
BCAA I-Claim
granules I-Claim
in I-Claim
patients I-Claim
with I-Claim
cirrhosis I-Claim
reduced I-Claim
the I-Claim
occurrence I-Claim
of I-Claim
muscle I-Claim
cramps I-Claim
in I-Claim
the I-Claim
leg I-Claim
but I-Claim
did I-Claim
not I-Claim
improve I-Claim
the I-Claim
patients I-Claim
' I-Claim
QOL I-Claim
. I-Claim

Treatment O
of O
patients O
with O
advanced O
or O
metastatic O
esophagogastric O
adenocarcinoma O
should O
not O
only O
prolong O
life O
but O
also O
provide O
relief O
of O
symptoms O
and O
improve O
quality O
of O
life O
( O
QOL O
) O
. O

Esophagogastric O
adenocarcinoma O
mainly O
occurs O
in O
elderly O
patients O
, O
but O
they O
are O
underrepresented O
in O
most O
clinical O
trials O
and O
often O
do O
not O
receive O
effective O
combination O
chemotherapy O
, O
most O
probably O
for O
fear O
of O
intolerance O
. O

Using O
validated O
instruments O
, O
we O
prospectively O
assessed O
QOL O
within O
the O
randomized O
FLOT65 O
+ O
phase O
II O
trial O
. O

Within O
the O
FLOT65 O
+ O
trial O
, O
a O
total O
of O
143 O
patients O
aged O
â‰¥65 O
years O
were O
randomly O
allocated O
to O
receive O
biweekly O
oxaliplatin O
plus O
5 O
- O
fluorouracil O
( O
5 O
- O
FU O
) O
continuous O
infusion O
and O
folinic O
acid O
( O
FLO O
) O
or O
the O
same O
regimen O
in O
combination O
with O
docetaxel O
50 O
mg O
/ O
m O
( O
2 O
) O
( O
FLOT O
) O
. O

The O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ O
- O
C30 O
) O
and O
the O
gastric O
module O
STO22 O
were O
administered O
every O
8 O
weeks O
until O
progression O
. O

Time O
to O
definitive O
deterioration O
of O
QOL O
parameters O
was O
analyzed O
and O
compared O
within O
the O
treatment O
arms O
. O

The O
median O
age O
of O
patients O
was O
70 O
years O
. O

Patients B-Premise
receiving I-Premise
FLOT I-Premise
exhibited I-Premise
higher I-Premise
response I-Premise
rates I-Premise
and I-Premise
had I-Premise
improved I-Premise
disease I-Premise
- I-Premise
free I-Premise
and I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
. I-Premise

The O
proportions O
of O
patients O
with O
evaluable O
baseline O
EORTC O
QLQ O
- O
C30 O
and O
STO22 O
questionnaires O
were O
balanced O
( O
83 O
% O
in O
FLOT O
and O
89 O
% O
in O
FLO O
) O
. O

Considering O
evaluable O
patients O
with O
assessable O
questionnaires O
( O
n O
= O
123 O
) O
, O
neither O
functioning O
nor O
symptom O
parameters O
differed O
significantly O
in O
favor O
of O
one O
of O
the O
two O
treatment O
groups O
. O

Particularly O
, O
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
regarding I-Premise
time I-Premise
to I-Premise
definitive I-Premise
deterioration I-Premise
of I-Premise
global I-Premise
health I-Premise
status I-Premise
/ I-Premise
quality I-Premise
of I-Premise
life I-Premise
from I-Premise
baseline I-Premise
( I-Premise
primary I-Premise
endpoint I-Premise
) I-Premise
. I-Premise

Notably O
, O
patients B-Premise
receiving I-Premise
FLO I-Premise
or I-Premise
FLOT I-Premise
as I-Premise
palliative I-Premise
treatment I-Premise
( I-Premise
n I-Premise
= I-Premise
98 I-Premise
) I-Premise
achieved I-Premise
comparable I-Premise
QOL I-Premise
results I-Premise
. I-Premise

Although B-Premise
toxicity I-Premise
was I-Premise
higher I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
FLOT I-Premise
, I-Premise
no B-Premise
negative I-Premise
impact I-Premise
of I-Premise
the I-Premise
addition I-Premise
of I-Premise
docetaxel I-Premise
on I-Premise
QOL I-Premise
parameters I-Premise
could I-Premise
be I-Premise
demonstrated I-Premise
. I-Premise

Thus O
, O
elderly B-Claim
patients I-Claim
in I-Claim
need I-Claim
of I-Claim
intensified I-Claim
chemotherapy I-Claim
may I-Claim
receive I-Claim
FLOT I-Claim
without I-Claim
compromising I-Claim
patient I-Claim
- I-Claim
reported I-Claim
outcome I-Claim
parameters I-Claim
. I-Claim

To O
compare O
the O
toxicities O
, O
tumor O
control O
, O
survival O
, O
and O
quality O
of O
life O
of O
nasopharyngeal O
cancer O
( O
NPC O
) O
patients O
treated O
with O
sequential O
neoadjuvant O
chemotherapy O
followed O
by O
concurrent O
cisplatin O
- O
radiotherapy O
( O
CRT O
) O
or O
CRT O
alone O
. O

Previously O
untreated O
stage O
III O
to O
IVB O
NPC O
were O
randomly O
assigned O
to O
( O
1 O
) O
neoadjuvant O
docetaxel O
75 O
mg O
/ O
m O
( O
2 O
) O
and O
cisplatin O
75 O
mg O
/ O
m O
( O
2 O
) O
every O
3 O
weeks O
for O
two O
cycles O
, O
followed O
by O
cisplatin O
40 O
mg O
/ O
m O
( O
2 O
) O
/ O
wk O
concurrent O
with O
radiotherapy O
, O
or O
( O
2 O
) O
CRT O
alone O
. O

Planned O
accrual O
was O
30 O
patients O
per O
arm O
to O
detect O
20 O
% O
difference O
of O
toxicities O
based O
on O
95 O
% O
CIs O
. O

From O
November O
2002 O
to O
November O
2004 O
, O
65 O
eligible O
patients O
were O
randomly O
assigned O
to O
neoadjuvant O
chemotherapy O
followed O
by O
CRT O
( O
n O
= O
34 O
) O
or O
CRT O
alone O
( O
n O
= O
31 O
) O
. O

There B-Premise
was I-Premise
a I-Premise
high I-Premise
rate I-Premise
of I-Premise
grade I-Premise
3 I-Premise
/ I-Premise
4 I-Premise
neutropenia I-Premise
( I-Premise
97 I-Premise
% I-Premise
) I-Premise
but I-Premise
not I-Premise
neutropenic I-Premise
fever I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
during I-Premise
neoadjuvant I-Premise
chemotherapy I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
in I-Premise
rates I-Premise
of I-Premise
acute I-Premise
toxicities I-Premise
were I-Premise
observed I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
during I-Premise
CRT I-Premise
. I-Premise

Dose B-Premise
intensities I-Premise
of I-Premise
concurrent I-Premise
cisplatin I-Premise
, I-Premise
late I-Premise
RT I-Premise
toxicities I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
were I-Premise
comparable I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

The B-Premise
3 I-Premise
- I-Premise
year I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
for I-Premise
neoadjuvant I-Premise
versus I-Premise
control I-Premise
arm I-Premise
was I-Premise
88 I-Premise
. I-Premise
2 I-Premise
% I-Premise
and I-Premise
59 I-Premise
. I-Premise
5 I-Premise
% I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
0 I-Premise
. I-Premise
49 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
20 I-Premise
to I-Premise
1 I-Premise
. I-Premise
19 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
12 I-Premise
) I-Premise
. I-Premise

The B-Premise
3 I-Premise
- I-Premise
year I-Premise
overall I-Premise
survival I-Premise
for I-Premise
neoadjuvant I-Premise
versus I-Premise
control I-Premise
arm I-Premise
was I-Premise
94 I-Premise
. I-Premise
1 I-Premise
% I-Premise
and I-Premise
67 I-Premise
. I-Premise
7 I-Premise
% I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
0 I-Premise
. I-Premise
24 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
078 I-Premise
to I-Premise
0 I-Premise
. I-Premise
73 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
012 I-Premise
) I-Premise
. I-Premise

Neoadjuvant B-Claim
docetaxel I-Claim
- I-Claim
cisplatin I-Claim
followed I-Claim
by I-Claim
CRT I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
with I-Claim
a I-Claim
manageable I-Claim
toxicity I-Claim
profile I-Claim
that I-Claim
allowed I-Claim
subsequent I-Claim
delivery I-Claim
of I-Claim
full I-Claim
- I-Claim
dose I-Claim
CRT I-Claim
. I-Claim

Preliminary B-Claim
results I-Claim
suggested I-Claim
a I-Claim
positive I-Claim
impact I-Claim
on I-Claim
survival I-Claim
. I-Claim

A O
phase O
III O
study O
to O
definitively O
test O
this O
neoadjuvant O
- O
concurrent O
strategy O
is O
warranted O
. O

Fatigue O
is O
a O
frequent O
problem O
after O
surgical O
treatment O
of O
solid O
tumours O
. O

Aerobic B-Claim
exercise I-Claim
and I-Claim
psychosocial I-Claim
interventions I-Claim
have I-Claim
been I-Claim
shown I-Claim
to I-Claim
reduce I-Claim
the I-Claim
severity I-Claim
of I-Claim
this I-Claim
symptom I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Therefore O
, O
we O
compared O
the O
effect O
of O
the O
two O
therapies O
on O
fatigue O
in O
a O
randomised O
controlled O
study O
. O

Seventy O
- O
two O
patients O
who O
underwent O
surgery O
for O
lung O
( O
n O
= O
27 O
) O
or O
gastrointestinal O
tumours O
( O
n O
= O
42 O
) O
were O
assigned O
to O
an O
aerobic O
exercise O
group O
( O
stationary O
biking O
30 O
min O
five O
times O
weekly O
) O
or O
a O
progressive O
relaxation O
training O
group O
( O
45 O
min O
three O
times O
per O
week O
) O
. O

Both O
interventions O
were O
carried O
out O
for O
3 O
weeks O
. O

At O
the O
beginning O
and O
the O
end O
of O
the O
study O
, O
we O
evaluated O
physical O
, O
cognitive O
and O
emotional O
status O
and O
somatic O
complaints O
with O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
Core O
Module O
( O
EORTC O
- O
QLQ O
- O
30 O
) O
questionnaire O
, O
and O
maximal O
physical O
performance O
with O
an O
ergometric O
stress O
test O
. O

Physical B-Premise
performance I-Premise
of I-Premise
the I-Premise
training I-Premise
group I-Premise
improved I-Premise
significantly I-Premise
during I-Premise
the I-Premise
programme I-Premise
( I-Premise
9 I-Premise
. I-Premise
4 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
20 I-Premise
watts I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
but I-Premise
remained I-Premise
unchanged I-Premise
in I-Premise
the I-Premise
relaxation I-Premise
group I-Premise
( I-Premise
1 I-Premise
. I-Premise
5 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
14 I-Premise
. I-Premise
8 I-Premise
watts I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
37 I-Premise
) I-Premise
. I-Premise

Fatigue B-Premise
and I-Premise
global I-Premise
health I-Premise
scores I-Premise
improved I-Premise
in I-Premise
both I-Premise
groups I-Premise
during I-Premise
the I-Premise
intervention I-Premise
( I-Premise
fatigue I-Premise
: I-Premise
training I-Premise
group I-Premise
21 I-Premise
% I-Premise
, I-Premise
relaxation I-Premise
group I-Premise
19 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
global I-Premise
health I-Premise
of I-Premise
both I-Premise
groups I-Premise
19 I-Premise
% I-Premise
, I-Premise
p I-Premise
for I-Premise
all I-Premise
< I-Premise
or I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
however B-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
changes I-Premise
in I-Premise
the I-Premise
scores I-Premise
of I-Premise
both I-Premise
groups I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
67 I-Premise
) I-Premise
. I-Premise

We B-Claim
conclude I-Claim
that I-Claim
a I-Claim
structured I-Claim
aerobic I-Claim
training I-Claim
programme I-Claim
improves I-Claim
the I-Claim
physical I-Claim
performance I-Claim
of I-Claim
patients I-Claim
recovering I-Claim
from I-Claim
surgery I-Claim
for I-Claim
solid I-Claim
tumours I-Claim
. I-Claim

However B-Claim
, I-Claim
exercise I-Claim
is I-Claim
not I-Claim
better I-Claim
than I-Claim
progressive I-Claim
relaxation I-Claim
training I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
fatigue I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

The O
randomized O
, O
controlled O
BOLERO O
- O
2 O
( O
Breast O
Cancer O
Trials O
of O
Oral O
Everolimus O
) O
trial O
demonstrated O
significantly O
improved O
progression O
- O
free O
survival O
with O
the O
use O
of O
everolimus O
plus O
exemestane O
( O
EVE O
+ O
EXE O
) O
versus O
placebo O
plus O
exemestane O
( O
PBO O
+ O
EXE O
) O
in O
patients O
with O
advanced O
breast O
cancer O
who O
developed O
disease O
progression O
after O
treatment O
with O
nonsteroidal O
aromatase O
inhibitors O
. O

This O
analysis O
investigated O
the O
treatment O
effects O
on O
health O
- O
related O
quality O
of O
life O
( O
HRQOL O
) O
. O

Using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
- O
Core O
30 O
( O
EORTC O
QLQ O
- O
C30 O
) O
questionnaire O
, O
HRQOL O
was O
assessed O
at O
baseline O
and O
every O
6 O
weeks O
thereafter O
until O
disease O
progression O
and O
/ O
or O
treatment O
discontinuation O
. O

The O
30 O
items O
in O
15 O
subscales O
of O
the O
QLQ O
- O
C30 O
include O
global O
health O
status O
wherein O
higher O
scores O
( O
range O
, O
0 O
- O
100 O
) O
indicate O
better O
HRQOL O
. O

This O
analysis O
included O
a O
protocol O
- O
specified O
time O
to O
definitive O
deterioration O
( O
TDD O
) O
analysis O
at O
a O
5 O
% O
decrease O
in O
HRQOL O
versus O
baseline O
, O
with O
no O
subsequent O
increase O
above O
this O
threshold O
. O

The O
authors O
report O
additional O
sensitivity O
analyses O
using O
10 O
- O
point O
minimal O
important O
difference O
decreases O
in O
the O
global O
health O
status O
score O
versus O
baseline O
. O

Treatment O
arms O
were O
compared O
using O
the O
stratified O
log O
- O
rank O
test O
and O
Cox O
proportional O
hazards O
model O
adjusted O
for O
trial O
stratum O
( O
visceral O
metastases O
, O
previous O
hormone O
sensitivity O
) O
, O
age O
, O
sex O
, O
race O
, O
baseline O
global O
health O
status O
score O
and O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
, O
prognostic O
risk O
factors O
, O
and O
treatment O
history O
. O

Baseline O
global O
health O
status O
scores O
were O
found O
to O
be O
similar O
between O
treatment O
groups O
( O
64 O
. O
7 O
vs O
65 O
. O
3 O
) O
. O

The B-Premise
median I-Premise
TDD I-Premise
in I-Premise
HRQOL I-Premise
was I-Premise
8 I-Premise
. I-Premise
3 I-Premise
months I-Premise
with I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
versus I-Premise
5 I-Premise
. I-Premise
8 I-Premise
months I-Premise
with I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0 I-Premise
. I-Premise
74 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
0084 I-Premise
) I-Premise
. I-Premise

At B-Premise
the I-Premise
10 I-Premise
- I-Premise
point I-Premise
minimal I-Premise
important I-Premise
difference I-Premise
, I-Premise
the I-Premise
median I-Premise
TDD I-Premise
with I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
was I-Premise
11 I-Premise
. I-Premise
7 I-Premise
months I-Premise
versus I-Premise
8 I-Premise
. I-Premise
4 I-Premise
months I-Premise
with I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0 I-Premise
. I-Premise
80 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
1017 I-Premise
) I-Premise
. I-Premise

In B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
who I-Claim
develop I-Claim
disease I-Claim
progression I-Claim
after I-Claim
treatment I-Claim
with I-Claim
nonsteroidal I-Claim
aromatase I-Claim
inhibitors I-Claim
, I-Claim
EVE I-Claim
+ I-Claim
EXE I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
longer I-Claim
TDD I-Claim
in I-Claim
global I-Claim
HRQOL I-Claim
versus I-Claim
PBO I-Claim
+ I-Claim
EXE I-Claim
. I-Claim

Mucositis B-Premise
occurs I-Premise
in I-Premise
almost I-Premise
all I-Premise
patients I-Premise
treated I-Premise
with I-Premise
radiotherapy I-Premise
for I-Premise
head I-Premise
and I-Premise
neck I-Premise
cancer I-Premise
. I-Premise

The O
aim O
of O
this O
multicenter O
, O
double O
- O
blind O
, O
prospective O
, O
randomized O
trial O
was O
to O
evaluate O
the O
clinical O
efficacy O
of O
an O
economically O
viable O
antimicrobial O
lozenge O
( O
bacitracin O
, O
clotrimazole O
, O
and O
gentamicin O
[ O
BcoG O
] O
) O
in O
the O
alleviation O
of O
radiation O
- O
induced O
mucositis O
in O
patients O
with O
head O
and O
neck O
cancer O
. O

One O
hundred O
thirty O
- O
seven O
eligible O
patients O
were O
randomized O
to O
treatment O
with O
either O
antimicrobial O
lozenge O
( O
69 O
patients O
) O
or O
placebo O
lozenge O
( O
68 O
patients O
) O
. O

The O
primary O
end O
point O
of O
the O
study O
was O
the O
time O
to O
development O
of O
severe O
mucositis O
from O
the O
start O
of O
radiotherapy O
. O

Secondary O
end O
points O
included O
severity O
and O
duration O
of O
mucositis O
, O
pain O
measurement O
, O
radiation O
therapy O
interruption O
, O
and O
quality O
of O
life O
. O

Mucositis O
was O
scored O
using O
a O
validated O
mucositis O
scoring O
system O
. O

Toxicity B-Premise
profiles I-Premise
were I-Premise
similar I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
of I-Premise
the I-Premise
study I-Premise
. I-Premise

The B-Premise
median I-Premise
time I-Premise
to I-Premise
development I-Premise
of I-Premise
severe I-Premise
mucositis I-Premise
from I-Premise
the I-Premise
start I-Premise
of I-Premise
radiotherapy I-Premise
was I-Premise
3 I-Premise
. I-Premise
61 I-Premise
weeks I-Premise
on I-Premise
BCoG I-Premise
and I-Premise
3 I-Premise
. I-Premise
96 I-Premise
weeks I-Premise
on I-Premise
placebo I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
61 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
arms I-Premise
in I-Premise
the I-Premise
extent I-Premise
of I-Premise
severe I-Premise
mucositis I-Premise
as I-Premise
measured I-Premise
by I-Premise
physician I-Premise
, I-Premise
in I-Premise
oral I-Premise
toxicities I-Premise
as I-Premise
recorded I-Premise
by I-Premise
patients I-Premise
, I-Premise
or I-Premise
in I-Premise
radiotherapy I-Premise
delays I-Premise
. I-Premise

This O
study O
was O
conducted O
on O
the O
basis O
of O
a O
pilot O
study O
that O
demonstrated O
the O
BCoG O
lozenge O
to O
be O
tolerable O
and O
microbiologically O
efficacious O
. O

A O
validated O
mucositis O
scoring O
system O
was O
used O
. O

However O
, O
in B-Claim
this I-Claim
group I-Claim
of I-Claim
patients I-Claim
treated I-Claim
with I-Claim
conventional I-Claim
radiotherapy I-Claim
, I-Claim
the I-Claim
lozenge I-Claim
did I-Claim
not I-Claim
impact I-Claim
significantly I-Claim
on I-Claim
the I-Claim
severity I-Claim
of I-Claim
mucositis I-Claim
. I-Claim

Whether B-Claim
such I-Claim
a I-Claim
lozenge I-Claim
would I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
treatment I-Claim
situations I-Claim
where I-Claim
rate I-Claim
of I-Claim
severe I-Claim
mucositis I-Claim
is I-Claim
higher I-Claim
( I-Claim
ie I-Claim
, I-Claim
in I-Claim
patients I-Claim
treated I-Claim
with I-Claim
unconventional I-Claim
fractionation I-Claim
or I-Claim
with I-Claim
concomitant I-Claim
chemotherapy I-Claim
) I-Claim
is I-Claim
unknown I-Claim
. I-Claim

For B-Claim
men I-Claim
with I-Claim
localised I-Claim
prostate I-Claim
cancer I-Claim
, I-Claim
surgery I-Claim
provides I-Claim
a I-Claim
survival I-Claim
benefit I-Claim
compared I-Claim
with I-Claim
watchful I-Claim
waiting I-Claim
. I-Claim

Treatments O
are O
associated O
with O
morbidity O
. O

Results O
for O
functional O
outcome O
and O
quality O
of O
life O
are O
rarely O
reported O
beyond O
10 O
years O
and O
are O
lacking O
from O
randomised O
settings O
. O

We O
report O
results O
for O
quality O
of O
life O
for O
men O
in O
the O
Scandinavian O
Prostate O
Cancer O
Group O
Study O
Number O
4 O
( O
SPCG O
- O
4 O
) O
after O
a O
median O
follow O
- O
up O
of O
more O
than O
12 O
years O
. O

All O
living O
Swedish O
and O
Finnish O
men O
( O
400 O
of O
695 O
) O
randomly O
assigned O
to O
radical O
prostatectomy O
or O
watchful O
waiting O
in O
SPCG O
- O
4 O
from O
1989 O
to O
1999 O
were O
included O
in O
our O
analysis O
. O

An O
additional O
281 O
men O
were O
included O
in O
a O
population O
- O
based O
control O
group O
matched O
for O
region O
and O
age O
. O

Physical O
symptoms O
, O
symptom O
- O
induced O
stress O
, O
and O
self O
- O
assessed O
quality O
of O
life O
were O
evaluated O
with O
a O
study O
- O
specific O
questionnaire O
. O

Longitudinal O
data O
were O
available O
for O
166 O
Swedish O
men O
who O
had O
answered O
quality O
- O
of O
- O
life O
questionnaires O
at O
an O
earlier O
timepoint O
. O

182 O
( O
88 O
% O
) O
of O
208 O
men O
in O
the O
radical O
prostatectomy O
group O
, O
167 O
( O
87 O
% O
) O
of O
192 O
men O
in O
the O
watchful O
- O
waiting O
group O
, O
and O
214 O
( O
76 O
% O
) O
of O
281 O
men O
in O
the O
population O
- O
based O
control O
group O
answered O
the O
questionnaire O
. O

Men O
in O
SPCG O
- O
4 O
had O
a O
median O
follow O
- O
up O
of O
12 O
Â· O
2 O
years O
( O
range O
7 O
- O
17 O
) O
and O
a O
median O
age O
of O
77 O
Â· O
0 O
years O
( O
range O
61 O
- O
88 O
) O
. O

High B-Premise
self I-Premise
- I-Premise
assessed I-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
reported I-Premise
by I-Premise
62 I-Premise
( I-Premise
35 I-Premise
% I-Premise
) I-Premise
of I-Premise
179 I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
, I-Premise
55 I-Premise
( I-Premise
34 I-Premise
% I-Premise
) I-Premise
of I-Premise
160 I-Premise
men I-Premise
assigned I-Premise
to I-Premise
watchful I-Premise
waiting I-Premise
, I-Premise
and I-Premise
93 I-Premise
( I-Premise
45 I-Premise
% I-Premise
) I-Premise
of I-Premise
208 I-Premise
men I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Anxiety B-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
SPCG I-Premise
- I-Premise
4 I-Premise
groups I-Premise
( I-Premise
77 I-Premise
[ I-Premise
43 I-Premise
% I-Premise
] I-Premise
of I-Premise
178 I-Premise
and I-Premise
69 I-Premise
[ I-Premise
43 I-Premise
% I-Premise
] I-Premise
of I-Premise
161 I-Premise
men I-Premise
) I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
68 I-Premise
[ I-Premise
33 I-Premise
% I-Premise
] I-Premise
of I-Premise
208 I-Premise
men I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
relative I-Premise
risk I-Premise
1 I-Premise
Â· I-Premise
42 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
1 I-Premise
Â· I-Premise
07 I-Premise
- I-Premise
1 I-Premise
Â· I-Premise
88 I-Premise
) I-Premise
. I-Premise

Prevalence B-Premise
of I-Premise
erectile I-Premise
dysfunction I-Premise
was I-Premise
84 I-Premise
% I-Premise
( I-Premise
146 I-Premise
of I-Premise
173 I-Premise
men I-Premise
) I-Premise
in I-Premise
the I-Premise
radical I-Premise
prostatectomy I-Premise
group I-Premise
, I-Premise
80 I-Premise
% I-Premise
( I-Premise
122 I-Premise
of I-Premise
153 I-Premise
) I-Premise
in I-Premise
the I-Premise
watchful I-Premise
- I-Premise
waiting I-Premise
group I-Premise
, I-Premise
and I-Premise
46 I-Premise
% I-Premise
( I-Premise
95 I-Premise
of I-Premise
208 I-Premise
) I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
prevalence I-Premise
of I-Premise
urinary I-Premise
leakage I-Premise
was I-Premise
41 I-Premise
% I-Premise
( I-Premise
71 I-Premise
of I-Premise
173 I-Premise
) I-Premise
, I-Premise
11 I-Premise
% I-Premise
( I-Premise
18 I-Premise
of I-Premise
164 I-Premise
) I-Premise
, I-Premise
and I-Premise
3 I-Premise
% I-Premise
( I-Premise
six I-Premise
of I-Premise
209 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Distress B-Premise
caused I-Premise
by I-Premise
these I-Premise
symptoms I-Premise
was I-Premise
reported I-Premise
significantly I-Premise
more I-Premise
often I-Premise
by I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
than I-Premise
by I-Premise
men I-Premise
assigned I-Premise
to I-Premise
watchful I-Premise
waiting I-Premise
. I-Premise

In B-Premise
a I-Premise
longitudinal I-Premise
analysis I-Premise
of I-Premise
men I-Premise
in I-Premise
SPCG I-Premise
- I-Premise
4 I-Premise
who I-Premise
provided I-Premise
information I-Premise
at I-Premise
two I-Premise
follow I-Premise
- I-Premise
up I-Premise
points I-Premise
9 I-Premise
years I-Premise
apart I-Premise
, I-Premise
38 I-Premise
( I-Premise
45 I-Premise
% I-Premise
) I-Premise
of I-Premise
85 I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
and I-Premise
48 I-Premise
( I-Premise
60 I-Premise
% I-Premise
) I-Premise
of I-Premise
80 I-Premise
men I-Premise
allocated I-Premise
watchful I-Premise
waiting I-Premise
reported I-Premise
an I-Premise
increase I-Premise
in I-Premise
number I-Premise
of I-Premise
physical I-Premise
symptoms I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
50 I-Premise
( I-Premise
61 I-Premise
% I-Premise
) I-Premise
of I-Premise
82 I-Premise
and I-Premise
47 I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
of I-Premise
74 I-Premise
men I-Premise
, I-Premise
respectively I-Premise
, I-Premise
reported I-Premise
a I-Premise
reduction I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

For B-Premise
men I-Premise
in I-Premise
SPCG I-Premise
- I-Premise
4 I-Premise
, I-Premise
negative I-Premise
side I-Premise
- I-Premise
effects I-Premise
were I-Premise
common I-Premise
and I-Premise
added I-Premise
more I-Premise
stress I-Premise
than I-Premise
was I-Premise
reported I-Premise
in I-Premise
the I-Premise
control I-Premise
population I-Premise
. I-Premise

In B-Claim
the I-Claim
radical I-Claim
prostatectomy I-Claim
group I-Claim
, I-Claim
erectile I-Claim
dysfunction I-Claim
and I-Claim
urinary I-Claim
leakage I-Claim
were I-Claim
often I-Claim
consequences I-Claim
of I-Claim
surgery I-Claim
. I-Claim

In B-Claim
the I-Claim
watchful I-Claim
- I-Claim
waiting I-Claim
group I-Claim
, I-Claim
side I-Claim
- I-Claim
effects I-Claim
can I-Claim
be I-Claim
caused I-Claim
by I-Claim
tumour I-Claim
progression I-Claim
. I-Claim

The B-Claim
number I-Claim
and I-Claim
severity I-Claim
of I-Claim
side I-Claim
- I-Claim
effects I-Claim
changes I-Claim
over I-Claim
time I-Claim
at I-Claim
a I-Claim
higher I-Claim
rate I-Claim
than I-Claim
is I-Claim
caused I-Claim
by I-Claim
normal I-Claim
ageing I-Claim
and I-Claim
a I-Claim
loss I-Claim
of I-Claim
sexual I-Claim
ability I-Claim
is I-Claim
a I-Claim
persistent I-Claim
psychological I-Claim
problem I-Claim
for I-Claim
both I-Claim
interventions I-Claim
. I-Claim

An O
understanding O
of O
the O
patterns O
of O
side O
- O
effects O
and O
time O
dimension O
of O
their O
occurrence O
for O
each O
treatment O
is O
important O
for O
full O
patient O
information O
. O

For B-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
, I-Claim
treatment I-Claim
is I-Claim
primarily I-Claim
palliative I-Claim
, I-Claim
relying I-Claim
mainly I-Claim
on I-Claim
the I-Claim
suppression I-Claim
of I-Claim
systemic I-Claim
androgen I-Claim
hormone I-Claim
levels I-Claim
. I-Claim

To O
help O
document O
the O
achievement O
of O
palliation O
and O
to O
characterize O
positive O
and O
negative O
effects O
of O
treatment O
, O
we O
evaluated O
quality O
- O
of O
- O
life O
( O
QOL O
) O
parameters O
in O
patients O
with O
metastatic O
prostate O
cancer O
who O
were O
randomly O
assigned O
to O
two O
methods O
of O
androgen O
deprivation O
. O

Patients O
( O
n O
= O
739 O
) O
with O
stage O
M1 O
( O
bone O
or O
soft O
tissue O
metastasis O
) O
prostate O
cancer O
were O
enrolled O
in O
a O
QOL O
protocol O
that O
was O
a O
companion O
to O
Southwest O
Oncology O
Group O
INT O
- O
0105 O
, O
a O
randomized O
double O
- O
blind O
trial O
comparing O
treatment O
with O
bilateral O
orchiectomy O
( O
surgical O
castration O
) O
plus O
either O
flutamide O
or O
placebo O
. O

Patients O
completed O
a O
comprehensive O
battery O
of O
QOL O
questionnaires O
at O
random O
assignment O
to O
treatment O
and O
at O
1 O
, O
3 O
, O
and O
6 O
months O
later O
. O

Data O
were O
collected O
on O
three O
treatment O
- O
specific O
symptoms O
( O
diarrhea O
, O
gas O
pain O
, O
and O
body O
image O
) O
, O
on O
physical O
functioning O
, O
and O
on O
emotional O
functioning O
. O

All O
P O
values O
are O
two O
- O
sided O
. O

Questionnaire O
return O
rates O
for O
this O
study O
never O
dropped O
below O
80 O
% O
"""" O
; O
"""" O
only O
2 O
% O
of O
the O
patients O
did O
not O
submit O
baseline O
QOL O
assessments O
. O

Cross B-Premise
- B-Premise
sectional B-Premise
analyses I-Premise
( I-Premise
corrected I-Premise
for I-Premise
multiple I-Premise
testing I-Premise
) I-Premise
identified I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
that I-Premise
favored I-Premise
orchiectomy I-Premise
plus I-Premise
placebo I-Premise
for I-Premise
two I-Premise
of I-Premise
the I-Premise
five I-Premise
primary I-Premise
QOL I-Premise
parameters I-Premise
as I-Premise
follows I-Premise
: I-Premise
patients I-Premise
receiving I-Premise
flutamide I-Premise
reported I-Premise
more I-Premise
diarrhea I-Premise
at I-Premise
3 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
worse I-Premise
emotional I-Premise
functioning I-Premise
at I-Premise
3 I-Premise
and I-Premise
6 I-Premise
months I-Premise
( I-Premise
both I-Premise
P I-Premise
< I-Premise
. I-Premise
003 I-Premise
) I-Premise
. I-Premise

Longitudinal B-Premise
analyses I-Premise
replicated I-Premise
these I-Premise
findings I-Premise
. I-Premise

Other B-Premise
analyzed I-Premise
QOL I-Premise
parameters I-Premise
favored I-Premise
the I-Premise
group I-Premise
receiving I-Premise
placebo I-Premise
but B-Premise
were I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
after I-Premise
adjustment I-Premise
for I-Premise
multiple I-Premise
testing I-Premise
. I-Premise

We B-Claim
found I-Claim
a I-Claim
consistent I-Claim
pattern I-Claim
of I-Claim
better I-Claim
QOL I-Claim
outcomes I-Claim
at I-Claim
each I-Claim
follow I-Claim
- I-Claim
up I-Claim
assessment I-Claim
during I-Claim
the I-Claim
first I-Claim
6 I-Claim
months I-Claim
of I-Claim
treatment I-Claim
for I-Claim
orchiectomized I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
who I-Claim
received I-Claim
placebo I-Claim
versus I-Claim
flutamide I-Claim
. I-Claim

Improvement B-Claim
over I-Claim
time I-Claim
was I-Claim
evident I-Claim
in I-Claim
both I-Claim
treatment I-Claim
groups I-Claim
but I-Claim
more I-Claim
so I-Claim
for I-Claim
patients I-Claim
receiving I-Claim
placebo I-Claim
. I-Claim

Regularly O
collecting O
patient O
- O
reported O
outcomes O
( O
PROs O
) O
of O
health O
- O
related O
quality O
of O
life O
with O
feedback O
to O
oncologists O
may O
assist O
in O
eliciting O
and O
monitoring O
patients O
' O
problems O
during O
cancer O
treatment O
. O

This O
study O
examined O
how O
PRO O
feedback O
had O
an O
impact O
on O
patient O
- O
physician O
communication O
over O
time O
to O
gain O
a O
better O
understanding O
of O
how O
it O
may O
influence O
patient O
care O
. O

Exploratory O
analyses O
were O
performed O
on O
a O
data O
set O
from O
a O
previous O
study O
. O

Patients O
were O
randomly O
assigned O
to O
intervention O
( O
regular O
completion O
of O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
- O
Core O
30 O
and O
Hospital O
Anxiety O
and O
Depression O
Scale O
with O
feedback O
to O
oncologists O
) O
, O
attention O
- O
control O
( O
completion O
of O
same O
questionnaires O
without O
feedback O
) O
, O
and O
control O
( O
standard O
care O
) O
arms O
. O

The O
content O
of O
consultation O
audio O
recordings O
between O
28 O
oncologists O
and O
198 O
patients O
over O
four O
consecutive O
visits O
( O
792 O
consultations O
) O
was O
analyzed O
. O

Mixed O
- O
effects O
models O
and O
multivariate O
regressions O
were O
used O
to O
examine O
the O
longitudinal O
impact O
of O
the O
intervention O
on O
patient O
- O
physician O
communication O
, O
dynamics O
of O
patient O
- O
physician O
interaction O
, O
and O
the O
association O
between O
PROs O
and O
the O
content O
of O
clinic O
discussion O
. O

Patients B-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
discussed I-Premise
more I-Premise
symptoms I-Premise
over I-Premise
time I-Premise
compared I-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
attention I-Premise
- I-Premise
control I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
008 I-Premise
) I-Premise
and I-Premise
control I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
04 I-Premise
) I-Premise
arms I-Premise
. I-Premise

No B-Premise
study I-Premise
arm I-Premise
effect I-Premise
was I-Premise
observed I-Premise
for I-Premise
function I-Premise
discussions I-Premise
. I-Premise

Discussion O
topics O
were O
predominantly O
raised O
by O
patients O
/ O
relatives O
, O
regardless O
of O
arm O
allocation O
. O

Clinic B-Premise
discussions I-Premise
were I-Premise
associated I-Premise
with I-Premise
severity I-Premise
of I-Premise
patient I-Premise
- I-Premise
reported I-Premise
symptoms I-Premise
but I-Premise
not I-Premise
with I-Premise
patient I-Premise
- I-Premise
reported I-Premise
functional I-Premise
concerns I-Premise
. I-Premise

A B-Premise
positive I-Premise
longitudinal I-Premise
impact I-Premise
of I-Premise
the I-Premise
intervention I-Premise
on I-Premise
symptom I-Premise
discussion I-Premise
was I-Premise
observed I-Premise
, I-Premise
but B-Premise
not I-Premise
for I-Premise
function I-Premise
discussion I-Premise
, I-Premise
suggesting I-Premise
that I-Premise
potentially I-Premise
serious I-Premise
problems I-Premise
may I-Premise
remain I-Premise
unaddressed I-Premise
. I-Premise

Training B-Claim
oncologists I-Claim
in I-Claim
responding I-Claim
to I-Claim
patient I-Claim
- I-Claim
reported I-Claim
functional I-Claim
concerns I-Claim
may I-Claim
increase I-Claim
the I-Claim
impact I-Claim
of I-Claim
this I-Claim
intervention I-Claim
. I-Claim

Anemia B-Claim
is I-Claim
an I-Claim
expected I-Claim
consequence I-Claim
of I-Claim
intensive I-Claim
chemotherapy I-Claim
regimens I-Claim
administered I-Claim
to I-Claim
patients I-Claim
with I-Claim
acute I-Claim
leukemia I-Claim
. I-Claim

This O
study O
was O
designed O
to O
determine O
whether O
epoetin O
alpha O
would O
decrease O
the O
number O
of O
transfusion O
events O
and O
units O
of O
packed O
erythrocytes O
( O
PRBCs O
) O
transfused O
, O
and O
the O
secondary O
objective O
was O
to O
study O
the O
effects O
of O
epoetin O
alpha O
on O
quality O
of O
life O
( O
QOL O
) O
and O
complete O
remission O
( O
CR O
) O
rates O
. O

Patients O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
, O
lymphoblastic O
lymphoma O
( O
LL O
) O
, O
or O
Burkitt O
lymphoma O
( O
BL O
) O
who O
were O
receiving O
frontline O
myelosuppressive O
chemotherapy O
were O
randomized O
to O
receive O
epoetin O
alpha O
or O
no O
epoetin O
during O
the O
first O
6 O
cycles O
of O
their O
planned O
chemotherapy O
. O

QOL O
was O
assessed O
by O
using O
the O
Edmonton O
Symptom O
Assessment O
Scale O
( O
ESAS O
) O
and O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT O
) O
- O
Anemia O
questionnaires O
. O

Fifty O
- O
five O
patients O
were O
randomized O
to O
receive O
epoetin O
alpha O
, O
and O
54 O
patients O
received O
no O
epoetin O
. O

Transfusion O
data O
were O
available O
for O
79 O
of O
81 O
evaluable O
patients O
( O
98 O
% O
) O
who O
completed O
the O
treatment O
/ O
observation O
period O
. O

The B-Premise
trial I-Premise
was I-Premise
stopped I-Premise
early I-Premise
because I-Premise
of I-Premise
poor I-Premise
accrual I-Premise
before I-Premise
the I-Premise
target I-Premise
of I-Premise
123 I-Premise
evaluable I-Premise
patients I-Premise
was I-Premise
met I-Premise
. I-Premise

A B-Premise
mean I-Premise
of I-Premise
10 I-Premise
. I-Premise
6 I-Premise
units I-Premise
of I-Premise
PRBCs I-Premise
over I-Premise
5 I-Premise
months I-Premise
were I-Premise
administered I-Premise
to I-Premise
those I-Premise
who I-Premise
received I-Premise
epoetin I-Premise
alpha I-Premise
compared I-Premise
with I-Premise
13 I-Premise
units I-Premise
for I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
receive I-Premise
epoetin I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
04 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
QOL I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
FACT I-Premise
- I-Premise
Anemia I-Premise
or I-Premise
ESAS I-Premise
instruments I-Premise
. I-Premise

The B-Premise
CR I-Premise
rate I-Premise
and I-Premise
the I-Premise
3 I-Premise
- I-Premise
year I-Premise
CR I-Premise
duration I-Premise
were I-Premise
not I-Premise
affected I-Premise
adversely I-Premise
by I-Premise
use I-Premise
of I-Premise
epoetin I-Premise
alpha I-Premise
. I-Premise

Epoetin B-Claim
alpha I-Claim
decreased I-Claim
the I-Claim
number I-Claim
of I-Claim
PRBC I-Claim
transfusions I-Claim
and I-Claim
did I-Claim
not I-Claim
appear I-Claim
to I-Claim
have I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
remission I-Claim
duration I-Claim
. I-Claim

No B-Claim
difference I-Claim
in I-Claim
QOL I-Claim
was I-Claim
observed I-Claim
. I-Claim

A O
single O
- O
item O
linear O
analogue O
self O
- O
assessment O
scale O
for O
mood O
was O
compared O
with O
a O
28 O
- O
item O
adjective O
checklist O
for O
emotional O
well O
- O
being O
. O

To O
confirm O
its O
concurrent O
validity O
and O
responsiveness O
to O
treatment O
and O
recurrence O
in O
patients O
with O
breast O
cancer O
, O
emotional O
well O
- O
being O
was O
assessed O
every O
3 O
months O
for O
2 O
years O
and O
at O
1 O
and O
6 O
months O
after O
recurrence O
in O
1 O
, O
169 O
patients O
who O
were O
premenopausal O
and O
960 O
patients O
who O
were O
postmenopausal O
. O

These O
patients O
were O
enrolled O
in O
two O
International O
Breast O
Cancer O
Study O
Group O
randomized O
clinical O
trials O
in O
operable O
breast O
cancer O
conducted O
from O
1986 O
to O
1993 O
. O

To O
assess O
concurrent O
validity O
, O
Pearson O
' O
s O
correlation O
between O
the O
linear O
analogue O
self O
- O
assessment O
scale O
and O
the O
adjective O
checklist O
were O
calculated O
for O
each O
time O
- O
point O
within O
each O
treatment O
group O
and O
for O
the O
two O
assessments O
after O
recurrence O
. O

Responsiveness O
to O
treatment O
and O
recurrence O
were O
analyzed O
using O
paired O
t O
tests O
and O
the O
squared O
ratio O
of O
these O
t O
tests O
, O
an O
estimate O
of O
relative O
efficiency O
. O

Concurrent O
validity O
of O
the O
mood O
linear O
analogue O
self O
- O
assessment O
was O
consistently O
confirmed O
across O
four O
language O
groups O
. O

Both B-Claim
measures I-Claim
were I-Claim
responsive I-Claim
"""" I-Claim
; I-Claim
"""" I-Claim
out B-Premise
of I-Premise
24 I-Premise
changes I-Premise
over I-Premise
time I-Premise
, I-Premise
19 I-Premise
were I-Premise
in I-Premise
the I-Premise
expected I-Premise
direction I-Premise
for I-Premise
the I-Premise
linear I-Premise
analogue I-Premise
self I-Premise
- I-Premise
assessment I-Premise
scale I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
0 I-Premise
. I-Premise
05 I-Premise
for I-Premise
9 I-Premise
of I-Premise
19 I-Premise
) I-Premise
and I-Premise
17 I-Premise
for I-Premise
the I-Premise
adjective I-Premise
checklist I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
0 I-Premise
. I-Premise
05 I-Premise
for I-Premise
10 I-Premise
of I-Premise
17 I-Premise
) I-Premise
. I-Premise

The B-Premise
linear I-Premise
analogue I-Premise
self I-Premise
- I-Premise
assessment I-Premise
scale I-Premise
was I-Premise
less I-Premise
but I-Premise
significantly I-Premise
efficient I-Premise
for I-Premise
detection I-Premise
of I-Premise
treatment I-Premise
effects I-Premise
, I-Premise
with I-Premise
relative I-Premise
efficiency I-Premise
estimates I-Premise
ranging I-Premise
from I-Premise
0 I-Premise
. I-Premise
16 I-Premise
to I-Premise
2 I-Premise
. I-Premise
45 I-Premise
and I-Premise
a I-Premise
median I-Premise
of I-Premise
0 I-Premise
. I-Premise
66 I-Premise
among I-Premise
the I-Premise
comparisons I-Premise
with I-Premise
relatively I-Premise
stable I-Premise
estimates I-Premise
( I-Premise
/ I-Premise
t I-Premise
/ I-Premise
> I-Premise
or I-Premise
= I-Premise
1 I-Premise
. I-Premise
0 I-Premise
) I-Premise
and I-Premise
more I-Premise
efficient I-Premise
for I-Premise
recurrence I-Premise
than I-Premise
the I-Premise
adjective I-Premise
checklist I-Premise
. I-Premise

The B-Claim
mood I-Claim
linear I-Claim
analogue I-Claim
self I-Claim
- I-Claim
assessment I-Claim
scale I-Claim
is I-Claim
a I-Claim
valid I-Claim
indicator I-Claim
of I-Claim
emotional I-Claim
well I-Claim
- I-Claim
being I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
large I-Claim
multicenter I-Claim
, I-Claim
multicultural I-Claim
trials I-Claim
in I-Claim
which I-Claim
comprehensive I-Claim
scales I-Claim
are I-Claim
less I-Claim
feasible I-Claim
. I-Claim

This B-Claim
investigation I-Claim
supports I-Claim
the I-Claim
clinical I-Claim
relevance I-Claim
of I-Claim
linear I-Claim
analogue I-Claim
self I-Claim
- I-Claim
assessment I-Claim
scales I-Claim
as I-Claim
indicators I-Claim
of I-Claim
components I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
cancer I-Claim
clinical I-Claim
trials I-Claim
. I-Claim

To O
analyze O
the O
predictive O
value O
of O
PSA O
for O
progression O
and O
the O
role O
of O
testosterone O
for O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
androgen O
deprivation O
therapy O
( O
ADT O
) O
for O
metastatic O
prostate O
cancer O
. O

PSA O
and O
testosterone O
data O
were O
used O
from O
a O
phase O
III O
trial O
randomizing O
patients O
without O
progression O
and O
PSA O
< O
4 O
ng O
/ O
ml O
( O
n O
= O
193 O
) O
, O
after O
6 O
months O
induction O
course O
, O
between O
continuous O
( O
CAD O
) O
( O
n O
= O
96 O
) O
and O
intermittent O
( O
IAD O
) O
( O
n O
= O
97 O
) O
ADT O
. O

The O
2 O
- O
year O
risk O
of O
progression O
was O
calculated O
for O
baseline O
PSA O
, O
' O
fast O
' O
and O
' O
slow O
' O
PSA O
decline O
to O
< O
4 O
ng O
/ O
ml O
( O
60 O
days O
cut O
- O
off O
) O
, O
PSA O
nadir O
, O
performance O
status O
and O
pain O
. O

Testosterone O
kinetics O
and O
QOL O
were O
also O
evaluated O
. O

Univariate O
Kaplan O
Meier O
survival O
analysis O
and O
log O
rank O
tests O
were O
used O
to O
compare O
the O
risk O
of O
progression O
. O

For O
progression O
analysis O
, O
173 O
patients O
' O
data O
were O
available O
. O

The O
2 O
- O
year O
risk O
of O
progression O
for O
baseline O
PSA O
< O
50 O
ng O
/ O
ml O
, O
50 O
to O
< O
500 O
ng O
/ O
ml O
, O
and O
â‰¥ O
500 O
ng O
/ O
ml O
was O
25 O
% O
, O
55 O
% O
, O
and O
76 O
% O
( O
P O
= O
0 O
. O
03 O
) O
in O
CAD O
, O
and O
38 O
% O
, O
64 O
% O
, O
and O
85 O
% O
( O
P O
= O
0 O
. O
006 O
) O
in O
IAD O
, O
respectively O
. O

The B-Premise
2 I-Premise
- I-Premise
year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
for I-Premise
PSA I-Premise
nadir I-Premise
â‰¤ I-Premise
0 I-Premise
. I-Premise
2 I-Premise
ng I-Premise
/ I-Premise
ml I-Premise
, I-Premise
and I-Premise
> I-Premise
0 I-Premise
. I-Premise
2 I-Premise
to I-Premise
4 I-Premise
ng I-Premise
/ I-Premise
ml I-Premise
in I-Premise
CAD I-Premise
was I-Premise
31 I-Premise
% I-Premise
and I-Premise
70 I-Premise
% I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In B-Premise
the I-Premise
IAD I-Premise
group I-Premise
, I-Premise
a I-Premise
similar I-Premise
trend I-Premise
was I-Premise
seen I-Premise
. I-Premise

Patients B-Premise
with I-Premise
PSA I-Premise
nadir I-Premise
â‰¤ I-Premise
0 I-Premise
. I-Premise
2 I-Premise
ng I-Premise
/ I-Premise
ml I-Premise
, I-Premise
though I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
2 I-Premise
- I-Premise
year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
compared I-Premise
to I-Premise
CAD I-Premise
( I-Premise
53 I-Premise
% I-Premise
vs I-Premise
. I-Premise
31 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

PSA O
decline O
showed O
no O
predictive O
value O
. O

Patients B-Premise
without I-Premise
pain I-Premise
had I-Premise
a I-Premise
significantly I-Premise
lower I-Premise
2 I-Premise
- I-Premise
year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

Without B-Premise
ADT I-Premise
testosterone I-Premise
remained I-Premise
at I-Premise
castrate I-Premise
level I-Premise
for I-Premise
4 I-Premise
months I-Premise
. I-Premise

After O
the O
first O
and O
second O
IAD O
cycle O
92 O
% O
and O
46 O
% O
, O
respectively O
, O
had O
a O
normalized O
testosterone O
. O

No B-Premise
QOL I-Premise
difference I-Premise
was I-Premise
found I-Premise
, I-Premise
although I-Premise
more I-Premise
side I-Premise
effects I-Premise
occurred I-Premise
in I-Premise
CAD I-Premise
. I-Premise

Metastatic B-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
high I-Claim
baseline I-Claim
PSA I-Claim
, I-Claim
pain I-Claim
, I-Claim
and I-Claim
high I-Claim
PSA I-Claim
nadir I-Claim
have I-Claim
a I-Claim
poor I-Claim
prognosis I-Claim
with I-Claim
ADT I-Claim
. I-Claim

Patients B-Claim
with I-Claim
low I-Claim
PSA I-Claim
nadir I-Claim
do I-Claim
significantly I-Claim
worse I-Claim
with I-Claim
IAD I-Claim
compared I-Claim
with I-Claim
CAD I-Claim
. I-Claim

Low O
testosterone O
after O
ADT O
and O
incomplete O
testosterone O
recovery O
may O
explain O
similar O
QOL O
. O

Therefore O
, O
IAD B-Claim
is I-Claim
not I-Claim
a I-Claim
good I-Claim
treatment I-Claim
option I-Claim
for I-Claim
many I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

To O
compare O
the O
efficacy O
of O
low O
- O
frequency O
low O
- O
intensity O
electrotherapy O
and O
manual O
lymphatic O
drainage O
in O
the O
treatment O
of O
chronic O
upper O
limb O
breast O
cancer O
- O
related O
lymphoedema O
. O

Cross O
- O
over O
single O
- O
blind O
random O
clinical O
trial O
. O

Rehabilitation O
service O
. O

Thirty O
- O
six O
women O
with O
chronic O
upper O
limb O
breast O
cancer O
- O
related O
lymphoedema O
. O

Patients O
were O
randomized O
to O
undergo O
10 O
sessions O
of O
manual O
lymphatic O
drainage O
followed O
by O
10 O
sessions O
of O
low O
- O
frequency O
low O
- O
intensity O
electrotherapy O
or O
to O
undergo O
first O
low O
- O
frequency O
low O
- O
intensity O
electrotherapy O
followed O
by O
manual O
lymphatic O
drainage O
. O

There O
was O
a O
month O
of O
washout O
time O
between O
treatments O
. O

Each O
patient O
was O
examined O
just O
before O
and O
after O
each O
treatment O
. O

Researchers O
and O
outcome O
assessors O
were O
blinded O
for O
assigned O
treatment O
. O

Outcomes O
were O
lymphoedema O
volume O
, O
pain O
, O
heaviness O
and O
tightness O
, O
and O
health O
- O
related O
quality O
of O
life O
measured O
with O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
Questionnaire O
for O
Breast O
Cancer O
version O
4 O
( O
FACT O
- O
B O
+ O
4 O
) O
. O

Carry O
- O
over O
, O
period O
and O
treatment O
effects O
were O
analysed O
. O

Treatment O
effect O
was O
assessed O
using O
paired O
t O
- O
test O
. O

Thirty O
patients O
finalized O
treatment O
. O

Comparing B-Premise
the I-Premise
changes I-Premise
in I-Premise
low I-Premise
- I-Premise
frequency I-Premise
low I-Premise
- I-Premise
intensity I-Premise
electrotherapy I-Premise
with I-Premise
manual I-Premise
lymphatic I-Premise
drainage I-Premise
changes I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
. I-Premise

Low B-Premise
- B-Premise
frequency B-Premise
low I-Premise
- I-Premise
intensity I-Premise
electrotherapy I-Premise
did I-Premise
not I-Premise
reduce I-Premise
lymphoedema I-Premise
volume I-Premise
( I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
19 I-Premise
. I-Premise
77 I-Premise
mL I-Premise
, I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
36 I-Premise
) I-Premise
, I-Premise
but O
significant B-Premise
reductions I-Premise
were I-Premise
observed I-Premise
in I-Premise
pain I-Premise
, I-Premise
heaviness I-Premise
and I-Premise
tightness I-Premise
( I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
13 I-Premise
. I-Premise
1 I-Premise
, I-Premise
16 I-Premise
. I-Premise
2 I-Premise
and I-Premise
6 I-Premise
. I-Premise
4 I-Premise
mm I-Premise
, I-Premise
respectively I-Premise
) I-Premise
, I-Premise
and I-Premise
FACT I-Premise
- I-Premise
B I-Premise
+ I-Premise
4 I-Premise
summaries I-Premise
improved I-Premise
significantly I-Premise
( I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
5 I-Premise
. I-Premise
4 I-Premise
, I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
015 I-Premise
) I-Premise
. I-Premise

Manual B-Premise
lymphatic I-Premise
drainage I-Premise
showed I-Premise
no I-Premise
significant I-Premise
changes I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
outcomes I-Premise
. I-Premise

Although B-Claim
there I-Claim
are I-Claim
no I-Claim
significant I-Claim
differences I-Claim
between I-Claim
treatment I-Claim
changes I-Claim
, I-Claim
the B-Claim
observed I-Claim
trend I-Claim
towards I-Claim
a I-Claim
better I-Claim
health I-Claim
- I-Claim
related I-Claim
quality I-Claim
of I-Claim
life I-Claim
is I-Claim
remarkable I-Claim
in I-Claim
low I-Claim
- I-Claim
frequency I-Claim
low I-Claim
- I-Claim
intensity I-Claim
electrotherapy I-Claim
. I-Claim

Molecular O
markers O
to O
predict O
response O
to O
5 O
- O
fluorouracil O
( O
FU O
) O
- O
based O
treatment O
of O
recurrent O
or O
metastasised O
colorectal O
cancer O
( O
mCRC O
) O
are O
not O
established O
. O

The O
aim O
of O
this O
trial O
was O
to O
determine O
the O
value O
of O
thymidylate O
synthase O
( O
TS O
) O
, O
a O
key O
enzyme O
of O
DNA O
synthesis O
and O
target O
of O
5 O
- O
FU O
, O
to O
predict O
response O
to O
chemotherapy O
of O
mCRC O
. O

Tumour O
tissue O
was O
obtained O
from O
168 O
patients O
with O
mCRC O
for O
relative O
thymidylate O
synthase O
( O
TS O
) O
mRNA O
quantitation O
. O

Patients O
were O
randomised O
to O
receive O
either O
5 O
- O
FU O
/ O
folinic O
acid O
( O
FA O
, O
FUFA O
) O
alone O
or O
in O
combination O
with O
irinotecan O
5 O
- O
fluorouracil O
/ O
folinic O
acid O
and O
irinotecan O
( O
FOLFIRI O
) O
stratified O
by O
TS O
( O
low O
versus O
high O
) O
. O

Primary O
end O
- O
point O
was O
overall O
response O
to O
first O
- O
line O
treatment O
among O
TS O
high O
patients O
. O

All O
parties O
, O
except O
for O
the O
randomisation O
centre O
, O
were O
blinded O
for O
TS O
status O
. O

Biopsies O
( O
n O
= O
168 O
) O
were O
taken O
without O
complications O
. O

TS O
levels O
were O
available O
for O
147 O
patients O
( O
87 O
. O
5 O
% O
) O
. O

Analysing B-Premise
response I-Premise
to I-Premise
FUFA I-Premise
and I-Premise
FOLFIRI I-Premise
in I-Premise
the I-Premise
per I-Premise
protocol I-Premise
set I-Premise
( I-Premise
n I-Premise
= I-Premise
119 I-Premise
) I-Premise
after I-Premise
un I-Premise
- I-Premise
blinding I-Premise
TS I-Premise
in I-Premise
the I-Premise
data I-Premise
base I-Premise
revealed I-Premise
a I-Premise
trend I-Premise
to I-Premise
better I-Premise
overall I-Premise
response I-Premise
to I-Premise
FOLFIRI I-Premise
( I-Premise
9 I-Premise
/ I-Premise
19 I-Premise
, I-Premise
47 I-Premise
% I-Premise
) I-Premise
in I-Premise
TS I-Premise
high I-Premise
compared I-Premise
to I-Premise
FUFA I-Premise
( I-Premise
5 I-Premise
/ I-Premise
23 I-Premise
, I-Premise
22 I-Premise
% I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
077 I-Premise
) I-Premise
. I-Premise

In B-Premise
patients I-Premise
with I-Premise
biopsies I-Premise
taken I-Premise
from I-Premise
liver I-Premise
lesions I-Premise
( I-Premise
n I-Premise
= I-Premise
91 I-Premise
) I-Premise
overall I-Premise
response I-Premise
to I-Premise
FOLFIRI I-Premise
and I-Premise
FUFA I-Premise
in I-Premise
TS I-Premise
high I-Premise
was I-Premise
53 I-Premise
% I-Premise
( I-Premise
9 I-Premise
/ I-Premise
17 I-Premise
) I-Premise
and I-Premise
18 I-Premise
% I-Premise
( I-Premise
3 I-Premise
/ I-Premise
17 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
035 I-Premise
) I-Premise
. I-Premise

In B-Premise
patients I-Premise
with I-Premise
low I-Premise
TS I-Premise
, I-Premise
no I-Premise
remarkable I-Premise
difference I-Premise
in I-Premise
overall I-Premise
response I-Premise
to I-Premise
FOLFIRI I-Premise
and I-Premise
FUFA I-Premise
was I-Premise
observed I-Premise
. I-Premise

Taking B-Claim
a I-Claim
pre I-Claim
- I-Claim
treatment I-Claim
biopsy I-Claim
is I-Claim
a I-Claim
safe I-Claim
and I-Claim
feasible I-Claim
procedure I-Claim
in I-Claim
mCRC I-Claim
. I-Claim

After B-Claim
validation I-Claim
of I-Claim
our I-Claim
data I-Claim
in I-Claim
a I-Claim
larger I-Claim
group I-Claim
TS I-Claim
determination I-Claim
may I-Claim
have I-Claim
the I-Claim
potential I-Claim
to I-Claim
better I-Claim
help I-Claim
direct I-Claim
systemic I-Claim
treatment I-Claim
in I-Claim
patients I-Claim
with I-Claim
primarily I-Claim
non I-Claim
- I-Claim
resectable I-Claim
mCRC I-Claim
. I-Claim

It O
is O
not O
known O
whether O
low O
- O
dose O
radioiodine O
( O
1 O
. O
1 O
GBq O
[ O
30 O
mCi O
] O
) O
is O
as O
effective O
as O
high O
- O
dose O
radioiodine O
( O
3 O
. O
7 O
GBq O
[ O
100 O
mCi O
] O
) O
for O
treating O
patients O
with O
differentiated O
thyroid O
cancer O
or O
whether O
the O
effects O
of O
radioiodine O
( O
especially O
at O
a O
low O
dose O
) O
are O
influenced O
by O
using O
either O
recombinant O
human O
thyrotropin O
( O
thyrotropin O
alfa O
) O
or O
thyroid O
hormone O
withdrawal O
. O

At O
29 O
centers O
in O
the O
United O
Kingdom O
, O
we O
conducted O
a O
randomized O
noninferiority O
trial O
comparing O
low O
- O
dose O
and O
high O
- O
dose O
radioiodine O
, O
each O
in O
combination O
with O
either O
thyrotropin O
alfa O
or O
thyroid O
hormone O
withdrawal O
before O
ablation O
. O

Patients O
( O
age O
range O
, O
16 O
to O
80 O
years O
) O
had O
tumor O
stage O
T1 O
to O
T3 O
, O
with O
possible O
spread O
to O
nearby O
lymph O
nodes O
but O
without O
metastasis O
. O

End O
points O
were O
the O
rate O
of O
success O
of O
ablation O
at O
6 O
to O
9 O
months O
, O
adverse O
events O
, O
quality O
of O
life O
, O
and O
length O
of O
hospital O
stay O
. O

A O
total O
of O
438 O
patients O
underwent O
randomization O
"""" O
; O
"""" O
data O
could O
be O
analyzed O
for O
421 O
. O

Ablation B-Premise
success I-Premise
rates I-Premise
were I-Premise
85 I-Premise
. I-Premise
0 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
receiving I-Premise
low I-Premise
- I-Premise
dose I-Premise
radioiodine I-Premise
versus I-Premise
88 I-Premise
. I-Premise
9 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
receiving I-Premise
the I-Premise
high I-Premise
dose I-Premise
and I-Premise
87 I-Premise
. I-Premise
1 I-Premise
% I-Premise
in I-Premise
the I-Premise
thyrotropin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
86 I-Premise
. I-Premise
7 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
undergoing I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
. I-Premise

All B-Premise
95 I-Premise
% I-Premise
confidence I-Premise
intervals I-Premise
for I-Premise
the I-Premise
differences I-Premise
were I-Premise
within I-Premise
Â±10 I-Premise
percentage I-Premise
points I-Premise
, I-Premise
indicating I-Premise
noninferiority I-Premise
. I-Premise

Similar B-Premise
results I-Premise
were I-Premise
found I-Premise
for I-Premise
low I-Premise
- I-Premise
dose I-Premise
radioiodine I-Premise
plus I-Premise
thyrotropin I-Premise
alfa I-Premise
( I-Premise
84 I-Premise
. I-Premise
3 I-Premise
% I-Premise
) I-Premise
versus I-Premise
high I-Premise
- I-Premise
dose I-Premise
radioiodine I-Premise
plus I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
( I-Premise
87 I-Premise
. I-Premise
6 I-Premise
% I-Premise
) I-Premise
or I-Premise
high I-Premise
- I-Premise
dose I-Premise
radioiodine I-Premise
plus I-Premise
thyrotropin I-Premise
alfa I-Premise
( I-Premise
90 I-Premise
. I-Premise
2 I-Premise
% I-Premise
) I-Premise
. I-Premise

More B-Premise
patients I-Premise
in I-Premise
the I-Premise
high I-Premise
- I-Premise
dose I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
low I-Premise
- I-Premise
dose I-Premise
group I-Premise
were I-Premise
hospitalized I-Premise
for I-Premise
at I-Premise
least I-Premise
3 I-Premise
days I-Premise
( I-Premise
36 I-Premise
. I-Premise
3 I-Premise
% I-Premise
vs I-Premise
. I-Premise
13 I-Premise
. I-Premise
0 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

The B-Premise
proportions I-Premise
of I-Premise
patients I-Premise
with I-Premise
adverse I-Premise
events I-Premise
were I-Premise
21 I-Premise
% I-Premise
in I-Premise
the I-Premise
low I-Premise
- I-Premise
dose I-Premise
group I-Premise
versus I-Premise
33 I-Premise
% I-Premise
in I-Premise
the I-Premise
high I-Premise
- I-Premise
dose I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
007 I-Premise
) I-Premise
and I-Premise
23 I-Premise
% I-Premise
in I-Premise
the I-Premise
thyrotropin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
30 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
undergoing I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
11 I-Premise
) I-Premise
. I-Premise

Low B-Claim
- B-Claim
dose B-Claim
radioiodine I-Claim
plus I-Claim
thyrotropin I-Claim
alfa I-Claim
was I-Claim
as I-Claim
effective I-Claim
as I-Claim
high I-Claim
- I-Claim
dose I-Claim
radioiodine I-Claim
, I-Claim
with I-Claim
a I-Claim
lower I-Claim
rate I-Claim
of I-Claim
adverse I-Claim
events I-Claim
. I-Claim

Although O
numerous O
treatment O
modalities O
have O
been O
explored O
in O
patients O
with O
advanced O
HCC O
, O
the O
therapeutic O
options O
are O
still O
limited O
. O

Somatostatin B-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
have I-Claim
antimitotic I-Claim
activity I-Claim
in I-Claim
endocrine I-Claim
as I-Claim
well I-Claim
as I-Claim
in I-Claim
a I-Claim
variety I-Claim
of I-Claim
nonendocrine I-Claim
tumors I-Claim
. I-Claim

Expression B-Premise
of I-Premise
somatostatin I-Premise
receptors I-Premise
is I-Premise
found I-Premise
in I-Premise
HCCs I-Premise
, I-Premise
but O
the B-Claim
efficacy I-Claim
of I-Claim
the I-Claim
somatostatin I-Claim
analogue I-Claim
octreotide I-Claim
remains I-Claim
controversial I-Claim
. I-Claim

Therefore O
, O
a O
randomized O
double O
- O
blind O
placebo O
- O
controlled O
multicenter O
trial O
was O
performed O
to O
assess O
the O
efficacy O
of O
long O
- O
acting O
octreotide O
for O
the O
treatment O
of O
advanced O
HCC O
. O

One O
hundred O
twenty O
untreated O
patients O
with O
histologically O
confirmed O
HCC O
were O
randomized O
to O
receive O
either O
long O
- O
acting O
octreotide O
( O
Sandostation O
LAR O
30 O
mg O
) O
intramuscularly O
every O
4 O
weeks O
or O
placebo O
. O

The O
study O
groups O
were O
comparable O
with O
respect O
to O
clinical O
characteristics O
. O

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
the I-Premise
cumulative I-Premise
survival I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
time I-Premise
was I-Premise
4 I-Premise
. I-Premise
7 I-Premise
months I-Premise
in I-Premise
the I-Premise
octreotide I-Premise
group I-Premise
compared I-Premise
with I-Premise
5 I-Premise
. I-Premise
3 I-Premise
months I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Six B-Premise
- B-Premise
month B-Premise
survival I-Premise
rates I-Premise
were I-Premise
41 I-Premise
% I-Premise
for I-Premise
octreotide I-Premise
patients I-Premise
and I-Premise
42 I-Premise
% I-Premise
for I-Premise
control I-Premise
patients I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
unadjusted I-Premise
relative I-Premise
risk I-Premise
for I-Premise
mortality I-Premise
in I-Premise
the I-Premise
octreotide I-Premise
group I-Premise
compared I-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
was I-Premise
1 I-Premise
. I-Premise
11 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0 I-Premise
. I-Premise
76 I-Premise
- I-Premise
1 I-Premise
. I-Premise
63 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
59 I-Premise
) I-Premise
. I-Premise

When B-Premise
adjusted I-Premise
for I-Premise
Okuda I-Premise
, I-Premise
CTP I-Premise
, I-Premise
and I-Premise
Cancer I-Premise
of I-Premise
the I-Premise
Liver I-Premise
Italian I-Premise
Program I-Premise
( I-Premise
CLIP I-Premise
) I-Premise
scores I-Premise
, I-Premise
the I-Premise
relative I-Premise
risk I-Premise
for I-Premise
octreotide I-Premise
did I-Premise
not I-Premise
change I-Premise
markedly I-Premise
and I-Premise
was I-Premise
1 I-Premise
. I-Premise
05 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0 I-Premise
. I-Premise
71 I-Premise
- I-Premise
1 I-Premise
. I-Premise
55 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
83 I-Premise
) I-Premise
. I-Premise

The B-Claim
CLIP I-Claim
score I-Claim
seems I-Claim
to I-Claim
predict I-Claim
survival I-Claim
better I-Claim
than I-Claim
both I-Claim
Okuda I-Claim
and I-Claim
CTP I-Claim
score I-Claim
. I-Claim

The B-Claim
randomized I-Claim
controlled I-Claim
double I-Claim
- I-Claim
blind I-Claim
HECTOR I-Claim
trial I-Claim
showed I-Claim
no I-Claim
survival I-Claim
benefit I-Claim
for I-Claim
HCC I-Claim
patients I-Claim
treated I-Claim
with I-Claim
long I-Claim
- I-Claim
acting I-Claim
octreotide I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
. I-Claim

We O
investigated O
the O
role O
of O
tamoxifen O
and O
radiotherapy O
( O
RT O
) O
for O
the O
prevention O
and O
treatment O
of O
gynecomastia O
and O
breast O
pain O
during O
adjuvant O
bicalutamide O
monotherapy O
after O
radical O
prostatectomy O
( O
RP O
) O
in O
patients O
with O
prostate O
cancer O
. O

Also O
, O
we O
evaluated O
their O
effects O
on O
patient O
hormonal O
status O
, O
quality O
of O
life O
( O
QOL O
) O
, O
sexual O
function O
and O
prostate O
specific O
antigen O
relapse O
- O
free O
survival O
. O

This O
was O
a O
multicenter O
prospective O
trial O
. O

From O
January O
2002 O
to O
February O
2004 O
, O
102 O
patients O
who O
had O
undergone O
RP O
for O
localized O
or O
locally O
advanced O
prostate O
cancer O
were O
recruited O
and O
randomized O
into O
3 O
groups O
, O
namely O
group O
1 O
- O
those O
receiving O
only O
150 O
mg O
bicalutamide O
as O
adjuvant O
hormonal O
therapy O
, O
group O
2 O
- O
those O
receiving O
bicalutamide O
and O
10 O
mg O
tamoxifen O
, O
and O
group O
3 O
- O
those O
receiving O
bicalutamide O
and O
RT O
. O

Patients O
in O
group O
1 O
in O
whom O
gynecomastia O
or O
breast O
pain O
developed O
were O
subsequently O
randomized O
to O
receive O
tamoxifen O
or O
RT O
soon O
after O
symptoms O
started O
. O

Gynecomastia O
, O
breast O
pain O
, O
prostate O
specific O
antigen O
, O
QOL O
, O
sexual O
function O
and O
hormonal O
levels O
were O
assessed O
. O

Minimum O
followup O
was O
12 O
months O
. O

Of B-Premise
group I-Premise
1 I-Premise
patients I-Premise
67 I-Premise
% I-Premise
had I-Premise
gynecomastia I-Premise
compared I-Premise
with I-Premise
8 I-Premise
% I-Premise
in I-Premise
group I-Premise
2 I-Premise
and I-Premise
34 I-Premise
% I-Premise
in I-Premise
group I-Premise
3 I-Premise
. I-Premise

Breast B-Premise
pain I-Premise
was I-Premise
more I-Premise
frequent I-Premise
in I-Premise
group I-Premise
1 I-Premise
than I-Premise
in I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
( I-Premise
58 I-Premise
% I-Premise
vs I-Premise
7 I-Premise
% I-Premise
and I-Premise
30 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Differences B-Premise
were I-Premise
significant I-Premise
between I-Premise
groups I-Premise
1 I-Premise
and I-Premise
2 I-Premise
( I-Premise
OR I-Premise
0 I-Premise
. I-Premise
12 I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
and I-Premise
groups I-Premise
1 I-Premise
and I-Premise
3 I-Premise
( I-Premise
OR I-Premise
0 I-Premise
. I-Premise
52 I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise

In B-Premise
patients I-Premise
in I-Premise
group I-Premise
1 I-Premise
who I-Premise
had I-Premise
gynecomastia I-Premise
or I-Premise
breast I-Premise
pain I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
symptoms I-Premise
was I-Premise
achieved I-Premise
in I-Premise
those I-Premise
receiving I-Premise
tamoxifen I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

Treatments B-Premise
were I-Premise
well I-Premise
tolerated I-Premise
in I-Premise
the I-Premise
3 I-Premise
groups I-Premise
. I-Premise

No B-Premise
differences I-Premise
in I-Premise
QOL I-Premise
between I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
were I-Premise
found I-Premise
. I-Premise

At B-Premise
a I-Premise
median I-Premise
followup I-Premise
of I-Premise
26 I-Premise
months I-Premise
we I-Premise
observed I-Premise
12 I-Premise
biochemical I-Premise
relapses I-Premise
. I-Premise

Gynecomastia B-Claim
and I-Claim
breast I-Claim
pain I-Claim
induced I-Claim
by I-Claim
bicalutamide I-Claim
monotherapy I-Claim
after I-Claim
RP I-Claim
can I-Claim
be I-Claim
prevented I-Claim
and I-Claim
treated I-Claim
. I-Claim

Tamoxifen B-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
be I-Claim
more I-Claim
effective I-Claim
and I-Claim
safe I-Claim
than I-Claim
RT I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

QOL B-Claim
and I-Claim
sexual I-Claim
function I-Claim
are I-Claim
not I-Claim
negatively I-Claim
influenced I-Claim
by I-Claim
these I-Claim
2 I-Claim
treatment I-Claim
options I-Claim
. O

To O
test O
the O
hypothesis O
that O
modulation O
of O
Bcl O
- O
2 O
with O
13 O
- O
cis O
retinoic O
acid O
( O
CRA O
) O
/ O
interferon O
- O
alpha2b O
( O
IFN O
) O
with O
paclitaxel O
( O
TAX O
) O
, O
or O
mitoxantrone O
, O
estramustine O
and O
vinorelbine O
( O
MEV O
) O
will O
have O
clinical O
activity O
in O
men O
with O
metastatic O
castrate O
- O
resistant O
prostate O
cancer O
( O
CRPC O
) O
. O

70 O
patients O
were O
treated O
with O
either O
MEV O
( O
Arm O
A O
) O
in O
a O
3 O
- O
week O
cycle O
or O
CRA O
/ O
IFN O
/ O
TAX O
with O
an O
8 O
- O
week O
cycle O
( O
Arm O
B O
) O
. O

Patients O
were O
assessed O
for O
response O
, O
toxicity O
, O
quality O
of O
life O
( O
QOL O
) O
, O
and O
the O
effect O
of O
treatment O
on O
Bcl O
- O
2 O
levels O
in O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
. O

The B-Premise
PSA I-Premise
response I-Premise
rates I-Premise
were I-Premise
50 I-Premise
% I-Premise
and I-Premise
23 I-Premise
% I-Premise
, I-Premise
measurable I-Premise
disease I-Premise
response I-Premise
rates I-Premise
( I-Premise
CR I-Premise
+ I-Premise
PR I-Premise
) I-Premise
14 I-Premise
% I-Premise
and I-Premise
15 I-Premise
% I-Premise
, I-Premise
and I-Premise
median I-Premise
overall I-Premise
survival I-Premise
19 I-Premise
. I-Premise
4 I-Premise
months I-Premise
and I-Premise
13 I-Premise
. I-Premise
9 I-Premise
months I-Premise
on I-Premise
Arm I-Premise
A I-Premise
and I-Premise
Arm I-Premise
B I-Premise
respectively I-Premise
. I-Premise

Transient B-Premise
grade I-Premise
4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
18 I-Premise
and I-Premise
2 I-Premise
patients I-Premise
, I-Premise
and I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
thrombosis I-Premise
in I-Premise
7 I-Premise
patients I-Premise
and I-Premise
1 I-Premise
patient I-Premise
in I-Premise
Arm I-Premise
A I-Premise
and I-Premise
Arm I-Premise
B I-Premise
respectively I-Premise
. I-Premise

Patients B-Premise
on I-Premise
Arm I-Premise
B I-Premise
reported I-Premise
a I-Premise
clinically I-Premise
significant I-Premise
decline I-Premise
in I-Premise
QOL I-Premise
between I-Premise
baseline I-Premise
and I-Premise
week I-Premise
9 I-Premise
/ I-Premise
10 I-Premise
( I-Premise
. I-Premise
71 I-Premise
s I-Premise
. I-Premise
d I-Premise
. I-Premise
) O
, I-Premise
and I-Premise
a I-Premise
significantly I-Premise
lower I-Premise
level I-Premise
of I-Premise
QOL I-Premise
than I-Premise
Arm I-Premise
A I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise

As B-Premise
hypothesized I-Premise
, I-Premise
Bcl I-Premise
- I-Premise
2 I-Premise
levels I-Premise
decreased I-Premise
with I-Premise
CRA I-Premise
/ I-Premise
IFN I-Premise
therapy I-Premise
only I-Premise
in I-Premise
Arm I-Premise
B I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
03 I-Premise
) I-Premise
. I-Premise

Treatment B-Claim
with I-Claim
MEV I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
demonstrated I-Claim
clinical I-Claim
activity I-Claim
in I-Claim
patients I-Claim
with I-Claim
CRPC I-Claim
. I-Claim

Given B-Claim
the I-Claim
adverse I-Claim
effect I-Claim
of I-Claim
CRA I-Claim
/ I-Claim
IFN I-Claim
/ I-Claim
TAX I-Claim
on I-Claim
QOL I-Claim
, I-Claim
the I-Claim
study I-Claim
of I-Claim
other I-Claim
novel I-Claim
agents I-Claim
that I-Claim
target I-Claim
Bcl I-Claim
- I-Claim
2 I-Claim
family I-Claim
proteins I-Claim
is I-Claim
warranted I-Claim
. I-Claim

The O
feasibility O
of O
measuring O
Bcl O
- O
2 O
protein O
in O
a O
cooperative O
group O
setting O
is O
hypothesis O
generating O
and O
supports O
further O
study O
as O
a O
marker O
for O
Bcl O
- O
2 O
targeted O
therapy O
. O

Taxol B-Premise
( I-Premise
paclitaxel I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
Bristol I-Premise
- I-Premise
Myers I-Premise
Squibb I-Premise
, I-Premise
Wallingford I-Premise
, I-Premise
CT I-Premise
) I-Premise
is I-Premise
a I-Premise
new I-Premise
anticancer I-Premise
agent I-Premise
with I-Premise
activity I-Premise
in I-Premise
a I-Premise
number I-Premise
of I-Premise
human I-Premise
tumors I-Premise
, I-Premise
including I-Premise
epithelial I-Premise
ovarian I-Premise
cancer I-Premise
. I-Premise

In O
nonrandomized O
trials O
, O
doses O
studied O
have O
ranged O
from O
135 O
mg O
/ O
m2 O
to O
250 O
mg O
/ O
m2 O
administered O
over O
24 O
hours O
with O
premedication O
to O
avoid O
hypersensitivity O
reactions O
( O
HSRs O
) O
. O

This O
study O
addressed O
two O
questions O
: O
the O
dose O
- O
response O
relationship O
of O
Taxol O
in O
relapsed O
ovarian O
cancer O
and O
the O
safety O
of O
a O
short O
infusion O
given O
with O
premedication O
. O

Women O
with O
platinum O
- O
pretreated O
epithelial O
ovarian O
cancer O
and O
measurable O
recurrent O
disease O
were O
randomized O
in O
a O
bifactorial O
design O
to O
receive O
either O
175 O
or O
135 O
mg O
/ O
m2 O
of O
Taxol O
over O
either O
24 O
or O
3 O
hours O
. O

Major O
end O
points O
were O
the O
frequency O
of O
significant O
HSRs O
and O
objective O
response O
rate O
. O

Secondary O
end O
points O
were O
progression O
- O
free O
and O
overall O
survival O
. O

Of O
407 O
patients O
randomized O
, O
391 O
were O
eligible O
and O
382 O
assessable O
for O
response O
. O

Analysis O
was O
performed O
according O
to O
the O
bifactorial O
design O
. O

Severe B-Premise
HSRs I-Premise
were I-Premise
rare I-Premise
( I-Premise
1 I-Premise
. I-Premise
5 I-Premise
% I-Premise
patients I-Premise
) I-Premise
and I-Premise
were I-Premise
not I-Premise
affected I-Premise
by I-Premise
either I-Premise
dose I-Premise
or I-Premise
schedule I-Premise
. I-Premise

Response B-Premise
was I-Premise
slightly I-Premise
higher I-Premise
at I-Premise
the I-Premise
175 I-Premise
- I-Premise
mg I-Premise
/ I-Premise
m2 I-Premise
dose I-Premise
( I-Premise
20 I-Premise
% I-Premise
) I-Premise
than I-Premise
at I-Premise
135 I-Premise
mg I-Premise
/ I-Premise
m2 I-Premise
( I-Premise
15 I-Premise
% I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
2 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
in I-Premise
the I-Premise
high I-Premise
- I-Premise
dose I-Premise
group I-Premise
( I-Premise
19 I-Premise
v I-Premise
14 I-Premise
weeks I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise

Significantly B-Premise
more I-Premise
neutropenia I-Premise
was I-Premise
seen I-Premise
when I-Premise
Taxol I-Premise
was I-Premise
administered I-Premise
as I-Premise
a I-Premise
24 I-Premise
- I-Premise
hour I-Premise
infusion I-Premise
. I-Premise

Response B-Premise
rates I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
- I-Premise
24 I-Premise
and I-Premise
3 I-Premise
- I-Premise
hour I-Premise
groups I-Premise
( I-Premise
19 I-Premise
% I-Premise
and I-Premise
16 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
6 I-Premise
) I-Premise
. I-Premise

No B-Premise
survival I-Premise
differences I-Premise
were I-Premise
noted I-Premise
. I-Premise

The B-Claim
3 I-Claim
- I-Claim
hour I-Claim
infusion I-Claim
of I-Claim
Taxol I-Claim
is I-Claim
safe I-Claim
when I-Claim
given I-Claim
with I-Claim
premedication I-Claim
and I-Claim
is I-Claim
associated I-Claim
with I-Claim
less I-Claim
neutropenia I-Claim
. I-Claim

There O
is O
a O
modest O
dose O
effect O
with O
longer O
time O
to O
progression O
at O
175 O
mg O
/ O
m2 O
. O

The B-Claim
observation I-Claim
that I-Claim
longer I-Claim
infusion I-Claim
produces I-Claim
more I-Claim
myelosuppression I-Claim
but I-Claim
does I-Claim
not I-Claim
yield I-Claim
higher I-Claim
response I-Claim
rates I-Claim
should I-Claim
lead I-Claim
to I-Claim
further I-Claim
studies I-Claim
to I-Claim
determine I-Claim
the I-Claim
optimal I-Claim
dose I-Claim
and I-Claim
schedule I-Claim
of I-Claim
this I-Claim
interesting I-Claim
new I-Claim
agent I-Claim
. I-Claim

Anaemia O
is O
common O
in O
patients O
receiving O
chemotherapy O
, O
causing O
symptoms O
that O
have O
a O
major O
impact O
on O
quality O
of O
life O
( O
QoL O
) O
. O

Epoetin O
beta O
rapidly O
increases O
haemoglobin O
( O
Hb O
) O
levels O
and O
improves O
QoL O
in O
anaemic O
patients O
with O
a O
variety O
of O
tumours O
. O

This O
was O
a O
randomized O
, O
double O
- O
blind O
, O
parallel O
- O
group O
, O
dose O
- O
finding O
study O
assessing O
the O
efficacy O
and O
safety O
of O
once O
- O
weekly O
epoetin O
beta O
in O
patients O
with O
solid O
tumours O
receiving O
chemotherapy O
. O

Adult O
patients O
with O
anaemia O
( O
Hb O
< O
11 O
g O
/ O
dL O
) O
were O
randomized O
to O
receive O
epoetin O
beta O
30 O
, O
000 O
IU O
or O
20 O
, O
000 O
IU O
once O
weekly O
for O
12 O
weeks O
. O

All O
patients O
received O
oral O
iron O
supplementation O
. O

Haemoglobin O
levels O
, O
transfusion O
need O
and O
QoL O
[ O
Functional O
Assessment O
of O
Cancer O
Therapy O
- O
fatigue O
( O
FACT O
- O
F O
) O
subscale O
score O
] O
were O
assessed O
at O
regular O
intervals O
. O

Fifty O
patients O
were O
randomized O
"""" O
; O
"""" O
30 O
patients O
received O
epoetin O
beta O
30 O
, O
000 O
IU O
once O
weekly O
and O
20 O
received O
20 O
, O
000 O
IU O
once O
weekly O
. O

Mean B-Premise
( I-Premise
+ I-Premise
/ I-Premise
- I-Premise
SD I-Premise
) I-Premise
increase I-Premise
in I-Premise
Hb I-Premise
from I-Premise
baseline I-Premise
to I-Premise
week I-Premise
12 I-Premise
was I-Premise
1 I-Premise
. I-Premise
75 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
2 I-Premise
. I-Premise
15 I-Premise
g I-Premise
/ I-Premise
dL I-Premise
in I-Premise
the I-Premise
30 I-Premise
, I-Premise
000 I-Premise
IU I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
008 I-Premise
vs I-Premise
. I-Premise
baseline I-Premise
) I-Premise
and I-Premise
1 I-Premise
. I-Premise
04 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
1 I-Premise
. I-Premise
75 I-Premise
g I-Premise
/ I-Premise
dL I-Premise
in I-Premise
the I-Premise
20 I-Premise
, I-Premise
000 I-Premise
IU I-Premise
group I-Premise
( I-Premise
non I-Premise
- I-Premise
significant I-Premise
) I-Premise
. I-Premise

Haemoglobin B-Premise
response I-Premise
( I-Premise
increase I-Premise
in I-Premise
Hb I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
g I-Premise
/ I-Premise
dL I-Premise
from I-Premise
baseline I-Premise
) I-Premise
was I-Premise
observed I-Premise
in I-Premise
78 I-Premise
. I-Premise
3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
epoetin I-Premise
beta I-Premise
30 I-Premise
, I-Premise
000 I-Premise
IU I-Premise
and I-Premise
66 I-Premise
. I-Premise
7 I-Premise
% I-Premise
receiving I-Premise
epoetin I-Premise
beta I-Premise
20 I-Premise
, I-Premise
000 I-Premise
IU I-Premise
. I-Premise

Improvements O
in O
FACT O
- O
F O
subscale O
score O
were O
significantly O
( O
P O
< O
0 O
. O
001 O
) O
correlated O
with O
increases O
in O
Hb O
level O
. O

Transfusion O
use O
was O
low O
during O
the O
study O
in O
both O
groups O
. O

Both B-Premise
epoetin I-Premise
beta I-Premise
regiments I-Premise
were I-Premise
well I-Premise
tolerated I-Premise
and I-Premise
there I-Premise
were I-Premise
no I-Premise
dose I-Premise
- I-Premise
dependent I-Premise
adverse I-Premise
events I-Premise
. I-Premise

Epoetin B-Claim
beta I-Claim
30 I-Claim
, I-Claim
000 I-Claim
IU I-Claim
once I-Claim
weekly I-Claim
is I-Claim
an I-Claim
effective I-Claim
and I-Claim
well I-Claim
- I-Claim
tolerated I-Claim
treatment I-Claim
of I-Claim
anaemia I-Claim
in I-Claim
patients I-Claim
with I-Claim
solid I-Claim
tumours I-Claim
. I-Claim

Before O
the O
knowledge O
that O
5 O
years O
of O
adjuvant O
tamoxifen O
is O
less O
efficacious O
than O
2 O
to O
3 O
years O
of O
tamoxifen O
followed O
by O
2 O
to O
3 O
years O
of O
anastrozole O
/ O
exemestane O
, O
we O
designed O
a O
multicenter O
double O
- O
blind O
randomized O
controlled O
trial O
in O
women O
taking O
tamoxifen O
with O
a O
thickened O
endometrium O
to O
compare O
uterine O
and O
quality O
- O
of O
- O
life O
parameters O
between O
those O
switching O
to O
anastrozole O
and O
those O
continuing O
tamoxifen O
. O

Asymptomatic O
postmenopausal O
women O
who O
took O
adjuvant O
tamoxifen O
for O
2 O
to O
3 O
years O
for O
operable O
breast O
cancer O
with O
a O
double O
endometrial O
thickness O
greater O
than O
7 O
mm O
were O
randomized O
to O
20 O
mg O
tamoxifen O
or O
1 O
mg O
anastrozole O
for O
the O
remaining O
duration O
, O
totaling O
5 O
years O
. O

Tablets O
were O
unrecognizable O
for O
drug O
assignment O
. O

The O
primary O
endpoints O
were O
the O
differences O
in O
double O
endometrial O
thickness O
and O
uterine O
volume O
after O
1 O
year O
. O

Uterine O
and O
quality O
- O
of O
- O
life O
data O
were O
analyzed O
using O
regression O
methods O
, O
and O
missing O
values O
were O
handled O
using O
multiple O
imputation O
. O

Seventy O
- O
two O
women O
( O
median O
age O
, O
60 O
y O
) O
were O
randomized O
in O
five O
hospitals O
. O

Relative B-Premise
to I-Premise
women I-Premise
continuing I-Premise
tamoxifen I-Premise
, I-Premise
women I-Premise
switching I-Premise
to I-Premise
anastrozole I-Premise
experienced I-Premise
a I-Premise
decrease I-Premise
of I-Premise
53 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
41 I-Premise
% I-Premise
- I-Premise
63 I-Premise
% I-Premise
) I-Premise
in I-Premise
double I-Premise
endometrial I-Premise
thickness I-Premise
and I-Premise
a I-Premise
decrease I-Premise
of I-Premise
51 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
39 I-Premise
% I-Premise
- I-Premise
60 I-Premise
% I-Premise
) I-Premise
in I-Premise
uterine I-Premise
volume I-Premise
. I-Premise

Vaginal B-Premise
dryness I-Premise
( I-Premise
b I-Premise
= I-Premise
0 I-Premise
. I-Premise
064 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
016 I-Premise
- I-Premise
0 I-Premise
. I-Premise
112 I-Premise
) I-Premise
and I-Premise
sexual I-Premise
problems I-Premise
( I-Premise
b I-Premise
= I-Premise
0 I-Premise
. I-Premise
054 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
007 I-Premise
- I-Premise
0 I-Premise
. I-Premise
102 I-Premise
) I-Premise
increased I-Premise
in I-Premise
women I-Premise
taking I-Premise
anastrozole I-Premise
compared I-Premise
with I-Premise
women I-Premise
taking I-Premise
tamoxifen I-Premise
. I-Premise

Treatment B-Premise
arms I-Premise
did I-Premise
not I-Premise
differ I-Premise
regarding I-Premise
withdrawal I-Premise
rate I-Premise
and I-Premise
the I-Premise
experience I-Premise
of I-Premise
( I-Premise
serious I-Premise
) I-Premise
adverse I-Premise
events I-Premise
. I-Premise

Despite O
premature O
trial O
closure O
, O
our O
data O
provided O
valuable O
insights O
. O

Switching B-Claim
to I-Claim
anastrozole I-Claim
strongly I-Claim
decreased I-Claim
the I-Claim
endometrial I-Claim
thickness I-Claim
and I-Claim
uterine I-Claim
volume I-Claim
but I-Claim
increased I-Claim
sexual I-Claim
disturbances I-Claim
. I-Claim

Safe B-Claim
and I-Claim
effective I-Claim
interventions I-Claim
are I-Claim
needed I-Claim
to I-Claim
alleviate I-Claim
sexual I-Claim
dysfunction I-Claim
. I-Claim

Depression B-Claim
, I-Claim
anxiety I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
impaired I-Claim
wellbeing I-Claim
are I-Claim
common I-Claim
, I-Claim
important I-Claim
, I-Claim
and I-Claim
closely I-Claim
related I-Claim
in I-Claim
advanced I-Claim
cancer I-Claim
. I-Claim

We O
aimed O
to O
identify O
the O
effects O
of O
an O
established O
antidepressant O
on O
these O
symptoms O
and O
survival O
in O
patients O
with O
advanced O
cancer O
who O
did O
not O
have O
major O
depression O
as O
assessed O
by O
clinicians O
. O

Between O
July O
, O
2001 O
, O
and O
February O
, O
2006 O
, O
189 O
patients O
with O
advanced O
cancer O
were O
randomly O
assigned O
sertraline O
50 O
mg O
( O
n O
= O
95 O
) O
, O
or O
placebo O
( O
n O
= O
94 O
) O
, O
once O
per O
day O
. O

The O
primary O
outcome O
was O
depression O
as O
assessed O
by O
the O
Centre O
for O
Epidemiologic O
Studies O
Depression O
scale O
( O
CES O
- O
D O
) O
"""" O
; O
"""" O
the O
main O
secondary O
outcomes O
were O
: O
anxiety O
as O
assessed O
by O
Hospital O
Anxiety O
and O
Depression O
Scales O
( O
HADS O
- O
A O
) O
"""" O
; O
"""" O
overall O
quality O
of O
life O
and O
fatigue O
as O
assessed O
by O
Functional O
Assessment O
of O
Cancer O
Therapy O
General O
and O
Fatigue O
scales O
( O
FACT O
- O
G O
and O
FACT O
- O
F O
, O
respectively O
) O
"""" O
; O
"""" O
and O
clinicians O
' O
ratings O
of O
quality O
of O
life O
by O
use O
of O
Spizter O
' O
s O
Quality O
of O
Life O
Index O
( O
SQLI O
) O
. O

Multiple O
measures O
were O
used O
for O
corroboration O
of O
the O
most O
important O
outcomes O
. O

Primary O
analyses O
were O
done O
by O
intention O
to O
treat O
and O
were O
based O
on O
scale O
scores O
at O
4 O
weeks O
and O
8 O
weeks O
. O

The O
benefits O
of O
sertraline O
compared O
with O
placebo O
are O
expressed O
on O
a O
range O
from O
100 O
( O
ie O
, O
maximum O
benefit O
) O
to O
- O
100 O
( O
ie O
, O
maximum O
harm O
) O
"""" O
; O
"""" O
a O
difference O
of O
10 O
was O
deemed O
clinically O
significant O
. O

This O
clinical O
trial O
is O
registered O
at O
Current O
Controlled O
Trials O
website O
http O
: O
/ O
/ O
www O
. O
controlled O
- O
trials O
. O
com O
/ O
ISRCTN72466475 O
. O

Sertraline B-Premise
had I-Premise
no I-Premise
significant I-Premise
effect I-Premise
( I-Premise
scale I-Premise
, I-Premise
benefit I-Premise
over I-Premise
placebo I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
) I-Premise
on I-Premise
depression I-Premise
( I-Premise
CES I-Premise
- I-Premise
D I-Premise
0 I-Premise
. I-Premise
4 I-Premise
[ I-Premise
- I-Premise
2 I-Premise
. I-Premise
6 I-Premise
to I-Premise
3 I-Premise
. I-Premise
4 I-Premise
] I-Premise
) I-Premise
, I-Premise
anxiety I-Premise
( I-Premise
HADS I-Premise
- I-Premise
A I-Premise
2 I-Premise
. I-Premise
0 I-Premise
[ I-Premise
- I-Premise
1 I-Premise
. I-Premise
5 I-Premise
to I-Premise
5 I-Premise
. I-Premise
5 I-Premise
] I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
FACT I-Premise
- I-Premise
F I-Premise
0 I-Premise
. I-Premise
3 I-Premise
[ I-Premise
- I-Premise
4 I-Premise
. I-Premise
3 I-Premise
to I-Premise
4 I-Premise
. I-Premise
9 I-Premise
] I-Premise
) I-Premise
, I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
FACT I-Premise
- I-Premise
G I-Premise
1 I-Premise
. I-Premise
7 I-Premise
[ I-Premise
- I-Premise
1 I-Premise
. I-Premise
3 I-Premise
to I-Premise
4 I-Premise
. I-Premise
7 I-Premise
] I-Premise
) I-Premise
, I-Premise
or I-Premise
clinicians I-Premise
' I-Premise
ratings I-Premise
( I-Premise
SQLI I-Premise
2 I-Premise
. I-Premise
0 I-Premise
[ I-Premise
- I-Premise
2 I-Premise
. I-Premise
5 I-Premise
to I-Premise
6 I-Premise
. I-Premise
5 I-Premise
] I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
95 I-Premise
% I-Premise
CI I-Premise
ruled I-Premise
out I-Premise
a I-Premise
clinically I-Premise
significant I-Premise
benefit I-Premise
for I-Premise
all I-Premise
main I-Premise
outcomes I-Premise
. I-Premise

Sertraline B-Premise
was I-Premise
discontinued I-Premise
more I-Premise
often I-Premise
and I-Premise
earlier I-Premise
than I-Premise
was I-Premise
placebo I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
1 I-Premise
. I-Premise
46 I-Premise
[ I-Premise
1 I-Premise
. I-Premise
03 I-Premise
- I-Premise
2 I-Premise
. I-Premise
06 I-Premise
] I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
03 I-Premise
) I-Premise
. I-Premise

Recruitment O
was O
stopped O
after O
the B-Premise
first I-Premise
planned I-Premise
interim I-Premise
analysis I-Premise
in I-Premise
February I-Premise
2006 I-Premise
( I-Premise
n I-Premise
= I-Premise
150 I-Premise
) I-Premise
showed I-Premise
that I-Premise
survival I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
placebo I-Premise
than I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
sertraline I-Premise
( I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
1 I-Premise
. I-Premise
60 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
1 I-Premise
. I-Premise
04 I-Premise
- I-Premise
2 I-Premise
. I-Premise
45 I-Premise
] I-Premise
, I-Premise
log I-Premise
- I-Premise
rank I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
adjusted I-Premise
hazard I-Premise
ratio I-Premise
1 I-Premise
. I-Premise
62 I-Premise
[ I-Premise
1 I-Premise
. I-Premise
06 I-Premise
- I-Premise
2 I-Premise
. I-Premise
41 I-Premise
] I-Premise
, I-Premise
Cox I-Premise
model I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
at I-Premise
the I-Premise
final I-Premise
analysis I-Premise
in I-Premise
July I-Premise
2006 I-Premise
of I-Premise
all I-Premise
patients I-Premise
( I-Premise
n I-Premise
= I-Premise
189 I-Premise
) I-Premise
and I-Premise
with I-Premise
longer I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
survival I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
1 I-Premise
. I-Premise
35 I-Premise
[ I-Premise
0 I-Premise
. I-Premise
95 I-Premise
- I-Premise
1 I-Premise
. I-Premise
91 I-Premise
] I-Premise
, I-Premise
log I-Premise
- I-Premise
rank I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
09 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
adjusted I-Premise
hazard I-Premise
ratio I-Premise
1 I-Premise
. I-Premise
27 I-Premise
[ I-Premise
0 I-Premise
. I-Premise
87 I-Premise
- I-Premise
1 I-Premise
. I-Premise
84 I-Premise
] I-Premise
, I-Premise
Cox I-Premise
model I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
20 I-Premise
) I-Premise
. I-Premise

The O
trial O
was O
closed O
because O
it O
had O
ruled O
out O
a O
significant O
benefit O
of O
sertraline O
. O

Sertraline B-Claim
did I-Claim
not I-Claim
improve I-Claim
symptoms I-Claim
, I-Claim
wellbeing I-Claim
, I-Claim
or I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
who I-Claim
do I-Claim
not I-Claim
have I-Claim
major I-Claim
depression I-Claim
, I-Claim
and I-Claim
should I-Claim
be I-Claim
reserved I-Claim
for I-Claim
those I-Claim
with I-Claim
a I-Claim
proven I-Claim
indication I-Claim
. I-Claim

This O
double O
- O
blind O
randomized O
phase O
II O
trial O
examined O
whether O
vandetanib O
, O
an O
inhibitor O
of O
vascular O
endothelial O
and O
epidermal O
growth O
factor O
receptors O
, O
could O
prolong O
progression O
- O
free O
survival O
in O
responding O
patients O
with O
small O
- O
cell O
lung O
cancer O
. O

Eligible O
patients O
with O
complete O
response O
( O
CR O
) O
or O
partial O
response O
( O
PR O
) O
to O
combination O
chemotherapy O
( O
+ O
/ O
- O
thoracic O
or O
prophylactic O
cranial O
radiation O
) O
received O
oral O
vandetanib O
300 O
mg O
/ O
d O
or O
matched O
placebo O
. O

With O
100 O
patients O
and O
77 O
events O
, O
the O
study O
had O
80 O
% O
power O
to O
detect O
an O
improvement O
in O
median O
progression O
- O
free O
survival O
from O
4 O
to O
6 O
. O
5 O
months O
( O
one O
- O
sided O
, O
10 O
% O
- O
level O
test O
) O
. O

Between O
May O
2003 O
and O
March O
2006 O
, O
107 O
patients O
were O
accrued O
"""" O
; O
"""" O
46 O
had O
limited O
disease O
and O
61 O
extensive O
disease O
. O

There O
were O
fewer O
patients O
with O
a O
performance O
status O
of O
0 O
( O
n O
= O
11 O
v O
20 O
) O
, O
and O
fewer O
had O
CR O
to O
initial O
therapy O
( O
n O
= O
4 O
v O
8 O
) O
in O
the O
vandetanib O
arm O
. O

Vandetanib B-Premise
patients I-Premise
had I-Premise
more I-Premise
toxicity I-Premise
and I-Premise
required I-Premise
more I-Premise
dose I-Premise
modifications I-Premise
for I-Premise
gastrointestinal I-Premise
toxicity I-Premise
and I-Premise
rash I-Premise
. I-Premise

Asymptomatic B-Premise
Corrected I-Premise
QT I-Premise
interval I-Premise
( I-Premise
QTC I-Premise
) I-Premise
prolongation I-Premise
was I-Premise
observed I-Premise
in I-Premise
eight I-Premise
vandetanib I-Premise
patients I-Premise
. I-Premise

Median B-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
for I-Premise
vandetanib I-Premise
and I-Premise
placebo I-Premise
was I-Premise
2 I-Premise
. I-Premise
7 I-Premise
and I-Premise
2 I-Premise
. I-Premise
8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
1 I-Premise
. I-Premise
01 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
80 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
75 I-Premise
to I-Premise
1 I-Premise
. I-Premise
36 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
one I-Premise
- I-Premise
sided I-Premise
P I-Premise
= I-Premise
. I-Premise
51 I-Premise
) I-Premise
. I-Premise

Overall B-Premise
survival I-Premise
for I-Premise
vandetanib I-Premise
was I-Premise
10 I-Premise
. I-Premise
6 I-Premise
versus I-Premise
11 I-Premise
. I-Premise
9 I-Premise
months I-Premise
for I-Premise
placebo I-Premise
( I-Premise
HR I-Premise
, I-Premise
1 I-Premise
. I-Premise
43 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
80 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1 I-Premise
. I-Premise
00 I-Premise
to I-Premise
2 I-Premise
. I-Premise
05 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
one I-Premise
- I-Premise
sided I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
9 I-Premise
) I-Premise
. I-Premise

In B-Premise
planned I-Premise
subgroup I-Premise
analyses I-Premise
, I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
was I-Premise
noted I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
01 I-Premise
) I-Premise
: I-Premise
limited I-Premise
- I-Premise
stage I-Premise
vandetanib I-Premise
patients I-Premise
had I-Premise
longer I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HR I-Premise
, I-Premise
0 I-Premise
. I-Premise
45 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
one I-Premise
- I-Premise
sided I-Premise
P I-Premise
= I-Premise
. I-Premise
07 I-Premise
) I-Premise
and I-Premise
extensive I-Premise
- I-Premise
stage I-Premise
vandetanib I-Premise
patients I-Premise
shorter I-Premise
survival I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
HR I-Premise
, I-Premise
2 I-Premise
. I-Premise
27 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
one I-Premise
- I-Premise
sided I-Premise
P I-Premise
= I-Premise
. I-Premise
996 I-Premise
) I-Premise
. I-Premise

Vandetanib B-Claim
failed I-Claim
to I-Claim
demonstrate I-Claim
efficacy I-Claim
as I-Claim
maintenance I-Claim
therapy I-Claim
for I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
. I-Claim

Cancer O
cells O
rely O
on O
angiogenesis O
for O
growth O
and O
dissemination O
, O
and O
small O
cell O
lung O
cancer O
( O
SCLC O
) O
is O
a O
highly O
angiogenic O
tumor O
. O

We O
evaluated O
thalidomide O
, O
an O
anti O
- O
angiogenic O
agent O
, O
when O
combined O
with O
chemotherapy O
and O
as O
maintenance O
treatment O
. O

A O
total O
of O
724 O
patients O
( O
51 O
% O
with O
limited O
and O
49 O
% O
with O
extensive O
disease O
) O
were O
randomly O
assigned O
to O
receive O
placebo O
or O
thalidomide O
capsules O
, O
100 O
- O
200 O
mg O
daily O
for O
up O
to O
2 O
years O
. O

All O
patients O
received O
etoposide O
and O
carboplatin O
every O
3 O
weeks O
for O
up O
to O
six O
cycles O
. O

Endpoints O
were O
overall O
survival O
, O
progression O
- O
free O
survival O
, O
tumor O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
QoL O
) O
. O

Hazard O
ratios O
( O
HRs O
) O
for O
comparing O
thalidomide O
against O
placebo O
were O
estimated O
using O
Cox O
regression O
modeling O
. O

Statistical O
tests O
were O
two O
- O
sided O
. O

The B-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
10 I-Premise
. I-Premise
5 I-Premise
months I-Premise
( I-Premise
placebo I-Premise
) I-Premise
and I-Premise
10 I-Premise
. I-Premise
1 I-Premise
months I-Premise
( I-Premise
thalidomide I-Premise
) I-Premise
( I-Premise
HR I-Premise
for I-Premise
death I-Premise
= I-Premise
1 I-Premise
. I-Premise
09 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0 I-Premise
. I-Premise
93 I-Premise
to I-Premise
1 I-Premise
. I-Premise
27 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
28 I-Premise
) I-Premise
. I-Premise

Among B-Premise
patients I-Premise
with I-Premise
limited I-Premise
- I-Premise
stage I-Premise
disease I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
survival I-Premise
difference I-Premise
( I-Premise
HR I-Premise
for I-Premise
death I-Premise
= I-Premise
0 I-Premise
. I-Premise
91 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0 I-Premise
. I-Premise
73 I-Premise
to I-Premise
1 I-Premise
. I-Premise
15 I-Premise
) I-Premise
, I-Premise
but B-Premise
among I-Premise
patients I-Premise
with I-Premise
extensive I-Premise
disease I-Premise
, I-Premise
survival I-Premise
was I-Premise
worse I-Premise
in I-Premise
the I-Premise
thalidomide I-Premise
group I-Premise
( I-Premise
HR I-Premise
for I-Premise
death I-Premise
= I-Premise
1 I-Premise
. I-Premise
36 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1 I-Premise
. I-Premise
10 I-Premise
to I-Premise
1 I-Premise
. I-Premise
68 I-Premise
) I-Premise
. I-Premise

Progression B-Premise
- B-Premise
free B-Premise
survival I-Premise
rates I-Premise
were I-Premise
also I-Premise
similar I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
( I-Premise
HR I-Premise
= I-Premise
1 I-Premise
. I-Premise
07 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0 I-Premise
. I-Premise
92 I-Premise
to I-Premise
1 I-Premise
. I-Premise
24 I-Premise
) I-Premise
. I-Premise

Thalidomide B-Premise
was I-Premise
associated I-Premise
with I-Premise
an I-Premise
increased I-Premise
risk I-Premise
of I-Premise
having I-Premise
a I-Premise
thrombotic I-Premise
event I-Premise
, I-Premise
mainly I-Premise
pulmonary I-Premise
embolus I-Premise
and I-Premise
deep I-Premise
vein I-Premise
thrombosis I-Premise
( I-Premise
19 I-Premise
% I-Premise
thalidomide I-Premise
vs I-Premise
10 I-Premise
% I-Premise
placebo I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
HR I-Premise
= I-Premise
2 I-Premise
. I-Premise
13 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1 I-Premise
. I-Premise
41 I-Premise
to I-Premise
3 I-Premise
. I-Premise
20 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
treatments I-Premise
in I-Premise
hematological I-Premise
and I-Premise
nonhematological I-Premise
toxic I-Premise
effects I-Premise
, I-Premise
except B-Premise
more I-Premise
patients I-Premise
in I-Premise
the I-Premise
thalidomide I-Premise
group I-Premise
had I-Premise
rash I-Premise
, I-Premise
constipation I-Premise
, I-Premise
or I-Premise
neuropathy I-Premise
. I-Premise

Overall O
, O
QoL B-Claim
scores I-Claim
were I-Claim
similar I-Claim
in I-Claim
the I-Claim
two I-Claim
treatment I-Claim
groups I-Claim
, I-Claim
but B-Claim
thalidomide I-Claim
was I-Claim
associated I-Claim
with I-Claim
less I-Claim
insomnia I-Claim
and I-Claim
diarrhea I-Claim
and I-Claim
more I-Claim
constipation I-Claim
and I-Claim
peripheral I-Claim
neuropathy I-Claim
. I-Claim

In O
this O
large O
randomized O
trial O
, O
thalidomide B-Claim
in I-Claim
combination I-Claim
with I-Claim
chemotherapy I-Claim
did I-Claim
not I-Claim
improve I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
SCLC I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
an I-Claim
increased I-Claim
risk I-Claim
of I-Claim
thrombotic I-Claim
events I-Claim
. I-Claim

Vinorelbine B-Claim
, I-Claim
a I-Claim
semisynthetic I-Claim
vinca I-Claim
alkaloid I-Claim
, I-Claim
represents I-Claim
a I-Claim
well I-Claim
- I-Claim
tolerated I-Claim
treatment I-Claim
for I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non I-Claim
- I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

We O
explored O
the O
quality O
of O
life O
( O
QoL O
) O
of O
such O
patients O
in O
a O
multicenter O
randomized O
trial O
that O
compared O
vinorelbine O
treatment O
with O
supportive O
care O
alone O
. O

Eligible O
patients O
were O
70 O
years O
of O
age O
or O
older O
, O
had O
stage O
IV O
or O
IIIB O
NSCLC O
that O
was O
ineligible O
for O
radiotherapy O
, O
and O
had O
a O
performance O
status O
of O
0 O
- O
2 O
( O
a O
status O
of O
fully O
active O
to O
a O
status O
of O
capable O
of O
all O
self O
- O
care O
but O
unable O
to O
work O
) O
. O

Vinorelbine O
was O
given O
intravenously O
on O
days O
1 O
and O
8 O
of O
a O
21 O
- O
day O
treatment O
cycle O
, O
for O
a O
total O
of O
six O
cycles O
. O

QoL O
was O
evaluated O
with O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
questionnaires O
QLQ O
- O
C30 O
and O
QLQ O
- O
LC13 O
, O
and O
the O
QoL O
data O
were O
analyzed O
by O
fitting O
a O
linear O
mixed O
model O
for O
each O
QoL O
scale O
. O

Survival O
curves O
were O
plotted O
and O
were O
compared O
with O
the O
Mantel O
- O
Haenszel O
test O
. O

Relative O
hazards O
of O
death O
and O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
were O
estimated O
by O
the O
Cox O
model O
. O

Investigators O
, O
blinded O
to O
the O
results O
, O
stopped O
the O
trial O
early O
because O
of O
a O
low O
enrollment O
rate O
. O

( O
From O
April O
1996 O
to O
November O
1997 O
, O
191 O
of O
the O
350 O
targeted O
patients O
were O
randomly O
assigned O
. O
) O

Data O
from O
161 O
patients O
have O
been O
analyzed O
. O

Vinorelbine B-Premise
- B-Premise
treated B-Premise
patients I-Premise
scored I-Premise
better I-Premise
than I-Premise
control I-Premise
patients I-Premise
on I-Premise
QoL I-Premise
functioning I-Premise
scales I-Premise
, I-Premise
and I-Premise
they I-Premise
reported I-Premise
fewer I-Premise
lung I-Premise
cancer I-Premise
- I-Premise
related I-Premise
symptoms I-Premise
but I-Premise
reported I-Premise
worse I-Premise
toxicity I-Premise
- I-Premise
related I-Premise
symptoms I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
two I-Premise
- I-Premise
sided I-Premise
P I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
vinorelbine I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
median B-Premise
survival I-Premise
increased I-Premise
from I-Premise
21 I-Premise
to I-Premise
28 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
vinorelbine I-Premise
- I-Premise
treated I-Premise
group I-Premise
. I-Premise

The B-Premise
relative I-Premise
hazard I-Premise
of I-Premise
death I-Premise
for I-Premise
vinorelbine I-Premise
- I-Premise
treated I-Premise
patients I-Premise
was I-Premise
0 I-Premise
. I-Premise
65 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0 I-Premise
. I-Premise
45 I-Premise
- I-Premise
0 I-Premise
. I-Premise
93 I-Premise
) I-Premise
. I-Premise

Vinorelbine B-Claim
improves I-Claim
survival I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
and I-Claim
possibly I-Claim
improves I-Claim
overall I-Claim
QoL I-Claim
. I-Claim

The O
management O
of O
cancer O
- O
related O
anorexia O
/ O
cachexia O
syndrome O
( O
CACS O
) O
is O
a O
great O
challenge O
in O
clinical O
practice O
. O

To O
date O
, O
practice O
guidelines O
for O
the O
prevention O
and O
treatment O
of O
CACS O
are O
lacking O
. O

The O
authors O
conducted O
a O
randomized O
study O
to O
confirm O
the O
effectiveness O
and O
safety O
of O
treatment O
of O
CACS O
utilizing O
megestrol O
acetate O
( O
MA O
) O
plus O
thalidomide O
. O

One O
hundred O
and O
two O
candidates O
with O
CACS O
were O
randomly O
assigned O
to O
two O
treatment O
groups O
( O
trial O
group O
and O
control O
group O
) O
: O
the O
trial O
group O
received O
MA O
( O
160 O
mg O
po O
, O
bid O
) O
plus O
thalidomide O
( O
50 O
mg O
po O
, O
bid O
) O
, O
while O
the O
control O
group O
received O
MA O
( O
160 O
mg O
po O
, O
bid O
) O
alone O
. O

Treatment O
duration O
was O
8 O
weeks O
. O

Analysis B-Premise
of I-Premise
the I-Premise
trial I-Premise
group I-Premise
demonstrated I-Premise
a I-Premise
significant I-Premise
increase I-Premise
from I-Premise
baseline I-Premise
in I-Premise
body I-Premise
weight I-Premise
( I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
and I-Premise
grip I-Premise
strength I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
and I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
fatigue I-Premise
, I-Premise
Glasgow I-Premise
Prognostic I-Premise
Score I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
Eastern I-Premise
Cooperative I-Premise
Oncology I-Premise
Group I-Premise
performance I-Premise
status I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
IL I-Premise
- I-Premise
6 I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor I-Premise
- I-Premise
Î± I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise

In B-Premise
contrast I-Premise
, I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
endpoints I-Premise
with I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
from I-Premise
baseline I-Premise
included I-Premise
body I-Premise
weight I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
and I-Premise
appetite I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
changes I-Premise
in I-Premise
the I-Premise
endpoints I-Premise
from I-Premise
baseline I-Premise
in I-Premise
the I-Premise
trial I-Premise
group I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
: I-Premise
in I-Premise
the I-Premise
primary I-Premise
endpoints I-Premise
, I-Premise
body I-Premise
weight I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
and I-Premise
in I-Premise
the I-Premise
secondary I-Premise
endpoints I-Premise
, I-Premise
grip I-Premise
strength I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
Glasgow I-Premise
Prognostic I-Premise
Score I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
, I-Premise
Eastern I-Premise
Cooperative I-Premise
Oncology I-Premise
Group I-Premise
performance I-Premise
status I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
, I-Premise
IL I-Premise
- I-Premise
6 I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor I-Premise
- I-Premise
Î± I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise

Toxicity B-Premise
was I-Premise
found I-Premise
to I-Premise
be I-Premise
relatively I-Premise
negligible I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

A B-Claim
combination I-Claim
regimen I-Claim
of I-Claim
MA I-Claim
and I-Claim
thalidomide I-Claim
is I-Claim
more I-Claim
effective I-Claim
than I-Claim
MA I-Claim
alone I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
CACS I-Claim
. I-Claim

This O
randomised O
non O
- O
inferiority O
trial O
was O
designed O
to O
assess O
whether O
radiosurgery O
plus O
adjuvant O
whole O
brain O
radiotherapy O
( O
RS O
+ O
WBRT O
) O
is O
as O
effective O
as O
surgery O
plus O
whole O
brain O
radiotherapy O
( O
S O
+ O
WBRT O
) O
for O
cancer O
patients O
with O
a O
solitary O
brain O
metastasis O
, O
with O
respect O
to O
overall O
survival O
and O
quality O
of O
life O
. O

Major O
inclusion O
criteria O
were O
a O
history O
of O
systemic O
cancer O
within O
5 O
years O
and O
enhanced O
magnetic O
resonance O
imaging O
- O
confirmed O
solitary O
brain O
metastasis O
suitable O
for O
both O
radiosurgery O
and O
surgery O
. O

All O
patients O
were O
to O
receive O
WBRT O
( O
30 O
Gy O
in O
10 O
fractions O
) O
. O

Between O
February O
2003 O
and O
April O
2009 O
, O
40 O
patients O
were O
considered O
eligible O
, O
22 O
consented O
to O
randomisation O
and O
21 O
were O
analysed O
( O
11 O
RS O
+ O
WBRT O
, O
10 O
S O
+ O
WBRT O
) O
. O

The O
trial O
was O
closed O
early O
due O
to O
slow O
accrual O
. O

The B-Premise
estimated I-Premise
median I-Premise
overall I-Premise
survival I-Premise
times I-Premise
for I-Premise
RS I-Premise
+ I-Premise
WBRT I-Premise
and I-Premise
S I-Premise
+ I-Premise
WBRT I-Premise
patients I-Premise
were I-Premise
6 I-Premise
. I-Premise
2 I-Premise
and I-Premise
2 I-Premise
. I-Premise
8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
0 I-Premise
. I-Premise
53 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
0 I-Premise
. I-Premise
20 I-Premise
- I-Premise
1 I-Premise
. I-Premise
43 I-Premise
, I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
20 I-Premise
) I-Premise
. I-Premise

Corresponding B-Premise
median I-Premise
failure I-Premise
- I-Premise
free I-Premise
survival I-Premise
times I-Premise
were I-Premise
3 I-Premise
. I-Premise
1 I-Premise
and I-Premise
1 I-Premise
. I-Premise
7 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
20 I-Premise
) I-Premise
. I-Premise

For B-Premise
19 I-Premise
' I-Premise
per I-Premise
protocol I-Premise
' I-Premise
patients I-Premise
, I-Premise
2 I-Premise
/ I-Premise
10 I-Premise
in I-Premise
the I-Premise
RS I-Premise
+ I-Premise
WBRT I-Premise
arm I-Premise
had I-Premise
distant I-Premise
intracranial I-Premise
failure I-Premise
( I-Premise
one I-Premise
also I-Premise
had I-Premise
local I-Premise
failure I-Premise
) I-Premise
and I-Premise
3 I-Premise
/ I-Premise
9 I-Premise
S I-Premise
+ I-Premise
WBRT I-Premise
patients I-Premise
had I-Premise
distant I-Premise
intracranial I-Premise
failure I-Premise
( I-Premise
no I-Premise
local I-Premise
failures I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
late I-Premise
radiation I-Premise
toxicities I-Premise
. I-Premise

Two B-Claim
months I-Claim
after I-Claim
starting I-Claim
treatment I-Claim
there I-Claim
were I-Claim
no I-Claim
significant I-Claim
differences I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
between I-Claim
the I-Claim
arms I-Claim
. I-Claim

This B-Claim
randomised I-Claim
trial I-Claim
encountered I-Claim
the I-Claim
accrual I-Claim
difficulties I-Claim
and I-Claim
consequent I-Claim
low I-Claim
statistical I-Claim
power I-Claim
commonly I-Claim
associated I-Claim
with I-Claim
interdisciplinary I-Claim
studies I-Claim
drawing I-Claim
from I-Claim
a I-Claim
small I-Claim
eligible I-Claim
population I-Claim
, I-Claim
but O
can O
contribute O
to O
future O
overviews O
on O
the O
management O
of O
solitary O
brain O
metastases O
. O

The B-Claim
impact I-Claim
of I-Claim
treatment I-Claim
on I-Claim
health I-Claim
- I-Claim
related I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
HRQoL I-Claim
) I-Claim
is I-Claim
an I-Claim
important I-Claim
consideration I-Claim
in I-Claim
the I-Claim
adjuvant I-Claim
treatment I-Claim
of I-Claim
operable I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Here O
we O
report O
mature O
HRQoL O
outcomes O
from O
the O
ATAC O
trial O
, O
comparing O
anastrozole O
with O
tamoxifen O
as O
primary O
adjuvant O
therapy O
for O
postmenopausal O
women O
with O
localized O
breast O
cancer O
. O

Patients O
completed O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
- O
Breast O
( O
FACT O
- O
B O
) O
questionnaire O
plus O
endocrine O
subscale O
( O
ES O
) O
at O
baseline O
, O
3 O
and O
6 O
months O
, O
and O
every O
6 O
months O
thereafter O
. O

Baseline O
characteristics O
in O
the O
HRQoL O
sub O
- O
protocol O
were O
well O
balanced O
between O
the O
anastrozole O
( O
n O
= O
335 O
) O
and O
tamoxifen O
( O
n O
= O
347 O
) O
groups O
in O
the O
primary O
analysis O
population O
. O

As B-Premise
with I-Premise
previously I-Premise
published I-Premise
results I-Premise
at I-Premise
2 I-Premise
years I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
of I-Premise
the I-Premise
FACT I-Premise
- I-Premise
B I-Premise
, I-Premise
the I-Premise
primary I-Premise
endpoint I-Premise
of I-Premise
the I-Premise
study I-Premise
, I-Premise
between I-Premise
treatments I-Premise
at I-Premise
5 I-Premise
years I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
in I-Premise
ES I-Premise
total I-Premise
scores I-Premise
. I-Premise

Consistent O
with O
the O
2 O
- O
year O
analysis O
, O
there B-Claim
were I-Claim
differences I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
in I-Claim
patient I-Claim
- I-Claim
reported I-Claim
side I-Claim
effects I-Claim
: I-Claim
diarrhea B-Premise
( I-Premise
anastrozole I-Premise
3 I-Premise
. I-Premise
1 I-Premise
% I-Premise
vs I-Premise
. I-Premise
tamoxifen I-Premise
1 I-Premise
. I-Premise
3 I-Premise
% I-Premise
) I-Premise
, I-Premise
vaginal I-Premise
dryness I-Premise
( I-Premise
18 I-Premise
. I-Premise
5 I-Premise
% I-Premise
vs I-Premise
. I-Premise
9 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
, I-Premise
diminished I-Premise
libido I-Premise
( I-Premise
34 I-Premise
. I-Premise
0 I-Premise
% I-Premise
vs I-Premise
. I-Premise
26 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
dyspareunia I-Premise
( I-Premise
17 I-Premise
. I-Premise
3 I-Premise
% I-Premise
vs I-Premise
. I-Premise
8 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
were I-Premise
significantly I-Premise
more I-Premise
frequent I-Premise
with I-Premise
anastrozole I-Premise
compared I-Premise
to I-Premise
tamoxifen I-Premise
. I-Premise

Dizziness B-Premise
( I-Premise
3 I-Premise
. I-Premise
1 I-Premise
% I-Premise
vs I-Premise
. I-Premise
5 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
and I-Premise
vaginal I-Premise
discharge I-Premise
( I-Premise
1 I-Premise
. I-Premise
2 I-Premise
% I-Premise
vs I-Premise
. I-Premise
5 I-Premise
. I-Premise
2 I-Premise
% I-Premise
) I-Premise
were I-Premise
significantly I-Premise
less I-Premise
frequent I-Premise
with I-Premise
anastrozole I-Premise
compared I-Premise
to I-Premise
tamoxifen I-Premise
. I-Premise

In B-Claim
this I-Claim
, I-Claim
the I-Claim
first I-Claim
report I-Claim
of I-Claim
HRQoL I-Claim
over I-Claim
5 I-Claim
years I-Claim
of I-Claim
initial I-Claim
adjuvant I-Claim
therapy I-Claim
with I-Claim
an I-Claim
aromatase I-Claim
inhibitor I-Claim
, I-Claim
we I-Claim
conclude I-Claim
that I-Claim
anastrozole I-Claim
and I-Claim
tamoxifen I-Claim
had I-Claim
similar I-Claim
impacts I-Claim
on I-Claim
HRQoL I-Claim
, I-Claim
which I-Claim
was I-Claim
maintained I-Claim
or I-Claim
slightly I-Claim
improved I-Claim
during I-Claim
the I-Claim
treatment I-Claim
period I-Claim
for I-Claim
both I-Claim
groups I-Claim
. I-Claim

Axillary B-Claim
clearance I-Claim
in I-Claim
early I-Claim
breast I-Claim
cancer I-Claim
aims I-Claim
to I-Claim
improve I-Claim
locoregional I-Claim
control I-Claim
and I-Claim
provide I-Claim
staging I-Claim
information I-Claim
but O
is O
associated O
with O
undesirable O
morbidity O
. O

We O
therefore O
investigated O
whether O
avoiding O
axillary O
surgery O
in O
older O
women O
would O
result O
in O
improved O
quality O
of O
life O
( O
QL O
) O
with O
similar O
disease O
- O
free O
survival O
( O
DFS O
) O
and O
overall O
survival O
( O
OS O
) O
. O

Between O
1993 O
and O
2002 O
, O
women O
> O
or O
= O
60 O
years O
old O
with O
clinically O
node O
- O
negative O
operable O
breast O
cancer O
in O
whom O
adjuvant O
tamoxifen O
was O
considered O
indicated O
regardless O
of O
pathologic O
nodal O
status O
were O
randomly O
assigned O
to O
primary O
surgery O
plus O
axillary O
clearance O
( O
Sx O
+ O
Ax O
) O
followed O
by O
tamoxifen O
( O
Tam O
) O
versus O
Sx O
without O
Ax O
followed O
by O
Tam O
for O
5 O
consecutive O
years O
. O

The O
primary O
end O
point O
was O
QL O
reported O
by O
the O
patient O
and O
by O
physician O
assessment O
. O

A O
total O
of O
473 O
patients O
( O
234 O
to O
Sx O
+ O
Ax O
, O
239 O
to O
Sx O
) O
were O
randomly O
assigned O
. O

The O
median O
age O
was O
74 O
years O
"""" O
; O
"""" O
80 O
% O
had O
estrogen O
receptor O
- O
positive O
disease O
. O

In B-Premise
both I-Premise
the I-Premise
patients I-Premise
' I-Premise
subjective I-Premise
assessment I-Premise
of I-Premise
their I-Premise
QL I-Premise
and I-Premise
the I-Premise
physicians I-Premise
' I-Premise
perception I-Premise
of I-Premise
the I-Premise
patients I-Premise
' I-Premise
QL I-Premise
, I-Premise
the I-Premise
largest I-Premise
adverse I-Premise
QL I-Premise
effects I-Premise
of I-Premise
Ax I-Premise
were I-Premise
observed I-Premise
from I-Premise
baseline I-Premise
to I-Premise
the I-Premise
first I-Premise
postoperative I-Premise
assessment I-Premise
, I-Premise
but B-Premise
the I-Premise
differences I-Premise
tended I-Premise
to I-Premise
disappear I-Premise
in I-Premise
6 I-Premise
to I-Premise
12 I-Premise
months I-Premise
. I-Premise

At B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
6 I-Premise
. I-Premise
6 I-Premise
years I-Premise
, I-Premise
results I-Premise
for I-Premise
Sx I-Premise
+ I-Premise
Ax I-Premise
and I-Premise
Sx I-Premise
yielded I-Premise
similar I-Premise
DFS I-Premise
( I-Premise
6 I-Premise
- I-Premise
year I-Premise
DFS I-Premise
, I-Premise
67 I-Premise
% I-Premise
v I-Premise
66 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
Sx I-Premise
+ I-Premise
Ax I-Premise
/ I-Premise
Sx I-Premise
, I-Premise
1 I-Premise
. I-Premise
06 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
79 I-Premise
to I-Premise
1 I-Premise
. I-Premise
42 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
69 I-Premise
) I-Premise
and I-Premise
OS I-Premise
( I-Premise
6 I-Premise
- I-Premise
year I-Premise
OS I-Premise
, I-Premise
75 I-Premise
% I-Premise
v I-Premise
73 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
HR I-Premise
Sx I-Premise
+ I-Premise
Ax I-Premise
/ I-Premise
Sx I-Premise
, I-Premise
1 I-Premise
. I-Premise
05 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
76 I-Premise
to I-Premise
1 I-Premise
. I-Premise
46 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
77 I-Premise
) I-Premise
. I-Premise

Avoiding B-Claim
axillary I-Claim
clearance I-Claim
for I-Claim
women I-Claim
> I-Claim
or I-Claim
= I-Claim
60 I-Claim
years I-Claim
old I-Claim
who I-Claim
have I-Claim
clinically I-Claim
node I-Claim
- I-Claim
negative I-Claim
disease I-Claim
and I-Claim
receive I-Claim
Tam I-Claim
for I-Claim
endocrine I-Claim
- I-Claim
responsive I-Claim
disease I-Claim
yields I-Claim
similar I-Claim
efficacy I-Claim
with I-Claim
better I-Claim
early I-Claim
QL I-Claim
. I-Claim

Chemotherapy B-Claim
is I-Claim
moderately I-Claim
efficient I-Claim
as I-Claim
a I-Claim
treatment I-Claim
for I-Claim
pancreatic I-Claim
adenocarcinoma I-Claim
, I-Claim
but B-Claim
patient I-Claim
survival I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
has I-Claim
improved I-Claim
with I-Claim
this I-Claim
modality I-Claim
in I-Claim
some I-Claim
trials I-Claim
. I-Claim

In O
a O
previous O
phase O
II O
trial O
, O
5 O
- O
fluorouracil O
( O
5 O
- O
FU O
) O
plus O
cisplatin O
( O
FUP O
) O
yielded O
a O
26 O
. O
5 O
% O
response O
rate O
and O
a O
29 O
% O
survival O
rate O
at O
1 O
year O
. O

The O
present O
study O
aimed O
to O
compare O
FUP O
with O
5 O
- O
FU O
alone O
, O
which O
was O
the O
control O
arm O
in O
former O
Mayo O
Clinic O
trials O
. O

Patients O
with O
untreated O
cytologically O
or O
histologically O
proven O
metastatic O
or O
locally O
advanced O
adenocarcinoma O
of O
the O
pancreas O
were O
deemed O
measurable O
or O
evaluable O
. O

Chemotherapy O
regimens O
consisted O
of O
a O
control O
FU O
arm O
( O
5 O
- O
FU O
500 O
mg O
/ O
m O
( O
2 O
) O
/ O
day O
for O
5 O
days O
) O
and O
the O
investigational O
FUP O
arm O
( O
continuous O
5 O
- O
FU O
1000 O
mg O
/ O
m O
( O
2 O
) O
/ O
day O
for O
5 O
days O
plus O
cisplatin O
100 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
or O
day O
2 O
) O
. O

In O
both O
arms O
, O
chemotherapy O
was O
repeated O
at O
day O
29 O
. O

Two O
- O
hundred O
and O
seven O
patients O
from O
18 O
centres O
were O
randomised O
: O
103 O
in O
the O
FU O
arm O
and O
104 O
in O
FUP O
arm O
. O

Treatment O
arms O
were O
balanced O
with O
respect O
to O
performance O
status O
grade O
0 O
- O
1 O
( O
83 O
% O
versus O
86 O
% O
, O
respectively O
) O
and O
the O
presence O
of O
metastases O
( O
92 O
% O
versus O
89 O
% O
, O
respectively O
) O
. O

The O
median O
number O
of O
cycles O
administered O
was O
two O
in O
both O
arms O
( O
range O
0 O
- O
14 O
) O
. O

Five O
patients O
did O
not O
receive O
any O
chemotherapy O
and O
45 O
received O
only O
one O
cycle O
. O

Toxicity B-Premise
( I-Premise
WHO I-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
) I-Premise
was I-Premise
lower I-Premise
with I-Premise
FU I-Premise
than I-Premise
with I-Premise
FUP I-Premise
( I-Premise
20 I-Premise
% I-Premise
versus I-Premise
48 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
as I-Premise
was I-Premise
neutropenia I-Premise
( I-Premise
6 I-Premise
% I-Premise
versus I-Premise
23 I-Premise
% I-Premise
) I-Premise
, I-Premise
vomiting I-Premise
( I-Premise
4 I-Premise
% I-Premise
versus I-Premise
17 I-Premise
% I-Premise
) I-Premise
and I-Premise
toxicity I-Premise
- I-Premise
related I-Premise
deaths I-Premise
( I-Premise
one I-Premise
versus I-Premise
four I-Premise
early I-Premise
in I-Premise
the I-Premise
trial I-Premise
) I-Premise
. I-Premise

The B-Premise
response I-Premise
rate I-Premise
was I-Premise
low I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
but I-Premise
superior I-Premise
in I-Premise
the I-Premise
FUP I-Premise
arm I-Premise
: I-Premise
12 I-Premise
% I-Premise
versus I-Premise
0 I-Premise
% I-Premise
( I-Premise
intention I-Premise
- I-Premise
to I-Premise
- I-Premise
treat I-Premise
analysis I-Premise
, I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise

The B-Premise
survival I-Premise
rates I-Premise
at I-Premise
6 I-Premise
months I-Premise
were I-Premise
28 I-Premise
% I-Premise
and I-Premise
38 I-Premise
% I-Premise
for I-Premise
the I-Premise
FU I-Premise
and I-Premise
FUP I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
, I-Premise
and I-Premise
1 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
9 I-Premise
% I-Premise
and I-Premise
17 I-Premise
% I-Premise
( I-Premise
log I-Premise
- I-Premise
rank I-Premise
test I-Premise
, I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
10 I-Premise
) I-Premise
. I-Premise

One B-Premise
- B-Premise
year B-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
was I-Premise
0 I-Premise
% I-Premise
with I-Premise
FU I-Premise
versus I-Premise
10 I-Premise
% I-Premise
with I-Premise
FUP I-Premise
( I-Premise
log I-Premise
- I-Premise
rank I-Premise
test I-Premise
, I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise

In B-Claim
advanced I-Claim
pancreatic I-Claim
carcinomas I-Claim
with I-Claim
a I-Claim
poor I-Claim
prognosis I-Claim
, I-Claim
FUP I-Claim
was I-Claim
superior I-Claim
to I-Claim
FU I-Claim
in I-Claim
terms I-Claim
of I-Claim
response I-Claim
and I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
, I-Claim
but I-Claim
not I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
survival I-Claim
. I-Claim

